

## 1190

### QUANTITATIVE PCR-BASED ASSESSMENT OF ANGIOSTRONGYLUS CANTONENSIS IN RATTUS RATTUS FROM HAWAII

Rebecca Bandea<sup>1</sup>, Wesley Warashina<sup>2</sup>, Arlene Buchholz<sup>2</sup>, Sarah Y. Park<sup>2</sup>, Yvonne Qvarnstrom<sup>1</sup>, Alexandre J. da Silva<sup>1</sup>

<sup>1</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States,

<sup>2</sup>Hawaii Department of Health, Honolulu, HI, United States

*Angiostrongylus cantonensis* is the most common parasite causing human eosinophilic meningitis worldwide. This nematode's infectious larvae develop in mollusks, but can also be present in paratenic hosts. The major route of infection is thought to be accidental consumption of infected mollusks in fresh produce or other foods. A survey performed in 2007 on mollusks collected in Hawaii main island showed an infective rate ranging from 24 to 78% depending on the mollusk species analyzed. The severe cases of eosinophilic meningitis recently reported could be due to overexposure of humans to highly infected mollusks; there are no measures in place to control the spread of *A. cantonensis* in Hawaii. The aim of this study was to determine the prevalence of *A. cantonensis* in rats, the most efficient definitive hosts for this parasite. A total of 62 rats were trapped in 4 Hawaiian communities. The presence of *A. cantonensis* was initially assessed by morphologic identification of adult worms in lungs and hearts of the animals. DNA was then extracted from 28 randomly selected lung and heart tissue samples obtained from these animals. The DNA extracts were evaluated using a quantitative TaqMan PCR validated for diagnostic detection of *A. cantonensis*. A total of 60% (n=37) of the rats were positive by morphology, while 100% of the tissue samples examined with the PCR were positive. A quantitative analysis of the PCR results indicated that 32% (n=9) of the rat samples contained *A. cantonensis* DNA corresponding to more than 100 larvae in approximately 25 mg of tissue. Together with previous studies, this data indicates that angiostrongyliasis may be a more serious public health issue in Hawaii than currently estimated and that measures to control its spread in mollusks and rodents may be warranted.

## 1191

### INCREASED BASOPHIL RESPONSIVENESS AFTER ANTHELMINTIC TREATMENT IN A COASTAL ECUADORAN POPULATION

David Larson<sup>1</sup>, Marc P. Hübner<sup>1</sup>, Philip J. Cooper<sup>2</sup>, Edward Mitre<sup>1</sup>

<sup>1</sup>Uniformed Services University of the Health Sciences, Bethesda, MD, United States, <sup>2</sup>Instituto de Microbiología, Universidad San Francisco de Quito, Quito, Ecuador

As basophils function as allergy effector cells and may be involved in initiating and perpetuating allergic diseases, it is possible that much of the allergy-protective effect conferred by helminths is through their effect on basophils. Recently, we demonstrated that basophil responsiveness decreases in murine models of chronic helminth infection. In this study, we tested the hypothesis that basophil responsiveness is suppressed during helminth infection of humans. Twenty-three children infected with intestinal helminths were identified by parasitological examination of stool samples in Esmeraldas, Ecuador. Peripheral blood cells from these children were washed twice and stimulated with increasing concentrations of anti-IgE and 5 µg/ml ionomycin. Basophil activation was determined by measuring histamine release into the supernatant using a competitive ELISA. Children were then treated with ivermectin and 2 doses of albendazole and histamine release from blood basophils measured again two weeks later. A two week timepoint was chosen as basophil half-life is estimated to be between 5-8 days. Significantly more histamine was released from basophils after anthelmintic treatment when blood was stimulated with 0.5, 0.125, and 0.031 µg/ml anti-IgE (mean % of total histamine release from infected children before treatment = 40.38, 43.12, 31.49 vs. 55.17, 60.53, 44.89 from children post-treatment, p < 0.01, p

< 0.001, p < 0.05). A similar increase in histamine release was seen when stimulating with ionomycin (mean % of total histamine release from infected children before treatment = 49.30 vs. 76.71 from children post-treatment, p < 0.0008). These results suggest that the ability of basophils to respond to IgE-dependent and IgE-independent activation is suppressed during intestinal helminth infection of humans. This suppression appears to require the continuous presence of helminths as basophil histamine releasability increases shortly after helminths are eliminated. These findings may explain why helminth infections protect against allergic disease.

## 1192

### SPATIAL PATTERNING OF HEALTH DISPARITIES AND ENVIRONMENTAL FACTORS ASSOCIATED WITH ASCARIS LUMBRICOIDES PREVALENCE IN BOLIVIA

Julie A. Clennon, Alexandra D. Huttinger, Emily R. Smith, Christine L. Moe

Emory University, Rollins School of Public Health, Atlanta, GA, United States

Infection with *Ascaris lumbricoides*, a soil-transmitted helminth (STH), affects as many as one billion people worldwide, and causes an estimated 10.5 million disability-adjusted life-years (DALYs) lost. STH prevalence data for Bolivia is sparse. A 2009 literature review found only 7 studies in the last 25 years that offer prevalence estimates for any region of Bolivia. A review conducted in 2006, that reported data from 1976-2003, showed that *A. lumbricoides* infection prevalence varies geographically across Bolivia, from 1-28% in the Western high plains to 15-96% in the Eastern tropical lowlands. Although data on STH prevalence in Bolivia is patchy, there is information available on environmental and social risk factors known to be associated with *A. lumbricoides* prevalence. Environmental conditions, particularly temperature and soil moisture, largely determine global distribution of *A. lumbricoides*. Social factors, such as piped water, sanitation and improved housing (absence of dirt floors), are associated with lower STH infection. Using spatial autocorrelation statistics (Moran's I and Local Indicator of Spatial Association [LISA]), we examined the spatial distribution of risk factors associated with increased prevalence of *A. lumbricoides* infection. Subsequently, we created a risk model integrating environmental and social factors with previous community-level *A. lumbricoides* survey data. This model is a cost-effective way to predict areas of high and low STH endemicity in the absence of nationally representative prevalence data. The model can be used to inform efforts to fill information gaps on prevalence and intensity of STH infections and better focus mass drug administration campaigns and water, sanitation and housing infrastructure investments to mitigate STH infections across Bolivia.

## 1193

### HOOKWORM AND TRICHURIS INFECTIONS ASSOCIATED WITH ANEMIA DURING PREGNANCY

Theresa W. Gyorkos<sup>1</sup>, Nicolas L. Gilbert<sup>1</sup>, Renee Larocque<sup>2</sup>, Martin Casapia<sup>3</sup>

<sup>1</sup>McGill University, Montreal, QC, Canada, <sup>2</sup>Global Health Research Initiative, Ottawa, ON, Canada, <sup>3</sup>Asociacion Civil Selva Amazonica, Iquitos, Peru

The objective of this study was to assess changes during pregnancy in the association between the intensity of soil-transmitted helminth (STH) infections and hemoglobin (Hb) levels, following iron supplementation and mebendazole administration, in an endemic region of Peru. Data from a randomized clinical trial on the effect of mebendazole on birthweight were re-analyzed. Pregnant women (N=935) recruited in their second trimester provided baseline data on STH infections and anemia. All women were given iron supplements (60 mg/d); half were randomly allocated to receive single dose 500mg mebendazole and half placebo. Hb was also determined in the third trimester. Mean Hb level increased from 11.03 to 11.39 g/dL between the second and the third trimester. Hookworm

(prevalence 46.3%) and *Trichuris* (76.1%) infections, but not *Ascaris* (63.9%), in the second trimester were independently associated with lower Hb in both the second and third trimester. *Trichuris* >1200 epg was also associated with a lower increase of Hb between the second and the third trimester ( $\Delta\text{Hb} = -0.26$  g/dL,  $p=0.026$ ). The prevalence of anemia ( $\text{Hb} < 11$  g/dL) decreased from 46.8% to 34.7% between the second and the third trimesters. Hookworm and *Trichuris* infections were significantly and independently associated with increased risk of anemia in the third trimester. The adjusted OR for hookworms >600 epg was 1.52 (95% CI 1.01 to 2.28), and the adjusted OR for *Trichuris* >1200 epg was 1.72 (95% CI 1.14 to 2.61). Mebendazole treatment was not associated with Hb or with the prevalence of anemia, and did not modify the relationship between helminths and Hb. In conclusion, in pregnancy, both hookworm and *Trichuris* infections are associated with increased risk of anemia. Infected women remain at higher risk of anemia throughout pregnancy, irrespective of mebendazole administration. These data suggest that more effective deworming interventions be targeted to pregnant women in endemic areas.

## 1194

### TUBERCULOSIS (TB) CONTROL AMONG HEALTH CARE WORKERS (HCW), RESEARCHERS, TRAINEES AND TRAVELERS TO A TB-ENDEMIC AREA WITH AN ACADEMIC, INTERNATIONAL, MEDICAL EXCHANGE PROGRAM

Adrian Gardner<sup>1</sup>, Ted Cohen<sup>2</sup>, E. Jane Carter<sup>1</sup>

<sup>1</sup>Warren Alpert School of Medicine at Brown University, Providence, RI, United States, <sup>2</sup>Brigham and Women's Hospital and Harvard School of Public Health, Boston, MA, United States

Although individuals from low TB burden countries experience an increased risk of TB infection when traveling to high burden countries for medical training or service, degree of risk has not been well quantified. Improved knowledge will aid development of guidelines for TB screening, pre/post-travel education and risk reduction. 608 individuals who traveled to Eldoret, Kenya with the AMPATH medical exchange program between July, 2004 - June, 2009 were invited to complete an online survey. Survey questions included demographic characteristics, pre-travel TB counseling, in-country activities, and post-travel TB testing. 418/608 (69%) responded. The majority were young adults (65% between 22-40 years old) and 55% were female. 7% had chronic medical conditions predisposing to increased risk of TB. Pre-travel, respondents sought travel advice from a number of different sources: travel clinic (54%), CDC travel website (31%). 58% reported that TB prevention was discussed in travel preparations. Pre-travel, 81% reported negative Tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA); 11% reported unknown infection status. Most commonly reported duration of visits was 5-8 weeks. Most-common activities included direct medical care in adult medical ward (49%) and non-direct medical care activities in a lab or on hospital grounds (38%). Respondents also commonly visited Kenyan homes (65%) and used public transport (40%). 13 individuals (3 under age 21) converted to a positive TST during their travel. One reported an episode of active TB. 113 (28%) of survey participants reported "ideal" care (definition: pre-travel TST (within one year of travel), pre-travel counseling, and a repeat post-travel TST). In conclusion, travelers to TB endemic areas with international, medical exchange programs are at significant risk for TB infection. Many receive inadequate pre and post-travel TB counseling and testing. Efforts should be made to improve TB education for program participants. Further study is needed to quantify the risk of TB infection.

## 1195

### MOLECULAR EPIDEMIOLOGY OF BOVINE TUBERCULOSIS ACROSS THE UNITED STATES-MEXICO BORDER: SUPPORTING STRATEGIES FOR ANIMAL AND PUBLIC HEALTH INTERVENTIONS

James Higgins, Tod Stuber, Patrick Camp, Doris Bravo, David Farrell, Beth Harris

NVSL, APHIS, United States Department of Agriculture, Ames, IA, United States

Bovine tuberculosis, caused by *Mycobacterium bovis*, is a major global cause of respiratory disease and decreased production in beef and dairy cattle. Human infections with *M. bovis* represent an emerging public health concern in immigrant communities in the US. The epidemiology of zoonotic *M. bovis* infection is complex, but may be associated with exposure to contaminated animal products such as soft cheeses and unpasteurized milk. Elucidating the epidemiology of *M. bovis* prevalence and transmission among cattle in the US, particularly among animals imported from Mexico, can be an important component of strategies to reduce the economic and public health impacts of this disease. Using techniques to genotype *M. bovis* strains, such as spoligotyping and variable number tandem repeat (VNTR) analyses, we have examined the molecular epidemiology of bovine tuberculosis outbreaks in southwestern states in the US. In the majority of these outbreaks, the data indicate that the *M. bovis* isolates do not display the genotypic profiles common to isolates present in cervids, which are considered to be a major source of bovine TB infections among cattle in the central and eastern regions of the US. Rather, the genotypic profiles for the *M. bovis* isolates recovered from US animals are representative of those documented to occur in cattle originating from Mexico. Efforts are underway to expand databases of molecular fingerprinting data for *M. bovis* isolates obtained from cattle and wild animals to enhance the USDA's abilities to identify foci of the disease in cattle populations, and improve efforts to control bovine tuberculosis within the US.

## 1196

### QUALITATIVE FINDINGS AND IMPLICATIONS FOR SCALING UP AN IMPROVED COOKSTOVE PROJECT IN RURAL KENYA

Bobbie Person<sup>1</sup>, Jennifer Loo<sup>1</sup>, Mercy Owour<sup>2</sup>, Lorraine Ogange<sup>3</sup>, Adam Cohen<sup>1</sup>

<sup>1</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States,

<sup>2</sup>Tropical Institute of Community Health, Kisumu, Kenya, <sup>3</sup>Kenya Medical Research Institute, Kisumu-Kisian, Kenya

Traditional indoor, three-stone cooking fire pits, a staple in rural households in resource-poor countries are not without costs to human health and the environment. We conducted a pilot intervention to promote the purchase and use of an improved cookstove in rural Kenya. In order to improve the scaling up of the stove promotion effort to the larger community, we conducted a qualitative inquiry to better understand the activities and strategies vendors used to promote the stove, the motivations of community members to purchase and use the stove, and the perceived benefits and challenges of stove use among very poor Luo women. Purposive sampling was used to recruit 10 health promoter-stove vendors and 30 stove purchasers of the stove in the Luo community. Formative research was conducted through qualitative semi-structured key informant interviews with a topic guide. Data were transcribed and imported into Atlas-ti and a thematic analysis conducted to identify patterns representing a comprehensive picture of personal and collective experiences. Women who purchased the improved cook stove reported the most influential promotion strategies were interpersonal communication through informal social networks, observations of someone using the stove, and actual cooking demonstrations. Luo women reported the need for less firewood, fuel costs savings, reduced smoke, increased cooking efficiency, and reduced eye irritation, lung congestion

and coughing as major benefits. While there were notable financial and health benefits along with a decreased workload for women, the cost of the stove and the associated role of men in decision making for household purchases appeared to be possible barriers to wider spread adoption. In conclusion, qualitative findings noted that the price of the stove will need to be reduced or subsidized if there is a commitment for community-wide access to the health benefits of this newer technology. Promotion activities employing interpersonal communication and cooking demonstrations were critical for scaling up the project.

## 1197

### UNDERSTANDING RESPIRATORY INFECTION IN BANGLADESH: COMMUNITY PERCEPTIONS, SOCIAL NORMS AND CURRENT PRACTICES

**Md. Fosiul A. Nizame**<sup>1</sup>, Sharifa Nasreen<sup>1</sup>, Leanne Unicomb<sup>1</sup>, Dorothy Southern<sup>1</sup>, Emily S. Gurley<sup>1</sup>, Shaila Arman<sup>1</sup>, Mohammad Abdul Kadir<sup>1</sup>, Peter J. Winch<sup>2</sup>, Eduardo Azziz Baumgartner<sup>1</sup>, Stephen P. Luby<sup>1</sup>

<sup>1</sup>International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States

Respiratory infections are the leading cause of childhood death in Bangladesh. Non-pharmaceutical interventions such as respiratory hygiene (covering the nose and mouth when coughing or sneezing and washing hands after having contact with respiratory secretions and contaminated objects) may be effective in reducing infection transmission. This formative study explored community perceptions about respiratory infections, why they occur, how they are spread, and the preventive measures that can be taken to protect themselves and their families. We used semi-structured interviews and focus group discussions with community members, leaders and school children to explore respiratory infection and hygiene related perceptions, social norms and practices. From both the semi-structured interviews and focus group discussions, we found that our informants were not familiar with the term "respiratory disease" as translated into Bengali. When asked to give examples of respiratory diseases, they named diseases some of which had no relation to respiratory function. The informants identified a number of social norms related to respiratory hygiene, including covering coughs or sneezes, turning face away during sneezing and coughing, and not spitting on the ground, but very few people practice these. During semi-structured interviews, all informants cited hot/cold weather changes and using cold water as the cause for catching cold during the previous twelve months. Yet, when asked about modes of transmission, these were associated with close contact with the breath, spit or cough droplets of a sick person. The most effective way to prevent respiratory infection was to avoid these. Although most of our informants perceived that handwashing after coughing and/or sneezing might prevent illness, most of them felt that this was not practical after every event. In conclusion, informants related their personal experience of catching a cold to the local explanatory model of hot-cold imbalance including perceived changes in body temperature and environment. But for transmission and prevention they related to both the biomedical construct and the cultural contagion model. This gap provides useful insights for message development that can be incorporated into "culturally compelling" communication interventions to make people conscious about respiratory hygiene and to increase their self efficacy.

## 1198

### INCIDENCE OF INFLUENZA INFECTION IN EARLY INFANCY IN SOUTH ASIA

**Mark C. Steinhoff**<sup>1</sup>, Emily Henkle<sup>2</sup>, Saad B. Omer<sup>3</sup>, William J. Moss<sup>2</sup>, Shams E. Arifeen<sup>4</sup>, Rubhana Raqib<sup>4</sup>, Monica McNeal<sup>1</sup>, Robert F. Breiman<sup>5</sup>, K. Zaman<sup>4</sup>

<sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, <sup>2</sup>Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States, <sup>3</sup>Rollins School of Public Health, Emory University, Atlanta, GA, United States, <sup>4</sup>International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh, <sup>5</sup>Centers for Disease Control and Prevention, Nairobi, Kenya

Young infants 0-6 months of age in the US have a reported influenza incidence of 12% and high rates of 'flu hospitalization. Historically influenza has not been considered a frequent or serious illness of infants in the tropics, partly because of the lack of data. We report the serology and 'flu antigen data from 131 infants of mothers who received pneumococcal vaccine as controls in a 'flu vaccine study. A full description of the Mother'sGift trial has been published. 340 pregnant women in Dhaka were randomized to receive pneumococcal or trivalent inactivated influenza vaccine. From Aug 2004 - Oct 2005, non-'flu vaccine control mothers and their infants were visited weekly from birth to 6 months to record symptoms of febrile respiratory illness. Influenza antigen was tested by rapid antigen-detection test (RADT) in symptomatic infants. A standard hemagglutination inhibition (HAI) assay was done on infant sera collected at birth, 10, and ~ 22 weeks of age. We defined serological infection as a  $\geq 4$ -fold increase of the expected declining later titers compared to the earlier titer. Of 131 infants with prospective data 29 experienced 31 serologically-defined influenza infections. Adding 10 distinct RADT-proven infections resulted in a total of 41 influenza infections or a cumulative incidence of 31.3/100 0-6 month old infants (95% CI: 23.6-41.4). Maternal HAI data is being analyzed. In conclusion, additional studies of the incidence of influenza in young infants in Asian and other tropical regions should be carried out to define the burden of preventable influenza illness. Antenatal immunization is a proven prevention strategy in this vulnerable group.

## 1199

### PREVENTIVE MEASURES ASSOCIATED WITH PROBABLE CASES OF A (H1N1) INFLUENZA IN INHABITANTS OF THE FEDERAL DISTRICT OF MEXICO CITY

**Ana Flisser**<sup>1</sup>, Veronica Cruz-Licea<sup>1</sup>, Fernando Gonzalez-Dominguez<sup>2</sup>

<sup>1</sup>UNAM, Faculty of Medicine, Mexico City, Mexico, <sup>2</sup>Hospital General "Dr. Manuel Gea Gonzalez, SSA, Mexico City, Mexico

When pandemic A (H1N1) Influenza (flu) broke out in the spring of 2009 in Mexico, the Ministry of Health established and profusely promoted preventive and control measures that could slow or stop transmission. The objective of this study was to evaluate if inhabitants of the Federal District of Mexico City understood and implemented the measures recommended and if there was an association with probable cases of the flu. An ad-hoc questionnaire was given to 4003 subjects who voluntarily agreed to participate in a household survey aimed at detecting cases of influenza between August and September 2009. The average age was 46±16 years of age and 64% were women. Most people reported to wash hands and open windows at home, but only 32% covered their nose with the forearm when sneezing, 34% used alcohol gel and 70% kept shaking hands or kissing when greeting others. The frequency of symptoms of flu like disease occurring from January to September 2009, were: 29% running nose, 25% coughing, 17% head, muscle or joint ache and 7% sudden high fever and 11% had 3 or 4 of these symptoms (probable cases); 62% attended a physician when flu symptoms appeared, 22% self-medicated and 17% did not do anything. Significant associations were found between probable cases and not washing hands, and also for



inadequate techniques when sneezing or greeting. The potential impact of these factors on the frequency of probable cases, calculated as the attributable risk for the exposed, ranged from 29 to 55%. The fact that a third of the population used the appropriate technique to cover their nose while sneezing or used alcohol gel, measures newly recommended by the government, suggests that people follow novel advices, while a similar proportion changed inadequate habits, such as touching or kissing. This study was performed only 3 months after the pandemic started and allowed identifying public health information that should be intensified or modified, especially because the survey was carried out among the general population and not only in diagnosed cases.

## 1200

### OUTBREAK OF PANDEMIC INFLUENZA A (H1N1) IN RWANDA, OCTOBER 2009

Thierry Nyatanyi<sup>1</sup>, Joseph Rukelibuga<sup>2</sup>, Marie Aimée Muhimpundu<sup>1</sup>, Richard Nkunda<sup>3</sup>, Adeline Kabeja<sup>1</sup>, Alice Kabanda<sup>3</sup>, John Rusine<sup>3</sup>, John Ruyonga<sup>4</sup>, Ange Irakoze<sup>1</sup>, Noella Umulisa<sup>1</sup>, David Lowrance<sup>5</sup>, Zara Ahmed<sup>5</sup>, Simon Antara<sup>6</sup>, Caitlin Biedron<sup>5</sup>, David McAlister<sup>5</sup>, Jean Baptiste Koama<sup>5</sup>, Eugenie Kayirangwa<sup>5</sup>, Odette Mukabayire<sup>3</sup>, Corine Karema<sup>1</sup>, Pratima Raghunathan<sup>5</sup>, Justin Wane<sup>7</sup>

<sup>1</sup>Center for Treatment and Reserach on AIDS Rwanda, Kigali, Rwanda, <sup>2</sup>CDC Rwanda, Kigali, Rwanda, <sup>3</sup>National Reference Laboratory Rwanda, Kigali, Rwanda, <sup>4</sup>Ministry of Health, Rwanda, Kigali, Rwanda, <sup>5</sup>CDC-GAP Rwanda, Kigali, Rwanda, <sup>6</sup>African Field Epidemiology Network, Rwanda, Kigali, Rwanda, <sup>7</sup>King Faycal Hospital Rwanda, Kigali, Rwanda

On October 9th, 2009 Pandemic Influenza A (H1N1) outbreak was confirmed in Rwanda. The index case a Rwandan female, 39 years old traveled to US and arrived in Kigali on October 3rd, 2009. She presented with fever, cough and joint pains on October 4th, 2009. We describe the epidemiology of this novel virus in Rwanda. Methods: We undertook epidemiologic investigations around the index case. We collected respiratory specimens from suspect cases using a WHO case definition and tested specimens by real time RT-PCR at the National Reference Laboratory. From October 8th through October 31st, 2009, we tested 810 specimens. Of these, 127 (15.7%) were positive for pandemic H1N1. Of confirmed cases, 81 (63.8%) were children <15 including 17 children < 5 years old, 74 (58.2%) were female, 35 (27.6%) were in a high-risk category. Two (1.6%) cases were hospitalized and subsequently discharged; all other cases were outpatients. One hundred and seventeen (98%) confirmed cases received treatment with oseltamivir and two received post-exposure prophylaxis. Confirmed cases occurred in two referral hospitals, five schools all in Kigali city and in 46 households in Kigali City, northern and western Provinces. The attack rates at the two schools with the largest H1N1 clusters were 2.4% and 3.8%. Twelve (9.4%) confirmed cases of third-generation transmission occurred and 87 (68.5%) cases had unknown exposure to known confirmed cases. In conclusion, transmission of Pandemic influenza A (H1N1) was confirmed in Rwanda and documented in diverse settings, including health facilities, schools, and households. Most confirmed cases were female and children. Disease appears mild, similar to that seen in other East African countries. We recommended mitigation measures, including public education on home care, enhanced training of health care workers, use of targeted laboratory testing and treatment, and robust surveillance.

## 1201

### SPATIAL AND TEMPORAL VARIATION IN VECTOR COMPETENCE OF *CULEX PIPIENS* AND *CX. RESTUANS* MOSQUITOES FOR WEST NILE VIRUS

A. Marm Kilpatrick<sup>1</sup>, Dina M. Fonseca<sup>2</sup>, Greg D. Ebel<sup>3</sup>, Michael R. Reddy<sup>4</sup>, Laura D. Kramer<sup>5</sup>

<sup>1</sup>University of California, Santa Cruz, Santa Cruz, CA, United States, <sup>2</sup>Rutgers University, New Brunswick, NJ, United States, <sup>3</sup>University of New Mexico, Albuquerque, NM, United States, <sup>4</sup>Harvard University, Boston, MA, United States, <sup>5</sup>New York State Department of Health, Albany, NY, United States

Vector competence, the probability that a vector will transmit a pathogen after feeding on an infected host, is known to vary among vector species, populations, days since feeding, and temperature during the extrinsic incubation period. However, the extent of spatio-temporal variability and consistency in vector competence of populations is not known. We examined vector competence of *Culex pipiens* Linnaeus and *Cx. restuans* Theobald mosquitoes for West Nile virus (WNV) collected over three years from sixteen sites to measure spatial and temporal scales of variation in vector competence. We found extreme variation with 0-52% of mosquitoes transmitting WNV at a single site between different sampling periods, and similar variation across populations. However, we also found that within a smaller geographic range vector competence varied somewhat synchronously, suggesting that environmental and population genetic factors might influence vector competence. These results highlight the spatio-temporal variability in vector competence and the role of local processes.

## 1202

### WEST NILE VIRUS ENVELOPE PROTEIN GLYCOSYLATION AFFECTS VIRUS-VECTOR INTERACTIONS IN A SPECIES-SPECIFIC MANNER

Robin M. Moudy, Anne F. Payne, Brittany L. Dodson, Laura D. Kramer

Wadsworth Center/New York State Department of Health, Albany, NY, United States

Many, but not all, strains of *West Nile virus* (WNV) contain a single N-linked glycosylation site on their envelope (E) proteins. Previously, we found that a WNV that lacked the glycosylation site (ENONGLY) replicated less efficiently than glycosylated WNV (EGLY) in *Culex pipiens* and *Cx. tarsalis* mosquitoes. Additionally, transmission of WNV by mosquitoes that fed on ENONGLY was associated with viral reversion to a glycosylated phenotype. We have recently expanded these studies to include an additional important WNV vector, *Cx. quinquefasciatus*. To determine if replicative differences were present in this species, we inoculated mosquitoes intrathoracically with 10pfu of either ENONGLY or EGLY and determined titers in the mosquitoes from 1 to 10 days post inoculation. As we previously observed with *Cx. pipiens* and *Cx. tarsalis*, replication of ENONGLY was decreased relative to that of EGLY in *Cx. quinquefasciatus*. Similar decreases in replication were observed in individual mosquito tissues (midguts and salivary glands). To determine whether viral genotype affected infectivity and transmission in *Cx. quinquefasciatus*, we fed mosquitoes a bloodmeal containing either EGLY or ENONGLY and examined infection, dissemination, and transmission rates at various days post-feeding (dpf). At all dpf, infection rates were greater in mosquitoes that had fed on a bloodmeal containing EGLY, similar to previous results in *Cx. pipiens*. However, dissemination and transmission rates were higher at 7 and 14 dpf in mosquitoes that fed on a bloodmeal containing the ENONGLY virus. In contrast to previous results with both *Cx. pipiens* and *Cx. tarsalis*, none of the viruses transmitted by *Cx. quinquefasciatus* following feeding on the ENONGLY bloodmeal exhibited reversion to EGLY phenotype. Taken together, these data suggest that E protein glycosylation

affects WNV-vector interactions differently in different *Culex* mosquito species and confirms earlier studies with WN02 and NY99 showing that *Cx. quinquefasciatus* differs from its sibling species *Cx. pipiens*.

## 1203

### LACK OF GENETIC BOTTLENECKS DURING WEST NILE VIRUS INFECTION OF *CULEX PIPENS QINQUEFASCIATUS*

**Doug E. Brackney**, Ivy K. Brown, Kelly A. Fitzpatrick, Gregory D. Ebel

*University of New Mexico, Albuquerque, NM, United States*

The introduction and adaptation of arthropod-borne viruses (arboviruses) to new ecological niches pose an ongoing threat to human health. Understanding the evolution of arboviruses in the context of their transmission cycles and how this impacts viral emergence, adaptation and persistence is paramount to effectively minimizing public health risk. Introduced into North America in 1999, West Nile virus (WNV; *Flaviviridae, Flavivirus*) has adapted to local transmission cycles and is now considered endemic. Previous studies have shown that WNV exists within hosts as a genetically diverse group of competing viral variants, and that the complexity of the WNV quasispecies is greater in mosquitoes than birds. The mechanism(s) responsible for this observed difference and the impact of mosquito infections on viral evolution are unknown. Therefore, using WNV and *Culex pipiens quinquefasciatus* mosquitoes as a model system, we addressed the role mosquito infections have in shaping arbovirus populations. We offered *Cx. p. quinquefasciatus* mosquitoes an infectious bloodmeal containing a highly genetically diverse WNV population and quantified viral genetic diversity in three well-characterized stages (infection, dissemination, and transmission) from three mosquitoes at three time points (7, 14, and 21 days post infection). WNV RNA corresponding to the E-NS1 coding region (nt 1971-2928) was reverse transcribed, amplified with high fidelity polymerase and cloned. Subsequently, thirty clones from each sample were sequenced. Baseline levels of input viral genetic diversity were determined from whole-body mosquitoes recovered immediately post blood feeding. The genetic diversity of virus obtained from three freshly fed mosquitoes was extremely high (0.170%). Further, on average, 14.7 haplotypes were identified with many of these haplotypes being shared among individuals. Examination of midguts from later timepoints revealed genetic restriction with a reduced number of haplotypes and an overall genetic diversity of 0.021%. Sampling of the legs (dissemination) and saliva (transmission) revealed that many of the input haplotypes that had been lost in the midgut were recovered, and viral genetic diversity was greater than in the midgut. Overall, these data suggest that the *Culex* mosquito midgut fails to impose a genetic bottleneck on WNV populations and that WNV genetic diversity accumulates during the course of an infection.

## 1204

### INSIGHTS INTO ARBOVIRAL MUTANT SWARM DYNAMICS USING EXPERIMENTAL EVOLUTION OF FLAVIVIRUSES

**Alexander T. Ciota**, Greta V. Jerzak, Dylan J. Ehrbar, Graham G. Willsey, Anne F. Payne, Laura D. Kramer

*Wadsworth Center, New York State Department of Health, Slingerlands, NY, United States*

The rapid production of mutants created by the combination of high rates of replication and error prone nature of the RdRp of arboviruses results in a population of variants collectively called the mutant swarm. In order to fully understand how selection acts on these populations one must first fully describe the role of the mutant swarm both within and among hosts. Understanding the role of minority variants in viral fitness and plasticity is particularly important for arboviruses, which require replication in disparate hosts and tissues. In addition, an understanding how bottlenecks within and among hosts work to shape the arboviral mutant swarm is still lacking. Using *in vitro* and *in vivo*-passed strains of West Nile virus (WNV) and St. Louis encephalitis virus (SLEV) we evaluated the importance of the

mutant swarm in viral fitness, the distribution of variants in cell-adapted populations, the potential for strain complementation, and the size of the neutral bottlenecks within *Cx. pipiens* mosquitoes. Previous results have demonstrated that passed populations are highly adapted and, that the WNV mutant swarm is important in adaptive phenotypes. WNV viral diversity has been shown to accumulate at high levels with passage and adaptation to both mosquitoes and mosquito cells, while SLEV has not. Preliminary *in vitro* competition assays with WNV suggest that increases in strain co-infection in mosquito cells limit the relative fitness of the adapted strain, suggesting strain complementation in co-infected cells. In addition, preliminary results using equally fit WNV variants have allowed us to quantify the probability that minority variants will survive both dissemination throughout and transmission from *Cx. pipiens* mosquitoes given their starting concentrations in the population. Taken together, these results provide crucial insight into arboviral mutant swarm dynamics which have significant impact on the understanding of arbovirus adaptation, evolution, and epidemiology.

## 1205

### PATTERN FORMATION IN THE DYNAMICS OF WEST NILE VIRUS AMPLIFICATION IN A TRANSMISSION HOT SPOT IN CHICAGO, U.S.A.

**Tavis K. Anderson**<sup>1</sup>, Gabriel L. Hamer<sup>1</sup>, Edward D. Walker<sup>2</sup>, Luis F. Chaves<sup>3</sup>, Uriel D. Kitron<sup>3</sup>, Jeffrey D. Brawn<sup>4</sup>, Marilyn O. Ruiz<sup>4</sup>, Tony L. Goldberg<sup>1</sup>

*<sup>1</sup>University of Wisconsin-Madison, Madison, WI, United States, <sup>2</sup>Michigan State University, East Lansing, MI, United States, <sup>3</sup>Emory University, Atlanta, GA, United States, <sup>4</sup>University of Illinois at Urbana-Champaign, Champaign, IL, United States*

Untangling the influence of host and vector diversity on West Nile virus (WNV) persistence and transmission is relatively complex given the large numbers of species and interactions. Although the complexity of these networks have been hypothesized to affect transmission, at times positively or negatively, the actual mechanisms that facilitate repeated outbreaks of WNV remain largely unknown. It has been suggested that "super spreaders," may be important in the WNV system, defined as a minority of individuals, or host species, that give rise to the majority of secondary infections. Here we examine this idea, using a series of computer simulations of pathogen transmission. Under most conditions, we find that cascades of WNV transmission are not solely driven by super spreaders, but rather by a critical mass of infected individuals. Although these data do not exclude the possibility that super spreaders are important, they suggest that making assumptions about their influence on pathogen dynamics requires careful testing.

## 1206

### IL-10 AND PD-L1 IMPAIR THE T CELL RESPONSE IN THE CENTRAL NERVOUS SYSTEM DURING PERSISTENT WEST NILE VIRUS INFECTION

Barbara S. Stewart<sup>1</sup>, Chrystal M. Chadwick<sup>2</sup>, Sharone Green<sup>3</sup>, **Kristen A. Bernard**<sup>4</sup>

*<sup>1</sup>University at Albany, Albany, NY, United States, <sup>2</sup>Wadsworth Center, Albany, NY, United States, <sup>3</sup>University of Massachusetts Medical School, Worcester, MA, United States, <sup>4</sup>University of Wisconsin-Madison, Madison, WI, United States*

West Nile virus (WNV) can lead to a persistent infection in humans and in several animal models. In mouse studies from our laboratory, WNV RNA persists in the central nervous system (CNS) for up to 6 months post-inoculation (p.i.), and infectious virus can be isolated from CNS tissues for up to 4 months p.i. We also showed that plasma cells in the CNS of WNV-inoculated mice secreted WNV-specific antibody for at least 16 weeks p.i. Additionally, we detected epitope-specific CD8+ T cells in the CNS for up to 16 weeks p.i., using a MHC class I dimer assay for a dominant WNV epitope (SSVWNATTA). We hypothesized that CD8+ T cells are

ineffective in clearing the virus from the CNS, resulting in viral persistence. We assessed the function of T cells using intracellular staining for IFN- $\gamma$  and found that only 20% of the epitope-specific CD8+ T cells in the brain were able to secrete IFN- $\gamma$  at 2 to 16 weeks p.i. In contrast, approximately 95% of the epitope-specific CD8+ T cells in the spleen produced IFN- $\gamma$  after peptide stimulation. Similar results with TNF- $\alpha$  production were obtained. We examined the possibility that the CD8+ T cells were inhibited by IL-10 and/or programmed death receptor ligand-1 (PD-L1). WNV-inoculated mice were treated with antibodies to IL-10 receptor (1L-10R) and/or PD-L1 every three days for five treatments starting at 2 weeks p.i. Three days after the last treatment, mice were sacrificed, and CD8+ T cell function and WNV persistence were compared to isotype antibody treated controls. The function of the epitope-specific CD8+ T cells was partially restored upon blockade of IL-10R and/or PD-L1. In addition, infectious WNV was found in two of nine mice treated with antibodies to both IL-10R and PD-L1 compared to eight of eight mice treated with isotype control antibodies (Fisher's exact test,  $P=0.002$ ). In summary, these results suggest that CD8+ T cells are impaired in the CNS of mice due to IL-10 and PD-L1, and blockade of these molecules promotes viral clearance.

## 1207

### KERATINOCYTES ARE CELL TARGETS OF WEST NILE VIRUS *IN VIVO*

Pei-Yin Lim<sup>1</sup>, Gang Zou<sup>2</sup>, Chrystal M. Chadwick<sup>2</sup>, Kristen A. Bernard<sup>1</sup>

<sup>1</sup>University of Wisconsin, Madison, WI, United States, <sup>2</sup>Wadsworth Center, New York State Department of Health, Albany, NY, United States

West Nile virus (WNV) is transmitted to humans through the bite of an infected mosquito at the skin. Langerhan cells, resident dendritic cells in the skin, are postulated to become infected with WNV and migrate to the draining lymph nodes. We hypothesized that WNV infects additional cell types in the skin because high levels of infectious virus are detected in both the skin and draining lymph node at 24 hour post-inoculation (hpi) and persist for at least seven days. The goal of this study was to identify the cell target(s) of WNV in the skin. We inoculated mice subcutaneously (SC) in the left rear footpad with WNV replicon particles containing a luciferase reporter and monitored luciferase activities in various tissues. Luciferase activity was detected in the skin at the inoculation site at 24 hpi and increased ~100-fold at 72 hpi. These results suggest that WNV infects non-migrating cells in the skin, which continually support virus replication. We inoculated mice SC in the footpads with WNV and performed immunohistochemical assays on the skin to determine the cell tropism of WNV. WNV-positive cells were found only in the epidermal layer of the skin of the WNV-inoculated mice at 96 hpi, and these cells were identified morphologically as keratinocytes. We inoculated mouse primary skin cells with WNV and analyzed the cells by flow cytometry for expression of WNV E antigen and cell surface markers - the pan-leukocyte marker CD45 and a keratinocyte marker K10. Approximately 4% of the skin cells expressed WNV antigen, and ~64% of these cells expressed K10, further confirming that mouse keratinocytes were susceptible to WNV infection. No WNV-positive cells expressed CD45, but they may not have been detected since there were low numbers of CD45-positive cells (~2.5%) in the skin cell population. In addition, primary human keratinocytes were permissive for WNV and supported virus production for at least six days. In summary, the skin is an initial replication site for WNV, and keratinocytes are cell targets *in vivo* in the skin.

## 1208

### THE IMPACT OF A SENTINEL SITE MALARIA SURVEILLANCE PROGRAM ON IMPROVING CASE MANAGEMENT IN UGANDA

Asadu Sserwanga<sup>1</sup>, Ruth Kigozi<sup>1</sup>, Hasifa Bukirwa<sup>1</sup>, Stella Kakeeto<sup>1</sup>, Anne Gasasira<sup>1</sup>, Manoj Menon<sup>2</sup>, Sussann Nasr<sup>2</sup>, Scott Filler<sup>2</sup>, Jamal Harris<sup>3</sup>, Grant Dorsey<sup>3</sup>, Ebony Quinto<sup>4</sup>, Moses Kanya<sup>5</sup>

<sup>1</sup>Uganda Malaria Surveillance Project, Kampala, Uganda, <sup>2</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States, <sup>3</sup>University of California at San Francisco, San Francisco, CA, United States, <sup>4</sup>Ministry of Health, Kampala, Uganda, <sup>5</sup>Makerere University College of Health Sciences, Kampala, Uganda

Malaria surveillance is critical for monitoring trends in malaria morbidity and mortality, but can also be used as a tool for improving case management. The WHO now recommends ACTs for the treatment of uncomplicated *falciparum* malaria along with prompt laboratory confirmation in all patients suspected of malaria before treatment is started. From August 2006 - January 2007 we implemented a sentinel site malaria surveillance system at the outpatient departments of 5 government health centers in Uganda with a 6th site added in September 2008. This system was established by the Uganda Malaria Surveillance Project in collaboration with the Ministry of Health and Health Management Information System. Individual patient data is entered electronically onsite using a standardized case record form and sent monthly to a core facility using cellular technology. Through February 2010, a total of 397,407 patients were seen of which 54% (range 47-63% at the 6 sites) were suspected of having malaria. We compared data from the first two months of surveillance with data from the most recent two months (Jan-Feb 2010) to evaluate key indicators in malaria case management. The proportion of patients with suspected malaria for whom a laboratory test was done increased from 44% (range 32-64%) to 97% (range 93-99%). The proportion of patients with a laboratory test done who were appropriately prescribed an antimalarial drug (negative test not prescribed an antimalarial, positive test prescribed an antimalarial) increased from 64% (range 51-78%) to 94% (range 87-98%). The proportion of patients with a positive laboratory test who were prescribed an ACT increased from 50% (35-88%) to 74% (35-91%), although these results were highly variable across the sites. The implementation of sentinel site malaria surveillance system in the context of the existing government system was associated with dramatic improvements in utilization of laboratory services and rationale antimalarial treatment decision making. However, further improvement is needed in ACT prescribing practices.

## 1209

### MATERNAL AND PLACENTAL MALARIA AND LOW BIRTH WEIGHT AFTER INTRODUCTION OF INTERMITTENT PREVENTIVE TREATMENT PROGRAM USING SULFADOXINE-PYRIMETHAMINE IN PREGNANT WOMEN IN BAMAKO, MALI, WEST AFRICA

Mahamadou Diakite, Aminata Famanta, Seidina A. Diakité, Sory Ibrahim Diawara, Saibou Doumbia, Karim Traoré, Drissa S. Konaté, Mory Doumbia, Abdoul Salam Keita, Daouda Thiéro, Sékou Fantamady Traoré, Seydou Doumbia

University of Bamako, Bamako, Mali

In 2006, the Malian government established a program for free insecticide-treated net (ITNs) and intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) for pregnant women. In March to November of 2009, we conducted a cross-sectional study in periurban areas of Bamako, Mali to determine the malaria prevalence among pregnant women and their newborn children. We included 379 pregnant women aged 15 to 45 years. At delivery, malaria was diagnosed using peripheral thick smears in mothers and newborns, as well as



umbilical cord blood and placental blood. The prevalence of *P. falciparum* malaria was 2.4%, 1.6% and 0.5% respectively in mother, placenta and cord samples. Approximately 77% of our parturient were housewives. The illiteracy rate among this group was 72.3%. Of the 379 women, 72.8% had at least three prenatal visits, 82.8% had received at least one free ITNs, and 71.8% had received IPTp-SP during antenatal visit. Among them, 80.7% claimed to have complied with IPTp-SP. We observed a low birth weight rate of 12.1%. We did not find any congenital malaria. The prevalence of malaria in both mother and newborn has show a significant decrease in Bamako, compared with previous studies before the implementation of IPTp-SP policy in Mali. This study shows a high rate of coverage in use of IPTp-SP and ITNs correlated with low malaria prevalence in pregnant women.

## 1210

### MALARIA RESURGENCE IN WESTERN KENYA IN THE ERA OF MALARIA INTERVENTIONS

**Guofa Zhou**<sup>1</sup>, Yaw A. Afrane<sup>2</sup>, Anne M. Vardo-Zalik<sup>1</sup>, Guiyun Yan<sup>1</sup>

<sup>1</sup>University of California at Irvine, Irvine, CA, United States, <sup>2</sup>ICIPE, Nairobi, Kenya

Despite significant increases in the supply of mosquito bednets since 2006, the link between interventions and their impact is not always clear in malaria endemic south Sahara Africa. To monitor the impacts of insecticide treated bed nets on malaria prevalence and mosquito density, we conducted monthly surveys in three sites in Western Kenya beginning in January 2007. Our results illustrate a resurgence of malaria in all three of our study sites (2 highland and one lowland) after an initial decline in 2006. Despite a high household bed net coverage rate of 50-80%, asymptomatic malaria prevalence and mosquito density have increased in all study sites since 2007, with an approximate 4-10 fold increase in *Anopheles funestus* and *An. gambiae* densities. Upon examination of households that used bednets, the majority of nets were in good condition, but only 60% were regularly used. Additionally, almost half of the bed nets were 4 or more years old, so their efficacy was waning. We also found a decrease in the prescription of ACT to treat malaria cases, even though ACT is the most effective drug at the moment. The increase in malaria prevalence and vector densities suggests that the current control methods are not sufficient and that future control effort should include a more intensive distribution of long-lasting insecticidal nets and the provisions for a sustainable supply of effective antimalarial drugs.

## 1211

### SIGNIFICANT DECREASE IN ANEMIA IN AREAS OF VERY LOW MALARIA TRANSMISSION AFTER INTERRUPTION OF TRANSMISSION

**Gregory S. Noland**<sup>1</sup>, George Ayodo<sup>1</sup>, James S. Hodges<sup>2</sup>, John M. Vulule<sup>3</sup>, Chandry C. John<sup>1</sup>

<sup>1</sup>Center for Global Pediatrics, University of Minnesota Medical School, Minneapolis, MN, United States, <sup>2</sup>Department of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, United States, <sup>3</sup>Kenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya

The potential effect of malaria control measures on prevalence of anemia in areas of low and unstable malaria transmission has not been well characterized. In the adjoining highland areas of Kapsisiywa and Kipsamoite, Kenya, areas of low and unstable malaria transmission, we assessed hemoglobin levels and frequency of anemia in a cohort of randomly selected asymptomatic individuals in May 2007 and July 2008 (Kapsisiywa, n=910, Kipsamoite, n=787). Widespread indoor residual spraying of insecticide led to a 12-month interruption of malaria transmission in both areas starting in April 2007, and none of the individuals in the cohort had clinical malaria between May 2007 and July 2008. In May 2007, anemia was common in both sites, with 57.5%,

21.7% and 22.7% prevalence in Kapsisiywa for individuals <5 years, 5-14 years and >15 years of age, respectively, and 47.2%, 19.3% and 17.5% prevalence in Kipsamoite for individuals <5 years, 5-14 years and >15 years of age, respectively. Fourteen months later, malaria interruption was associated with significant increases in hemoglobin levels and consequent decreases in the prevalence of anemia for individuals in Kapsisiywa <5 years of age (34.1% reduction of anemia,  $P<0.0001$ ), 5-14 years of age (51.6%,  $P<0.0001$ ) and >15 years of age (26.9%,  $P=0.004$ ), and in Kipsamoite for individuals <5 years of age (33.7%,  $P=0.001$ ). Insecticide treated net (ITN) use was infrequent in both sites (16.8% in Kapsisiywa, 11.3% in Kipsamoite), and was associated with an increase in hemoglobin level only in pregnant women. Even in areas of very low malaria transmission, anemia occurs frequently, particularly in children. Reduction or interruption of malaria transmission in these low transmission areas is associated with highly significant decreases in the prevalence of anemia.

## 1212

### INTERMITTENT PREVENTIVE THERAPY IN THE POST-DISCHARGE MANAGEMENT OF SEVERE MALARIAL ANAEMIA IN PRE-SCHOOL CHILDREN; A MULTI-CENTRE RANDOMIZED PLACEBO CONTROLLED TRIAL IN SOUTHERN MALAWI

**Kamija Phiri**<sup>1</sup>, Michael Esan<sup>2</sup>, Michael Boele van Hensbroek<sup>3</sup>, Brian Faragher<sup>4</sup>, Sarah White<sup>1</sup>, Feiko O. ter Kuile<sup>4</sup>

<sup>1</sup>Malawi-Liverpool Wellcome Trust Research Programme and Haematology Department, College of Medicine, Blantyre, Malawi, <sup>2</sup>Malawi-Liverpool Wellcome Trust Research Programme, Blantyre, Malawi, <sup>3</sup>Global Child Health Group, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, <sup>4</sup>Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Despite adequate in-hospital treatment with blood transfusions and antimalarials, young children admitted with severe malarial anaemia in malaria endemic regions in southern Malawi and western Kenya are at high risk of dying or being re-admitted in the first few months after discharge. They may represent a particularly vulnerable group due to a combination of parasite, host, environmental and socio-behavioural factors. In highly endemic areas, failure to clear the initial malaria infection and the acquisition of new infections in the first few months after discharge may negate the initial improvements in haemoglobin concentrations resulting from the blood transfusion. Interventions that result in radical cure of the initial infection and prevention of subsequent malaria episodes will provide a time-window in which the bone marrow can recover to restore haemoglobin levels. We have completed a randomized placebo controlled trial of the efficacy and safety of Intermittent Preventive Therapy post-discharge (IPTpd) in children aged 4-59 months admitted for severe malarial anaemia requiring blood transfusion in 4 hospitals in southern Malawi. Convalescent children who had successfully received a blood transfusion and quinine were randomized to receive either 3 treatment courses of artemether-lumefantrine given at discharge, and again at 1 and 2 months post-discharge, or a single treatment course of AL at discharge followed by placebo at 1 and 2 months. Children were followed for a total of 6 months to compare the rates of rebound severe malaria, severe anaemia, or death 1-3 months after discharge (the intervention period) and during the subsequent 3 months. Between June 2006 and Aug 2009, 1435 children aged 4-59 months were recruited from the Queens Elizabeth Central Hospital in Blantyre and 3 adjacent district hospitals within 1 hour drive from Blantyre; over 90% were followed-up successfully. Analysis is ongoing and study results will be presented.

## 1213

**THE IMPACT OF INSECTICIDE-TREATED NETS ON ACQUIRED HUMORAL IMMUNITY TO *PLASMODIUM FALCIPARUM***

Sandra Chishimba<sup>1</sup>, Tamaki Kobayashi<sup>2</sup>, Musapa Mulenga<sup>1</sup>, Masiliso Phiri<sup>1</sup>, Sungano Mharakurwa<sup>1</sup>, Philip Thuma<sup>1</sup>, William J. Moss<sup>2</sup>

<sup>1</sup>Malaria Institute at Macha, Choma, Zambia, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States

Acquisition of immunity to malaria is attributed to frequent exposure to the parasite. Lack of exposure can result in loss of immunity, leaving individuals at higher risk for severe disease and death. Intensified malaria control interventions have played a major role in reducing malaria incidence and mortality. An important intervention has been the mass distribution of long-lasting, insecticide-treated bed nets (LLINs). Following implementation of these effective control programs, population immunity is expected to decrease. It is, therefore, important to monitor population immunity to measure the impact of control measures and anticipate future epidemics upon reintroduction of the parasite and vector. We investigated the relationship between the distribution of insecticide-treated bed nets and acquired humoral immunity to *Plasmodium falciparum* in a low malaria transmission area of Macha, Southern Province, Zambia one year after the widespread distribution of LLINs. IgG antibody levels were measured using an enzyme immunoassay against whole, asexual stage *P. falciparum* antigens derived from NF54 strain schizont cell lysate. Seropositivity was defined as an optical density value > 0.57 based on the mean plus three standard deviations from 10 individuals never exposed to malaria. Plasma was extracted from whole blood samples stored as dried blood spots. Samples were collected between March and November 2008 from 313 individuals residing in randomly-selected households in southern Zambia. 56.5% of the study participants were seropositive for antibodies to whole *P. falciparum* antigens. 31% of seropositive individuals reported sleeping under a bed net, compared with 39% of seronegative individuals. Within one year of introducing LLINs for malaria control in southern Zambia, we found no significant reduction in seropositivity to whole *P. falciparum* antigens in those who reported sleeping under a bed net compared to those who did not. Further monitoring of changes in population immunity to malaria is warranted in regions implementing accelerated control efforts.

## 1214

**A SURVEILLANCE SYSTEM TO MEASURE CHILDHOOD MORTALITY AND DRUG RELATED ADVERSE EVENTS IN THREE DISTRICTS IN SENEGAL**

BA K. Elhadji<sup>1</sup>, J.L. Ndiaye<sup>2</sup>, C. Sokhna<sup>1</sup>, B. Cisse<sup>2</sup>, J.F. Gomis<sup>1</sup>, A. Marra<sup>1</sup>, E. Faye<sup>2</sup>, B. Faye<sup>2</sup>, O. Faye<sup>2</sup>, B.M. Greenwood<sup>3</sup>, J.F. Trape<sup>1</sup>, O. Gaye<sup>2</sup>, P.J.M. Milligan<sup>3</sup>

<sup>1</sup>IRD Institut de Recherche pour le Developpement, Dakar, Senegal, <sup>2</sup>Universite Cheikh Anta Diop de Dakar, Dakar, Senegal, <sup>3</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom

A simplified Demographic Surveillance System (DSS) was established in three health districts in Senegal to measure childhood mortality and for monitoring the incidence of serious adverse events in an area where seasonal IPTc is being implemented. The DSS covers a population of 602,000 people living in rural and semi-urban communities served by 54 health posts in three districts, and includes the area of the long-standing Niakhar DSS. Births deaths and migrations, ITN use and hospitalizations are recorded in 6-monthly household rounds. Verbal autopsies are performed on all deaths in the population served by 12 of the health posts. Mothers of children under 10 years are issued with a DSS card bearing details of all the children in their care. This card is used to record any health interventions delivered at village level including malaria IPT, and to confirm child identity when the child visits a health facility. Incidence of malaria confirmed by rapid diagnostic test was recorded by passive case detection at health facilities. A cluster sample survey of the under-5

population was done at the end of the transmission season to estimate the prevalence of malaria parasitaemia and anaemia. In 2008 there was no evidence of the seasonal peak in deaths from September to November which was characteristic of the pattern of mortality in previous years. A dramatic reduction in under-5 mortality observed in the population maintained under long term surveillance in the Niakhar DSS is borne out in the much larger area covered by the new surveillance system. Incidence of malaria among children <5yrs was less than 1 per 1000. The prevalence of *P. falciparum* parasitaemia at the end of the 2008 transmission season was less than 4%. Very low incidence of malaria in 2008 was associated with substantial improvement in child survival and disappearance of the usual seasonal peak in under 5 deaths associated with malaria transmission, in a large rural population not previously kept under demographic surveillance.

## 1215

**NOVEL MEMBRANE-ASSOCIATED PROTEIN KINASES IN TRYPANOSOMES**

Bryan C. Jensen<sup>1</sup>, John A. Flaspohler<sup>2</sup>, Marilyn Parsons<sup>1</sup>

<sup>1</sup>Seattle Biomedical Research Institute, Seattle, WA, United States, <sup>2</sup>Concordia College, Moorhead, MN, United States

Protein kinases modulate cellular responses to signals from the environment or from within the cell. Their ATP binding pocket renders them sensitive to small molecule inhibitors, making kinases attractive drug targets. *Trypanosoma brucei* possesses over 150 protein kinases; less than one-fourth of these have been studied in any detail. We have identified nine kinases that bear predicted transmembrane domains and hence could function to regulate processes spanning compartments within the parasite or between the parasite and its external environment. The presence of multiple transmembrane domains in the predicted structures of these kinases is unprecedented, indicating a novel means of signal transduction between the putative sensing and catalytic domains. Surprisingly, these kinases are localized to diverse structures within the parasite, indicating that they have varied cellular functions. One modulates the biogenesis of lipid bodies, organelles than function in intracellular lipid homeostasis. Two kinases localize to the secretory system, although these kinases do not resemble host cell ER kinases. Several of the kinases appear to be essential for bloodstream form viability, suggesting their potential use as drug targets.

## 1216

**T CELL RESPONSES IN INDIVIDUALS WITH DISCORDANT TRYPANOSOMA CRUZI SEROLOGY**

Diana Martin<sup>1</sup>, Gerson Galdos-Cardenas<sup>2</sup>, Michael Z. Levy<sup>3</sup>, Brook Goodhew<sup>1</sup>, Jenny Ancca<sup>4</sup>, Cesar Naquira<sup>4</sup>, Manuela Verastegui<sup>5</sup>, Patricia Escalante-Mejia<sup>4</sup>, Michelle Kaplinski<sup>6</sup>, Katty Borini<sup>4</sup>, Juan G. Cornejo del Carpio<sup>7</sup>, Cesar Bocangel, Jr.<sup>6</sup>, Cesar Bocangel, Sr.<sup>7</sup>, Caryn Bern<sup>1</sup>, Robert Gilman<sup>2</sup>

<sup>1</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States, <sup>2</sup>Johns Hopkins University, Baltimore, MD, United States, <sup>3</sup>University of Pennsylvania, Philadelphia, PA, United States, <sup>4</sup>Universidad Peruana Cayetano Heredia, Arequipa, Peru, <sup>5</sup>Universidad Peruana Cayetano, Lima, Peru, <sup>6</sup>PRISMA, Arequipa, Peru, <sup>7</sup>Oficina regional del Ministerio de Salud, Arequipa, Peru

Chagas disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a major cause of morbidity and mortality in Central and South America. Serological diagnosis of *T. cruzi* infection requires positive testing on two of three independent immunoassays. Geographic variations in the concordance of these diagnostic assays suggest that local parasite strain diversity may play a role in the strength of the anti-*T. cruzi* antibody response. Peru in particular has a high rate of discordant serology. To determine whether T cell responses could be used as a surrogate diagnosis in individuals with discordant serology, IFN $\gamma$  production from peripheral blood mononuclear cells were stimulated with *T. cruzi* antigen was measured by ELISPOT assay. The studies were conducted in the



city of Arequipa and the town of LaJoya in the Peruvian Andes. Of the 103 subjects enrolled, 24 were seronegative, 53 were concordant by conventional serology ("seropositive"), and 26 were discordant by conventional serology ("discordant"). Peripheral blood mononuclear cells were stimulated with five different strains of *T. cruzi* - a laboratory strain (Brazil), two strains isolated from LaJoya, and two isolated from Bolivia - in order to determine if patients responded differently to parasites isolated from distinct geographic regions. Seronegative patients did not respond to the *T. cruzi* antigen. In the discordant and seropositive groups, the percent producing IFN $\gamma$  in response to antigen stimulation was similar (approximately 67% in each group), and the frequency of IFN $\gamma$ -producing cells was not statistically different in the discordant (mean = 39.7 spot-forming units/400,000 cells) and seropositive groups (mean = 42.7). Similar frequencies of IFN $\gamma$  producing cells were detected regardless of the stimulating parasite strain, although responses were slightly lower in response to the Brazil strain. These data suggest that patients with discordant serology are likely infected with *T. cruzi* and that T cell responses may have utility as diagnostic tools in instances of inconclusive serology.

## 1217

### ROLE OF HLA CLASS-II ALLELES (HLA DR AND DQ) IN PROTECTION/SUSCEPTIBILITY TO VISCERAL LEISHMANIASIS IN SUDAN

**Mona E. Elfaki**<sup>1</sup>, Eltahir A. Khalil<sup>1</sup>, Ahmed M. Musa<sup>1</sup>, Brima M. Younis<sup>1</sup>, Ahmed M. El-Hassan<sup>1</sup>, Kerstin Muller<sup>2</sup>, Rainer Blasczyk<sup>2</sup>  
<sup>1</sup>Institute of Endemic Diseases/University of Khartoum, Khartoum, Sudan,  
<sup>2</sup>Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany

The antigen-presenting molecules of the HLA class-II (DR, DQ and DP) have a possible role in the susceptibility to autoimmune and infectious diseases. In this study the possible role of these alleles in susceptibility/protection against visceral leishmaniasis (VL), a potentially fatal parasitic disease was investigated. Following informed consent, fifty four individuals with parasitologically confirmed history of VL together with forty individuals with no history of VL were enrolled. The volunteers were mostly from the Masalit (Nilo-Saharan; Zurga) and the Fellata (Bargo/Maba/Wadians) tribes of eastern Sudan. Genomic DNA was extracted from peripheral blood mononuclear cells and buccal wash deposit using the Phenol-Chloroform Isoamyl technique. The HLA-Class II alleles were identified using high resolution PCR-Sequencing Based Typing (PCR-SBT) technique. The DRB1\*1101 allele was detected in 28.6% of patients with VL and in 17.7% of those in those with no history of VL ( $p=0.5$ ). DRB1\*1001-DQA1\*0501-DQB1\*0501/DRB1\*1001-DQA1\*0102-DQB1\*0501 haplotypes were detected with highly significant frequencies in individuals who contracted VL compared to those who did not ( $p=0.01$ - $p=0.00012$  respectively). On the otherhand DRB1\*0804-DQA1\*0101 haplotype was significantly more predominant in individuals who did not develop the disease compared to those who did ( $p=0.000000$ ). In conclusion: the DRB1\*0804-DQA1\*0101 haplotype is a probable protection haplotype, while DRB1\*1001-DQA1\*0501-DQB1\*0501/DRB1\*1001-DQA1\*0102-DQB1\*0501 haplotypes are probable susceptibility haplotypes for visceral leishmaniasis in the some ethnic groups of Sudan. Study findings could be helpful in peptide vaccine development for VL.

## 1218

### LEISHMANIA MEXICANA INFECTED PHEBOTOMUS YUCATNICUS: NO PRODUCTION BY LYMPHOCYTES-MACROPHAGES

**Fernando J. Andrade-Narvaez**, Ely N. Loria-Cervera, Liliana E. Villanueva-Lizama, Erika I. Sosa-Bibiano, Nicole R. Van Wynsberghe

Universidad Autonoma de Yucatan, Merida, Yucatan, Mexico

The Yucatan peninsula of Mexico is a well known endemic area of cutaneous leishmaniasis (CL) caused predominantly by *Leishmania (Leishmania) mexicana*. Studies of CL in the murine model (C57BL/6 infected with *L. major*) have documented the nitric oxide (NO) role in the elimination of the parasite through the classical macrophage activation by IFN- $\gamma$  produced by CD4 Th1 lymphocytes. *Phebotomus yucatanicus* a primary reservoir of *L. mexicana* has been adapted to captivity and a colony for experimental studies has been developed. The main purpose was to compare NO production between cocultured macrophages and lymphocytes from *P. yucatanicus* infected with *L. mexicana* stimulated with or without SLA with and macrophages alone. Group A was inoculated with 1x10<sup>2</sup> promastigotes of *L. mexicana*; group B with 2.5x10<sup>6</sup> promastigotes; and group C inoculated with RPMI (n=14, per group). They were followed-up for 12 weeks to register clinical signs. At the end they were sacrificed to determine indirect nitrite oxide production employing Griess reaction. No one of the group A (subclinical) develops signs of CL, whereas in 13/14 (92.9%) of Group B show signs of CL. Nitrite oxide production was significative higher ( $p<0.05$ ) in both Groups A and B (co-cultured lymphocytes and macrophages with or without SLA). Results support the employment of *P. yucatanicus* as a new experimental model to study CL.

## 1219

### CHARACTERIZATION OF UNKNOWN PREDICTED GPI ANCHORED PROTEINS IN TRYPANOSOMA BRUCEI BRUCEI

**Amy F. Savage**<sup>1</sup>, Gustavo C. Cerqueira<sup>2</sup>, Yineng Wu<sup>1</sup>, Sandesh Regmi<sup>1</sup>, Najib El Sayed<sup>2</sup>, Serap Aksoy<sup>1</sup>

<sup>1</sup>Yale University, New Haven, CT, United States, <sup>2</sup>University of Maryland, College Park, MD, United States

African trypanosomes of the *Trypanosoma brucei* complex undergo several differentiation steps during development in the tsetse fly, including differentiation to the procyclic form in the fly midgut, epimastigote forms in the proventriculus, and ultimately to mammalian infective metacyclic trypomastigotes in the salivary glands. Finally, metacyclics develop into the bloodstream form in the mammalian host. An in-silico screen of the *T. brucei* genome yielded 111 unknown proteins containing glycosylphosphatidylinositol (GPI) anchor structures. GPI anchors typically bind proteins to cell membranes and as such, these hypothetical proteins may be expressed on the parasite cell surface. To determine if these unknown genes were preferentially expressed in particular developmental stages, expression analysis was performed on parasite infected salivary glands, proventriculus, and midguts, as well as bloodstream parasites. cDNAs were prepared, normalized, and expression levels were tested with gene-specific primers using a semi-quantitative assay. This revealed that the majority (66%) of the unknown genes were expressed in parasite stages infecting the proventriculus or salivary glands. Results were validated using quantitative PCR analysis. Twenty-one genes were determined to be specifically expressed in the salivary glands, and 15 of these were found to be expressed in the mammalian infective metacyclic form collected from tsetse saliva. A few of these genes were selected for further characterization at the RNA and protein level. Antibodies to the recombinant protein corresponding to one of these gene products have been used to demonstrate the expression profile of this protein in the both the immature (attached) salivary gland stages and free metacyclics. These

data can identify novel targets for blocking trypanosome transmission, and increase our broader understanding of this complex host-parasite interaction.

## 1220

### INCREASED INTERFERON- $\gamma$ LEVELS OCCUR IN THE CEREBRAL SPINAL FLUID DURING THE CHRONIC PHASE OF *TRYPANOSOMA BRUCEI BRUCEI* INFECTION IN CATTLE

**Monica Namayanja**<sup>1</sup>, Rosemary Flores<sup>2</sup>, Ann Nanteza<sup>1</sup>, Zachariah Nsadhah<sup>1</sup>, Sam Eyanu<sup>1</sup>, Roger Prichard<sup>3</sup>, Elisabeth Knapp<sup>2</sup>, Vidadi Yusibov<sup>2</sup>, George W. Lubega<sup>1</sup>

<sup>1</sup>Department for Veterinary Parasitology and Microbiology, Makerere University, Kampala, Uganda, <sup>2</sup>Fraunhofer USA Inc., Center for Molecular Biotechnology, Newark, DE, United States, <sup>3</sup>Institute of Parasitology, McGill University, Montreal, QC, Canada

*Trypanosoma brucei brucei*, one of the causative agents of nagana in animals, is a tissue invasive parasite. Monitoring of *T.b.brucei* infection in cattle is hampered by the lack of a clear parameter or marker that correlates with disease severity. In turn, this has made it difficult to measure benefits of disease intervention efforts such as immunization. *T.b.brucei* infection in cattle appears to mimic sleeping sickness in humans whereby it occurs in two phases, an acute or early phase where trypanosomes are readily seen in blood and a chronic or late phase where trypanosomes remain in tissues including the brain. In humans interferon gamma (IFN- $\gamma$ ) has been shown to be up-regulated in the cerebral spinal fluid (CSF) during the second stage of the disease and has been proposed as one of the markers of disease severity. However, the pathophysiological role of this cytokine in cattle has not yet been investigated. To substantiate this role, we carried out an experimental cattle infection under controlled indoor conditions. We analyzed the (IFN- $\gamma$ ) levels in the CSF during the acute phase and chronic phase and found that IFN- $\gamma$  levels were elevated during the chronic phase of the disease. In addition to this, the levels of IFN- $\gamma$  in the CSF were proportional to the dose used to initiate the infection. These data suggest that brain involvement plays a major part in the pathogenesis of *T.b.brucei* infection and IFN- $\gamma$  is a marker for disease severity in cattle as has been proposed in humans

## 1221

### DEVELOPMENT AND *IN VIVO* TESTING OF AN EFFECTIVE NOVEL DELIVERY VEHICLE FOR HETEROLOGOUS PROTEINS TO BOVINE ANIMALS

**Glenn A. Mott**<sup>1</sup>, Ray Wilson<sup>1</sup>, Anu Fernando<sup>1</sup>, Dick Schaap<sup>2</sup>, Theo Schetters<sup>2</sup>, Jacqueline Matthews<sup>1</sup>, Keith Matthews<sup>1</sup>

<sup>1</sup>University of Edinburgh, Edinburgh, United Kingdom, <sup>2</sup>Intervet Schering Plough Animal Health, Boxmeer, The Netherlands

We have developed a novel protozoan vehicle for the expression and delivery of heterologous proteins to bovines. Conditions for growth of the vehicle in a cell-free culture system have been developed and expression constructs engineered which permit the stable expression of a range of vaccine candidates or other proteins. These have been stably introduced and successfully expressed in the delivery vehicle, generating significant levels of the expressed protein. To evaluate the delivery-vehicle *in vivo*, the expression and immunogenicity of a known protective vaccine candidate against *Babesia divergens* has been evaluated. Inoculation in cattle resulted in the rapid establishment and stable maintenance of the vehicle over 9 weeks, without any adverse consequence for cattle welfare. Monitoring of the reactivity of the sero-response of the inoculated cattle by quantitative ELISA analysis demonstrated that specific antibodies to the delivered antigen were generated which progressively increased over time, achieving antibody titres known to be in the protective range. This novel delivery system offers potential as a flexible system, for example, for the generation of protective immune responses in cattle to a wide range of potential pathogens.

## 1222

### COMPARATIVE GENOMIC HYBRIDISATION OF PHENOTYPICALLY DISTINCT *SCHISTOSOMA JAPONICUM* GEOGRAPHICAL ISOLATES

**Geoffrey N. Gobert**

Queensland Institute of Medical Research, Brisbane, Australia

Geographical isolates of *Schistosoma japonicum* from China and the Philippines exhibit a number of morphological and phenotypic differences, including pre-patent period, tegument topography, adult worm size, virulence and the subspecies of snail intermediate host infected. However, major genotypic differences have yet to be identified between the two strains. To address this deficit we have utilised microarray analysis to identify copy number variations within the genome of the two *S. japonicum* strains.

We have designed a *Schistosoma japonicum* custom microarray using EST data to examine 14,171 contigs. Since we intended to use the microarray to probe gDNA instead of mRNA, each probe was checked for relative specificity against the *S. japonicum* (Chinese) genomic supercontig assembly. We identified 8,310 microarray probes (of the total 14,171) with greater than 95% homology to only one region of the genome. This sub-group of probes present a high degree of specificity to the genome, since 60mer oligonucleotide probes with lower homology to the target sequence are known to result in significantly lower hybridisation efficiencies. The microarray platform was used to comparatively hybridise genomic DNA from Chinese mainland strain, and Philippine strain *S. japonicum*, in two colour experiments. Genomic DNAs from separate adult female or male parasites were used for comparison. We identified 306 contigs with differential hybridisation between the two *S. japonicum* isolates in both male and female parasites, which may represent a copy number difference. Validation and further characterisation of a subset of differentially hybridised genome regions is currently underway. It is hoped that these new data will provide insights into key aspects of the biology of this important human pathogen.

## 1223

### GENETIC DIFFERENTIATION OF *SCHISTOSOMA MANSONI* LABORATORY POPULATIONS

**Walter A. Blank**<sup>1</sup>, Matthew R. Test<sup>1</sup>, Shi Fan Liu<sup>1</sup>, Fred A. Lewis<sup>2</sup>, Ronald E. Blanton<sup>1</sup>

<sup>1</sup>Case Western Reserve University, Cleveland, OH, United States,

<sup>2</sup>Biomedical Research Institute, Rockville, MD, United States

Changes in the composition of schistosome populations under differing environmental conditions, in differing hosts, and between developmental stages can be studied in parasite lab strains. A longitudinal study was performed with archived samples collected over 16 years from a population of *Schistosoma mansoni* maintained at CWRU and samples collected over 9 years from a related strain at the Biomedical Research Institute (BRI). Pooled samples of worms or cercariae were genotyped to obtain allele frequencies at 14 microsatellite loci and analyzed for the genetic differentiation measure *D*. Low levels of differentiation (first sample vs. other samples,  $D < 0.05$ ) were observed throughout the period examined for the BRI strain and for most of the CWRU samplings, with the exception of two time periods. The first was the result of an admixture event when the CWRU life cycle was supplemented with cercariae from an external source (first sample vs. pre-mixture,  $D = 0.07$ , vs. post-mixture,  $D = 0.13$ ). The BRI strain was shown to be the external source (pre-mixture CWRU vs. BRI,  $D = 0.35$ ;  $D = 0.07$  post-mixture). The second event was a reduction in the number of mice used to maintain the CWRU life cycle, which increased genetic drift (prior to reduction mean *D* per generation = 0.002; 0.014 after reduction). To investigate how immunological background of the host influences differentiation, mice from 4 strains (C57, CF1, BALB/c, and BALB/c IFNg KO) which had been previously infected with *S. mansoni* were reinfected. Worms were

perfused, pooled by host strain, and genotyped. Negligible differentiation (mean  $D < 0.01$ ) was seen between host strains. Very low differentiation was also observed between all life cycle stages in previously uninfected CF1 mice (for cercariae vs. worms, cercariae vs. eggs, and worms vs. eggs mean  $D < 0.01$ ). Although the laboratory is a simpler and more controlled environment, these studies demonstrate the potential for monitoring the dynamics of field populations.

## 1224

### PHYSICAL CONTACT MODULATES LARGE-SCALE GENE EXPRESSION IN *SCHISTOSOMA MANSONI* ADULT MALES AND FEMALES

Giulliana T. Almeida, Sergio Verjovski-Almeida

Departamento de Bioquímica, Instituto de Química Universidade de São Paulo, Sao Paulo - SP, Brazil

A continuous pairing with male is essential for *Schistosoma mansoni* female sexual maturation and to maintain reproductive activity and egg production. Our aim was to identify genes that are modulated by either physical contact or by the possible diffusion of proteins and/or hormones in the medium. Males and females from mixed infections were recovered by perfusion and triplicates of adult worms were maintained *in vitro* at 5 different culture conditions during 13 days (paired, separated males or females isolated from the opposite sex, females kept in the presence of males without physical contact, and couples remated for 7 days after separation for 6 days). We used oligonucleotide microarrays with ~44,000 probes. Statistical multiclass analysis of female data (paired, separated, females in the presence of male, and remated females) identified 1010 differentially expressed genes (FDR = 0.01%). This analysis revealed that remating restored gene expression profile of separate females to a similar profile as that of paired females. Furthermore, we observed that females in the presence of males, without physical contact showed a different gene expression from that of females in the absence of males. Statistical multiclass analysis of male data (paired, separated and remated males) identified 277 differentially expressed genes (FDR 1%). Males' gene expression was modulated by direct contact with females in paired couples, since paired male expression profile was significantly different from that of isolated males. Remating of separated males led to a gene expression profile similar to that of paired males. These results provide strong evidence for the influence of physical contact on large-scale gene expression of male and female adult worms. They also show that some genes, for which the change in expression does depend on the presence but not on direct contact between male and female, are possibly regulated by the diffusion of proteins and/or hormones released by the parasites in the medium.

## 1225

### CHARACTERIZATION AND FUNCTIONAL ANALYSIS OF *SCHISTOSOMA MANSONI* U6 PROMOTER

Mary A. Ayuk<sup>1</sup>, Sutas Suttiprapa<sup>2</sup>, Gabriel Rinaldi<sup>2</sup>, Victoria H. Mann<sup>2</sup>, Clarence M. Lee<sup>1</sup>, Paul J. Brindley<sup>2</sup>

<sup>1</sup>Howard University, Washington, DC, United States, <sup>2</sup>The George Washington University, Washington, DC, United States

The recent release of draft genome sequences of two of the major human schistosomes has underscored the pressing need to develop functional genomics approaches for these significant pathogens. The use of small interfering RNA (siRNA) molecules to achieve double stranded RNA-mediated interference (RNAi) has emerged as a powerful approach to sequence-specific gene knockdown. Vector based methods using siRNA expressing plasmid are used to induce RNAi in cells of eukaryotes and provide a long-term knockdown effect. We are developing vector based RNAi in *Schistosoma mansoni* using the U6 promoter to drive short hairpin RNA targeting reporter firefly luciferase. An upstream region of the U6 snRNA gene predicted to contain the U6 promoter was amplified from genomic DNA of *S. mansoni*, cloned and sequenced. A short hairpin RNA

construct driven by U6 promoter targeting luciferase was engineered and cloned into pXL-Bac II (a *piggyBac* transposon donor construct). One day after mechanical transformation from cercariae, schistosomules of *S. mansoni* were exposed to the short hairpin construct by square wave electroporation. Short interfering RNAs (siRNA) specific for luciferase and a scrambled sequence short hairpin construct were used as positive and negative controls, respectively. 48h after exposure to short hairpin RNA constructs, schistosomules were electroporated with luciferase mRNA, harvested 3 hours later, and luciferase activity assayed. Short hairpin driven by *S. mansoni* U6 successfully knocked down luciferase activity by 20 to 50%. We are now transferring this technique to knock down endogenous genes in *S. mansoni* and to establish retrovirus and transposon based vector RNAi in transgenic schistosomes.

## 1226

### TRANSCRIPTOMAL ANALYSES OF *SCHISTOSOMA MANSONI* PR1 TREATED WITH PRAZIQUANTEL

Jarrett Hines, Pauline M. Cupit, Anthony D. Aragon, Charles Cunningham

University of New Mexico, Albuquerque, NM, United States

*Schistosoma mansoni* is one of the most common etiological agents of human schistosomiasis and is estimated to infect more than 83 million people in 54 countries. Praziquantel (PZQ) is the least expensive, easiest to use and most readily available of all current anti-schistosomal drugs. One problem associated with PZQ treatment is that it does not kill schistosomes for a period of 2-4 weeks after they infect the human host. A second potential problem is the presence of drug resistance traits in natural populations of worms. As a result there is an urgent need to develop a new generation of anti-schistosomal drugs, a task that will be made easier by understanding the mechanism of action of PZQ. As yet, neither the molecule to which PZQ binds nor the means by which it kills mature schistosomes is known. The overarching aim of our study is to understand the molecular basis of PZQ sensitivity in *S. mansoni*. We hypothesize that PZQ sensitivity is a reflection of the differential expression of a gene that encodes either the PZQ binding partner or a downstream component of a biochemical pathway whose activity is influenced by PZQ binding to its partner molecule. Four and six week post infection (p.i.) *S. mansoni* PR1 have been treated *in vitro* with multiple sub-lethal as well as lethal doses of praziquantel. mRNA was extracted from replicate samples, cRNA prepared and labeled with Cy5 for transcriptomal analysis using a 44K *S. mansoni* microarray. All samples were compared against a common reference sample labeled with Cy3. Our initial analyses suggests that a number of genes associated with programmed cell death including cathepsins, Bax Interacting Factor 1 and death associated protein kinase (DAPK) are induced in 6 week (p.i.) praziquantel treated but not untreated schistosomes. DAPK has also been implicated in the phosphorylation of myosin light chains which has been reported to lead to vacuolation of cells and membrane blebbing - an often observed effect of PZQ on the mature but not juvenile worm tegument that may provide a more direct route to worm death.

## 1227

### EXPRESSION LEVELS OF *SCHISTOSOMA MANSONI* MULTIDRUG RESISTANCE TRANSPORTERS INCREASE IN RESPONSE TO PRAZIQUANTEL AND ARE CORRELATED WITH REDUCED DRUG SUSCEPTIBILITY

Ravi S. Kasinathan, William M. Morgan, Robert M. Greenberg

University of Pennsylvania, Philadelphia, PA, United States

P-glycoprotein (Pgp) and the multidrug resistance-associated proteins (MRPs) are members of the ATP-binding cassette (ABC) superfamily of proteins involved in transport of toxins and xenobiotics from cells. These transporters likely play important physiological roles in the parasite's excretion of wastes and metabolites and provide attractive candidate targets for novel antischistosomal agents. Additionally, these



transporters are associated with development of drug resistance, and have been implicated in resistance to anthelmintics. We have previously shown that expression of *Schistosoma mansoni* Pgp (SMDR2) is altered in worms exposed to praziquantel (PZQ), the current drug of choice against schistosomiasis, and is expressed at higher levels in worms from isolates with reduced PZQ susceptibility. We have also shown that PZQ inhibits SMDR2, and also appears to be a substrate of SMDR2. Here, we examine the relationship between PZQ and SmMRP1, a *S. mansoni* homolog of mammalian MRP1, a transporter of anionic and GSH-detoxified compounds. SmMRP1 RNA is differentially expressed in adult males and females, which also show differences in the distribution of MRP1 immunoreactivity. Levels of SmMRP1 RNA increase transiently following exposure of adult worms to sub-lethal concentrations of PZQ. A corresponding, though delayed, increase in anti-MRP1 immunoreactive protein also occurs following exposure of worms to PZQ. PZQ-insensitive juvenile worms express higher levels of both SmMRP1 and SMDR2 RNA than mature adults, consistent with the hypothesis that increases in levels of schistosome multidrug transporters may be playing a role in development or maintenance of reduced susceptibility to PZQ. We are currently using molecular genetic and pharmacological approaches to define the physiological roles played by these transporters and to dissect the mechanisms by which they interact with PZQ and may modulate responsiveness to the drug.

## 1228

### FORWARD GENETICS FOR *SCHISTOSOMA MANSONI*: QTL MAPPING OF OXAMNIQUINE RESISTANCE

**Claudia Valentim**<sup>1</sup>, Claudia Queiroz<sup>1</sup>, Matthew Berriman<sup>2</sup>, Philip T. LoVerde<sup>1</sup>, Timothy J. Anderson<sup>3</sup>

<sup>1</sup>University of Texas Health Science Center, San Antonio, TX, United States, <sup>2</sup>Wellcome Trust Sanger Institute, Hinxton, United Kingdom, <sup>3</sup>Southwest Foundation for Biomedical Research, San Antonio, TX, United States

Schistosomes show heritable variation in biomedically important traits such as drug resistance, host specificity, and virulence. Our central aim is to develop forward genetic methods (i.e. linkage mapping) to identify parasite genes that underlie this phenotypic variation. This approach is well suited to *S. mansoni* as the lifecycle can be maintained in the laboratory and clonal propagation of parasites within snails generates large numbers of genetically identical parasites. To provide proof-of-principle that this approach is feasible and powerful, we have mapped a genome region that underlies resistance to oxamniquine (OXA). Resistance to OXA has arisen in nature, has a simple recessive basis and results in ~500-fold reduction in drug sensitivity. We crossed resistant and sensitive parasites (parents) and then crossed two F1 individuals to generate multiple F2 progeny, at each stage isolating individual parasite genotypes by infecting snails with single miracidia. We measured OXA-resistance by monitoring death of cultured worms following drug exposure and genotyped parents, F1 and F2 progeny using 64 microsatellite markers distributed at ~20cM intervals across the genome. As expected trait segregation in the cross was consistent with recessive inheritance as F1s were sensitive and ~25% of F2 progeny were resistant. We used the *S. mansoni* linkage map developed by our group to locate quantitative trait loci (QTL) underlying OXA resistance. We found a strong QTL (LOD = 5.43) on the p arm of chromosome 6 where microsatellite markers segregate closely with OXA resistance. The two parents of this cross have now been sequenced, simplifying fine mapping and identification of candidate genes. Successful identification of gene(s) that underlie OXA-resistance will provide insights into mode of drug action, allow development of modified compounds that kill resistant parasites, generate selectable markers for genetic manipulation, and set the stage for forward genetic analyses of a range of biomedically important traits including praziquantel resistance.

## 1229

### BURDEN OF MALARIA IN HIV-POSITIVE PREGNANT WOMEN IN IBADAN, SOUTHWEST NIGERIA: AN ONGOING STUDY

**Catherine O. Falade**<sup>1</sup>, Olusegun G. Ademowo<sup>2</sup>, IkeOluwapo O. Ajayi<sup>3</sup>, Olubukola A. Adesina<sup>4</sup>, Hannah O. Dada-Adegbola<sup>5</sup>, Isaac F. Adewole<sup>6</sup>, Phylis Kanki<sup>6</sup>

<sup>1</sup>Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria, <sup>2</sup>IMRAT, University of Ibadan, Ibadan, Nigeria, <sup>3</sup>EMSEH, University of Ibadan, Ibadan Nigeria, <sup>4</sup>Department of Obstetrics and Gynecology, University of Ibadan, Ibadan Nigeria, <sup>5</sup>Department of Medical Microbiology, University of Ibadan, Ibadan, Nigeria, <sup>6</sup>APIN Plus (PEPFAR) Project, College of Medicine, University of Ibadan, Ibadan, Nigeria

Pregnancy and HIV infection individually increase susceptibility to malaria. This gives the HIV-positive pregnant woman a double burden. Malaria transmission is intense and occurs all year round in southwest Nigeria. We evaluated the prevalence of malaria parasitemia by expert microscopy of Geimsa stained thick blood smear among HIV-positive (+ve) women at the PEPFAR Clinic and uninfected pregnant women at the antenatal clinic at booking both located at the University College Hospital Ibadan in southwest Nigeria. The prevalence of malaria parasitemia was 18.8% (24/128) among HIV +ve women and 5.9% (24/406) HIV -ve women ( $p < 0.0001$ , OR 3.673; 95% CI 2.004 -6.732). The geometric parasite density was higher among HIV +ve women but this was not significant. Mean hematocrit was significantly lower among HIV +ve women compared with their normal counterparts ( $30.37\% \pm 4.11$  versus  $34.5\% \pm 3.76$ ;  $p < 0.0001$ ; *f-statistics* 107.129). The use of opportunistic infection chemoprophylaxis or antiretroviral therapy did not significantly influence the prevalence of malaria parasitemia. HIV -ve women booked significantly earlier than the HIV +ve women ( $21.26 \pm 8.71$  week versus  $19.44 \pm 7.64$  weeks;  $p < 0.029$ ; *f-statistics* 4.834). All socio-economic indicators (level of education of the women and their spouses, occupation of the women and their spouses, type of wall in accommodation, type of toilet facility, type of portable water and ownership of various gargets) were significantly ( $p < 0.0001$ ) lower among HIV +ve women. In conclusion, malaria exerts significant burden on HIV positive women in southwest Nigeria. These findings underscore the need for an adequate regimen of IPTp as well as other malaria control efforts (ITN, IRS and prompt case management) specifically targeted at HIV +ve women.

## 1230

### HUMAN IMMUNODEFICIENCY VIRUS (HIV) TYPES WESTERN BLOT PROFILES AS SURROGATE MARKERS OF HIV DISEASE PROGRESSION

**Kerina Duri**<sup>1</sup>, Fredrik Müller<sup>2</sup>, Felicity Z. Gumbo<sup>1</sup>, Munyaradzi P. Mapingure<sup>1</sup>, Mike Z. Chirenje<sup>1</sup>, Babill Stray-Pedersen<sup>2</sup>

<sup>1</sup>University of Zimbabwe, Harare, Zimbabwe, <sup>2</sup>University of Oslo, Oslo, Norway

A nested case-control study within a PMTCT cohort of antiretroviral therapy naive pregnant women. HIV-1/2 Western blot test and surrogate markers of HIV disease progression were determined at 36 gestational weeks. Among the 64 pregnant women with HIV infection 98.4 % had pure HIV-1 infections and one woman (1.6%) had dual HIV-1/ HIV-2 infections, with 100% band reactivity to both the envelope and polymerase proteins. However reactions to the *gag* core protein genes varied, being 100%, 90%, 70% and 63% for the p24, p17, p39 and p55 respectively. Lack of antibody reaction to *gag* p39 protein was significantly associated with disease progression among women with chronic HIV-1 infection as demonstrated by the presence of lymphadenopathy, anemia and higher viral load,  $p=0.010$ ,  $0.025$  and  $0.016$  respectively. Although not statistically significant, women who had *gag* protein p39 missing were 1.4 times more likely to transmit the virus to their infants. In conclusion, absence of *gag* p39 and *pol* gene bands was significantly associated with disease progression and sero-conversion respectively. This data emphasises the importance of considering both the *env* and *pol* genes

proteins in the interpretation of positive Western blot HIV test results. Band profiles and simple laboratory tests like differential counts together with clinical symptoms could be useful in establishing and evaluating disease progression prior to antiretroviral therapy.

## 1231

### MARKED REDUCTION IN THE PREVALENCE OF MALARIA AND ANEMIA IN HIV-INFECTED PREGNANT WOMEN TAKING COTRIMOXAZOLE WITH OR WITHOUT SP-IPT IN MALAWI

**Atupele Kapito-Tembo<sup>1</sup>**, Steven R. Meshnick<sup>1</sup>, Michaël Boele van Hensbroek<sup>2</sup>, Kamija Phiri<sup>3</sup>, Margaret Fitzgerald<sup>4</sup>, Victor Mwapasa<sup>5</sup>

<sup>1</sup>University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, United States, <sup>2</sup>Emma Children's Hospital AMC, University of Amsterdam, Amsterdam, The Netherlands, <sup>3</sup>Malawi-Liverpool-Wellcome Trust Clinical Research Programme, College of Medicine, Blantyre, Malawi, <sup>4</sup>Médecins Sans Frontières (Belgium), Thyolo, Malawi, <sup>5</sup>Department of Community Health, College of Medicine, Blantyre, Malawi

HIV-infected women are at risk for both malaria and other opportunistic infection. Current WHO guidelines recommend cotrimoxazole for all HIV-infected pregnant women. However, it is not known whether this regimen is as effective as sulfadoxine-pyrimethamine (SP) intermittent preventive therapy (IPTp) in preventing malaria. Here, we compare the effectiveness of cotrimoxazole and SP-IPTp in protecting against malaria in a cohort of HIV-infected pregnant women in Malawi. From 2005 to 2009, we conducted a cross-sectional study of HIV-infected pregnant women attending routine antenatal services at Thyolo district hospital, Malawi. Peripheral blood was tested for anemia (hemoglobin < 11g/dl) and malaria by both microscopy and PCR. We also collected data on use of anti-malaria interventions and other potential risk factors. CTX prophylaxis for HIV-infected pregnant women was introduced as policy in 2007, but implementation problems resulted in some women receiving CTX alone, SP-IPTp or both. We enrolled 1,142 women of whom 1,121 had data on CTX and/or SP-IPTp intake. Of these, 49.7%, 29.8%, and 15.4% reported taking SP-IPTp only, CTX only and SP-IPTp plus CTX respectively. Compared with women taking SP-IPTp only, those taking CTX (with or without SP-IPTp) were less likely to have microscopic malaria (OR, [95%CI]: 0.09, [0.01-0.66] and 0.43, [0.19-0.97] respectively) or PCR-detected malaria infections (OR 0.24; 95%CI 0.10-0.62 and 0.44; 95%CI 0.25-0.78 respectively) or anemia (PR, [95% CI]: 0.67, [0.54-0.83] and 0.72, [0.61-0.83] respectively). In conclusion, in HIV-infected pregnant women, CTX with or without SP-IPTp reduces the risk of malaria and anemia compared to SP-IPTp only. Longitudinal studies need to assess the effects of these drugs on birth outcomes and toxicity.

## 1232

### INCIDENCE OF MALARIA EPISODES IN WEST AFRICAN ADULTS HIV-1 INFECTED PATIENTS EXPOSED OR NOT TO COTRIMOXAZOLE: MALHIV COHORT STUDY

**Frédéric N. Ello<sup>1</sup>**, Mariama Ouiminga<sup>1</sup>, Lise Denoed<sup>2</sup>, Adrien Sawadogo<sup>3</sup>, Alassane Hamar<sup>4</sup>, Soumaré Masserigne<sup>5</sup>, Serge P. Eholié<sup>1</sup>, Emmanuel Bissagnene<sup>1</sup>

<sup>1</sup>CHU Treichville, Abidjan, Côte D'Ivoire, <sup>2</sup>Hopital saint-antoine, Paris, France, <sup>3</sup>Hopital Sourou Sanon, Bobo-dioulasso, Burkina Faso, <sup>4</sup>Hopital Point G, Bamako, Mali, <sup>5</sup>CHU de Fann, Dakar, Senegal

A key issue of the interrelation between HIV/AIDS and malaria is the impact of cotrimoxazole chemoprophylaxis on the natural history of malaria among HIV-infected patients. The objective of this study was to determine the incidence of malaria among HIV-1 infected patients, receiving daily cotrimoxazole or not. West African adults HIV-1 infected patients, receiving or not cotrimoxazole were enrolled in the 30 months MALHIV cohort study. Patients were divided into two groups: Group A CD4 < 350/mm<sup>3</sup> exposed to cotrimoxazole and group B CD4 ≥ 350/mm<sup>3</sup> non exposed to cotrimoxazole. The cumulative incidence of clinical and parasitological malaria episodes was evaluated at baseline,

every six months and in case of fever. Comparison of incidence in the two groups was used to assess the influence of cotrimoxazole primary chemoprophylaxis. At inclusion, the 548 enrolled patients [mean age=35.1 year, sex ratio: 0.29] had a CD4 mean of 198/μl and a viral load mean of 5, 2 log<sub>10</sub>. 368 patients (68%) were included in group A and 168 (32%) in group B, of whom 23 (4%) were lost to follow-up and 11 (2%) died. 325 patients received antiretroviral therapy. Asymptomatic parasitemia was diagnosed in 13 patients (2, 5%). Overall 35 malaria episodes (6.4%) occurred in 30 patients (5 in group A, 30 in group B). One case of severe malaria was noted. Malaria episodes were less frequent in group A. (1.3% versus 17% [RR= 0.03, IC=0.07-0.19, P< 0.05]). Fever episodes were less frequent in group A. (18, 9 % versus 63% [RR= 0.45; IC=0.36-0, 55 and P<0.05]). In conclusion, there is a trend of protection against malaria and fever episodes in HIV infected patients receiving cotrimoxazole in stable malaria transmission areas, even at lower CD4 cell counts.

## 1233

### UTILITY OF PARACHECK-PF™ MALARIA RAPID DIAGNOSTIC TEST FOR THE DIAGNOSIS OF MALARIA AT POINT OF CARE AMONG ADULT HIV-POSITIVE PATIENTS IN IBADAN SOUTH WESTERN NIGERIA: AN ONGOING STUDY

**Catherine O. Falade<sup>1</sup>**, George O. Ademowo<sup>2</sup>, Olubukola A. Adesina<sup>3</sup>, Isaac F. Adewoluw<sup>3</sup>, Phylis Kanki<sup>3</sup>

<sup>1</sup>University of Ibadan, Ibadan, Nigeria, <sup>2</sup>Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan, Nigeria, <sup>3</sup>APIN Plus (PEPFAR) Project, College of Medicine, University of Ibadan, Ibadan, Nigeria

Malaria and HIV are major public health problems in sub-Saharan Africa. Febrile illnesses occur frequently among HI+ve patients and these febrile episodes are often first treated presumptively as malaria in endemic areas. In order to eliminate unnecessary treatments; reduce drug-drug interactions and the chances for emergence of drug resistant *Plasmodium*, the World Health Organization recommends a parasite-based diagnosis of malaria as much as possible. We evaluated 301 HIV+ve patients with febrile episode suspected of being malaria by expert microscopy and Paracheck *pf*™, (a histidine-rich protein-2 based malaria rapid diagnostic test, Orchid Biomedical Systems, Goa India) at the PEPFAR Clinic of the University College Hospital Ibadan, Nigeria. The mean age was 36.7 years (±9.2). About 80% (240/301) enrollees were female and 26.9% (81) had received various antimalarial drugs in the preceding two weeks. The prevalence of malaria parasitemia was 18.9% (357/301) by microscopy of thick blood smear with a geometric mean parasite density of 470/μL (range 39 - 204,000/μL). The prevalence of parasitemia by Paracheck *pf*™ was 18.5% (55/297) and four samples which were all blood smear negative gave indeterminate result for RDT testing. Sensitivity and specificity of Paracheck *pf*™ when compared with microscopy at all parasite densities were 54.4% and 90% while corresponding figures at parasite densities ≥ 200/μL were 93.9% and 91.7% respectively. Negative and positive predictive values at all parasite densities were 90% and 54.4%. Corresponding negative and positive predictive values for parasite density ≥ 200/μL were 99.2% and 58.5% respectively. The overall test accuracy was 83.2% while test accuracy at parasite density ≥ 200/μL was 91.9%. In conclusion, Paracheck *pf*™ malaria rapid diagnostic test accurately ruled malaria "in or out" at the point-of-care, facilitating appropriate clinical management and averting unnecessary antimalarial therapy.

## 1234

**DIAGNOSIS OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN SCHISTOSOMIASIS PATIENTS UNDERGOING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN WESTERN KENYA**

**Erick M. Muok**<sup>1</sup>, Diana Huis in 't Veld<sup>2</sup>, Anali Conesa-Botella<sup>2</sup>, Zipporah W. Ng'ang'a<sup>3</sup>, George O. Ogola O. Ogola<sup>4</sup>, Katja Polman<sup>2</sup>, Luc Kestens<sup>2</sup>, Diana M. Karanja<sup>1</sup>, Robert Colebunders<sup>2</sup>, Pauline N. Mwinzi<sup>1</sup>

<sup>1</sup>Kenya Medical Research Institute, Kisumu, Kenya, <sup>2</sup>Institute of Tropical Medicine, Antwerp, Belgium, <sup>3</sup>Jomo Kenyatta University, Nairobi, Kenya, <sup>4</sup>Maseno University, Maseno, Kenya

The immune reconstitution inflammatory syndrome (IRIS) is a frequent complication seen in HIV-TB co-infected patients during successful highly active antiretroviral therapy (HAART). IRIS is common in resource-limited countries where the underlying prevalence of opportunistic infections is high, and where patients initiating HAART are more likely to have advanced immunodeficiency. We conducted a clinical study to investigate the immunopathogenesis, clinical aspects and manifestation of IRIS in HIV-schistosome co-infected patients undergoing HAART along the shores of Lake Victoria in western Kenya. Adults who were exposed to snail-infested lake water and are dually infected with HIV and *Schistosoma mansoni* were enrolled into the study. Baseline and follow-up indicators included CD4 counts measured by four-color flow cytometry, viral load measured by PCR, *S. mansoni* egg counts by the Kato-Katz method and evaluation of liver pathology by ultrasound. The prevalence of *S. mansoni* infections in this population was over 90% while that of HIV infection was 16%, and 67.9 % of those that were HIV positive had dual infections. Only 4% had detectable liver pathology at baseline. The intensity of schistosome infection had no influence on either the percentage of T helper cells (CD4+) ( $p = 0.3640$ ) or the frequency of viral load copies ( $p = 0.8470$ ). However, individuals with *S. mansoni* infection only had significantly higher mean egg production compared to those with dual infections. Clinical monitoring of dually infected patients getting started on HAART is ongoing to determine the case definition and the prevalence of IRIS.

## 1235

**ALANYL-GLUTAMINE SUPPLEMENTATION PROTECTIVE EFFECTS ON NELFINAVIR-INDUCED INTESTINAL EPITHELIAL INJURY**

**Manuel B. Braga-Neto**<sup>1</sup>, Cirile A. Warren<sup>2</sup>, Bruna M. Oliveira<sup>1</sup>, Jamilly G. Maciel<sup>1</sup>, Jesus E. Sevilleja<sup>2</sup>, Aldo A. Lima<sup>1</sup>, Richard L. Guerrant<sup>2</sup>

<sup>1</sup>Federal University of Ceara, Brazil, Fortaleza, Brazil, <sup>2</sup>University of Virginia, Charlottesville, VA, United States

HIV protease inhibitors (PI) remain a crucial component of highly active therapy (HAART) contributing to reduce mortality and morbidity related to Human Immunodeficiency Virus (HIV) infection. However, discontinuation of therapy remains an important issue, which may be related to various side-effects, especially diarrhea. The aim of this study was to evaluate the effects of nelfinavir, an HIV PI, and of alanyl-glutamine supplementation, on intestinal cell migration, proliferation, apoptosis, necrosis, using a rat intestinal cell line, IEC-6, and on crypt depth, villi length, mitotic index and apoptosis using swiss mice. Migration was evaluated at 12 and 24h after injury, using a wounding assay. Proliferation was measured indirectly at 24 and 48h, using tetrazolium salt WST-1. Apoptosis and necrosis were measured by flow cytometry, using the Annexin V assay. We measured intestinal morphometry, mitotic index and apoptosis in mice following a seven day treatment with 100mg/kg of nelfinavir, given orally. Nelfinavir decreased IEC-6 cell proliferation and migration and increased apoptosis and necrosis. Alanyl-glutamine supplementation enhanced intestinal cell migration both at 12 and 24h and proliferation at 24 and 48h, but did not decrease apoptosis and necrosis after nelfinavir treatment. Nelfinavir

decreased duodenal villus height and villus surface area, which was reversed with the addition of alanyl-glutamine and increased apoptosis. Alanyl-glutamine also increased crypt depth in the duodenum, jejunum, and ileum and duodenal mitotic index in nelfinavir-treated mice. In conclusion, alanyl-glutamine reversed nelfinavir-induced intestinal epithelial damage *in vitro* and *in vivo*. Alanyl-glutamine supplementation may be beneficial in the prevention or treatment of diarrhea induced by PIs during HAART.

## 1236

**A NATIONAL MALARIA TRAINING MODEL FOR ACHIEVING RATIONAL USE OF ANTIMALARIAL MEDICINES IN SUB-SAHARAN AFRICA**

**Nancy L. Blum**<sup>1</sup>, Kelly Willis<sup>1</sup>, Umaru Ssekabira<sup>2</sup>

<sup>1</sup>Accordia Global Health Foundation, Washington, DC, United States, <sup>2</sup>Infectious Diseases Institute, Makerere University, Kampala, Uganda

Presumptive treatment of malaria is a common practice in Africa resulting in widespread overtreatment, misuse of costly artemisinin-combination therapy (ACT), and inappropriate treatment of non-malarial febrile illnesses. Accordia Global Health Foundation's Integrated Management of Malaria (IMM) course and an on-site training program using Rapid Diagnostic Tests (RDT), developed in partnership with the Infectious Diseases Institute (IDI) at Makerere University and others, target multidisciplinary clinical teams and achieve substantial declines in the unnecessary use of antimalarials. Research conducted in partnership with the Uganda Malaria Surveillance Project (UMSP) demonstrated that the improvement was achieved at no detriment to patient health outcomes. Recently-issued WHO guidelines for malaria treatment will substantially increase demand for training in correct laboratory and RDT diagnosis of malaria, for the many African countries who will strive to achieve them. To enable high quality training delivered cost-effectively to a national scale, Accordia complemented its IMM and RDT training programs with field-based and peer-facilitated versions of those courses, led by graduates of the IDI-based courses at a fraction of the cost of centralized training. Following completion of additional coursework at IDI, IMM graduates conducted "Cascade Training" and achieved reductions in antimalarial use similar to those shown in IDI-based training: in three sites that received Cascade Training, the probability of an antimalarial drug being prescribed to someone who had a negative blood smear decreased by 28%; there was a 25% decline at eight sites that received the IDI-based training. The resulting National Malaria Training Model, reinforced by periodic site visits by Mobile Teams and a toll-free call center for clinical consultation, presents a cost-effective approach to build national capacity in the appropriate diagnosis of malaria and rational use of antimalarial medicines in sub-Saharan African nations.

## 1237

**LARGE-SCALE IMPLEMENTATION OF INTERMITTENT PREVENTIVE TREATMENT IN INFANT WITH SULFADOXINE PYRIMETHAMINE FOR MALARIA IN RURAL AREAS OF HIGH TRANSMISSION IN SENEGAL**

**Mouhamed Ndiaye**<sup>1</sup>, Jean Louis Ndiaye<sup>1</sup>, Doudou Sow<sup>1</sup>, Youssoupha Ndiaye<sup>2</sup>, Magatte Ndiaye<sup>1</sup>, Sylvain Faye<sup>3</sup>, Roger Tine<sup>1</sup>, Babacar Faye<sup>1</sup>, Alexandra De Sousa<sup>4</sup>, Oumar Gaye<sup>1</sup>

<sup>1</sup>Laboratory of Parasitology, Faculty of Medicine, UCAD, Dakar, Senegal, <sup>2</sup>District Medical Office, Ministry of Health and Prevention, Saraya, Senegal, <sup>3</sup>Sociology Department, Faculty of Human Sciences UCAD, Dakar, Senegal, <sup>4</sup>Unit of Policy and Evidence, Health Section, UNICEF, New York, NY, United States

Intermittent Preventive Treatment in infants (IPTi) is a new promising intervention for malaria control in Sub Saharan Africa which can be delivered through the existing routine Expanded Programme on Immunization (EPI). Although the efficacy of IPTi is proven, there is



limited economic evaluation data on scaling up IPTi using sulfadoxine pyrimethamine (SP) as a strategy for malaria control in Senegal. Implementation scale-up cost was calculated by estimating IPTi incremental costs in the start-up year and in subsequent years. Costs included were the financial costs of delivering IPTi to infants (drugs and equipment) and of programme activities. In recurrent years, because a survey in IPTi areas showed high acceptability and health care worker knowledge, programme costs included only IPTi administration and safety surveillance. To estimate IPTi cost-effectiveness (IPTi net cost per case of malaria averted, per death averted, per year of life saved, and per disability adjusted life years) we calculated the intervention's economic costs in recurrent years using a pooled efficacy analysis. A time and motion study was also conducted to assess staff time on IPTi delivery and the associated costs. In order to delivery IPTi-SP to 17,500 infants the total amount of the financial expenditure of programme implementation was \$40,753.

IPTi incremental financial costs on start up year (3.31 \$US/infant) were substantially higher than in recurrent years (1.043 \$US/infant). In startup years communication activities mobilized the most important expenditure (30%) meanwhile, half of the total programme resources is allocated to capacity building development of professional staff. In routine, the part of programme costs was US\$ 0.81 per infant, and patient costs (drug and utensils) only 23.7 US cent/infant. The time needed to administer IPTi was an average of 2.19 min/child, representing 7% of the time spends by health workers in immunization clinics. The net cost per averted case of malaria was \$22.11. The cost per death averted was \$ 447, per year of life saved \$ 23.84 and per DALYs \$ 25.39. In conclusion, IPTi with SP through EPI can be scaled up successfully at a low cost. Using pooled efficacy results from previous IPTi trails we can see that it is a highly cost effective intervention in the study sites selected. But, the IPTi cost-effectiveness in the other areas in Senegal where malaria transmission is not high, worth assessing.

## 1238

### ARTEMETHER-LUMEFANTRINE VERSUS DIHYDROARTEMISININ-PIPERAQUINE FOR THE TREATMENT OF UNCOMPLICATED MALARIA: LONGITUDINAL OUTCOMES IN A COHORT OF YOUNG UGANDAN CHILDREN

Humphrey Wanzira<sup>1</sup>, Taylor Sandison<sup>2</sup>, Abel Kakuru<sup>1</sup>, Victor Bigira<sup>1</sup>, Emmanuel Arinaitwe<sup>1</sup>, Jaco Homsy<sup>3</sup>, Jordan W. Tappero<sup>4</sup>, Moses Kanya<sup>5</sup>, Grant Dorsey<sup>6</sup>

<sup>1</sup>Infectious Diseases Research Collaboration, Kampala, Uganda,

<sup>2</sup>Department of Medicine, University of Washington, Seattle, WA, United States,

<sup>3</sup>Institute for Global Health, University of California, San Francisco, San Francisco, CA, United States,

<sup>4</sup>GAP, Centers for Disease Control and Prevention, Atlanta, GA, United States,

<sup>5</sup>Department of Medicine, Makerere University, Kampala, Uganda,

<sup>6</sup>Department of Medicine, University of California, San Francisco, San Francisco, CA, United States

There are limited comparative data on the long term effects of artemisinin-combination therapies (ACTs) for the treatment of malaria. In a cohort of young Ugandan children living in a highly endemic area, we previously reported that artemether-lumefantrine (AL) and dihydroartemisinin-piperazine (DP) were both highly efficacious, but DP was associated with a longer post-treatment prophylactic effect. Here we aimed to compare longitudinal outcomes in this cohort. Children were given a long-lasting insecticide treated bednet (LLITN) at enrollment and followed for all their healthcare needs. 305 children with a median age of 10 months (range 4-40) were randomized to AL (n=155) or DP (n=150) at the time of their first episode of uncomplicated malaria. The same treatment was given for all subsequent episodes of uncomplicated malaria and episodes of complicated malaria were treated with quinine. After randomization, children were followed a median of 22 months and a total of 2,592 treatments for malaria were given. The incidence of malaria following randomization was higher in the AL arm (5.44 episodes PPY) compared to the DP arm (4.74 episodes PPY), although this difference did not reach statistical significance (IRR=1.13, p=0.06). After randomization, only 27

treatments with quinine (1%) were given for complicated malaria (17 with convulsions, 10 with severe anemia). The incidence of complicated malaria was significantly higher in those randomized to AL compared to DP (IRR=4.84, p=0.006). All 6 early treatment failures were due to the development of complicated malaria within 2 days of initiating treatment with AL. There was one death due to malaria in a child randomized to AL. In this cohort of young children living in a highly endemic area the incidence of malaria was very high despite the use of LLITNs. However, treatment with AL or DP was highly efficacious and the incidence of complicated malaria was relatively low. DP was associated with a trend towards a modest decrease in the incidence of malaria and may lower the risk of complicated malaria compared to AL.

## 1239

### COMMUNITY BASED MALARIA CONTROL IN SARAYA, SOUTHEASTERN SENEGAL

Demetri Blanas<sup>1</sup>, Youssoupha Ndiaye<sup>2</sup>

<sup>1</sup>Mount Sinai School, New York, NY, United States, <sup>2</sup>Senegalese Ministry of Health, Dakar, Senegal

In 2009, Senegal's National Malaria Control Program (NMCP) initiated a new Home-based Malaria Management (HMM) program, in which community health workers (CHWs) are trained to diagnose *Plasmodium falciparum* with rapid diagnostic tests and to treat appropriate patients with artemisinin-based combination therapy (artesunate + amodiaquine). The intention is to provide care to 30 villages of 200 to 500 inhabitants, which are all located 5 to 90 km from the nearest government health facility in the Saraya district of southeastern Senegal. The NMCP designed and implemented the 3-day training, which covered: modes of transmission and strategies for prevention; the clinical presentation of malarial infection; and the protocol to diagnose and treat uncomplicated malaria. The training was conducted in French and translated into Malinké. The training materials included a PowerPoint presentation and an instructional illustrated packet. This study evaluated the effectiveness of the training of CHWs. The same self-administered printed multiple-choice questionnaire was administered before and after the training. The questionnaire included questions to assess modes of transmission and strategies for prevention, the clinical presentation of malarial infection, and the protocol to diagnose and treat uncomplicated malaria. Scores in these three areas were determined. Before and after scores were evaluated using a two-tailed t-test. A P-value  $\leq 0.05$  was considered significant. Twenty-six CHWs participated in the training. Six CHWs were unable to read the training materials or questionnaires. The CHWs who could read and write assisted the others. The mean before and after scores were 52% vs. 73% (p=0.02) for CHWs understanding of transmission and prevention; 37% vs. 47% (p=0.21) for recognition of the clinical presentation of malaria; and 52% vs. 75% (p<0.01) for the ability to understand and carry out the HMM protocol. This study suggests that the training was successful in improving CHWs knowledge of transmission and prevention and ability to follow HMM protocol. Improvements should be made in the training the CHWs in disease recognition and future training should take the literacy level of CHWs into account. Further studies should be done to see how this knowledge translates into field practice and the need for training to reinforce these skills.

## 1240

**PHARMACOVIGILANCE AND ANTIMALARIAL TREATMENT IN UGANDA: RESULTS AND EXPERIENCE FROM A PILOT ACTIVE SURVEILLANCE SYSTEM**

Hasifa Bukirwa<sup>1</sup>, Charles Karumuna<sup>1</sup>, Susan Nayiga<sup>1</sup>, Sarah G. Staedke<sup>2</sup>, Ambrose O. Talisuna<sup>3</sup>

<sup>1</sup>Uganda Malaria Surveillance Project, Kampala, Uganda, <sup>2</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom, <sup>3</sup>Medicines for Malaria Venture, Kampala, Uganda

The safety of artemisinin combination therapies (ACTs) under large-scale operational use is not fully known. Continued careful monitoring after registration and release onto the market is therefore essential to establish ACT safety under routine conditions. An effective reporting system is a key requirement. Adverse event (AE) reports can be collected through passive spontaneous reports by users and prescribers and through active surveillance of patients receiving treatment. Active follow-up of patients to prospectively assess for AEs after treatment is ideal for detecting safety signals much more quickly and for estimating the incidence of AEs. Between November 2008 and October 2009 we actively followed up 842 patients treated with an antimalarial at public health facilities to assess the incidence of AEs at intervals until 28 days after treatment. Although artemether-lumefantrine (AL) is the recommended first-line treatment of uncomplicated malaria in Uganda, frequent stock-outs of AL resulted in use of many alternative antimalarials during the study period, including chloroquine, amodiaquine, sulfadoxine-pyrimethamine, artesunate monotherapy and quinine. Of 443 AEs reported, 271 (61%) were reported in association with ACT use. Cough, loss of appetite, flu-like symptoms, abdominal pain and weakness/fatigue were commonly reported but no serious AEs were reported. Drug stock-outs at the public health facilities forces patients to fill prescriptions outside formal systems, and affected the quality of collected information. Frequent changes of participants' addresses as well the high resource intensity of the system were major challenges. Effective active adverse event surveillance would require strengthening existing health infrastructure including health worker skills, diagnostic capacity for investigating and managing suspected adverse drug reactions and a good patient referral system.

## 1241

**PHARMACOVIGILANCE OF ARTEMETHER-LUMEFANTRINE IN PREGNANT WOMEN FOLLOWED UP UNTIL DELIVERY IN RWANDA**

Stephen Rulisa<sup>1</sup>, Nadine Kaligirwa<sup>2</sup>, Steven Agaba<sup>3</sup>, Petra F. Mens<sup>4</sup>, Adriana Tami<sup>4</sup>, Peter J. De Vries<sup>5</sup>

<sup>1</sup>Kigali University Teaching Hospital, National University of Rwanda, Kigali, Rwanda, <sup>2</sup>Centre for Treatment and Research on AIDS, Kigali, Rwanda, <sup>3</sup>Centre for Treatment and Research on AIDS (Trac-Plus), Kigali, Rwanda, <sup>4</sup>Royal Tropical Institute/KIT Biomedical Research, Amsterdam, The Netherlands, <sup>5</sup>Academic Medical Center, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, The Netherlands

Antimalarial drugs that are considered safe during pregnancy become increasingly ineffective. Many countries shifted their treatment guidelines to artemisinin combination treatment (ACT). WHO recommends ACT for uncomplicated *falciparum* malaria in the second and third trimester of pregnancy. In Rwanda, the current policy recommends treatment with artemether-lumefantrine (AL) for malaria during the second and third trimester of pregnancy. However, safety data on ACTs in pregnancy are still limited and more data are warranted. In this proactive pharmacovigilance study we followed pregnant women treated with AL and a matching control group (CG) of healthy pregnant women not exposed to AL in the current pregnancy. Routine antenatal and peripartum data, pregnancy outcomes, congenital malformation and adverse events (AEs) were captured during acute episodes of malaria, routine ante-natal visits, at delivery in the health center or within 48hrs after a home delivery, by

history taking and physical examination of the mother and the newborns at delivery. The data for 1783 women (AL n=881; CG n=902) showed: abortions: AL 8 (0.9%), CG 5 (0.6%); perinatal mortality: AL 28 (3.2%), CG 20 (2.2%); comprised stillbirth :AL 25 (2.8%), CG 16 (1.8%); neonatal death  $\leq 7$  days after birth :AL 3 (0.3%), CG 4 (0.4%), premature delivery AL :6 (0.7%), CG 3 (0.3%) and congenital malformations: AL 1 (0.1%), CG: 2 (0.2%). A total of 73 AEs were reported (AL 43 (4.9%), CG 30 (3.3%). The most common AEs were still birth. These data showed that the two arms were comparable in terms of pregnancy outcomes and AEs and did not show any specific safety concerns with AL treatment in pregnancy. The slight difference in AEs and pregnancy outcomes between the groups may be due to malaria itself but needs to be assessed further.

## 1242

**EFFECTS OF STEADY-STATE LOPINAVIR/RITONAVIR ON THE PHARMACOKINETICS OF QUININE IN HEALTHY VOLUNTEERS**

Myaing M. Nyunt<sup>1</sup>, Yanhui Lu<sup>2</sup>, Mahmood El-Gasim<sup>1</sup>, Theresa Parsons<sup>2</sup>, Brent G. Petty<sup>2</sup>, Craig W. Hendrix<sup>2</sup>

<sup>1</sup>Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, United States

Many antiretroviral and antimalarial drugs share overlapping cytochrome P450 (CYP) -mediated metabolic pathways, indicating potential for drug-drug interactions and clinically important changes in the efficacy or toxicity of these drugs. We conducted a phase I, multiple dose, sequential design pharmacokinetic study to assess the impact of chronic administration of ritonavir-boosted lopinavir (LPV/r), a fixed-dose combination of two HIV protease inhibitors increasingly used in developing countries, on the safety and pharmacokinetics of quinine sulfate in healthy volunteers. Thirteen adult volunteers received a single oral dose of quinine sulfate on Day 1 and Day 15, and LPV/r on Days 4-17. Blood samples were collected to measure plasma concentrations of total and free quinine and 3-hydroxy-quinine metabolite using HPLC-fluorescence detection. Adverse effects were common, mild-moderate in severity, and self-limited. EKG changes were seen in 7 of 13 participants. Day 15 to Day 1 geometric mean ratios (90% confidence interval) showed: free quinine area under the curve (AUC) 0.40 (0.74-0.22), maximal concentration (C<sub>max</sub>) 0.40 (0.58-0.27), terminal half-life (t<sub>1/2</sub>) 0.67 (1.0-0.45), apparent volume of distribution (V/F) 1.66 (1.15-2.40), apparent total clearance (Cl/F) 2.5 (1.34-4.65); total quinine AUC 0.49 (0.47-0.51), C<sub>max</sub> 0.51 (0.50-0.52), t<sub>1/2</sub> 0.79 (0.74-0.85), V/F 1.61 (1.59-1.63), Cl/F 2.0 (1.96-2.13). The addition of LPV/r caused a significant decrease in exposure of both total and free quinine and 3-hydroxyquinine, a decrease in protein binding and metabolite/parent ratio, and an increase in the apparent volume of distribution and total clearance. The study showed significant modification in quinine pharmacokinetics in the presence of LPV/r through a complex interplay of effects on CYP3A4, p-glycoprotein, and protein binding. Further studies are needed to assess changes in quinine pharmacokinetics and pharmacodynamics in individuals with malaria-HIV co-infection who are taking LPV/r-containing antiretroviral therapy.

## 1243

**SUSTAINABILITY OF INTERVENTION FOR HOME MANAGEMENT OF MALARIA: THE NIGERIAN EXPERIENCE**

Ikeoluwapo O. Ajayi<sup>1</sup>, Samuel A. Jegede<sup>2</sup>, Catherine O. Falade<sup>1</sup>

<sup>1</sup>College of Medicine, Ibadan, Nigeria, <sup>2</sup>Department of Sociology, University of Ibadan, Ibadan, Nigeria

An intervention was carried out between 2005-2007 to improve home management of malaria using artemether lumefantrine [Coartem<sup>®</sup>] in Ona-Ara Local Government Area (LGA) of Oyo State, Nigeria. At the expiration of the project, the community was implored to sustain the program and provide support to the trained community based medicine distributors (CMDs). This study evaluated the sustainability of the HMM project two years after its expiration. A community-based study was

conducted among CMDs and stakeholders in Ona-Ara LGA. A total of 12 FGDs was conducted among CMDs, mothers of children aged 0-5 years and community members. Ten Key Informant Interviews were conducted with community leaders, Primary Health Care Coordinator, Rollback Malaria Manager, and PHC unit staff. After transcribing and word processing the data, Word Atlas Ti software was used to analyse data according to themes. Most of the FGD participants and Key Informants indicated that they were aware of the home management of malaria project in the area. In fact, there was consensus that communities selected their CMDs who distributed Coartem®. Data revealed that the treatment guideline poster given to households was of good assistance for treating children with malaria and some participants could still recapitulate the required dosages for treating malaria among children of different ages. The participants were of the opinion that the occurrence and severity of malaria has reduced in the area. While some CMDs have abandoned the assignment, few continue to provide care to febrile children and distribute Coartem® when available as their own contribution to the good of the community. Source of Coartem® was still the nearest government health facilities but supply was irregular and hindered by incessant transfer of health workers who were acquaintances on the project. All the CMDs mentioned they did not receive any support from the community. Most of the participants wanted the project to continue to support treatment of malaria in the community. In conclusion, while the project has proved to be life transforming, community support for CMDs is a serious challenge to sustainable HMM.

## 1244

### NOVEL SYNTHETIC OZONIDE OZ439: TOLERABILITY AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS

Joerg J. Moehrle<sup>1</sup>, Sarah Arbe-Barnes<sup>2</sup>, Christoph Siethoff<sup>3</sup>, J. Carl Craft<sup>1</sup>, Stephan Duparc<sup>1</sup>, Susan A. Charman<sup>4</sup>, Maria Gutierrez<sup>5</sup>, Sergio Wittlin<sup>6</sup>, Jonathan L. Vennerstrom<sup>7</sup>

<sup>1</sup>Medicines for Malaria Venture, Geneva, Switzerland, <sup>2</sup>Fulcrum Pharma, Hemel Hempstead, United Kingdom, <sup>3</sup>Swiss BioQuant, Reinach, Switzerland, <sup>4</sup>Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia, <sup>5</sup>Comprehensive Phase One, Miramar, FL, United States, <sup>6</sup>Swiss Tropical Institute, Basel, Switzerland, <sup>7</sup>University of Nebraska, Omaha, NE, United States

OZ439 is a synthetic ozonide (1,2,4-trioxolane) that has potential value as a peroxide antimalarial agent. The clinical protocol design of a randomised, double-blind, placebo controlled study combined the multi-objectives of sequential single (SRD) and multiple dose rising (MRD) as well as a food-effect sub-study. The study was conducted under US-IND. Dose levels of OZ439 investigated in the SRD ranged from 50mg to 1600mg and in the MRD ranged 200mg to 800mg. The food effect (FE) component was studied with 800mg OZ439 in a placebo cross-over design. Healthy male and female subjects aged 18-55 years were recruited for the study. A total of 63 subjects (26 in SRD, 13 in FE, and 24 in MRD) were enrolled. Dose escalation was subject to approval from a Safety Review Board. Safety assessments consisted of vital signs, 12-lead and Holter ECG, laboratory tests, adverse events (AE), audiometry/BAEP parameters. Samples were taken for assay of OZ439 and its metabolites from blood drawn up to 96 hours post drug administration. OZ439 was shown to be safe and well tolerated at the doses studied in the SRD, MRD and fed/fasted state. The most common AEs for OZ439 (2 or more subjects) were headache, nausea, diarrhea, constipation, blood CPK increase, flushing, throat irritation and gastrointestinal hypermotility. One subject dosed with OZ439 (800mg) was prematurely discontinued due to syncope vasovagal (with ECG changes). There were no significant changes in laboratory values or mean changes in vital signs, audiometry/BAEP and ECG/QTc. On SRD and MRD, exposure to OZ439 and its metabolites (based on C<sub>max</sub> and AUC) increased with increasing dose, this being dose-proportional. Following MRD, mean plasma concentration-time profile of OZ439 was characterised by a median t<sub>max</sub> of 3.00 hours followed by a multi-phase

elimination. Mean t<sub>1/2</sub> of OZ439 ranged from 37.8 to 41.7 hours. The plasma concentration-time profiles of the metabolites resembled that of parent compound. Accumulation of OZ439 was less than 2-fold.

The study results justify pursuing the development of OZ439 in a combination therapy for uncomplicated malaria.

## 1245

### CHANGES IN *PLASMODIUM FALCIPARUM* ASEQUAL AND SEXUAL POPULATIONS IN CHILDREN WITH ACUTE INFECTIONS FOLLOWING TREATMENT WITH ARTEMISININ-BASED COMBINATION THERAPIES

Akintunde Sowunmi, Titilope M. Okuboyejo, Grace O. Gbotosho, Christian T. Happi, Obaro S. Michael, Onikepe A. Folarin

Department of Pharmacology and Therapeutics and Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria

Artemisinin-based combination therapies (ACTs) may influence malaria transmission but the mechanisms of their effects have not been totally elucidated. The changes in *Plasmodium falciparum* asexual and sexual populations in the first 16 h following treatment with artemether-lumefantrine (AL) or artesunate-amodiaquine (AA) were evaluated in 435 children with acute infections. In 162 children there were significant increases in peripheral asexual parasitaemia at 1 h, and in 9 of these, a simultaneous but insignificant increase in gametocytaemia at 1 h, followed thereafter by a precipitous and significant fall in all patients suggesting mobilization into peripheral circulation before a lethal effect. A fifth of mobilized gametocytes were young with a peak at 1 h. Young gametocytes were not found in peripheral blood after 16 h. Time-course of gametocyte sex ratio (GSR) showed a female-male-female-biased cycle at 0 h, 4 h and 8 h, respectively suggesting a selective lethal or removal effect on male gametocytes. Time-course of GSR was independent of density in another cohort of 52 gametocyte carriers treated with AL or AA. All dynamic effects were similar in AL- and AA-treated children. AL or AA acutely mobilize asexual and sexual parasites and alter GSR before a lethal effect, and may reduce transmission by these mechanisms.

## 1246

### CONSTRUCTION OF AN ANTIMALARIAL SET OF COMPOUNDS: A PUBLIC TOOL TO BOOST LEAD DISCOVERY

Laura Sanz<sup>1</sup>, Francisco-Javier Gamo<sup>1</sup>, Cristina de Cózar<sup>1</sup>, Jaime Vidal<sup>1</sup>, Sara Prats<sup>1</sup>, Emilio Alvarez<sup>2</sup>, Jose F. Garcia-Bustos<sup>1</sup>

<sup>1</sup>Diseases of the Developing World (DDW), Medicines Development Campus, GlaxoSmithKline, Tres Cantos (Madrid), Spain, <sup>2</sup>Centro de Investigacion Basica (CIB), Medicines Development Campus, GlaxoSmithKline, Tres Cantos (Madrid), Spain

Drug resistance to current antimalarials is widespread and no new class of antimalarials has been introduced into clinical practice since 1996. Target-based lead discovery has produced disappointing results, generally for lack of whole-cell activity of new compounds. To secure that property in all chemical starting points for new antimalarial leads, we have tested the approximately 2 million-compound library used for high throughput screening at GlaxoSmithKline for inhibitors of *Plasmodium falciparum* intraerythrocytic stages. Using a modified assay based on *P. falciparum* LDH activity as surrogate of parasite growth, we have found ca. 31K primary hits inhibiting *Plasmodium* growth more than 50% at a final compound concentration of 2 mM. To maximize the chances of selecting submicromolar inhibitors only those hits inhibiting more than 80% were retested to confirm activity (ca. 19K compounds). As result of these experiments a set of 13K compounds has been selected as confirmed inhibitors. This set has been named TCAMS (Tres Cantos Antimalarial set). Additional experiments to add knowledge to TCAMS have been performed and will be described. In order to encourage further research by the larger malaria community on the cellular targets and mode of



action of the compounds, we have made public the chemical structures, together with the above mentioned data. All the information is available at the next URL: <http://www.ebi.ac.uk/chemblntd> and ideally, this could catalyse a world-wide chemical genomics approach to better understand the drugable genome of *P. falciparum*.

## 1247

### ADVERSE EVENT PROFILE OF SEVEN-DAY COURSES OF ARTESUNATE IN PATIENTS WITH ACUTE *FALCIPARUM* MALARIA

**Delia Bethell<sup>1</sup>**, Youry Se<sup>1</sup>, Chanthap Lon<sup>1</sup>, David Saunders<sup>1</sup>, Sea Darapiseth<sup>2</sup>, Sabaithip Sriwichai<sup>1</sup>, Jessica Lin<sup>1</sup>, Ans Timmermans<sup>1</sup>, Mali Itveerakul<sup>1</sup>, Ses Sarim<sup>3</sup>, Stuart Tynes<sup>1</sup>, Duong Socheat<sup>2</sup>, Mark Fukuda<sup>1</sup>

<sup>1</sup>Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand, <sup>2</sup>Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia, <sup>3</sup>Tasanh Health Center, Samlot, Cambodia

In a clinical trial of artesunate monotherapy for the treatment of uncomplicated *P. falciparum* malaria in otherwise healthy adults, 143 patients were randomized to receive one of three artesunate regimens: 2, 4 or 6 mg/kg/day for 7 days (n=75, 40 and 28). Adverse events (AEs) were recorded daily for the first 7 days, then weekly for a further 5 weeks. Symptoms present at baseline were not classified as AEs unless they worsened significantly. Overall artesunate was well-tolerated; only 1 patient had to have a dose repeated. One patient in AS6 was withdrawn on Day 1 after developing signs of severe malaria. In total 375 separate AEs were recorded, of which 149 (40%) occurred during the week of artesunate treatment, 67 in AS2, 46 in AS4 and 36 in AS6. During week 1 gastrointestinal disturbances were relatively common and reported by 12%, 35% and 36% patients in AS2, AS4 and AS6 respectively; in contrast, neurological AEs (5%, 3% and 1% of patients) and rashes (3%, 3% and 5%) were relatively uncommon and did not appear to be affected by artesunate dose. Laboratory abnormalities were detected in 44, 53 and 50% patients in the 3 dosing groups; however the majority of these were due to eosinophilia, which was probably attributable to treatment of the malaria infection. The most significant laboratory abnormality was a reduction in absolute neutrophil count which was detected after 3 doses of artesunate in 2 patients (1 in AS4 and 1 in AS6), and in a further 4 patients in AS6 one week after artesunate monotherapy had been completed. This finding led to closure of the high-dose artesunate arm and early termination of the trial. In conclusion these findings confirm that artesunate remains a well-tolerated drug even at high daily doses given for 7 days. However the occurrence of neutropenia in the high-dose arm 7 days after completion of treatment indicates that artesunate has a significant myelosuppressive effect and should be used with caution when high cumulative doses are given.

## 1248

### A PHASE 4 RANDOMISED STUDY TO ASSESS THE TOLERABILITY OF ARTESUNATE-AMODIAQUINE (ASAQ) AND ARTEMETHER-LUMEFANTRINE (AL) FIXED DOSE COMBINATIONS (FDCS) FOR THE TREATMENT OF UNCOMPLICATED *PLASMODIUM FALCIPARUM* (PF) MALARIA IN LIBERIA

**Birgit Schramm<sup>1</sup>**, Parastou S. Valeh<sup>1</sup>, Elisabeth Baudin<sup>1</sup>, Charles S. Mazinda<sup>1</sup>, Richard Smith<sup>1</sup>, Loretxu Pinoges<sup>1</sup>, Timothy Sundaygar<sup>1</sup>, Yah M. Zolia<sup>2</sup>, Joel J. Jones<sup>2</sup>, Eric Comte<sup>3</sup>, Vincent Jullien<sup>4</sup>, Gwenaëlle Carn<sup>5</sup>, Jean-Rene Kiechel<sup>5</sup>, Elizabeth A. Ashley<sup>1</sup>, Philippe J. Guerin<sup>1</sup>

<sup>1</sup>Epicentre, Paris, France, <sup>2</sup>National Malaria Control Programme, Ministry of Health and Social Welfare, Monrovia, Liberia, <sup>3</sup>Médecins Sans Frontières, Geneva, Switzerland, <sup>4</sup>Saint-Vincent de Paul, Paris, France, <sup>5</sup>Drugs for Neglected Diseases initiative, Geneva, Switzerland

Thorough assessment of the tolerability of new artemisinin-based combination therapies (ACTs) in the post-registration phase is needed, especially for the detection of adverse events (AEs) of potential concern such as haematological, liver or neurological toxicities. Our objective was to provide information on ASAQ and AL tolerability in patients  $\geq$  6 years (a less studied population), in a highly endemic area. An open-label, randomized controlled trial was conducted in 1000 patients with uncomplicated Pf malaria in Nimba County, Northern Liberia. Drug allocation was 1:1 (ASAQ Winthrop® : AL Coartem®) to a 3-day observed oral regimen, dosed by weight (ASAQ once daily; AL twice daily with fatty food). Treatment emergent clinical signs and symptoms (open questions) and laboratory events were collected until Day28. PCR corrected cure rates were measured. Overall, 92.1% (ASAQ) and 90.2% (AL) of patients reported at least one AE. Severe AEs were rare and mostly asymptomatic (ASAQ: 3.4%; AL: 1.6%;  $p=0.064$ ). Derangement of liver function tests (ASAT/ALAT increases) classified as severe was infrequent (ASAQ: 0.6%; AL: 0.2%). Few severe but asymptomatic neutropenia AE were reported (ASAQ: 0.4%; AL: 0.2%), and only one patient with moderate anemia at baseline developed severe anemia (ASAQ arm). Some clinical AEs, i.e. fatigue (ASAQ: 39.8%, AL: 16.3%;  $p<0.001$ ), vomiting (ASAQ: 7.1%, AL: 1.6%;  $p<0.001$ ), nausea (ASAQ: 3.2%, AL: 1.0%;  $p=0.015$ ) as well as anemia (ASAQ: 14.9%, AL: 9.8%;  $p=0.013$ ) were reported with significantly higher frequency in the ASAQ arm. Clinical AEs were almost exclusively mild to moderate, occurred mainly during the first 3 days and did not lead to treatment discontinuation. No significant neurological AE was reported. Day28 PCR-corrected efficacy rates were high (ASAQ: 98%, AL: 100%) (No follow-up between Day7-28). Both ASAQ and AL were well tolerated in this large  $\geq$  6years population sample, with no AE-related treatment discontinuation. Notably, hepatotoxicity, neutropenia, anemia or clinically significant neurological toxicities were of no major concern in this study. Efficacy was high with both treatments.

## 1249

### A SURVEY ON CLINICAL SAFETY OF 8-AMINOQUINOLINES

**Hla Yin Myint<sup>1</sup>**, Colin Ohrt<sup>1</sup>, Larry Walker<sup>2</sup>, Nick White<sup>3</sup>, Alan Magill<sup>1</sup>

<sup>1</sup>Walter Reed Army Institute of Research, Silver Spring, MD, United States, <sup>2</sup>University of Mississippi, University, MS, United States, <sup>3</sup>Mahidol-Oxford Research Unit, Mahidol University, Bangkok, Thailand

The 8-aminoquinoline (8-AQ) antimalarials are the only class effective against *Plasmodium vivax* relapse and *P. falciparum* gametocytes. It has long been known that the patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency developed hemolysis and hemolytic anemia (HA) after the administration of 8-AQs. The purpose of this review is to compile all safety data in humans to better define risk-benefit of this class in an era of malaria elimination. We collected and reviewed the unpublished and published literature on safety of 8-AQs studies in human

by contacting research experts in the field, exploring and extracting database from libraries where data are available. Papers in languages other than English were also accessed. Data were entered and analyzed in Excel (2007) and SPSS for Windows, version 16. Between 1926 and December 2009, a total of 589 clinical series of 8-AQ in humans (N=469,375) were identified by the searches. An extensive literature on the safety of 8-AQs, mainly primaquine and pamaquine in humans has been identified. Primaquine receiving patients (N=435,626; 92.8%) were the highest proportion among 8-AQs receiving patients, followed by pamaquine (N=22,735; 4.8%). Among pamaquine receiving patients, 170 (0.7%) had HA resulting in 60 patients required blood transfusion and 10 patients had discontinuation of the drug. Six patients (0.3%) in pentaquine receiving patients had HA and 5 patients had to stop the drug. In primaquine receiving patients, 304 (0.07%) had HA resulting in 25 patients required blood transfusion and 43 patients needed to stop primaquine. Two patients (2/2395; 0.08%) in tafenoquine reported HA and one required blood transfusion. In overall literature, 11 deaths had been identified with pamaquine and only 4 deaths attributable to primaquine were identified in G6PD deficient children. No deaths were reported in other 8-AQs. In conclusion, this database will help public health official make risk-benefit decisions about of the use of the class of drugs for routine malaria management and in elimination operations.

## 1250

### A RANDOMISED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF TWO DIFFERENT DOSING REGIMENS OF DIHYDROARTEMISININ-PIPERAQUINE FOR INTERMITTENT PREVENTIVE TREATMENT OF ADULTS AT HIGH RISK OF MALARIA IN THAILAND

Khin Maung Lwin<sup>1</sup>, Julien Zwang<sup>1</sup>, Aung Phya Phyo<sup>1</sup>, Mya Ohn<sup>1</sup>, Stephane Proux<sup>1</sup>, Mara Leimanis<sup>1</sup>, Joel Tarning<sup>2</sup>, Niklas Lindegardh<sup>2</sup>, Phaikeyong Cheah<sup>2</sup>, Pratap Singhasivanon<sup>3</sup>, Nicholas J. White<sup>2</sup>, Francois Nosten<sup>1</sup>

<sup>1</sup>Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand, <sup>2</sup>Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, <sup>3</sup>Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Piperaquine is an effective antimalarial with a long elimination half life coformulated with dihydroartemisinin (DP). This ACT is efficacious, well-tolerated and has a long post treatment prophylactic effect. DP is a promising candidate for use as intermittent preventive therapy. In areas of low unstable transmission like the Thai-Myanmar border it is often young adult males who bear the brunt of malaria, as their occupation involves travel and exposure to foci of higher transmission. Between October 2006 and June 2008 a double-blind, randomised, placebo-controlled trial was performed in 1000 adult males at risk of acquiring malaria but with a negative malaria smear, attending the clinics of the Shoklo Malaria Research Unit in northwest Thailand. They were randomised into 1 of 3 groups: i) monthly DP treatment (DPm) ii) alternate month treatment (DPalt) and iii) monthly placebo. The primary endpoint was the protective efficacy at 36 weeks of follow-up, defined as one minus the rate ratio of the incidence in the treatment group compared to placebo. The incidence rate of malaria on DPm was 32 episodes per 1000 person-year at risk (PY), compared to 1068 episodes per 1000 PY in the placebo group giving a protective efficacy of 97% (95% CI 95-99, p=0.001). The incidence in the DPalt group was 239 per 1000 PY giving a protective efficacy of 78% (95% CI 72-80, p=0.001) compared to placebo. The number needed to treat (NNT) to prevent an additional case of malaria with DPm and DPalt compared to placebo would be 1 and 4.8 subjects respectively. The adverse event (AE) risk ratio in the DPm group was higher compared to the placebo group for dizziness and diarrhoea (p=0.001 for all comparisons). The mean (SD) number of episodes of AEs was 1.6 (0.5) in the DPm, 1.5 (0.4) in the DPalt, and 1.4 (0.3) in the placebo group. There was a significant difference (p<0.001) in average monthly drug concentrations for the DPm group [29.9 (29.1-30.6) mean (95% CI) ng/mL] compared to the DPalt group [15.4 (15.0-15.9) mean (95% CI) ng/mL]. The 52 subjects contracting malaria had significantly (p<0.001) lower

average monthly piperaquine concentrations [11.4 ng/ml (10.3-12.4)] compared to subjects without malaria episodes (n=747) [23.1 ng/ml (22.6-23.6)]. Monthly DP treatment brought about a dramatic reduction in the incidence of clinical episodes of malaria in adults compared to placebo and may be considered as an alternative malaria control strategy in high risk groups.

## 1251

### SOCIOCULTURAL FACTORS THAT INFLUENCE THE IMPLEMENTATION OF ACT INTERVENTIONS IN TANZANIA: BASELINE RESULTS FROM A QUALITATIVE EVALUATION

Denise Roth Allen<sup>1</sup>, Emmy Metta<sup>2</sup>, Catherine Goodman<sup>3</sup>, Salim Abdulla<sup>2</sup>, S. Patrick Kachur<sup>1</sup>

<sup>1</sup>Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States, <sup>2</sup>Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania, <sup>3</sup>London School of Tropical Medicine and Hygiene, London, United Kingdom

In 2010 Tanzania will begin providing subsidized antimalarial combination therapy (ACT) through retail drug outlets and supplying all government health facilities with malaria rapid diagnostic tests (RDT). A multidisciplinary evaluation to assess the effectiveness of these interventions on access and targeting of ACTs is currently underway in three regions. One component is examining sociocultural factors influencing implementation in two focus districts. We are using rapid ethnographic methods to document provider and community experiences with malaria diagnosis and treatment. Data will be collected at baseline and post-intervention and timed to capture seasonal differences. Baseline data collection in one site began in November 2009 and included 7 in-depth interviews with health facility and retail drug providers about their experiences with malaria case management, 4 focus groups with community members about their care seeking behaviors and experiences with ACT, and 15 in-depth interviews with people who experienced a recent fever episode to document actual care-seeking behaviors. Artemether-Lumefantrine (ALu) was viewed in a positive light at 3 of the 4 health facilities visited but was perceived as no longer efficacious at the fourth. Although retail providers also had a positive opinion of ALu, none were legally able to sell it. Some community members spoke of ALu's ability to cure malaria or cause side effects as dependent on an individual's body or blood group rather than on the drug itself. Although many viewed ALu in a positive light, complaints about "too many" tablets in the treatment dose were common. Both providers and community members decried the lack of diagnostic tests in government dispensaries. Community members referred to clinical diagnosis as "treating by guessing" and voiced concerns that ACTs were being prescribed for non-malarial illnesses. Despite these concerns, community members expressed a preference for health facilities over retail outlets for malaria treatment. In conclusion, provider and community perceptions of ALu are mostly positive, although some concerns about its efficacy and treatment regimen were noted. Widespread complaints about the lack malaria diagnostics suggest that the implementation of RDTs will be positively received, although acceptance of RDT results remains to be seen.

## 1252

### INVESTIGATING THE RELATIONSHIP BETWEEN PRIMAQUINE HEMOTOXICITY AND ANTI-MALARIAL EFFICACY THROUGH METABOLIC PROFILING I: METABOLITE IDENTIFICATION

Brandon S. Pybus, Jason Sousa, Xiannu Jin, Dustin Carroll, Thu Lan Luong, Rebecca Barnhart, NeCole Reese, Vanessa Collazo, Charlotte Lanteri, Hans Wei, Michael P. Kozar, Victor Melendez Walter Reed Army Institute of Research, Silver Spring, MD, United States

The 8-aminoquinoline drug primaquine (PQ) is currently the only approved drug for the treatment of relapsing malaria, yet PQ is known to cause hemolytic anemia in patients with G6PD deficiency. Proposed mechanisms of toxicity suggest a role for transient reactive oxygen species formed

as a byproduct of metabolism. Interestingly, evidence also points to an active metabolite playing a vital role in the drug's antimalarial efficacy. A complete understanding of the overall metabolic profile of PQ is necessary to identify potential routes to circumvent toxicity while maintaining efficacy. Our lab is currently seeking to fully characterize the role of biotransformation in both the efficacy and toxicity of PQ. Accordingly, we have initiated a series of experiments to detect previously postulated metabolites, identify and characterize previously unknown species, and determine the role of individual enzymes in PQ's metabolic pathway. We have begun to explore metabolite formation in a series of *in vitro* systems, including microsomal and hepatocyte incubations, as well as in *in vivo* samples from collaborators' pharmacokinetic studies. These initial studies indicate the presence of several previously postulated metabolites, such as carboxyprimaquine, 5-hydroxyprimaquine, and 6-desmethylprimaquine, as well as suggesting the presence of species that have not been previously reported, such as aldehyde, acetyl, and ketone metabolites. In conjunction with enzyme phenotyping studies (see "Investigating the Relationship Between Primaquine Hemotoxicity and Anti-malarial Efficacy Through Metabolic Profiling II: Enzyme Phenotyping"), we seek to better understand interspecies differences in PQ metabolism that may enhance interpretation of animal models, correlate metabolites with specific enzyme pathways, and provide insight into the relationship, if any, between PQ hemotoxicity and anti-malarial efficacy.

## 1253

### INVESTIGATING THE RELATIONSHIP BETWEEN PRIMAQUINE HEMOTOXICITY AND ANTI-MALARIAL EFFICACY THROUGH METABOLIC PROFILING II: ENZYME PHENOTYPING

**Xiannu Jin**, Brandon S. Pybus, Jason Sousa, Dustin Carroll, ThuLan Luong, Rebecca Barnhart, NeCole Reese, Vanessa Collazo, Michael P. Kozar, Victor Melendez

*Walter Reed Army Institute of Research, Silver Spring, MD, United States*

The 8-aminoquinoline drug primaquine (PQ) is currently the only drug in use against the persistent malaria caused by the hypnozoite forming strains *Plasmodium vivax* and *P. ovale*. However, the widespread use of PQ is complicated by its known hemotoxicity in patients with a genetic deficiency in G6PD, an enzyme implicated in cells' ability to combat oxidative stress. To date, the exact mechanisms and metabolic species responsible for PQ's hemotoxic and anti-malarial properties are not well understood. A better understanding of the metabolic profile of PQ may enable the development of analogs that maintain efficacy while minimizing or eliminating hemotoxicity. In the present study, the metabolism of PQ was evaluated in several *in vitro* systems, including: human hepatocytes and pooled human liver microsomes, with and without enzyme inhibitors; and recombinant metabolic enzymes from the cytochrome P450 (CYP), monoamine oxidase (MAO), and flavin-containing monooxygenase (FMO) families. PQ metabolism was measured as the decline of the parent compound peak in LC-MS chromatograms. As a result of this work, CYPs 1A2, 2D6, and 3A4, as well as MAO-A, MAO-B, and FMO-3 have been implicated as the key enzymes associated with PQ metabolism. Enzyme kinetics studies are currently in progress and will be presented. The incubation mixtures were also examined as part of our metabolite identification studies (see "Investigating the Relationship Between Primaquine Hemotoxicity and Anti-malarial Efficacy Through Metabolic Profiling I: Metabolite Identification"). Correlation of metabolites with specific enzymes will allow for a more complete understanding of the pathways associated with PQ metabolism and the relationship between efficacy and toxicity.

## 1254

### EVALUATION OF THE COMPARATIVE EFFICACY AND SAFETY OF ARTEMETHER-LUMEFANTRINE, ARTESUNATE PLUS AMODIAQUINE AND ARTESUNATE PLUS AMODIAQUINE PLUS CHLORPHENIRAMINE (ARTEMOCLO™) FOR ACUTE UNCOMPLICATED MALARIA IN NIGERIAN CHILDREN

**Catherine O. Falade**<sup>1</sup>, Hannah O. Dada-Adegbola<sup>2</sup>, Olusegun G. Ademowo<sup>3</sup>, Oyekanmi Nash<sup>3</sup>, Oluwatoyin O. Ogunkunle<sup>4</sup>

<sup>1</sup>*Department of Pharmacology and Therapeutic, University of Ibadan, Ibadan, Nigeria*, <sup>2</sup>*Department of Medical Microbiology, University of Ibadan, Ibadan, Nigeria*, <sup>3</sup>*IMRAT, University of Ibadan, Ibadan, Nigeria*, <sup>4</sup>*Department of Pediatrics, University of Ibadan, Ibadan, Nigeria*

Artemisinin based combination therapy (ACT) is the current gold standard for the treatment of acute uncomplicated malaria. Amodiaquine (AQ) plus artesunate (AS) is one of the preferred ACTs. Chlorpheniramine (CP) has been shown to enhance the efficacy of amodiaquine. In an open labeled randomized trial, the comparative efficacy and safety of artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and artesunate-amodiaquine-chlorpheniramine (AQC) was evaluated in 159 Nigerian children aged 6months to 10years with acute uncomplicated malaria. Enrollees were randomized to receive AL, ASAQ or AQC at standard doses over 3 days. (AQC: 100mg AS + 300AQ + 4mg CP/tablet using AQ 10mg/kg/day for dosing). Assessment was by 28day WHO 2003 efficacy test (PCR unadjusted cure rates only). 144/159 (90.6%) completed the study. Mean fever and parasite clearance times for AL, ASAQ and AQC were similar ( $p=0.94$  and  $0.12$  respectively). Day 14 ACPR was 100% for AL and AQC while that for ASAQ was 98% ( $p=0.39$ ). Day 28 ACPR were 91.1%, 92% and 95.9% for AL, ASAQ and AQC respectively ( $p=0.62$ ). ACPR at day 42 for 115/144 (79.9%) evaluable children were similar ( $p=0.48$ ). AQC gave the best parasitemia clearance and hematological recovery on day2 ( $p=0.022$  and  $0.018$  respectively). The three ACTs were well tolerated. In conclusion, the three drugs were efficacious and safe. AQC gave non-significant higher ACPR than the other two on days 28 and 42. The better hematological recovery and parasite clearance with AQC on day 2 may be a fine indication of the enhancement ASAQ effect.

## 1255

### INTERMITTENT PREVENTIVE TREATMENT WITH SULFADOXINE-PYRIMETHAMINE IN PREVENTING MALARIA AND ANEMIA IN PREGNANCY AMONG WOMEN VISITING KORLE-BU TEACHING HOSPITAL, ACCRA, GHANA

**Nana O. Wilson**<sup>1</sup>, Fatou Ceesay<sup>1</sup>, Yassa Ndjakani<sup>1</sup>, Naomi Lucchi<sup>2</sup>, Jonathan Stiles<sup>1</sup>

<sup>1</sup>*Morehouse School of Medicine, Atlanta, GA, United States*, <sup>2</sup>*Centers for Disease Control and Prevention, Malaria Branch, Atlanta, GA, United States*

Malaria and anemia takes a great toll on women in sub-Saharan Africa in terms of maternal morbidity and adverse birth outcomes. Intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) is currently recommended for prevention of malaria in pregnancy in endemic areas. However, the effectiveness of this approach in preventing malaria and anemia during pregnancy is unclear. The objective of the study was to evaluate the effectiveness of IPTp-SP in preventing malaria and anemia among pregnant women attending antenatal clinic (ANC) at Korle-Bu Teaching Hospital (KBTH) in Accra, Ghana. A cross-sectional study comparing malaria and anemia incidence among pregnant women using IPTp-SP with non-IPTp-SP users was conducted. A total of 363 pregnant women were recruited of which 202 were users of IPTp and 161 were IPTp non-users. Malaria parasites and hemoglobin levels were determined. Thirty-one (15.3%) women using IPTp had malaria compared to 72 (44.7%) of women who did not use IPTp,  $p < 0.001$ . The number of anemic women not utilizing IPTp was significantly higher (58.4%, 94/161) than women using IPTp (22.8%, 46/202),  $p < 0.001$ . Controlling for



age and other variables, the difference in the incidence of malaria (odds ratio (OR) = 0.26, 95% confidence interval (CI) = 0.15 - 0.44,  $p < 0.001$ ) and anemia (OR = 0.19, 95% CI = 0.11 - 0.34,  $p < 0.001$ ) remained significant. Regardless of reported resistance to SP for malaria treatment, the IPTp-SP regime is effective in preventing malaria and anemia among pregnant women visiting ANC at KBTH. The implementation of the IPTp-SP strategy holds great promise for reducing the burden of malaria and anemia in pregnancy in Ghana.

## 1256

### COST AND COST-EFFECTIVENESS OF INTERMITTENT PREVENTIVE TREATMENT OF MALARIA IN INFANTS WITH SULFADOXINE PYRIMETHAMINE IN SENEGAL

**Mouhamed Ndiaye**<sup>1</sup>, Jean Louis Ndiaye<sup>1</sup>, Abdou Diop<sup>1</sup>, Doudou Sow<sup>1</sup>, Ousmane Sy<sup>1</sup>, Alexandra De Sousa<sup>2</sup>, Oumar Gaye<sup>1</sup>

<sup>1</sup>Faculty of Medicine UCAD, Dakar, Senegal, <sup>2</sup>UNICEF, New York, NY, United States

Intermittent Preventive Treatment in infants (IPTi) is a new promising intervention for malaria control in Sub Saharan Africa which can be delivered through the existing routine Expanded Programme on Immunization (EPI). Although the efficacy of IPTi is proven, there is limited economic evaluation data on scaling up IPTi using sulfadoxine pyrimethamine (SP) as a strategy for malaria control in Senegal. Implementation scale-up cost was calculated by estimating IPTi incremental costs in the start-up year and in subsequent years. Costs included were the financial costs of delivering IPTi to infants (drugs and equipment) and of programme activities. In recurrent years, because a survey in IPTi areas showed high acceptability and health care worker knowledge, programme costs included only IPTi administration and safety surveillance. To estimate IPTi cost-effectiveness (IPTi net cost per case of malaria averted, per death averted, per year of life saved, and per disability adjusted life years) we calculated the intervention's economic costs in recurrent years using a pooled efficacy analysis. A time and motion study was also conducted to assess staff time on IPTi delivery and the associated costs. In order to deliver IPTi-SP to 17,500 infants the total amount of the financial expenditure of programme implementation was \$40,753. IPTi incremental financial costs on start up year (3.31 \$US/infant) were substantially higher than in recurrent years (1.043 \$US/infant). In startup years communication activities mobilized the most important expenditure (30%) meanwhile, half of the total programme resources is allocated to capacity building development of professional staff. In routine, the part of programme costs was US\$ 0.81 per infant, and patient costs (drug and utensils) only 23.7 US cent/infant. The time needed to administer IPTi was an average of 2.19 min/child, representing 7% of the time spends by health workers in immunization clinics. The net cost per averted case of malaria was \$22.11. The cost per death averted was \$ 447, per year of life saved \$ 23.84 and per DALYs \$ 25.39. In conclusion, IPTi with SP through EPI can be scaled up successfully at a low cost. Using pooled efficacy results from previous IPTi trials we can see that it is a highly cost effective intervention in the study sites selected. But, the IPTi cost-effectiveness in the other areas in Senegal where malaria transmission is not high, worth assessing.

## 1257

### MALARIA HIGH THROUGHPUT SCREENING ON A GLOBAL SCALE

**Sandra Duffy**<sup>1</sup>, Ian C. Bathurst<sup>2</sup>, Vicky M. Avery<sup>1</sup>

<sup>1</sup>Discovery Biology, Griffith University, Brisbane, Australia, <sup>2</sup>Medicines for Malaria Venture, Geneva, Switzerland

This poster provides a brief summary of the principles and performance of an Anti-Malarial Imaging Assay utilized to screen more than 2.5million compounds. In collaboration with MMV, chemical libraries, which are structurally highly diverse, have been sourced from pharmaceutical, biotech and academic partners world-wide. Data is presented on

significant aspects of assay development and HTS performance, including assay throughput, precision, reproducibility, sensitivity, and hit-rate. In addition, retest confirmation in dose response against at least one *Plasmodium* parasite strain and the mammalian cell line, HEK293, performed to ascertain the selectivity index, is discussed. The data described, demonstrates the variation of library formats from the different sources, including library storage plate specifications/descriptions, compound concentration and volume, plate seals and in-plate control well availability. All of these aspects have to be considered when processing the plates for HTS, as well as the handling of large data sets. An overview of the compound libraries screened to date and how they performed in the Anti-Malarial Imaging Assay is presented.

## 1258

### PLASMODIUM BERGHEI ANKA: SELECTION OF RESISTANCE TO PIPERAQUINE AND LUMEFANTRINE IN A MOUSE MODEL

**Daniel M. Kiboi**

Kenya Medical Research Institute, Nairobi, Kenya

We have selected piperazine (PQ) and lumefantrine (LM) resistant *Plasmodium berghei* ANKA parasite lines in mice by drug pressure. Effective doses that reduce parasitaemia by 90% (ED90) of PQ and LM against the parent line were 3.52 and 3.93 mg/kg respectively. After drug pressure (more than 27 passages), the selected parasite lines had PQ and LM resistance indexes (I90) [ED90 of resistant line/ED90 of parent line] of 68.86 and 63.55 respectively. After growing them in the absence of drug for 10 passages and cryo-preserving them at -80 °C for at least 2 months, the resistance phenotypes remained stable. Cross-resistance studies showed that the PQ-resistant line was highly resistant to LM, while the LM-resistant line remained sensitive to PQ. Thus, if the mechanism of resistance is similar in *P. berghei* and *P. falciparum*, the use of LM (as part of Coartem®) should not select for PQ resistance. The stability of these phenotypes indicates that underlying mechanisms of resistance are probably coded into the cell genome and hence form the platform for studies on mechanisms of resistance of LM and PQ in *P. berghei*.

## 1259

### EFFICACY OF CHLOROQUINE OR ARTEMETHER-LUMEFANTRINE AGAINST PLASMODIUM VIVAX AND ARTEMETHER-LUMEFANTRINE AGAINST UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN CENTRAL ETHIOPIA

**Bereket Hailegiorgis**<sup>1</sup>, Jimee Hwang<sup>2</sup>, Zenebe Melaku<sup>1</sup>, Samuel Girma<sup>1</sup>, Takele Teshi<sup>1</sup>, Sintayehu Gebresellasie<sup>1</sup>, Leykun Demeke<sup>1</sup>, David Hoos<sup>3</sup>, Kedir Gobena<sup>4</sup>, Moges Kassa<sup>5</sup>, Daddi Jima<sup>6</sup>, Richard Reithinger<sup>7</sup>, Joseph Malone<sup>8</sup>, S. Patrick Kachur<sup>2</sup>, Scott Filler<sup>2</sup>

<sup>1</sup>International Center for AIDS Care and Treatment Programs, Addis Ababa, Ethiopia, <sup>2</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States, <sup>3</sup>International Center for AIDS Care and Treatment Programs, New York, NY, United States, <sup>4</sup>Oromia Regional Health Bureau, Ethiopia, Addis Ababa, Ethiopia, <sup>5</sup>Ethiopian Health and Nutrition Research Institute, Addis Ababa, Ethiopia, <sup>6</sup>Federal Ministry of Health, Addis Ababa, Ethiopia, <sup>7</sup>United States Agency for International Development, Addis Ababa, Ethiopia, <sup>8</sup>Centers for Disease Control and Prevention, Addis Ababa, Ethiopia

In-vivo efficacy assessments of the first-line treatments for both *Plasmodium falciparum* (Pf) and *Plasmodium vivax* (Pv) are essential for effective case management in Ethiopia. In Ethiopia, first-line treatment is artemether-lumefantrine (AL) for Pf and chloroquine (CQ) for Pv. However, with stock-outs of chloroquine and limited laboratory confirmation of species, AL becomes the default treatment for all malaria infections. Between October-November 2009, we conducted a 42-day, three arm, open label study of AL for Pf, AL for Pv, and CQ for Pv in individuals >6 months age at two sites in Oromia Region who had documented Pf or

Pv mono-infection according to the standard WHO protocol. The primary and secondary endpoints were PCR uncorrected and corrected adequate clinical and parasitological response on days 28 and 42, respectively. Tests for drug levels, genotyping, and molecular markers of resistance for all three arms are currently in process to differentiate recrudescence from new infection. Of 4426 patients tested, those with confirmed *falciparum* malaria were enrolled and treated with AL (n=120); patients confirmed with vivax malaria were enrolled, randomized and treated with AL (n=122) or CQ (n=120). The uncorrected adequate clinical and parasitological response for Pf patients treated with AL was 99% on day 28 and 42. Eight Pf patients (7%) presented with Pv infection during follow-up and were excluded from the per protocol analysis. The cure rates for Pv patients treated with AL were 76% on day 28 and 58% on day 42; those for Pv patients treated with CQ were 91% on day 28 and 68% on day 42. There were very few day 3 positives with one case each in the Pf and Pv-CQ arms. There were no serious adverse events. Nausea/vomiting and oral lesions were the most common adverse events. AL remains a highly effective treatment for uncomplicated *falciparum* malaria in the study setting. Both treatments of vivax malaria were complicated by high rates of recurrent parasitemia. Molecular studies may help to differentiate recrudescence from new infections, but in either case, CQ was more effective than AL in delaying the recurrent parasitemia. Effectively managing Pv relapse poses a major challenge to malaria control.

## 1260

### NOVEL HIGH THROUGH-PUT MOLECULAR DIAGNOSTIC ASSAY DETECTS INCREASED *PLASMODIUM VIVAX* ANTIMALARIAL RESISTANCE IN PAPUA NEW GUINEA

Lincoln Timinao<sup>1</sup>, Céline Barnadas<sup>1</sup>, Serej D. Lee<sup>1</sup>, Ore Topurua<sup>1</sup>, Jonah Iga<sup>1</sup>, Peter A. Zimmerman<sup>2</sup>, Peter M. Siba<sup>1</sup>, Ivo Mueller<sup>1</sup>

<sup>1</sup>Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea, <sup>2</sup>Center for Global Health and Diseases, Case Western Reserve University, Cleveland, USA, Goroka, Papua New Guinea

Amodiaquine or chloroquine plus sulfadoxine pyrimethamine (SP) have been the first line antimalarial treatments in Papua New Guinea (PNG) since 2000. This regime was designed for treating *Plasmodium falciparum* infections but because four species of human malaria parasites are transmitted in PNG, potential for development of drug resistance exists for each individual species. In numerous studies, *P. falciparum* resistance to 4-aminoquinolines and SP has been associated with mutations in *dhfr* (dihydrofolate reductase), *dhps* (dihydropteroate synthase), *crt* (chloroquine resistance transporter) and *mdr1* (multidrug resistance 1) genes. Orthologs of these genes and similar patterns of sequence polymorphisms have been identified in *P. vivax*. Following development of a novel molecular diagnostic multiplex strategy (Polymerase Chain Reaction - Ligase Detection Reaction- Fluorescent-Microsphere based Assay), we conducted a study to screen *P. vivax* for molecular markers of resistance in *pvdhfr*, *pvdhps* and *pvmr1*. A total of 2381 blood samples collected from Madang and East Sepik Provinces were first evaluated for *Plasmodium* species infection status. Of these, 590 *P. vivax* infected samples were screened for single nucleotide polymorphisms (SNPs; 26 different alleles) using the multiplex drug resistance diagnostic assay. High rates of double and triple mutant parasites at *pvdhfr* codons 57-58-61 and mutant 117T were detected. We also detected a high rate of mutation at *pvdhps* codon 647 (S-->P) and at *pvmr1* codon 976 (Y-->F). Patients from Madang were significantly more often infected with highly mutant parasites than in East Sepik Province possibly reflecting a different evolution of parasites populations (p<0.01, *dhfr* triple mutant allele). Genotyping methods developed here will improve our understanding of drug resistance in *P. vivax* and help monitor the effectiveness of new artemisinin-based combinations in PNG.

## 1261

### MONITORING *EX VIVO* MALARIA DRUG SUSCEPTIBILITY IN SENEGAL AFTER INTRODUCTION OF ARTEMISININ-BASED COMBINATION THERAPIES

Papa Diogoye Sene<sup>1</sup>, Daouda Ndiaye<sup>1</sup>, Daria V. Tyne<sup>2</sup>, Amanda Lukens<sup>2</sup>, Kayla Barnes<sup>2</sup>, Vishal Patel<sup>3</sup>, Michelle LeRoux<sup>2</sup>, Omar Ndir<sup>1</sup>, Souleymane Mboup<sup>1</sup>, Sarah Volkman<sup>2</sup>, Johanna Daily<sup>4</sup>, Dyann Wirth<sup>2</sup>

<sup>1</sup>Faculty of Medicine and Pharmacy, Cheikh Anta Diop University, Dakar, Senegal, <sup>2</sup>Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, United States, <sup>3</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States, <sup>4</sup>Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States

Malaria remains an important public health issue in developing countries, despite efforts to reduce morbidity and mortality from this disease. Drug treatment with artemisinin-based combination therapy (ACT) is critical to achieving reduction of malaria burden. With increasing drug resistance, malaria drug policies changed in Senegal in 2006 and ACTs were introduced. In this study we determined the *ex vivo* drug resistance profile of ~250 field isolates from Thies, Senegal since 2007 using a non-radioactive DAPI assay to better anticipate resistance and ensure that ACTs are still effective. Testing each drug individually serves as an "early warning" system for reduced responses to either artemisinin compounds or the partner drugs before any clinical failures may be observed. Blood samples were collected from patients with clinical malaria during the three-month (September to December) transmission season in years 2007 through 2009. Blood samples containing 0.1 - 1% parasitemia were incubated with various drugs to determine IC50 values. For 2007, 2008 and 2009 there were 44, 110, and 90 samples analyzed, respectively. Parasites were found resistant (data by year: 2007, 2008 and 2009) to chloroquine (36.4%, 32%, 14%); amodiaquine (9%, 8%, 0%); pyrimethamine (52.27%, 68%, 74%); and tolerant to artemisinin (19%, 18%, 30%). In 2007 and 2009 quinine was tested with 27.7% and 4% resistance respectively and mefloquine showed 54% and 80% resistance in 2008 and 2009 respectively. Artesunate was only tested in 2009 and showed good correlation with artemisinin response. Several parasites stains demonstrated multiple drug resistance, with no evidence of cross-resistance between chloroquine and amodiaquine. Drug sensitivities were observed for all compound classes, however some parasites displayed significant levels of multi-drug resistance. With changing drug use, sensitivities to some drugs (such as chloroquine) are increasing. Decreasing responses to artemisinin suggests that parasites may become less responsive to these compounds and that careful monitoring is required. The decrease of artemisinin sensitivity and the increase of chloroquine sensitivity need to be continually monitored in order to inform drug policy makers.

## 1262

### MOLECULAR SURVEILLANCE OF DRUG RESISTANCE MARKER GENES IN *PLASMODIUM VIVAX* ISOLATES CAUSING SEVERE MANIFESTATIONS FROM INDIA

Shilpi Garg<sup>1</sup>, Vishal Saxena<sup>1</sup>, Dhanpat K. Kochar<sup>2</sup>, Sanjay K. Kochar<sup>3</sup>, Ashis Das<sup>1</sup>

<sup>1</sup>Birla Institute of Technology and Science, Pilani, Pilani, India, <sup>2</sup>Kothari Medical and Research Institute, Bikaner, Rajasthan, India, <sup>3</sup>S.P. Medical College, Bikaner, Rajasthan, India

India is a major contributing country to the worldwide burden of *Plasmodium vivax* contributing to almost 70% of the total cases in South East Asia with more than 50% owing to *P. vivax*. With the recent reports of Chloroquine resistance in *P. vivax* and the parasite causing severe manifestations like Cerebral Malaria, ARDS, Acute Renal Failure, Hepatic Dysfunction, etc. (as reported previously) the studies on this parasite

has become important. Due to the lack of information on the resistance pattern of various antimalarial drugs in severe *P. vivax* population, we studied the degree of polymorphism in the drug resistance marker genes that can hypothetically lead to an indication of the state of resistance of these parasites. In *P. falciparum*, it has been suggested that the increase in morbidity and mortality is due to rise in prevalence of parasite resistance to various antimalarial drugs. But in *P. vivax*, it is not known whether it is driven by drug failure or some other changes in intrinsic parasite factors that enhance parasite multiplication and virulence. In this study, the analysis of various drug resistance marker genes (*mdr-1* and *crt-o* for CQ resistance and *dhfr* and *dhps* for SP resistance respectively) showed mainly the wild type genotype. However, in contrast to the reported limited polymorphism in the *PvDHP5* gene, 4 novel mutations were observed in our severe *P. vivax* isolates. But the homology modeling and molecular docking studies showed no effect of these mutations on Sulfadoxine binding. Thus it appears to indicate the absence of a drug resistant status in these severe *P. vivax* samples. The recent reports have also suggested an increased expression of the chloroquine resistance marker genes in severe vivax malaria. The microarray expression data for our severe *P. vivax* isolates also showed any one of these genes; *Pvcrt* or *Pvm-dr-1* to be upregulated. These finding on increased expression levels of genes likely involved in antimalarials drug resistance supports to further explore potential of these genes as molecular markers of severe disease in *P. vivax*.

## 1263

### TOWARDS VALIDATION OF GENOTYPE: RESISTANCE INDEX AS A MOLECULAR TOOL IN MALARIA DRUG RESISTANCE SURVEILLANCE IN MALI

**Mamadou Wele**, Hamidou Niangaly, Aldiouma Guindo, Abdoul H Beavogui, Aboubacar Sadou, Blaise Dackouo, Cheik Omar Papa Sangare, Ogobara Doumbo, Abdoulaye Djimde  
MRTC, Bamako, Mali

The resistance of *Plasmodium falciparum* to the chloroquine is conferred by point mutations on PfCRT, a protein located on the digestive vacuole membrane. PfCRT 76 T mutations was identified as a molecular marker of *P. falciparum* *in vivo* and *in vitro* resistance to chloroquine. The prevalence of mutant allele PfCRT 76T was used by Djimde and collaborators in Mali to calculate the Genotype: Resistance Index. Given this importance, (GRI). We aimed in this work to enhance the use of this molecular marker in epidemiological surveillance of drug resistance in other sites in Mali. We conducted a prospective chloroquine efficacy studies in Kangaba, Kella in 2001/03 and Pongonon in 2007. Malaria is hyper-endemic in all villages with seasonal peaks of transmission. The protocol was reviewed and approved by the Institutional Review Board of the faculty of Medicine, Pharmacy and Stomatology, University of Bamako and the US national institut of Allergy and Infectious Disease. The informed consent was obtained from children parents or tutors prior to their enrollment in the study. The malaria cases were recruited according to WHO 2000 protocol. The cases were treated with chloroquine and followed on days 3, 7, and 14. *P. falciparum* DNA was extracted from finger prick blood blotted onto filter paper and the PfCRT K76T genotypes were analyzed by nested PCR. For analysis purposes, mixed infections were categorized as mutant PfCRT 76T and GRI was calculated dividing the PfCRT 76T prevalence by the therapeutic failure rate. We included 418 cases in Kella, 336 cases in Kangaba and 259 cases in Pongonon a total of 1,013 subjects with uncomplicated malaria. We determined the IGR for children less than 5 years, aged between 6 and 10 years and more than 11 years. We found that the parasitological failure rate was 2-3 times less than the prevalence of the mutant allele PfCRT 76T. The IGR means were 1.2; 1.25 and 1.6 respectively in Pongonon, Kangaba and Kella in children less than 5 years. In the general population, they were 1.9; 1.7 and 2.2 respectively in Pongonon, Kella and Kangaba. Our data have shown that the prevalence of mutant allele PfCRT 76T could be used to estimate a potential chloroquine treatment failure in Mali.

## 1264

### CHLOROQUINE RESISTANCE HAPLOTYPES IN THE *PF CRT* AND *MDR1* GENES OF GHANAIAN ISOLATES USING PCR AND SEQUENCE SPECIFIC OLIGONUCLEOTIDE PROBE-ENZYMELINKED IMMUNOSORBENT ASSAY (SSOP-ELISA)

**Sena A. Matrevi**<sup>1</sup>, Charles A. Brown<sup>2</sup>, Patrick F. Ayeh-Kumi<sup>3</sup>, Kwadwo A. Koram<sup>1</sup>

<sup>1</sup>Noguchi Memorial Institute for Medical Research, Accra, Ghana, <sup>2</sup>School of Allied Health Sciences, Accra, Ghana, <sup>3</sup>University of Ghana Medical School, Accra, Ghana

Despite decades of research to reduce the burden of malaria disease, malaria remains a major threat to humanity causing about 1.5 to 3 million deaths a year. Prompt diagnosis and effective treatment of malaria remain the main strategies to reduce the intolerable burden of the disease in the absence of an effective vaccine. Due to the widespread resistance of *Plasmodium falciparum* to the commonest and cheapest antimalarial drug, chloroquine (CQ), it is important to provide effective antimalarial drug resistance surveillance system in the country. The aim of this study was to determine the single nucleotide polymorphisms (SNPs) in the *crt*, and *mdr1* genes using PCR and SSOP-ELISA and to capture any SNPs that might have been missed by the use of PCR and restriction fragment length polymorphism (RFLP) in a previous work. The study was carried out in the Hohoe District and Navrongo War Memorial hospitals. Children <5years (male and female) reporting at the outpatients departments at the two hospitals with uncomplicated malaria were recruited. Nested PCR followed by SSOP-ELISA was performed to determine the presence of SNPs responsible for CQ resistance. Fifty-nine participants (29 males and 30 females) were recruited. The SSOP-ELISA results showed the baseline prevalence of the common CQ resistance haplotype CVIET observed for all resistant parasites to be 60% at Navrongo and 56% at Hohoe and the less common haplotype SVMNT (found sporadically in Africa) was 10% at Navrongo and 30.8% at Hohoe. The amino acid change at codon 86 for the *mdr1* genes had a prevalence of 90% at Navrongo and 95% and Hohoe. Using PCR and SSOP-ELISA, the SVMNT mutation which was missed in an earlier work was captured for the first time using only PCR and RFLP. PCR and SSOP-ELISA has a great potential to be used as a tool for general drug resistance surveillance in Ghana since it is faster, provides results comparable to those obtained in previous work and can also capture new point mutations.

## 1265

### HIGH THROUGHPUT GENOTYPING OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE *PLASMODIUM FALCIPARUM DHFR* GENE BY ASYMMETRIC PCR AND MELT-CURVE ANALYSIS

**Rochelle Cruz**<sup>1</sup>, Sandra Shokoples<sup>2</sup>, Dammika Manage<sup>1</sup>, Stephanie K. Yanow<sup>1</sup>

<sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Provincial Laboratory of Public Health, Edmonton, AB, Canada

Mutations within the *Plasmodium falciparum dhfr* gene confer resistance to sulfadoxine-pyrimethamine (SP). Single nucleotide polymorphisms (SNPs) within codons 51, 59, 108 and 164 in the *Pfdhfr* gene are associated with SP treatment failure. We developed an assay using asymmetric real-time PCR and melt-curve analysis to genotype clinical samples. Unlabeled probes specific to each SNP hybridize differentially to mutant and wild-type sequences within the amplicon, generating distinct melting curves. Analytical validation was performed using plasmids, genomic DNA from reference strains, and parasite cultures. Correct genotypes were identified with 100 copies of template. The performance of the assay was evaluated with a blind panel of clinical isolates with low parasitemias. Concordance with DNA sequencing ranged from 84% to 100%. Our assay provides a number of technical improvements that facilitate high throughput screening of patient samples to identify SP resistant malaria.



## 1266

**PREVALENCE OF *PFMDR1* AMPLIFICATION IN *PLASMODIUM FALCIPARUM* FROM FIVE SITES IN CAMBODIA**

Rithy Sem<sup>1</sup>, Dysoley Lek<sup>1</sup>, Sinuon Muth<sup>1</sup>, Socheat Duong<sup>1</sup>, Frederic Arie<sup>2</sup>, William O. Rogers<sup>3</sup>

<sup>1</sup>National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia, <sup>2</sup>Institut Pasteur du Cambodge, Phnom Penh, Cambodia, <sup>3</sup>Naval Medical Research Unit #2, Jakarta, Indonesia

Artemisinin resistance is a potentially serious threat to current artemisinin combination therapies (ACT) for *Plasmodium falciparum* malaria. In Cambodia, resistance to artesunate-mefloquine (A+M), the current first-line therapy for uncomplicated *P. falciparum* malaria in most of the country, may pose a significant problem. Since resistance to A+M is likely to arise on a background of mefloquine resistance, we sampled parasite genomes from five sites around Cambodia and assayed for amplification of the *pfmdr1* gene, a mutation associated with mefloquine resistance. We measured *pfmdr1* copy number using a previously described quantitative RT-PCR assay using the single copy *P. falciparum* beta-tubulin gene as an internal control. Among 776 cases the preliminary estimated prevalences and 95% confidence intervals of parasites with >1.5 copies of *pfmdr1* at the sites were, Chumkiri, 0.64 (0.49, 0.77); Trapeang Prasat 0.51 (0.47, 0.55); Kratie 0.09 (0.04, 0.19); Khsim 0.27 (0.12, 0.46); and Rattanakiri, 0.09 (0.04, 0.17). The estimated means and standard deviations of the *pfmdr1* copy number at the sites were, Chumkiri, 2.8 (2.1); Trapeang Prasat, 2.0 (1.4); Kratie, 1.0 (0.5); Khsim 1.3 (0.6); Rattanakiri, 1.1 (0.7). The finding of elevated *pfmdr1* copy number in Chumkiri is expected; A+M failure rates of approximately 15% were found in Chumkiri in 2006-2007. The lack of widespread *pfmdr1* amplification in the eastern sites, Kratie, Khsim, and Rattanakiri, is consistent with the reported continued efficacy of mefloquine in eastern Cambodia. The relatively high rate of *pfmdr1* amplification at Trapeang Prasat, Oddarmeanchey Province, may represent spread of mefloquine resistance from the nearby provinces on Cambodia's western border, and may represent a threat to the current first-line ACT, A+M, in this area; an *in vivo* efficacy study is underway to evaluate this possibility.

## 1267

**RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE**

Richard J. Maude<sup>1</sup>, Borislava Mihaylova<sup>2</sup>, Marian Warsame<sup>3</sup>, Jan Singlovic<sup>4</sup>, Wirichada Pongtavornpinyo<sup>1</sup>, Sompob Saralamba<sup>1</sup>, Arjen M. Dondorp<sup>1</sup>, Nicholas J. White<sup>1</sup>, Melba Gomez<sup>5</sup>, Lisa J. White<sup>1</sup>

<sup>1</sup>Wellcome Trust Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, <sup>2</sup>Health Economics Research Centre, Department of Public Health, University of Oxford, Oxford, United Kingdom, <sup>3</sup>Case Management and Research, Global Malaria Programme, World Health Organization, Geneva, Switzerland, <sup>4</sup>National Institute for Medical Research, Dar es Salaam, United Republic of Tanzania, <sup>5</sup>UNICEF/IUNDP/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland

Treatment of adult severe malaria with intravenous artesunate greatly reduces mortality when compared to quinine and is thus recommended first-line treatment for severe malaria in adults worldwide. A large study is underway to verify if the same is true in children. Pre-referral treatment with rectal artesunate for severe malaria was shown in a recent large study to reduce mortality in those whose treatment would be otherwise delayed. As these treatments become more widely available across the tropics there is great concern that the newly discovered artemisinin resistance in Cambodia may spread and compromise their effectiveness. A mathematical model for the spread of artemisinin resistance at the population level was developed based on data from two large community-based trials of rectal artesunate, two large hospital-based trials of

intravenous artesunate and recent data on artemisinin resistance from Cambodia. Various scenarios were considered including the introduction of these therapies alone and in combination, at different levels of coverage, in a variety of transmission settings and with varying efficiency of the referral system after administration of rectal artesunate. The model was used to predict the likely impact of a policy change to these therapies on the potential spread of artemisinin resistance and explore the effects of this resistance on malaria mortality and morbidity in Africa and Asia.

## 1268

**SULPHADOXINE-PYRIMETHAMINE BASED COMBINATION THERAPY IN TREATMENT OF UNCOMPLICATED MALARIA IN MALI: A RANDOMIZED CLINICAL TRIAL IN TWO VILLAGES ON CHILDREN LESS THAN FIVE YEARS**

Maiga Hamma, Beavogui Abdoul Habib, Toure Ousmane, Tekete Mamadou, Sangare Cheik Oumar Papa, Dara Antoine, Traore Zoumana Isaac, Traore Oumar Bila, N'Dong Christelle, Dama Souleymane, Niangaly Hamidou, Diallo Nouhoum, Dembele Demba, Doumbo Ogobara, Djimde Abdoulaye

MRTC, Bamako, Mali

Artemisinin-based combination therapies are now first line drugs in malaria treatment in Africa. Although they still remains effective in treatment of uncomplicated malaria in Africa, little cases of resistance risen in some areas in southern Asia. We initiated non ACT study to assess the effectiveness of SP+Amodiaquine (AQ) and SP+Artesunate (AS) vs. SP alone in two Malians villages. The purpose of this study was to assess the clinical and parasitological responses these SP combinations on uncomplicated *P. falciparum* malaria in Kolle and Bancoumana (both hyper-endemic areas). We conducted a prospective study from August to December 2004 and from July to December 2005 on children aged between 6 to 59 months. We used the *in vivo* standard follow up of 28 days of WHO for efficacy assessment. A total of 912 patients were included with 304, 306, and 302 in SP+AQ, SP+AS and SP alone respectively. We registered a total of 2% loss to follow-up. We observed only four (4) cases of early therapeutic failure (1.4%) all in the arm of SP alone. We found 1%, 1.7%, and 0% of late clinical failure (LCF) and 4.1%, 3.4% and 1.4% of late parasitological failures (LPF) in SP, SP+AS and SP+AQ respectively. We found that SP+AQ was less efficacy than SP+AS (p=0.024) and SP (p=0.043) regarding to LCF and LPF respectively. The rate of clinical and parasitological adequate response (RCPA) was 93.5%, 94.9% and 98.6% for SP, SP+AS and SP+AQ respectively. There was statistical significant differences between the three groups (p=0.007). After PCR correction using MSP2, the re-infection rates were 3.7%, 4.1%, and 1.4% in SP, SP+AS and SP+AQ group respectively. PCR-corrected cure rates at day 28 were 97.2%, 99% and 100% in SP, SP+AS, and SP+AQ and the difference was statistically significant (0.01). In conclusion, sulphadoxine-pyrimethamine only and its combination with artesunate or amodiaquine are clinically and parasitologically effective in Mali.

## 1269

**DIFFERENT MUTATION RATES IN THE DIHYDROFOLATE REDUCTASE AND DIHYDROPTEROATE SYNTHASE GENES IN *PLASMODIUM VIVAX* POPULATIONS FROM CHINA**

Miao Miao<sup>1</sup>, Zhaoqing Yang<sup>2</sup>, Long Cui<sup>1</sup>, Jessica Ahlum<sup>1</sup>, Yaming Huang<sup>3</sup>, Liwang Cui<sup>1</sup>

<sup>1</sup>Pennsylvania State University, State College, PA, United States, <sup>2</sup>Parasitology Department, Kunming Medical College, Kunming, Yunnan, China, <sup>3</sup>Malaria Department, Guangxi Centers for Disease Control and Prevention, Nanning, Guangxi, China

*Plasmodium vivax* genes encoding dihydrofolate reductase (*pvdhfr*) and dihydropteroate synthase (*pvdhps*) are considered to play a key role in folate biosynthesis. Point mutations in *pvdhfr/pvdhps* have been used to predict resistance to antifolates. In southern Asia and Africa, *P. vivax*

is considered highly resistant to sulfadoxine-pyrimethamine (SP) as an increasing use of SP in malaria treatment. In China, however, few pvdhfr/pvdhps mutants have been demonstrated until recently. We used direct sequencing to examine the prevalence of mutations in pvdhfr/pvdhps in 122 *P. vivax* clinical isolates collected from two areas in central (Anhui) and southern China (Guizhou). For pvdhfr, 36.9% were wild-type, whereas mutations were detected at four codons (57, 58, 61, and 117). S117N/T mutation was the most prevalent (48.4%), followed by the T61M mutation (18.9%). Six pvdhfr mutant alleles were found, ranging from 37.7 to 0.8%. The most prevalent mutant haplotype among all examined samples was F57S58T61N99S117 (36.9%). The dramatically different pvdhfr allele frequencies between the two *P. vivax* populations might be resulted from different drug histories or intrinsic difference between temperate and subtropical strains. In contrast, except polymorphisms within a repeat region, no resistance-conferring mutations were detected in pvdhps. Together with past clinical studies of pyrimethamine efficacy, our result suggests that *P. vivax* populations in China may be relatively susceptible to sulfadoxine-pyrimethamine.

## 1270

### IN VITRO AMODIAQUINE RESISTANCE AND ITS ASSOCIATION WITH MUTATIONS IN PFCRT AND PFMDR1 GENES OF PLASMODIUM FALCIPARUM ISOLATES FROM NIGERIA

**Onikepe A. Folarin**<sup>1</sup>, Carolina Bustamante<sup>2</sup>, Olusola G. Gbotosho<sup>1</sup>, Akin Sowunmi<sup>1</sup>, Mariano G. Zalis<sup>2</sup>, Ayoade M. Oduola<sup>3</sup>, Christian T. Happi<sup>1</sup>

<sup>1</sup>Malaria Research Laboratories, University of Ibadan, Ibadan, Nigeria, <sup>2</sup>Laboratory of Molecular Infectiology and Parasitology, Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil, <sup>3</sup>Special Program for Research and Training in Tropical Diseases, World Health Organization/ TDR, Geneva, Switzerland

Amodiaquine (AQ) is currently being used as a partner drug in combination with artesunate for treatment of uncomplicated malaria in most endemic countries of Africa. In the absence of molecular markers of artemisinin resistance, molecular markers of resistance to AQ can be useful for monitoring the development and spread of parasites resistance to Artesunate-Amodiaquine combination. This study was designed to explore the potential role of polymorphisms on pfcrt and pfmdr1 genes and parasite *in vitro* susceptibility for epidemiological surveillance of amodiaquine resistance in *Plasmodium falciparum*. The modified schizont inhibition assay was used to determine *in vitro* susceptibility profiles of 98 patients' isolates of *P. falciparum* to amodiaquine. Polymorphisms on parasites pfcrt and pfmdr1 genes were determined with nested PCR followed by sequencing. The geometric mean of AQ 50% inhibitory concentration (IC<sub>50</sub>) in the 98 *P. falciparum* isolates was 21.287±3.61 nM (range 1.25- 183.20 nM). Molecular analysis showed presence of mutant pfcrtThr76, pfmdr1Tyr86 and double mutant pfcrtThr76+pfmdr1Tyr86 alleles in 76%, 48% and 35% of the isolates respectively. The geometric mean of IC<sub>50</sub> of *P. falciparum* isolates harbouring both wild type pfcrtLys76+pfmdr1Asn86 were observed to be reduced (4.93 nM) compared to isolates harbouring double mutant pfcrtThr76+pfmdr1Tyr86 (50.29 nM). Reduced *in vitro* susceptibility of *P. falciparum* to amodiaquine was significantly associated with presence of mutant pfcrtThr76, pfmdr1Tyr86 or the double mutant pfcrtThr76+pfmdr1Tyr86 (p=0.0001). Results from this study suggest that polymorphisms in pfcrt and pfmdr1 genes are important for amodiaquine resistance and therefore may be useful for epidemiological surveillance of *P. falciparum* resistance to AQ.

## 1271

### ANALYSES OF PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANCE TRANSPORTER GENE (PFCRT) AND MICROSATELLITE DNA LOCI FLANKING THE GENE REVEALED GEOGRAPHICALLY DIFFERENT DISSEMINATION OF CHLOROQUINE RESISTANT MALARIA IN SOUTHEAST ASIA

**Moritoshi Iwagami**<sup>1</sup>, Pannapa Susomboon<sup>1</sup>, Noppadon Tangpukdee<sup>2</sup>, Polrat Wilairatana<sup>2</sup>, Srivicha Krudsood<sup>3</sup>, Le D. Dao<sup>4</sup>, Shusuke Nakazawa<sup>5</sup>, Muth Sinuon<sup>6</sup>, Duong Socheat<sup>6</sup>, Junko Yasuoka<sup>7</sup>, Masamine Jimba<sup>7</sup>, Shigeyuki Kano<sup>1</sup>

<sup>1</sup>Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan, <sup>2</sup>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, <sup>3</sup>Department of Tropical Hygiene, Mahidol University, Bangkok, Thailand, <sup>4</sup>Molecular Biology Department, National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam, <sup>5</sup>Department of Protozoology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan, <sup>6</sup>National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia, <sup>7</sup>Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

A mutation in *Plasmodium falciparum* chloroquine resistance transporter (*pfcrt*) gene in codon 76 (K76T) is associated with chloroquine (CQ) resistance and used to monitor the distribution and frequency of the CQ resistant malaria. Microsatellite (MS) DNA polymorphisms flanking the drug resistant genes can be used to study the evolution of the genes. In this study, we determined the frequency of the mutation in codon 72-76 in the *pfcrt* gene and the MS polymorphisms (2E10, 9B12, PE12A) flanking the gene, using *P. falciparum* isolates from Thailand (50 isolates), Vietnam (39 isolates) and Cambodia (26 isolates). All the isolates from Thailand were CQ resistant (CVIET). All the isolates from Cambodia were also CQ resistant (CVIET, CVIDT). In contrast, 27 of the 39 isolates (69%) from Vietnam were CQ susceptible (CVMNK), while the other 12 of them (31%) were CQ resistant (CVIET, CVIDT, CVMMDT) or mixed. Expected heterozygosity (*H*: gene diversity) of the each MS locus showed that the Thai population (*H*: 0.08-0.61, average: 0.35) and the Cambodian population (*H*: 0.00-0.21, average: 0.11) were less divergent than both the Vietnamese CQ resistant population (*H*: 0.73-0.86, average: 0.79) and the CQ susceptible population (*H*: 0.37-0.97, average: 0.71). The sizes of each MS locus of the Cambodian population were identical or very close to those of the Thai population. However, the sizes of some of the MS loci of the Vietnamese population were different from those of the Thai and Cambodian populations. These results suggest that the Thai and Cambodian populations had been under strong CQ selective pressure but the Vietnamese population had not, and that the origin of CQ resistant mutation in Vietnam might be different from Thailand and Cambodia.

## 1272

### MALARIA TRANSMISSION STUDIES: CAN THEY INDICATE NEW MARKERS OF DRUG RESISTANCE?

**Rachel L. Hallett**<sup>1</sup>, Teun Bousema<sup>1</sup>, Patrick Sawa<sup>2</sup>, Seif Shekalaghe<sup>2</sup>, Silas Otieno<sup>2</sup>, Sabah Omar<sup>2</sup>, Colin Sutherland<sup>1</sup>

<sup>1</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom, <sup>2</sup>Kenya Medical Research Institute, Nairobi, Kenya

Transmission endpoints can be included in antimalarial clinical trials, where appropriate facilities for experimental mosquito feeding exist. We have demonstrated previously that, after drug treatment, *Plasmodium falciparum* parasites carrying molecular markers of drug resistance are associated with higher oocyst burdens in mosquitoes and therefore greater transmission success. We propose that candidate molecular markers of ACT resistance should also be validated in this way, which may be possible before resistance has progressed to the level where a serious reduction in clinical efficacy occurs. We will present data from a clinical trial of

artemether-lumefantrine vs dihydroartemisinin-piperaquine in Mbita, Kenya, where more than 50 successful membrane-feeds, 7 days after drug treatment, resulted in 320 infected mosquitoes. Candidate molecular markers of ACT resistance include well-studied mutations in genes *pfcr* and *pfmdr1*, and less well described polymorphisms in genes *pfmrp*, *pfuhe*, *pfubp-1* and *pfatpase6*. Associations between these markers and oocyst burden in the infected mosquitoes are currently under investigation and will be presented.

## 1273

### A COMPARISON OF *IN VITRO* AND MOLECULAR MARKERS OF ANTIMALARIAL DRUG RESISTANCE IN NORTHERN AND WESTERN CAMBODIA

Stuart D. Tyner<sup>1</sup>, David L. Saunders<sup>1</sup>, Kritsanai Yingyuen<sup>1</sup>, Panjaporn Chaichana<sup>1</sup>, Paktiya Teja-isavadharm<sup>1</sup>, Phisit Khemawoot<sup>1</sup>, Sea Darapiseth<sup>2</sup>, Panita Gosi<sup>1</sup>, Delia B. Bethell<sup>1</sup>, Youry Se<sup>1</sup>, Nillawan Buathong<sup>1</sup>, Worachet Kuntawunginn<sup>1</sup>, Douglas S. Walsh<sup>1</sup>, Duong Socheat<sup>2</sup>, Chanthap Lon<sup>1</sup>, Mark M. Fukuda<sup>3</sup>

<sup>1</sup>Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand,

<sup>2</sup>National Center for Parasitology, Entomology and Malaria Control,

Phnom Penh, Cambodia, <sup>3</sup>Armed Forces Health Surveillance Command, Washington, DC, United States

Decreasing artemisinin effectiveness in western Cambodian *Plasmodium falciparum* strains, characterized by elevated IC50s and increased parasite clearance times, is developing in Southeast Asia. While the focus of artemisinin resistance has been geographically limited to the Thai-Cambodian border in the Cambodian provinces of Battambang and Pailin, we are attempting to evaluate the evidence for decreasing effectiveness of artemisinins elsewhere in Cambodia. AFRIMS is currently conducting a multi-year *in vitro* parasite surveillance study in various regions of Cambodia to investigate *in vitro* and molecular markers of resistance in isolates from patients with uncomplicated *P. falciparum*. The results received during our surveillance study conducted in Anlong Veng, Oddar Meanchey province in 2009-10 (n=153) were compared with previous results obtained in our seven day artesunate mono-therapy trial in Samlot District, Battambang province in 2008-9 (n=141). Although patient enrollment data between the sites were similar, parasites from northern Cambodia appear to be more sensitive *in vitro* to artemisinins compared to those from Western Cambodia. Geomeans of *in vitro* drug sensitivity (IC50) results for DHA when compared between the two sites were significantly different by Mann-Whitney U test, with a geomean of 3.06ng/ml (Battambang) and 1.96ng/ml (Anlong Veng) respectively (p<0.0002). *In vitro* IC50 analysis for other antimalarial drugs; artesunate, mefloquine, quinine, chloroquine, and lumefantrine is ongoing. Comparative analysis of *in vitro* phenotype and molecular markers of parasite resistance will be presented and compared with clinical data. Despite the apparent parasite IC50 difference between provinces, the genetic basis for the apparent geographic differences in parasite susceptibility in Cambodia has yet to be determined.

## 1274

### RELATIONSHIP BETWEEN CHLOROQUINE USE AND CHLOROQUINE RESISTANCE IN SUB-SAHARAN AFRICA

Meera Venkatesan, Anne E. Frosch, Miriam K. Laufer  
University of Maryland School of Medicine, Baltimore, MD, United States

Despite policy changes from chloroquine (CQ) and sulfadoxine-pyrimethamine to artemisinin-combination therapy (ACT) as the primary treatment for uncomplicated malaria in most malaria-endemic countries, these compromised drugs are still widely used. We hypothesized that differences in CQ use would be reflected in the prevalence of the molecular marker for CQ resistance, the *Plasmodium falciparum* chloroquine resistance transporter (*pfcr*) polymorphism at codon 76. To characterize the extent of recent CQ use, we compared data on reported

drug treatment in children from national surveys conducted between 2006 and 2007 in 21 African countries. CQ use was particularly high in West Africa, where it was the most commonly reported antimalarial in 11 of 12 countries surveyed. Reported use of CQ varied in East Africa, ranging from < 1% to nearly 50%. To investigate the effect of continued CQ pressure on drug resistance, we compared drug use data from all available national surveys (between 2000 and 2007) with temporal trends in the prevalence of CQ resistance marker *pfcr* 76T from published studies in 7 African countries. The proportion of resistant genotypes stayed stable over time in three countries with sustained high CQ use (Burkina Faso, Guinea Bissau and Uganda). The prevalence of *pfcr* 76T increased in Niger, the only country reporting increased CQ use during the survey period, and declined in three countries exhibiting low or sharply decreasing CQ use (Malawi, Tanzania and Kenya). These findings suggest that with declining use of CQ, we may expect to find a decline in CQ-resistant malaria. As ACT availability continues to expand in the region, CQ-susceptible malaria may begin to predominate in sub-Saharan Africa in the near- to medium-term future.

## 1275

### GENETIC DISSECTION OF THE ACCELERATED ACQUISITION OF DRUG RESISTANCE IN ARMD *PLASMODIUM FALCIPARUM*

Daniel L. Freeman, John White, Ramesh Gujjar, Karthikeyan Ganesan, Pradipsinh K. Rathod

University of Washington, Seattle, WA, United States

The in-field failure of most drugs against *Plasmodium falciparum* has contributed to the major global health burden of malaria. We have previously shown that parasites from Southeast Asia harbor the Accelerated Resistance to Multiple Drugs (ARMD) phenotype, as reported previously. Parasites from South East Asia consistently acquire resistance to new and unrelated antimalarials three to four orders of magnitude more frequently than parasites from other parts of the world. By assessing the ease with which progeny from an HB3xDd2 genetic cross (as reported previously) acquire resistance to the antifolate, 1843U89, we show that the ARMD phenotype is a complex, multigenic trait, with some progeny exhibiting intermediate phenotypes. Further, we show that this increased ability to acquire resistance to 1843U89 cannot be explained by external factors such as increased survivability in the presence of 1843U89 or our experimental setup. Using QTL analysis, we have identified at least four regions on chromosomes 4, 5, 7, and 13, acting in an additive or synergistic manner to confer the ARMD phenotype. Furthermore, to validate that our previously identified loci are involved in the accelerated acquisition of multiple drugs, we report on similar recent studies using an alternative antimalarial, BMS-388891, a protein farnesyl-transferase inhibitor.

## 1276

### SELECTION FOR ARTEMISININ RESISTANCE IN *PLASMODIUM FALCIPARUM* UNDER LABORATORY CONDITIONS AND POTENTIAL MECHANISMS

Long Cui, Liwang Cui

The Pennsylvania State University, University Park, PA, United States

To select an artemisinin resistant line in the laboratory, we have subjected *P. falciparum* Dd2 strain to dihydroartemisinin (DHA) selection with step-wise increments of drug concentrations over 13 months. We have obtained three lines with more than 20-fold increase in IC50 DHA. However, the resistance phenotype was unstable and the parasites could regain susceptibility to DHA after three months of culture in the absence of the drug selection pressure. Phenotype analysis showed that the resistant parasite displayed cross-resistance to a number of the commonly used antimalarial drugs. Analysis of potential drug targets did not detect point mutations in *pfcr*, *G7*, *G49*, *pfmrp* and *pfatp6* genes, but we identified increased copy number of *P. falciparum* multidrug resistance 1 (*pfmdr1*) gene associated with artemisinin resistance. In addition, the



DHA-resistant parasites also showed elevated activity of the antioxidant defense systems. Collectively, this study suggests that selection of artemisinin resistance under the laboratory conditions may be associated with multiple mechanisms

## 1277

### SELECTION FOR RESISTANCE FOLLOWING A VARIETY OF ANTI-MALARIAL TREATMENT REGIMES

**Silvie Huijben**, Brian Chan, Derek Sim, Danielle Tomasello, Andrew Read

*The Pennsylvania State University, University Park, PA, United States*

Drug resistance is a serious problem in health care. In the case of malaria, resistance against most antimalarial drugs is widespread, except against the recently-deployed artemisinin derivatives. The effect of drug treatment regimens on the spread of resistance is largely unknown. Using the rodent model *Plasmodium chabaudi*, we compared the effects of a variety of 'patient' treatment regimens on infections consisting of resistant and sensitive parasites, testing the impact of each regime on host health, infectiousness and the transmission of resistant parasites. In untreated mixed infections, resistant parasites starting at low frequencies in the initial inoculation produced gametocytes at densities that were barely detectable by PCR. However, drug treatment resulted in a rapid increase of resistant parasites, causing recurrent parasitaemia, increased anaemia, and a much increased transmission potential of resistant parasites. Shorter drug courses or lower drug dosages significantly reduced the fitness of the resistant parasites without compromising host health. Conventional drug treatment aimed at radical cure resulted in the greatest fitness gain for drug resistant parasites. These results demonstrate the need for more research on the role of drug treatment regimens on the spread of drug resistance in malaria. Currently recommended regimes inadvertently impose maximal selection for resistance when resistant parasites are present in an infection. There is a need to empirically evaluate the public health consequences of treating in excess of clinical need.

## 1278

### EFFECTS OF PLASMODIUM FALCIPARUM DIHYDROPTEROATE SYNTHASE MUTATIONS ON PARASITE FITNESS

**Edwin O. Ochong**, Philip J. Rosenthal

*University of California at San Francisco, San Francisco, CA, United States*

The antifolates sulfadoxine-pyrimethamine (SP) and trimethoprim-sulfamethoxazole (TMP/SMX) have potent activity against wild type *Plasmodium falciparum*, but activity is decreased due to resistance-mediating mutations in many areas. However, SP remains the drug of choice for intermittent preventive therapy in pregnant women and children, and TMP/SMX is widely used to prevent opportunistic infections in those with HIV infection. Resistance to antifolates is mediated by a series of mutations in the target enzymes dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), key enzymes in the folic acid biosynthetic pathway. In East Africa, parasites commonly harbor 3 DHFR mutations (S108N, N51I and C59R) and 2 DHPS mutations (A437G and K540E) that mediate an intermediate level of resistance. Additional point mutations, seen more commonly outside Africa, mediate higher-level resistance. We are studying the impact of various resistance-mediating mutations in DHFR and DHPS on the relative fitness of *P. falciparum*. To this aim, we are exploring the growth of parasites under different conditions and in competition assays. We are studying D10-strain parasites engineered to express DHPS with 1-3 mutations. In initial competition experiments, D10 wild-type and single mutant (A437G) strains outcompeted parasites with 2 (A437G + A581G or S436A + A437G) or 3 (S436A + A437G + K540E) mutations over 2 months of culture, as assessed by strain-specific PCR. Experiments to more stringently characterize relative growth of these strains utilizing folate-limiting culture conditions and quantitative PCR and to evaluate parasites with mutations

in DHFR are underway. Our preliminary results suggest that resistance-mediating mutations in DHPS engender a loss of fitness compared to that of wild type strains of *P. falciparum*.

## 1279

### MOLECULAR ANALYSIS REVEALED ANTIMALARIAL DRUG RESISTANCE AT THE AMAZON BASIN OF ECUADOR

**Francisco J. Morales**<sup>1</sup>, Mauricio Espinel<sup>1</sup>, Mette Schousboe<sup>2</sup>, Renato Leon<sup>1</sup>, Ulla Abildtrup<sup>2</sup>, Michael Alifrangis<sup>2</sup>

<sup>1</sup>Universidad San Francisco de Quito, Quito, Ecuador, <sup>2</sup>Center of Medical Parasitology, Copenhagen, Denmark

Currently, the main strategy to control malaria in Ecuador relies on rapid diagnosis and treatment. Due to therapeutic failure, the scheme using Chloroquine drug has been replaced by Artesunate for *Plasmodium falciparum* non-complicated cases of malaria. No resistance to *P. vivax* has been reported to date, though further surveillance using molecular tools could contribute to a better use of antimalarial drugs. Through SSOP-ELISA, 9 *P. falciparum* and 17 *P. vivax* blood samples from 7 communities in Sucumbíos province were analyzed for Single Nucleotide Polymorphisms in the following genes: Chloroquine resistance transporter (crt); Dihydrofolate reductase (Pfdhfr) and Dihydropteroate Synthetase (Pfdhps) for *P. falciparum* and Dihydrofolate Reductase (Pvdhfr) for *P. vivax*. Further DNA sequence analysis was used to confirm the ELISA data. The following haplotypes were identified in all *P. falciparum* samples: CVMNT at the Pfcrt gene; CNCNI at the Pfdhfr gene and the wild-type SAK at the Pfdhps gene. For *P. vivax*, 11/17 samples showed the double mutated haplotype (L2R2TS) for the Pvdhfr gene. In addition, the haplotypes FR2TN, FR1TN and FR2TS were found in 4, 1 and 1 samples respectively. A low frequency of mutations related to antimalarial drug resistance was observed in the study. The K76T mutation at the Pfcrt gene, previously reported from Colombia and Peru is dominant in the Ecuadorian Amazon basin and explains the high rate of treatment failure using Chloroquine reported in the past. Despite the high pressure to Sulfadoxine/Pyrimethamine (SP), low resistant haplotypes were found in Pfdhfr and Pfdhps genes. A similar scenario was found in Pvdhfr gene, which carries only double and single mutations not related with resistance to SP. Interestingly, 4 different genotypes in Pvdhfr gene were found, suggesting a high genetic diversity of *P. vivax*. Future studies increasing our sampling size will help to better understand the distribution and implications of these preliminary findings.

## 1280

### REVISITING THE ROLE OF MICROSCOPY IN PLASMODIUM FALCIPARUM ANTIMALARIAL DRUG EFFICACY TRIALS

**María E. Castellanos**, Lucía Ortiz, Norma R. Padilla

*Universidad del Valle de Guatemala, Guatemala, Guatemala*

Although some *Plasmodium falciparum* antimalarial drug efficacy studies include molecular tools for the identification and discrimination of *Plasmodium* species, many of them just rely on microscopic diagnosis, as WHO recommends. Furthermore, treatment outcomes are partially assessed by the presence of post-treatment asexual parasites. The aim of this study was to determine if the sole use of microscopy in *in vivo* antimalarial drug efficacy trials might lead to the misclassification of both mono and mixed *P. falciparum* infections and an underestimation of the true number of treatment failures. A total of 250 paired blood samples (50 patients) from a 28-days *in vivo* study, conducted in Escuintla, Guatemala during 1998-1999 were analyzed. At each time-point (days 0, 3, 7, 14 and 28), blood was spotted on filter paper and a thick blood smear was prepared. Malaria diagnosis was performed through Giemsa slide examination and nested PCR of the *Plasmodium* small sub-unit ribosomal gene (ssrRNA). In addition to the standard methodology, quality of DNA was assessed incorporating an internal beta-globin PCR. Results show that in 87.5% of the cases, microscopy was able to correctly identify mono-infection with *P. falciparum*. However, PCR analyses show that 10.4% of the samples were mixed *P. falciparum*-*P. vivax* infections and 2.1% of

them were actually *P. vivax* mono-infection. Reclassification of *Plasmodium* species and treatment outcomes based on PCR results should be taken into consideration for the calculation of sample size and adjustment of end-points. Microscopy alone is not enough for the accurate identification and discrimination of *Plasmodium* species in *P. falciparum* *in vivo* antimalarial drug efficacy trials and the use of other techniques, such as molecular testing, are strongly recommended.

## 1281

### ACTIVATION OF NADPH OXIDASE-REACTIVE OXYGEN SPECIES-INFLAMMATORY CYTOKINES PATHWAY CONTRIBUTE TO ACUTE MYOCARDIAL PATHOLOGY IN MICE INFECTED BY *TRYPANOSOMA CRUZI*

Monisha Dhiman, Nisha Jain Garg

University of Texas Medical Branch, Galveston, TX, United States

*Trypanosoma cruzi* is the etiologic agent of Chagas disease. In this study, we investigated the crosstalk between *T. cruzi*-induced ROS and immune activation of pro-inflammatory response, and its role in myocardial pathology in Chagas disease. Splenocytes of infected mice, *in vitro* stimulated with *T. cruzi* antigenic lysate (TcL), exhibited a statistically significant increase in NADPH oxidase (NOX) activity, ROS production and expression level of proinflammatory and other cytokines, measured by catalytic staining, fluorometry using amplex red and H2DCFDA probes, and Bioplex-ELISA assay, respectively. Addition of apocynin (NADPH oxidase inhibitor), but not inhibitors of myeloperoxidase and xanthine oxidase, resulted in up to 98% inhibition of ROS production, and a significant decline in cytokine release (IL-1 $\alpha$ , IL-1 $\beta$ , IL-4, IL-6, IL-10, IFN- $\gamma$  and TNF- $\alpha$ ) from TcL-stimulated splenocytes of infected mice. Likewise, RAW 264.7 macrophages incubated with live *T. cruzi* or TcL exhibited a substantial increase in NOX activity and cytokine (IL-1 $\beta$ , IL-4, IL-10, IFN- $\gamma$  and TNF- $\alpha$ ) release that was inhibited by apocynin and N-acetylcysteine (ROS scavenger) treatment. These data suggested that NOX-induced ROS signal cytokine production in macrophages and splenocytes of mice infected by *T. cruzi*. To determine the pathological significance of NOX/ROS, we treated infected mice with apocynin in drinking water. Apocynin-treated/infected mice exhibited a significant decline in endogenous and TcL-stimulated splenic cell proliferation, NOX/ROS production, and cytokines release as compared to that noted in infected/untreated mice. We observed no change in myocardial parasite burden, yet, symptoms of acute myocarditis, i.e., infiltration of inflammatory infiltrate (extensive presence of inflammatory foci or disseminated inflammation) and tissue oxidative damage (8-isoprostanes, protein carbonyls, 3-nitrotyrosine and 4-hydroxynonenal adducts) were significantly decreased in the myocardium of apocynin-treated/infected mice. We conclude that NOX-dependent ROS have an important role in regulation of splenic activation of inflammatory cells and cytokine production during acute infection, and contribute to infiltration of inflammatory infiltrate and oxidative injuries in Chagasic heart.

## 1282

### DEFINING TARGET SPECIFICITY OF OXADIAZOLE COMPOUNDS ON REDOX PATHWAY MEMBERS OF THE HOOKWORM *ANCYLOSTOMA CEYLANICUM*

Jon J. Vermeire<sup>1</sup>, Christopher D. Pool<sup>1</sup>, Christina C. Wong<sup>1</sup>, Lisa M. Harrison<sup>1</sup>, Ganesha Rai<sup>2</sup>, David J. Maloney<sup>2</sup>, Anton Simeonov<sup>2</sup>, Ajit Jadhav<sup>2</sup>, Craig J. Thomas<sup>2</sup>, David L. Williams<sup>3</sup>, Michael Cappello<sup>1</sup>

<sup>1</sup>Yale University School of Medicine, New Haven, CT, United States,

<sup>2</sup>National Institutes of Health Chemical Genomics Center, Rockville, MD, United States, <sup>3</sup>Rush University Medical Center, Chicago, IL, United States

Hookworms, parasitic nematodes that infect approximately 700 million people, are a major cause of anemia, malnutrition, and perinatal mortality in the tropic and subtropic regions of the developing world. Within an

appropriate host, larval hookworms develop into bleeding feeding adults, attaching to and lacerating the mucosa of the small intestine. Degradation of the ensuing bloodmeal leads to the production of reactive oxygen species (ROS), potentially hindering parasite development and survival. We hypothesize that adult hookworms possess fully functional thioredoxin (Trx) and glutathione (GSH) redox pathways that are essential for the breakdown of ROS produced during blood feeding and that neutralization of these redox systems will lead to reduction in hookworm induced pathogenesis. To characterize these pathways in the human hookworm *Ancylostoma ceylanicum*, we mined the NCBI *A. ceylanicum* expressed sequence tag (EST) database to identify sequences encoding representative members of the Trx and GSH pathways. Several full-length cDNAs were PCR amplified and expressed as recombinant proteins in *E. coli*. Utilizing a kinetic NADPH consumption assay, we determined the specific activity of a novel hookworm peroxiredoxin (AcePrx) and glutathione peroxidase (AceGPx). We also tested the effect of oxadiazoles, nitric oxide-donating compounds, on *A. ceylanicum* adult worms using an *ex vivo* survival assay. Exposure of adult *A. ceylanicum* to micromolar concentrations of select oxadiazole compounds resulted in the significant reduction in worm survival compared to controls treated with equivalent concentrations of albendazole or carrier alone. Furthermore, treatment of *A. ceylanicum*-infected hamsters with furoxan significantly diminished hookworm-induced anemia and worm burden in the host small intestine. This data suggests that oxadiazole compounds represent new lead drugs for the treatment of hookworm disease. Future experiments will investigate the impact of oxadiazoles on *A. ceylanicum* survival by determining the enzymatic activities targeted by these compounds in hookworms and their anthelmintic activity *in vivo*.

## 1283

### METHIONYL-TRNA SYNTHETASE AS A DRUG TARGET FOR *TRYPANOSOMA BRUCEI*

Frederick S. Buckner, Sayaka Shibata, Zhongsheng Zhang, John R. Gillespie, Kuzma V. Kovzun, Ranae M. Pefley, Christophe L. Verlinde, Ethan A. Merritt, Wesley C. Van Voorhis, Wim G. Hol, Erkan Fan

University of Washington, Seattle, WA, United States

Aminoacyl-tRNA synthetases (aaRS) covalently attach amino acids to their corresponding tRNAs, and are required for protein translation. AaRS enzymes make excellent drug targets for antimicrobial drug development as evidenced by mupirocin (a topical antibiotic acting on the isoleucyl-tRNA synthetase) and REP8839 (a clinical Phase II antibiotic acting on the methionyl-tRNA synthetase [MetRS]). Sequence analysis of aaRS enzymes of trypanosomatid parasites indicates significant differences in active site residues between *Trypanosoma brucei* and human homologs of MetRS justifying additional effort to exploit this protein as a drug target. The MetRS has been subjected to RNAi experiments in bloodstream form *T. brucei* and confirm the essentiality of this protein. An aminoacylation assay has been developed to measure enzyme activity and inhibitory action of test compounds. A series of compounds related to REP8839 were synthesized and the most potent had an IC50 ~1 nM on recombinant *T. brucei* metRS. When tested on bloodstream form *T. brucei*, the EC50 of the most potent compound was 4 nM. Another series of compounds (pyrimidine derivatives) had EC50 values as low as 75 nM on *T. brucei* cultures. The compounds are non-toxic to mammalian cells at concentrations >20  $\mu$ M. Our best compound (#1312) dramatically suppresses parasitemia in the murine model of acute *T. brucei* infection. The compounds appear to have poor penetration through the blood brain barrier as indicated by the MDR1-MDCK cell permeability assay. Thus, we are making analogs to try to improve this characteristic so as to make the compounds amenable for treating late stage *T. brucei* infection. Attempts to solve the crystal structure of the *T. brucei* met-RS bound to our inhibitors are underway so as to help guide rational drug development.

### A NOVEL FUNCTION OF THE *BRUGIA MALAYI* CATHEPSIN-LIKE CYSTEINE PROTEASES IN THE ENDOSYMBIOTIC INTERACTION WITH *WOLBACHIA*

Elena Melnikow<sup>1</sup>, Tiruneh Hailemariam<sup>1</sup>, Thomas R. Unnasch<sup>2</sup>, Elodie Ghedin<sup>3</sup>, Sara Lustigman<sup>1</sup>

<sup>1</sup>Lindsley F. Kimball Research Institute, New York, NY, United States,

<sup>2</sup>Department of Global Health, University of South Florida, Tampa, FL,

United States, <sup>3</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

*Wolbachia* is essential for the development and reproduction of *B. malayi*, the causative agent of Lymphatic Filariasis, which opened up a search for novel anti-*Wolbachia* drug targets in addition to antibiotics. Our study was aimed at identifying proteins that potentially have an essential function in this endosymbiotic relationship. We first characterized the effects of tetracycline treatment on the regulation of *Brugia malayi* transcripts 7 and 14 days post treatment using a whole genome microarray studies. We observe primarily up-regulation of *B. malayi* transcripts encoding proteins and enzymes involved in amino acid synthesis and protein translation. Moreover, a bimodal regulation pattern of *B. malayi* transcripts encoding signaling genes and cysteine proteases was observed when tested further by *in vitro* treatment with tetracycline and qRT-PCR. This pattern may be representative of the worms' response to *Wolbachia* death in different tissues; earlier effect on embryogenesis and a later effect on the *Wolbachia* within the hypodermis of the adult worms. Filial cysteine proteases are known to be involved in molting, embryogenesis and tissue remodeling, processes shown to be dependant on *Wolbachia*. To further elucidate the role cysteine proteases play during this symbiosis, we studied their time dependent expression pattern after anti-*Wolbachia* treatment. For example, the transcripts corresponding to *Bm-cpl-3* and *Bm-cpl-6* were found to be up-regulated 1 day post treatment, unchanged or down-regulated by day 3, but then up-regulated at day 6. Notably, RNAi knockdown of *Bm-cpl-5* that is detrimental for embryogenesis resulted in a specific reduction of *Wolbachia* in the hypodermis and microfilariae but not in the oocytes and embryos. This effect was further established by showing that in the *Bm-cpl-5* dsRNA RNAi treated worms, the transcript levels of a *Wolbachia*-specific ankyrin gene (*wBM0287*) were down-regulated by 10.2 fold. The possible role cysteine proteases play in the relationship between the endosymbiont and its *B. malayi* host will be further discussed.

### STAGE-SPECIFIC PATHWAYS OF *LEISHMANIA* ENTRY INTO MACROPHAGES

Nilda E. Rodriguez<sup>1</sup>, Upasna Gaur<sup>2</sup>, Lee-Ann H. Allen<sup>1</sup>, Mary E. Wilson<sup>1</sup>

<sup>1</sup>Veterans Affairs Medical Center and The University of Iowa, Iowa City, IA, United States, <sup>2</sup>The University of Iowa, Iowa City, IA, United States

*Leishmania* spp. have a life cycle with two stages: the promastigote, found in the sand fly vector and the amastigote, found in macrophages. We showed that infection of susceptible BALB/c mice macrophages with *L. infantum chagasi* increased the expression of caveolae components. Caveolae, a subset of lipid rafts, are membrane microdomains enriched in ganglioside-M1 and cholesterol. Promastigotes co-localized with the caveolae markers caveolin-1 and GM1 during entry and up to 24h after phagocytosis. Transient depletion of macrophage membrane cholesterol by 1h exposure to methyl- $\beta$ -cyclodextrin (M $\beta$ CD), impaired the phagocytosis of virulent, but not attenuated promastigotes. In addition, virulent promastigotes experienced increased lysosome fusion (P<0.001), and impaired replication (P<0.05), even though macrophage cholesterol was replenished by 4h. Amastigotes reside in phagolysosomes, hence we hypothesized that the use of cholesterol-rich microdomains to delay lysosome fusion is promastigote-specific. Accordingly, the entry of promastigotes, but not of amastigotes, is decreased in M $\beta$ CD-treated

macrophages (P<0.001). Furthermore, for up to 48h, the intracellular survival of amastigotes was not affected by transient cholesterol depletion. Unexpectedly, by 72h, amastigotes in pre-treated macrophages were unable to replicate (P<0.05). By 1h of infection, the early lysosome marker LAMP-1 was recruited to 80% and 20% of amastigote and promastigote compartments, respectively. The promastigote-to-amastigote conversion takes 24 to 48h, consequently, by 24h, the recruitment of LAMP-1 in promastigote-infected macrophages increased to 46% (P< 0.001). Disruption of macrophage lipid rafts increases LAMP-1 recruitment to promastigote compartments (P<0.001). In contrast, amastigotes readily associated with LAMP-1, regardless of treatment. Our results support the hypothesis that: virulent promastigotes exploit a caveolae-mediated pathway to enter macrophages, and this cholesterol-rich route facilitates their survival by delaying lysosome fusion until their conversion into amastigotes.

### ANTENATAL INFECTION WITH LYMPHATIC FILARIASIS INCREASES SUSCEPTIBILITY TO MALARIA IN KENYAN CHILDREN

Indu Malhotra<sup>1</sup>, Peter Mungai<sup>1</sup>, Alex Wamachi<sup>2</sup>, Eric Muchiri<sup>3</sup>, Daniel Tisch<sup>1</sup>, Christopher L. King<sup>1</sup>

<sup>1</sup>Case Western Reserve University, Cleveland, OH, United States, <sup>2</sup>Kenya Medical Research Institute, Nairobi, Kenya, <sup>3</sup>Division of Vector Borne Diseases, Nairobi, Kenya

We previously observed that antenatal exposure to schistosomiasis in women co-infected with malaria correlated with increased susceptibility to malaria during childhood. To examine the impact of lymphatic filariasis (LF) on malaria susceptibility we undertook a prospective cohort study of 700 newborns in a malaria endemic region of Kenya in which children were examined biannually from birth to age 3 for *Plasmodium falciparum* infection and the presence of malaria antigen-specific T cell responses. 13.6% of pregnant women were co-infected with LF and malaria and 32.6% were infected with LF alone. The risk of malaria increased by 58% (OR 1.58 [95% CI 1.05-2.38] P=0.027) in offspring of women infected with just malaria while the risk increased to almost 3-fold (OR 2.87 [95% CI 1.83-4.52] P=<0.0001) in offspring of women co-infected with malaria and LF as compared to offspring of women lacking any infection during pregnancy. We hypothesized that prenatal LF exposure impairs fetal immune responses to malaria antigens *in utero* thus acquiring a more tolerant phenotype. Cord blood mononuclear cells (CBMC) of newborns of women co-infected with LF and malaria had almost no malaria antigen-driven IFN- $\gamma$ /IL-2 or IL-5/IL-13 (1 and 5% respectively) compared to malaria-specific responses in CBMC from women infected with malaria alone (24 and 25%, P=0.04). This impaired T cell response persisted into childhood. A greater proportion of CBMC had malaria-antigen-driven IL-10 from women with LF and malaria as compared to women with malaria alone (P=0.05). Co-infection with LF and malaria during pregnancy was associated with reduced ability to generate MSP1-specific IgG in newborns. Thus, filariasis and malaria co-infections during pregnancy enhance risk for malaria infection in their offspring, possibly through a mechanism of immune suppression to protective malaria blood stage antigens. Treatment of filariasis and other helminths in pregnant woman may reduce the risk of malaria for their children.

### THE IMPACT OF SCHISTOSOMIASIS AND MALARIA ON THE PATHOLOGY OF DISEASE AND THE IMMUNE RESPONSE IN NON-HUMAN PRIMATE MODELS

Amma A. Semanya, JoAnn S. Sullivan, John W. Barnwell, W. Evan Secor

Centers for Disease Control and Prevention, Atlanta, GA, United States

Schistosomiasis and malaria are the two leading parasitic diseases worldwide. These diseases cause significant morbidity and mortality,



with malaria causing over 500 million clinical cases and up to a million deaths annually. Schistosomiasis affects an estimated 200 million people and causes approximately 280,000 deaths annually. Areas endemic for schistosomiasis and malaria overlap in sub-Saharan Africa as well as other parts of the world. Studies that have examined concurrent infections in mouse models have shown that the presence of helminth infections can adversely affect the protective immune response to malaria but similar studies in humans have been less clear. We hypothesized that in concurrently infected animals, a pre-existing schistosome infection would exacerbate a subsequent malaria infection. We percutaneously exposed four rhesus macaques to 500 cercariae of *Schistosomiasis mansoni*. At eight weeks of infection, these animals plus four additional macaques were exposed to the bites of *Anopheles dirus* mosquitoes infected with *Plasmodium coatneyi*. At day 12 and 13 following sporozoite challenge, parasitemia became patent and rapidly increased in both schistosomiasis positive and schistosomiasis negative animals. Both groups of animals were treated with anti-malarial drugs when parasitemia reached high levels around days 17, 18, or 19. In the presence of anti-malarial drug treatment, schistosomiasis positive animals obtained higher parasitemia levels for a longer time period than their malaria-only infected counterparts ( $p < 0.0001$ ). The mechanism underlying this difference in parasitemia is presumably due to a difference in the immune response. The cytokine and antibody responses are being studied to determine specific immune responses of the two groups of animals. These studies are critical for understanding the immunological and pathological consequences of concurrent infections and can aid in the design of vaccines, drug targets, and treatment regimens for individuals living in co-endemic areas.

## 1288

### ANTIGEN-SPECIFIC B MEMORY CELL RESPONSES TO *PLASMODIUM FALCIPARUM* BLOOD STAGE MALARIA ANTIGENS AND SCHISTOSOMAL ANTIGENS IN MALIAN CHILDREN WITH AND WITHOUT *SCHISTOSOMA HAEMATOBIIUM*

**Kirsten E. Lyke**<sup>1</sup>, Amy Wang<sup>1</sup>, Abdoulaye Dabo<sup>2</sup>, Charles Arama<sup>3</sup>, Modibo Daou<sup>2</sup>, Issa Diarra<sup>2</sup>, Sheetij Dutta<sup>4</sup>, Evelina Angov<sup>4</sup>, David E. Lanar<sup>4</sup>, Christopher V. Plowe<sup>5</sup>, Ogobara K. Doumbo<sup>2</sup>, Marcelo B. Szein<sup>1</sup>

<sup>1</sup>University of Maryland, Center for Vaccine Development, Baltimore, MD, United States, <sup>2</sup>University of Bamako, Bamako, Mali, <sup>3</sup>University of Stockholm, Stockholm, Sweden, <sup>4</sup>Walter Reed Army Institute of Research, Silver Spring, MD, United States, <sup>5</sup>Howard Hughes Medical Institute, University of Maryland, Center for Vaccine Development, Baltimore, MD, United States

Polyparasitism is common in the developing world. We have previously demonstrated that schistosomiasis-positive (SP) Malian children, aged 4-8 years, have protection from malaria compared to matched schistosomiasis-negative (SN) children. Evidence of durable immunologic memory to malaria antigens is conflicting, particularly in young children, and the effect, if any, of concomitant schistosomiasis on acquisition of memory is unknown. We examined antigen-specific B memory (BM) cell frequencies (expressed as percentage of total numbers of IgG-secreting cells) in expanded peripheral blood mononuclear cells (PBMC) from Malian children aged 4-14 to malaria blood-stage antigens, apical membrane antigen 1 (AMA1) and merozoite surface protein 1 (MSP1) and to schistosomal antigens, soluble worm antigen preparation (SWAP) and schistosoma egg antigen (SEA) during the malaria transmission season and again in the dry season. A ratio of greater than 0.01% was considered a positive response. Antigen-specific BM responses were detected in all age groups to all antigens. Memory B cell responses to SWAP, in SP children, were lower during the malaria transmission season compared to the subsequent dry season [4/16 (25%) vs. 10/16 (63%) responders,  $P = 0.04$ , X2 analysis]. Negligible SEA or SWAP-specific BM responses were detected in SN children. Enhanced MSP1-specific BM responses were noted across all age groups during the transmission season in SP versus SN children (10/16 [63%] vs. 4/16 [25%] responders,  $P = 0.04$ , X2 analysis;

ratio 0.056 vs. 0.017,  $P = 0.04$ ) but equalized by the following dry season. AMA1-specific BM responses were greater in SP versus SN children, aged 9-14 years, during the malaria transmission season (6/8 [75%] vs. 2/8 [25%] responders,  $P = 0.04$ , X2 analysis) and remained elevated at dry season follow-up (8/8 [100%] vs. 4/8 [50%],  $P = 0.04$ ). We conclude that detectable BM responses are present against both malaria and schistosomal antigens and that the presence of *S. haematobium* may be associated with enhanced BM responses to malaria antigens.

## 1289

### MSP-1-SPECIFIC MEMORY B CELL RESPONSES ARE STABLE BUT B CELL PHENOTYPE FREQUENCIES CHANGES AFTER PROLONGED ABSENCE OF MALARIA TRANSMISSION IN HIGHLAND WESTERN KENYA

**Cyrus Ayieko**<sup>1</sup>, Alexander Maue<sup>2</sup>, Gideon N. Magak<sup>3</sup>, Gregory Noland<sup>4</sup>, Walter G. Jura<sup>1</sup>, Ayub V. Ofula<sup>1</sup>, Rosemary Rochford<sup>2</sup>, Chandy C. John<sup>4</sup>

<sup>1</sup>Maseno University, Kisumu, Kenya, <sup>2</sup>SUNY Upstate Medical University, Syracuse, NY, United States, <sup>3</sup>Moi University, Eldoret, Kenya, <sup>4</sup>University of Minnesota, Minneapolis, MN, United States

Reduction of malaria transmission could lead to decreased B cell stimulation and lack of induction of B cell memory to *Plasmodium falciparum* antigens. Conversely, a decrease in malaria transmission might reduce the frequency of "exhausted" memory B cells seen in populations with high levels of malaria transmission. To investigate changes in B cell immunity in the absence of malaria transmission, we assessed memory B cell responses in adults living in a highland area of Kenya that recently reported interruption in malaria transmission. Proportions and frequencies of MSP1-specific memory B cells and B cell phenotypes were measured in a cohort of 57 adults at a time after malaria interruption for a one year period (April 2008) and one year subsequently (April 2009). Antigen-specific memory B cells were assessed by B cell ELISPOT and B cell phenotyping by flow cytometry. During the one-year period, none of the individuals tested developed clinical malaria. MSP1-specific memory B cell responses were present in 55% and 60% of individuals respectively in 2008 and 2009. 75% of the participants who had MSP1-specific memory B cells in 2008 maintained the responses one year later. Proportions of MSP1-specific memory B cells increased over the one year period ( $p = 0.02$ ). B cell phenotyping demonstrated that at the second time point, the proportion of circulating CD19+ cells increased ( $p = 0.0001$ ) but the proportions of activated classical memory B cells (CD19+IgD-CD27+CD21-) ( $p = 0.0001$ ) and splenic marginal zone B cells (CD19+IgD+IgM+CD27+) decreased ( $p = 0.0001$ ). The proportion of atypical memory B cells (CD19+IgD-CD27-CD21-) and classical memory B cells remained the same across the two time points. The percentages of "exhausted" memory B cells (CD19+CD19+IgD-CD27-CD21-FcRL4+) were however very low at both time points (<5%). In conclusion, MSP-1 specific memory B cells persist in adults in areas of unstable transmission, even in the absence of transmission. However, the effects of a reduction in malaria transmission on B cell immunity and phenotype may not be restricted to malaria antigen-specific responses.

## 1290

### ASSOCIATION BETWEEN *PLASMODIUM FALCIPARUM* ANTIBODY RESPONSES AND AMODIAQUINE-SULFADOXINE-PYRIMETHAMINE TREATMENT FAILURE IN KAMPALA, UGANDA

**Chris Keh**<sup>1</sup>, Aashish Jha<sup>1</sup>, Bridget Nzarubara<sup>2</sup>, Philip J. Rosenthal<sup>1</sup>, Grant Dorsey<sup>1</sup>, Douglas F. Nixon<sup>1</sup>, Bryan Greenhouse<sup>1</sup>

<sup>1</sup>University of California San Francisco, San Francisco, CA, United States, <sup>2</sup>Makerere University, Kampala, Uganda

Elimination of *Plasmodium falciparum* after partially effective therapy is influenced by host immunity. We previously showed that responses

to treatment for uncomplicated malaria with amodiaquine-sulfadoxine-pyrimethamine (AQ+SP) were associated with surrogates of immunity, including age and proximity to a mosquito breeding site. To further assess associations between immunity and treatment response we studied humoral antimalarial responses in children in Kampala aged 1-10 years who received AQ+SP for treatment of uncomplicated malaria. We measured IgG responses to the following 8 *P. falciparum* antigens via ELISA in 207 pairs of serum samples collected on the day of therapy (Day 0) and 14 days after treatment (Day 14): circumsporozoite protein (CSP), liver stage antigen 1 (LSA1), apical membrane antigen 1 (AMA1), merozoite surface proteins 1, 2, and 3 (MSP 1, 2, 3), and the R0 and R2 domains of glutamine rich protein (GLURP). Results were standardized against pooled immune serum from adults living in Kampala. Our primary outcome was the genotype-adjusted risk of recrudescence within 63 days. Associations were estimated using generalized estimating equations. Age-adjusted IgG responses to AMA1 on Day 0 and Day 14 were significantly higher in those living closer to the breeding site ( $p < 0.02$ ). Overall risk of treatment failure was 12%. After adjusting for age and parasite polymorphisms associated with treatment failure, the risk of failing therapy was significantly lower in those with higher AMA1 responses on Day 0 (OR=0.79 / doubling of titer,  $p=0.01$ ). IgG responses for the other antigens were not significantly associated with treatment response, however there was a trend for protection with higher Day 0 responses to MSP 2 (OR 0.79,  $p=0.06$ ) and 3 (OR 0.81,  $p=0.09$ ). Our findings demonstrate that antibody responses to AMA1 are associated with blood-stage immunity as measured by host clearance of parasites in the setting of partially effective therapy.

## 1291

### EVALUATION OF *PLASMODIUM FALCIPARUM* MULTI-ANTIGEN ANTIBODY DYNAMICS IN INDIVIDUALS EXPERIENCING SUCCESSIVE ANNUAL INFECTIONS LIVING IN THE HYPOENDEMIC PERUVIAN AMAZON

Eva H. Clark<sup>1</sup>, Onome Akpogheneta<sup>2</sup>, Alexander Kayatani<sup>3</sup>, Jean Hernandez<sup>4</sup>, Diane W. Taylor<sup>3</sup>, OraLee H. Branch<sup>2</sup>

<sup>1</sup>University of Alabama at Birmingham, Gurley, AL, United States, <sup>2</sup>New York University, New York, NY, United States, <sup>3</sup>University of Hawaii, Honolulu, HI, United States, <sup>4</sup>Universidad Nacional de la Amazonia Peruana, Iquitos, Peru

Years of exposure to *P. falciparum* are necessary for the development of immunity in high transmission areas, suggesting that protective humoral responses are disabled by parasite hyperexposure. However, in low transmission areas, such as the Peruvian Amazon, malaria-exposed individuals produce immune responses leading to clinical protection after only a few infections. To investigate the antigens responsible for these effective immune responses, this study used antigen-conjugated beads in a LUMINEX system to compare the pre-, during, and post-infection antibody responses to 8 antigens, including AMA1, CSP, EBA175, LSA1, MSP1, MSP2, MSP3, and MSP6. 34 adults and 21 children with samples from 2-3 successive infections spaced by ~1 year were evaluated. We found that adults maintained AMA1, EBA175, MSP1 and MSP3 responses for >300 days post-infection, while in children responses to only MSP1 and MSP3 lasted for >300 days. Although differences in the magnitude/longevity of responses among 1st, 2nd, and 3rd detected infections are recognizable, in adults there were no significant differences for any antigen. However, antibody levels to EBA175 and MSP-3 were significantly higher among children at the 3rd detected infection than at the 1st, suggesting that these responses are boosted earlier at each subsequent infection. After correlating each antigen response to the others, some antigen pairs were associated with more parasite exposure (AMA1&EBA175, AMA1&MSP3 and EBA175&MSP2), and some were associated with less exposure (EBA175&MSP1 and AMA1&MSP1). When comparing responses in asymptomatic versus symptomatic adults, responses to MSP1, MSP2, MSP3, and MSP6 were found to be significantly higher in asymptomatics than in symptomatics at the 2nd detected infection but not at the 1st. In summary, although MSP1 produced the largest post-infection responses

even at the 1st detected infection, other blood-stage antigens, particularly MSP3 (to which even children elicited long-lived responses), were found to be important players in the anti-malarial immune response despite low transmission exposure.

## 1292

### HAPLOTYPES OF FC GAMMA (FC $\Gamma$ ) RECEPTOR (FC $\Gamma$ RIIA AND FC $\Gamma$ RIIB) PREDICT SUSCEPTIBILITY TO HIGH-DENSITY PARASITEMIA AND FUNCTIONAL CHANGES IN CIRCULATING IFN- $\Gamma$ LEVELS IN CHILDREN WITH *PLASMODIUM FALCIPARUM* MALARIA IN WESTERN KENYA

Collins O. Ouma<sup>1</sup>, Gregory C. Davenport<sup>2</sup>, Samuel Kiplagat<sup>1</sup>, Stephen Garcia<sup>2</sup>, Prakasha Kempaiah<sup>2</sup>, Ateefa Chaudhary<sup>2</sup>, Tom Were<sup>1</sup>, Samuel B. Anyona<sup>1</sup>, Evans Raballah<sup>1</sup>, James B. Hittner<sup>3</sup>, John M. Vulule<sup>4</sup>, John M. Ong'echa<sup>1</sup>, Douglas Perkins<sup>2</sup>

<sup>1</sup>University of New Mexico/KEMRI, Kisumu, Kenya, <sup>2</sup>University of New Mexico, Albuquerque, NM, United States, <sup>3</sup>College of Charleston, Charleston, SC, United States, <sup>4</sup>KEMRI, Kisumu, Kenya

The development of protective immunity against *Plasmodium falciparum* is partially mediated through binding of malaria-specific IgG to Fc gamma ( $\gamma$ ) receptors. Human Fc $\gamma$ RIIA-H/R-131 and Fc $\gamma$ RIIB-NA1/NA2 exhibit polymorphic variability associated with differential binding to IgG subtypes and malaria disease outcomes. The role of Fc $\gamma$ RIIA-H/R131 and Fc $\gamma$ RIIB-NA1/NA2 haplotypes in conditioning susceptibility to high-density parasitemia (HDP;  $\geq 10,000$  parasites/ $\mu$ L), a clinical manifestation of severe malaria in *P. falciparum* holoendemic areas, however, is largely undefined. As such, the role of Fc $\gamma$ RIIA-H131R/Fc $\gamma$ RIIB-NA1/NA2 haplotypes was investigated in children (n=528) presenting with acute malaria at a rural hospital in western Kenya. Since variations in the Fc $\gamma$ R may alter interferon gamma (IFN- $\gamma$ ) levels, a mediator of both innate and adaptive immune responses, additional functional analyses were carried out in the context of the Fc $\gamma$ R haplotypes. Results reveal that circulating IFN- $\gamma$  was negatively correlated with parasitemia levels ( $r=-1.740$ ,  $P=0.005$ ). Children with HDP also had lower circulating IFN- $\gamma$  levels than the non-HDP group ( $P < 0.001$ ). Multivariate logistic regression analyses controlling for covariates revealed that carriage of the Fc $\gamma$ RIIA-131R/Fc $\gamma$ RIIB-NA1 haplotype was associated with protection against HDP (OR; 0.48, 95%CI, 0.31-0.76;  $P=0.002$ ), while carriage of Fc $\gamma$ RIIA-131H/Fc $\gamma$ RIIB-NA1 haplotype increased susceptibility to HDP (OR; 1.49, 95%CI, 1.04-2.14;  $P=0.031$ ) relative to individuals without these haplotypes. Carriers of the Fc $\gamma$ RIIA-131H/Fc $\gamma$ RIIB-NA1 (131H/NA1) haplotype had significantly lower IFN- $\gamma$  levels relative to non-carriers ( $P=0.046$ ), while Fc $\gamma$ RIIA-131R/Fc $\gamma$ RIIB-NA1 (131R/NA1) haplotype had elevated IFN- $\gamma$  levels relative to non-carriers ( $P=0.067$ ). These results demonstrate that variations at the Fc $\gamma$ R gene are associated with functional changes in IFN- $\gamma$  production, and susceptibility to HDP in children with *falciparum* malaria.

## 1293

### SPATIAL DISTRIBUTION, HABITAT CHARACTERIZATION AND DYNAMICS OF *ANOPHELES GAMBIAE* MOLECULAR FORMS LARVAL BIOTOPES ALONG AN URBANIZATION GRADIENT IN THE CITY OF YAOUNDÉ, CAMEROON

Billy F. Tene<sup>1</sup>, Christophe N. Antonio<sup>2</sup>, Colince Kamdem<sup>2</sup>, Philippe Bousses<sup>3</sup>, Didier Fontenille<sup>3</sup>, Nora J. Besansky<sup>4</sup>, Carlo Costantini<sup>1</sup>

<sup>1</sup>IRD-UR016/OCEAC, Yaoundé, Cameroon, <sup>2</sup>LRP-OCEAC, Yaoundé, Cameroon, <sup>3</sup>IRD-UR016, Montpellier, France, <sup>4</sup>University of Notre Dame, Notre Dame, IN, United States

Increasing urbanization in Africa is drawing the attention of public health managers on urban malaria, and it raises the question of whether malaria vectors have the potential to adapt to the environmental stressors normally encountered in the most densely populated cities. In the forest domain of southern Cameroon, the molecular forms M and S of *Anopheles gambiae* segregate along urbanization gradients, suggesting that a

process of adaptation by the M form to the urban environment is under way (Kamdem et al., submitted). This process is presumably driven by the ability of M larvae to develop successfully in polluted urban habitats. To characterize the larval biotopes of M and S and their dynamics, we conducted a longitudinal survey of *An. gambiae* larval habitats to assess their distribution and relationship with human activities in the capital Yaoundé and peri-urban neighborhoods. A total of 2,449 potential mosquito breeding sites were examined, of which about 20% contained *An. gambiae* larvae. Anopheline larval habitats were more abundant in urban compared to rural or suburban areas. Seasonal fluctuations in breeding sites availability were more pronounced in the rural than urban habitat. Draining streams and swamps were associated with no or very low larval densities. Human activities such as vegetable market gardening, housing in swampy areas, and construction sites were associated with breeding sites of *An. gambiae*. Unexpectedly, *An. gambiae* larvae were collected from urban breeding sites highly polluted with organic matter. PCR identification revealed that only the M molecular form of *An. gambiae* was present in the most urbanized settings, whereas the S form was by far the most abundant in the rural sites, the suburban ones being transitional between these extremes. These findings provide evidence that the malaria vector *An. gambiae* s.s. is adapting to urban waste waters, and clearly partition the distribution of the molecular forms M and S between urban and rural areas.

## 1294

### SPATIAL-TEMPORAL DISTRIBUTION OF IMMATURE AND ADULT MALARIA VECTORS IN FOUR ECOLOGICAL SETTINGS IN COASTAL KENYA

Francis M. Mutuku<sup>1</sup>, Charles H. King<sup>2</sup>, Peter L. Mungai<sup>1</sup>, Eric M. Muchiri<sup>1</sup>, Edward D. Walker<sup>3</sup>, Uriel Kitron<sup>4</sup>

<sup>1</sup>Division of Vector-Borne and Tropical Neglected Diseases, Msambweni, Kenya, <sup>2</sup>Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, United States, <sup>3</sup>Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, United States, <sup>4</sup>Department of Environmental Studies, Emory University, Atlanta, GA, United States

The on-going malaria control activities in Kenya through use of Insecticide treated nets (ITN) and Indoor residual spraying (IRS) necessitate up-to-date information on malaria vectors. An ecological study of the spatial-temporal distribution of immature and adult malaria vectors was conducted in eight villages (two in each of four ecological settings) in the south coast of Kenya. Longitudinal larval surveys were conducted monthly in selected larval habitats from May 2009 to March 2010 using standard dipper. Additionally, adult malaria vectors were concurrently collected using pythremum spray collection (PSC) and clay pots in 10 houses from March 2009 to March 2010. A total of 285 Anopheline larvae were sampled during the 10 months of larval sampling. The number and quality of larval habitats sampled in each ecological setting fluctuated with rainfall. *Anopheles* larvae were found most frequently in larval habitats located in the estuarine habitats, accounting for 81% of the total larvae sampled. The majority of the larvae were *An. gambiae* s.l (88%), with *An. funestus* comprising the rest (12%). Mean density of *Anopheles* larvae was 3 times higher in the estuarine habitats compared to the other three ecological settings combined. Abundance and density of *Anopheles* larvae was highly associated with depth, pH and conductivity of aquatic habitats. Correspondingly, 69% (962/1386) of the adult mosquitoes were *An. gambiae* s.l with *An. funestus* comprising the remaining 31% (424/1386). An average of 7 *An. gambiae* s.l and 2 *An. funestus* mosquitoes were collected each month in the estuarine environment compared to <1 mosquito of each species in the other ecological settings. Overall, densities of adult malaria vectors were low throughout the study period, and were highly dependent on rainfall throughout the 12 months. Both abundance and composition of malaria vectors was dependent on the ecological setting and modulated by rainfall. While these findings are not surprising,

only limited data was available for the south coast of Kenya. The findings of study will be useful for the planning and implementation of control strategies for malaria vectors.

## 1295

### ENVIRONMENTAL CHANGE AND THE MICROBIAL ECOLOGY OF ANOPHELES GAMBIAE

Thomas M. Gilbreath, III<sup>1</sup>, Eliningaya Kweka<sup>2</sup>, Guiyun Yan<sup>1</sup>

<sup>1</sup>University of California Irvine, Irvine, CA, United States, <sup>2</sup>Kenya Medical Research Institute, Kisumu, Kenya

Recent studies suggest that land use changes, such as deforestation, strongly enhance the productivity of malaria vectors, and thus malaria transmission. This is because deforestation exposes aquatic habitats to sunlight, resulting in increased temperatures. Further, sunlight may induce changes in the microbial communities that mosquito larvae use for nutrition. This study utilized field-based microcosm approaches in combination with water chemistry analyses and pyrosequencing for microbial diversity in order to examine the impacts of environmental change in *An. gambiae* larval habitats and habitat vector productivity. Results of habitat productivity in different land use scenarios have demonstrated a significant effect of land use and canopy cover on larval malaria vector survivorship and habitat productivity. Survivorship in semi-forested and naturally forested areas was reduced 20% and 99%, respectively when compared to areas that had been deforested. Interestingly, when microcosm temperature in the field was controlled, temperature was shown to have the strongest effect on pupation rate while larval survivorship was more affected by algal biomass. Microbial diversity analyses show significant differences in bacterial communities from deforested, semi-forested, and forested habitats. Bacterial communities in the surface microlayers and larval guts from the same habitat also showed significant differences in composition and suggested a selective assimilation of photosynthetic microbes. These preliminary results suggest that *An. gambiae* ss preferentially feeds on photosynthetic microbes in the surface microlayer of their habitats and that the role of microbial community changes induced by light may play a more important role than temperature in some scenarios.

## 1296

### PROFILING GUT MICROBIOTA IN MOSQUITO ANOPHELES GAMBIAE USING PYROSEQUENCING

Ying Wang<sup>1</sup>, Thomas M. Gilbreath, III<sup>2</sup>, Phanidhar Kukutla<sup>1</sup>, Guiyun Yan<sup>2</sup>, Jiannong Xu<sup>1</sup>

<sup>1</sup>New Mexico State University, Las Cruces, NM, United States, <sup>2</sup>University of California, Irvine, Irvine, CA, United States

Mosquito *Anopheles gambiae* is a major malaria vector. Vector competence is determined by the tripartite eco-interactions among microbes, malaria and mosquito immunity. Mosquito gut harbors diverse microbial communities. However, little is known about the dynamics of the gut microbiota from larva to adult and its impact on the gut eco-symbiotic interplays. Early studies of the gut bacteria relied on culture- and/or cloning-based low throughput techniques that characterize only a small fraction of the microbiota. Using pyrosequencing approach targeting the V1-3 hypervariable region of the 16S rRNA gene, we gained an unprecedented view of the diversity present in the gut microbiota and were able to detail the dynamics of the gut microbial community from larva to adult and assessed the effect of blood feeding on the gut community. Pyrosequencing yielded 79592 sequences from 14 samples of a lab reared *An. gambiae*. The sequences correspond to 260 genera belonging to 11 phyla with dominances of *Proteobacteria*, *Bacteroidetes*, *Actinobacteria* and *Firmicutes*. The structure of gut microbiota changes along the life stages. Among the tags obtained from larva, more than half (54.3%) belong to the Family *Enterobacteriaceae* (unable to classify to genus). *Microbacterium* (23.7%) is abundant only in larva. Pupa



harbors a complex community with the dominances of *Elizabethkingia* (26.1%), *Acidovorax* (10.5%) and *Enterobacteriaceae* (10.8%). In newly emerged adults, flora composition becomes simpler, dominated by *Elizabethkingia* (55.9%), *Staphylococcus* (8%), *Enterobacteriaceae* (7.5%) and *Leucobacter* (6.9%). At least 7 out of 20 (35%) genera that were present in pupa did not rise in the adult, likely being cleaned up by the sterilization process during the metamorphosis. *Finegoldia*, *Serretia* and *Pantoea* seem to be newly established in the adult. Bloodmeal reduces the diversity of gut microbiota. After blood feeding, 6 out of 17 (35.3%) genera disappeared. *Elizabethkingia* and *Enterobacteriaceae* dominate the community, accounting for up to 77% of the total tags. The diversity of gut communities reduced with operational taxonomic unit (OUT) dropping from 110 to 36. Richness of the communities was estimated by ACE and Chao implemented by the software Mothur. By picturing gut communities we have gone one step further towards a better understanding of the mosquito gut ecosystem.

## 1297

### SYMPATRIC PLASMODIUM FALCIPARUM - ANOPHELES GAMBIAE POPULATIONS PRODUCE LOWER INFECTION INTENSITIES IN AFRICA

Caroline Harris<sup>1</sup>, Isabelle Morlais<sup>2</sup>, Thomas S. Churcher<sup>3</sup>, Louis Clement Gouagna<sup>4</sup>, Roch D. Dabire<sup>5</sup>, Didier Fontenille<sup>1</sup>, Anna Cohuet<sup>4</sup>

<sup>1</sup>Institut de Recherche pour le Developpement, Montpellier, France, <sup>2</sup>Laboratoire de Recherche sur le Paludisme/Institut de Recherche pour le Developpement, Yaoundé, Cameroon, <sup>3</sup>Imperial College London, London, United Kingdom, <sup>4</sup>Institut de Recherche en Sciences de la Santé/Institut de Recherche pour le Developpement, Bobo Dioulasso, Burkina Faso, <sup>5</sup>Institut de Recherche en Sciences de la Santé, Bobo Dioulasso, Burkina Faso

Both *Plasmodium falciparum* and *Anopheles gambiae* show great diversity in Africa, in their own genetic makeup and malaria infection phenotypes. The genetics of the individual mosquito and parasite are known to play a role in determining the outcome of infection, but whether differences in infection phenotype vary between populations remains to be investigated. Here we conducted experimental infections using two recently established *An. gambiae* colonies from Cameroon and Burkina Faso and wild *P. falciparum* corresponding to their sympatric and allopatric populations. Infection phenotype was determined in terms of oocyst prevalence and intensity for at least nine infections for each vector-parasite combination and compared between infection types. We show that the mosquito colony used (sympatric or allopatric to the parasite) has no significant effect on infection prevalence, however has strong effects on infection intensity. Sympatric infections produced 25% fewer oocysts per midgut than allopatric infections, while prevalence was not affected by sympatric/allopatric interactions. The reduction in oocyst numbers in sympatric couples may benefit both the vector and parasite. It has been proposed that increasing the number of parasites ingested by a mosquito reduces its survival. If this is the case then a lower infection intensity, without affecting prevalence, would increase the fitness of infected mosquitoes while at the same time increasing the parasites chance of being transmitted. If the fitness costs are confirmed, this suggests local adaptation of the vector to the parasite and parasite to the vector, which has strong implications for malaria transmission dynamics.

## 1298

### THE EVOLUTIONARY CONSEQUENCES OF HOST SPECIES CHOICE FOR AFRICAN MALARIA VECTORS: COULD UNTREATED BED NETS SELECT FOR A HOST SHIFT?

Issa Lyimo<sup>1</sup>, Daniel Haydon<sup>2</sup>, Tanya Russell<sup>1</sup>, Kasian Mbina<sup>1</sup>, Ally Daraja<sup>1</sup>, Edgar Mbehela<sup>1</sup>, Richard Reeve<sup>2</sup>, Heather Ferguson<sup>2</sup>

<sup>1</sup>Ifakara Health Institute, Morogoro, United Republic of Tanzania, <sup>2</sup>University of Glasgow, Glasgow, United Kingdom

The host preference of malaria vectors is one of the key determinants of global transmission patterns. Here we conducted an experimental investigation of the major African malaria vectors *Anopheles gambiae* s.s and *An. arabiensis* to test whether their preference for humans over other commonly available animal hosts can be explained by the fitness benefits they derive from them, and whether the use of common interventions such as bednets can reduce the advantage of anthropily to the point where selection for a host species shift could be generated. Experiments were conducted in which one host of either cow, human (exposed or protected by untreated net), dog, goat or chicken was placed inside an experimental hut set within a unique Semi-Field System (SFS) at Ifakara Health Institute in Tanzania. Groups of 200 insectary-reared *An. gambiae* s.s or *An. arabiensis* were released into the chamber at dusk and left overnight with the host. The next morning mosquitoes were recaptured and their blood feeding success and subsequent fecundity and survival measured (6 replicates of each host and vector species combination).

Whereas *Anopheles arabiensis* had a significantly greater feeding success on its naturally preferred bovid hosts, the more anthropilic *An. gambiae* s.s. took considerably bigger blood meals and had greater survival after feeding on human than animal blood. The use of a bednet failed to completely prevent biting by either vector, but did reduce the expected fitness benefits from human hosts. By modeling the combined effect of all host species impacts on vector fitness, a mosquito life-history model predicted the lifetime egg production of *An. arabiensis* to be considerably higher on their naturally preferred bovinds than all other host types. However, the lifetime reproductive success of the naturally anthropilic *An. gambiae* s.s. was not predicted to be higher on humans than any other host species. Further study is required to identify the nature of selection favouring anthropily in this vector, and possibilities for reducing it through vector control and/or environmental management.

## 1299

### QUANTIFYING AND ANALYZING DANCE OF ANOPHELES GAMBIAE IN MATING SWARMS

Nicholas C. Manoukis<sup>1</sup>, Sachit Butail<sup>2</sup>, Derek Paley<sup>2</sup>, Alpha S. Yaro<sup>3</sup>, Moussa Diallo<sup>3</sup>, Sekou F. Traoré<sup>3</sup>, Adama Dao<sup>3</sup>, José M. Ribeiro<sup>1</sup>, Tovi Lehmann<sup>1</sup>

<sup>1</sup>Laboratory of Malaria and Vector Biology, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, United States, <sup>2</sup>Department of Aerospace Engineering, University of Maryland, College Park, MD, United States, <sup>3</sup>Malaria Research and Training Center, Faculté de Médecine, de Pharmacie et d'Odontostomatologie, Université de Bamako, Bamako, Mali

We describe a technological breakthrough achieved through interdisciplinary collaboration that allows us to track individual swarming *Anopheles gambiae* males and females from stereoscopic video footage obtained from the field in Mali, Africa in August 2009. Mating behaviors of malaria vectors in nature are rarely described or studied, and even more rarely quantified. The actual movement of individual members of a mating swarm of mosquitoes over time has never before been measured. The principal reason this stage of the life history remains unexplored is that direct observation and quantification of mating in a swarm is very difficult due to the small size of mosquitoes, their relatively fast rate of movement and their habit of aggregating under conditions of low light. Despite our lack of knowledge in this area, determinants of male mating success in

medically important species are of major interest from a fundamental and applied perspective. We estimate three-dimensional position and velocity of individual mosquitoes through space and time by employing advanced image processing and probabilistic estimation techniques in a semi-automated computer tracking system. We verify the accuracy of our tracking system along several parameters by comparing it with manually created ground-truth data. We have used the system to quantify and analyze three instances of couple formation in *An. gambiae* swarms. These measurements reveal that female *An. gambiae* spend much more time in a swarm composed almost entirely of males than previously thought: more than six seconds in one instance. We will describe ongoing studies in which we are quantifying the differences in the flight patterns of males and females within the mating swarm and studying male flight patterns for determinants of male mating success. These data and the increasingly automated capacity in which we generate them promise to greatly extend our fundamental understanding of *An. gambiae* mating biology and have implications for any release-based approach to its control as a malaria vector.

### 1300

#### IMPROVING AVAILABILITY OF KEY ANTIMALARIAL COMMODITIES: PILOTING AN ESSENTIAL DRUG LOGISTICS SYSTEM IN ZAMBIA

**Arturo Sanabria**, Wendy Nicodemus, Gamariel Simpungwe, Rabson Zyambo, Walter Proper

*United States Agency for International Development | DELIVER PROJECT, Lusaka, Zambia*

The successful implementation of malaria programs depends on a continuous supply of malaria-related commodities: artemisinin-based combination therapy (ACTs), rapid diagnostic tests (RDTs), sulphadoxine-pyrimethamine (SP), and quinine. From January 2009 to January 2010, the United States Agency for International Development | DELIVER PROJECT supported the Ministry of Health of Zambia when they conducted an essential drugs/malaria logistics systems pilot to determine what key logistics factors impact commodity availability and to identify and implement the most effective elements to ultimately improve efficiency in the supply chain. To ensure statistical power, the districts were selected using a random stratified technique; eight districts per pilot system were selected. Twenty-four districts were involved, including a control group of eight districts. Some of the factors used in the sampling included prevalence of malaria, accessibility, urban/rural factor, and number of facilities. With support from the United States Agency for International Development | DELIVER PROJECT, a steering committee of key partners designed and piloted two logistics systems. In one system, the district serves as a pass-through to distribute commodities that are pre-packaged by the central medical stores. In the other, the district stores, packages, and supplies the facilities directly. The two pilot systems were rolled out in 16 districts and 347 service delivery sites. Specific variables tested were the availability of antimalarial drugs, transport from district to facility, storage capacity, and commodity management at the district- and health-facility level. To determine the impact on stock availability in each of the pilots, teams conducted a final evaluation visit to 259 sites, which were randomly chosen. The results of the assessment, completed in March 2010, showed that introducing a logistics system drastically reduced the stockout levels of antimalarial products, even when some products had stockouts at the central level. For example, pediatric ACTs were available in 88% of the pilot facilities, compared with 51% in the control; they were available 345 days a year, compared with 247 days in the control.

### 1301

#### FIVE-YEAR OVERVIEW OF STRENGTHENING REGIONAL CAPACITY IN MEDICINES QUALITY IN THE MEKONG SUBREGION: A FOCUS ON COUNTERFEIT AND SUBSTANDARD MEDICINES

**Souly Phanouvong**

*United States Pharmacopeia, Rockville, MD, United States*

In the Mekong subregion, an estimated 10-35% of medicines are improperly made or illegally imported and sold. To help country authorities in this region address medicine quality problems, in collaboration with its partners, the Promoting the Quality of Medicines (PQM) program - funded by the United States Agency for International Development (United States Agency for International Development) and implemented by the United States Pharmacopeia (USP) - has introduced a regional mechanism for Medicine Quality Monitoring (MQM). The MQM program focuses on early detection of poor-quality antimalarial, anti-TB, antibiotic, antiretroviral, and Avian Influenza medicines and strengthening the capacity of regulatory authorities for enforcement actions based on evidence obtained from the field. The ultimate goal is to reduce the prevalence of poor-quality medicines\_counterfeit and substandard\_available in the public, private, and informal sectors in Cambodia, Lao PDR, Thailand, and Vietnam. A well-designed framework and protocol for sampling, testing, data management and reporting were used. Data collected in 2004 revealed the wide availability of poor quality medicines: in some Mekong countries, up to 44% of artesunate (a commonly used, highly efficacious antimalarial) samples collected and tested contained no active ingredient. In 2008, this figure dropped to 11.2%. From 2005-2009 in the Mekong Subregion, the MQM program sampled 3,021 antibiotic, 6,176 antimalarial, 625 anti-tuberculosis, and 234 antiretroviral medicines. Antibiotics and antimalarials had the highest failure rate of 2.3% and 2% respectively. To present, the total number of samples collected and tested has reached almost 4,000. While initial failure rates in the region averaged around 6%, there was a steady trend toward a decreasing prevalence at the 42 monitoring sentinel sites in the region and in 2009, the overall failure was 1.3%. Medicines quality data were used to raise public awareness and shared with national law enforcement agencies for appropriate actions. They were also shared with international agencies like World Health Organization and INTERPOL, for collective investigations and actions at regional and international levels. Despite these progresses and achievements, many challenges remain to be addressed and the MQM needs to be scaled up to cover the whole region.

### 1302

#### CHANGING GUIDELINES FOR MALARIA CASE MANAGEMENT: CAN HEALTH FACILITIES KEEP UP?

**Florence R. Nankya**<sup>1</sup>, Catherine Maiteki-Sebuguzi<sup>1</sup>, Deborah DiLiberto<sup>2</sup>, Miriam Kayendeke<sup>1</sup>, Moses R. Kanya<sup>3</sup>, Clare Chandler<sup>2</sup>, Sarah G. Staedke<sup>4</sup>

<sup>1</sup>*Infectious Diseases Collaboration Research, Kampala, Uganda*, <sup>2</sup>*London School of Hygiene and Tropical Medicine, London, United Kingdom*,

<sup>3</sup>*Infectious Diseases Collaboration Research, Department of Medicine, Makerere University, Kampala, Uganda*, <sup>4</sup>*Infectious Diseases Collaboration Research, London School of Hygiene and Tropical Medicine, Kampala, Uganda*

The World Health Organization (WHO) has recently released new guidelines for treatment of malaria, recommending that suspected cases be confirmed by a parasitological test when possible. However, the current capacity for diagnosis and management of malaria and other febrile illnesses within the existing health system is unclear. To inform the design of future interventions, we conducted a situational analysis of government-run health centers in rural Eastern Uganda. Health workers stationed at centers in five sub-counties in Tororo district were approached for study participation. Structured questionnaires

addressing staffing, training and supervision, and knowledge of malaria case management were administered to consenting health workers. We interviewed 81 (88%) of 92 health workers stationed at the 17 local health centers, representing the spectrum of staff cadres. Staffing shortages were a problem at nearly all health centers. Unpaid volunteers with limited medical training constituted 26% of staff interviewed, and 48% at the lowest-level health centers. Most health workers (56 [69%]) were trained in management of malaria with artemether-lumefantrine, but only 29 (26%) had received training in rapid diagnostic tests (RDTs) for malaria. Overall, knowledge about malaria case management was poor; mean knowledge scores ranged from 18% (vaccinators) to 45% (nursing officers). The in-charges of health centers scored surprisingly low, as did volunteers (mean scores 34% and 20%, respectively). When asked how to confirm the diagnosis of malaria, only eight (10%) health workers mentioned microscopy and two (2%) RDTs. Additional gaps in knowledge included recognition of danger signs for severe malaria, differential diagnosis of non-malarial febrile illnesses, and key elements of managing and treating malaria. The shift towards universal diagnostic testing for malaria is a major step to ensuring appropriate management of malaria and other febrile illnesses. We found that health centers in Eastern Uganda currently have limited capacity to adhere to WHO's new guidelines. Poor staffing of health centres and gaps in knowledge urgently need to be addressed.

### 1303

#### VOLUNTEER COMMUNITY HEALTH WORKERS: TEMPORARY FIX OR LONG-TERM SOLUTION?

**Kristin Banek**<sup>1</sup>, Joaniter Nankabirwa<sup>2</sup>, Deborah DiLiberto<sup>3</sup>, Lilian Taaka<sup>4</sup>, Clare I. Chandler<sup>5</sup>, Sarah G. Staedke<sup>5</sup>

<sup>1</sup>Uganda Malaria Surveillance Project, Kampala, Uganda, <sup>2</sup>Makerere University, Kampala, Uganda, <sup>3</sup>London School of Hygiene & Tropical Medicine, London, United Kingdom, <sup>4</sup>Infectious Disease Research Collaboration, Kampala, Uganda, <sup>5</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom

Community management of febrile children is evolving away from providing treatment of malaria only, toward a more integrated approach, focusing on malaria, pneumonia and diarrhea. However, more complex programmes place higher expectations on community health workers (CHWs). In Uganda, a policy of integrated community case management (iCCM) is being adopted. To investigate current challenges faced by CHWs, we conducted a situation analysis in rural Eastern Uganda. We interviewed 100 CHWs selected using convenience sampling from five sub-counties in Tororo district. A structured questionnaire addressing patient load was administered, and in-depth interviews were conducted. Focus group discussions were also conducted with health workers and community members. The CHWs reported receiving close to 20 patients per week (mean 19.5, SD 12.2, range 2-63), including 15 malaria patients (mean 15, SD 10.8). Only ten CHWs reported receiving specific incentives, such as payment, to motivate them to perform their duties. Interviews revealed that over 80% of CHWs were motivated by non-monetary incentives including altruistic reasons, good relationships with health workers, and self benefit, with the strongest theme focusing on respect or 'becoming someone important' through their work. However, over half of CHWs felt demotivated due to limited support from communities and the health system, unrealistic expectations of caregivers, lack of drugs and supplies, and lack of compensation. Although communities appeared to understand the role of CHWs, they often inappropriately attributed the logistical constraints and lack of CHW motivation to personal rather than system shortfalls. Our results suggest that many volunteer CHWs in Uganda are motivated by altruistic and/or self-serving motives. However, the non-monetary benefits of becoming a CHW, including social status, appear to wane after one year. Relying on minimally trained volunteers to deliver community programmes may temporarily address gaps in the health system but is unlikely to be a sustainable solution. Focus on

community programmes should not divert attention away from longer-term interventions to improve health care infrastructure and delivery of good quality health care by trained practitioners.

### 1304

#### DEMISTIFYING DRUG DELIVERY: A ONE-PAGE SOLUTION

**Deborah DiLiberto**<sup>1</sup>, Florence Nankya<sup>2</sup>, Miriam Kayendeke<sup>2</sup>, Christine Nabirye<sup>2</sup>, Clare I. Chandler<sup>1</sup>, Sarah G. Staedke<sup>1</sup>

<sup>1</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom, <sup>2</sup>Infectious Disease Research Collaboration, Uganda Malaria Surveillance Project, Kampala, Uganda

Drug stock-outs due to poorly functioning delivery systems are a major barrier to providing good quality health care in many resource-poor settings. In Uganda, stock-outs of artemether-lumefantrine (AL) threaten strategies to reduce malaria-related morbidity and mortality. Complex, large-scale initiatives have been suggested to improve health systems; however, few inexpensive, simple strategies exist to improve drug delivery at the periphery. To investigate challenges and possible solutions for drug delivery in Uganda, structured questionnaires were administered to representatives of 17 government-run health centers in Tororo district. We also conducted a literature review, in-depth interviews, and focus group discussions (FGDs) with health workers and key informants. Drug stock-outs are a major problem at most health centers, particularly at the lowest level. Two (12%) centers never stock AL, and only 13 (76%) had AL in stock on the day of the interview. Stock-outs of other antimalarial drugs, such as oral and injectable quinine and artesunate + amodiaquine, and other medications including panadol, amoxicillin, mebendazole, oral rehydration solution, and iron were also reported in most health centers. The literature review revealed several challenges to drug delivery including managerial inefficiencies, limitations in human resources, and logistical constraints. The interviews and FGDs revealed that health workers lack knowledge about the drug delivery system and are confused about the roles and responsibilities of staff involved in drug procurement. Challenges including inadequate transport, lack of funding, and delays in processing orders were cited as reasons for stock-outs. Most health workers agree that failure to provide drugs results in unmet expectations and poor quality health care. The challenges identified represent logistical nodes which should be operational to ensure effective and efficient drug delivery. We have developed a simple one-page tool based on formative evaluation and logistics measurement methodologies to help identify, communicate and resolve drug distribution issues. We plan to implement and evaluate the tool in a cluster-randomized control trial in Uganda.

### 1305

#### ANTIBIOTIC USE IN INFANTS IN A SETTING WHERE ANTIBIOTICS ARE AVAILABLE WITHOUT PRESCRIPTION: WHOSE RESPONSIBILITY?

**Lucie Ecker**<sup>1</sup>, Liset Olarte<sup>2</sup>, Gustavo Vilchez<sup>1</sup>, Theresa J. Ochoa<sup>2</sup>, Isabel Amemiya<sup>1</sup>, Ana I. Gil<sup>1</sup>, Claudio F. Lanata<sup>1</sup>, Thomas G. Cleary<sup>3</sup>

<sup>1</sup>Instituto de Investigación Nutricional, Lima, Peru, <sup>2</sup>Universidad Peruana Cayetano Heredia, Lima, Peru, <sup>3</sup>University of Texas Health Science Center at Houston, Houston, TX, United States

Antibiotics are the most commonly prescribed drugs in children. However their misuse has been associated with the development of resistant pathogens. Generally, it has been assumed that the availability of antibiotics without medical advice has been one of the most important causes of misuse. The aim of this study was to describe the use of antibiotics in Peruvian infants in a setting where antibiotics are available without prescription. Within a cohort study of 1023 children of peri-urban Lima, antibiotic use data were recorded in the clinical records at a study clinic. Children less than 2 months of age were enrolled and followed until 12 months of age. History of previous illnesses and drug use prior to enrollment and between the scheduled visits was recorded in the medical



record as well as the treatment offered by the study physician. Clinical records were reviewed and descriptive analysis was performed. During a one year period, 770 of 1023 (75.3%) children took 2085 courses of antibiotics. There were two courses/child/year, range (0-12). The mean age of usage was 6.5 months (range 9 days to 12.9 months). Higher rates of antibiotic use were found in children from 3 to 6 months of age (37.2%). Antibiotics were given to children in 8.5% of common colds, 59.1% of all pharyngitis, 68.9% of bronchitis, 64.4% of diarrheas, 23% of dermatitis, and 12% of bronchial obstruction. Physician prescription was the most common reason for antibiotic use (90.8%), self-medication was found in 6.9% and was preceded by a physician antibiotic prescription in 63.9%. The most frequently used antibiotics were penicillins (32.9%) and macrolides (23.4%). Upper respiratory tract infections were treated mainly with penicillins (56.4%), diarrhea with macrolides (49.6%) and bronchial obstruction with penicillins (44.6%). Based on the diagnoses 83.1% of the antibiotic prescribed drugs were inappropriate. In conclusion, infants are often exposed to antibiotics early in life in this peri-urban area. Antibiotic use is typically inappropriate (83.1% of courses) based on the most common etiologies for this age-group. Since physicians prescription was the most common reason for antibiotic use, interventions to improve use of antibiotics should focus on them.

### 1306

#### FEASIBILITY OF WEB-BASED TELECONFERENCING FOR REMOTE ULTRASOUND TRAINING AND QUALITY ASSURANCE IN REMOTE SETTINGS

Walter (Ted) Kuhn, Matthew Lyon

Medical College of Georgia, Augusta, GA, United States

Ultrasound (US) is an important adjunct to diagnosis and management in resource-limited settings. However, US is highly operator dependent and in remote locations, ongoing training is difficult. The objective of this study was to determine the feasibility of remote US training and quality assurance (QA) in a remote, resource-limited setting. Ultrasound training was provided to physicians working in the developing world using a SonoSite 180 Plus US machine with a C60 broadband curved array transducer. The investigators reviewed selected exams obtained on patients remotely as well as conducting on-line real time QA and educational sessions. Cases were reviewed from remote locations in South America and South-East Asia using two methods of web-based video conferencing: Skype and ooVoo. Skype worked well for one-on-one training using ultrasound images only, but did not allow for ultrasound video conferencing. However, the ultrasound equipment only allowed for still image archive. Skype also did not allow for PowerPoint based presentations. OoVoo allowed for video conferencing at more than one site. In this case, 4 sites were imaged simultaneously in 2 countries with streaming-video. OoVoo allowed for PowerPoint based presentations to be viewed by all participants. OoVoo required a faster Internet connection and one site had a long delay in the video images (Cambodia). Video conferencing allowed for training in patient positioning, sonographic windows, and also suggestions in improvement in scanning techniques. Review of one scan resulted in a change in diagnosis, which was significant, diagnosis of gallbladder cancer. The video conferencing using Skype from South America went well without loss of signal. With multiple video conferencing using ooVoo, there was a transmission delay, which was most pronounced in the South-East Asia site and resulted in loss of connection 3 times over the 90-minute session. In conclusion, web-based QA and ongoing training in US with remote, resource-limited sites is possible using commercially available programs.

### 1307

#### MOSQUITO CELLS SURVIVE FROM DENGUE 2 VIRUS INFECTION THROUGH AN ANTI-OXIDANT DEFENSE

Tien-Huang Chen, Petrus Tang, Ching-Kai Chuang, Yu-Tzu Shih, Chao-Fu Yang, Wei-June Chen

Chang Gung University, Tao-Yuan, Taiwan

Both mosquito and mammalian cells are essential for the propagation of dengue (Den) viruses during alternate transmission of the viruses. The viruses generally induce apoptosis in mammalian cells but cause only minor damages in mosquito cells, leading to persistent infection in most cases. In order to find genes involved in determining the cell fate, datasets derived from expressed sequence tags (ESTs) of C6/36 cells with and without infection were established. A total of 3876 unigenes which contained 875 contigs and 3001 singletons were obtained. Of which, 2267 and 2189 unigenes were respectively expressed in mock- and infected complementary DNA (cDNA) libraries. Among the generated unigenes, 600 (in addition to 7 viral proteins) were only found in infected cells, while 642 were only found in mock-infected cells. Chaperone protein including GRP78/BiP and endoplasmic reticulum were found to be significantly upregulated in C6/36 cells infected by Den-2 virus for 24 h. This suggests that Den-2 virus infection in mosquito cells, as in mammalian cells, activates the unfolded protein response (UPR) to cope with the endoplasmic reticulum (ER) stress at the early stage of infection. Changes of mitochondria membrane potential (MMP) and generation of superoxide provided further evidence that Den-2 virus induce the oxidative stress in spite most infected cells remain intact. Due to significant elevation of the superoxide dismutase (SOD) activity, mosquito cells are able to rescue themselves from viral infection through antioxidant defenses. The findings of this study have shed lights on interactions between the virus and host cells, particularly mosquito cells.

### 1308

#### DENGUE-2 ALTERS SALIVARY GLAND PROTEIN EXPRESSION IN INFECTED Aedes Aegypti MOSQUITOES

Daniel M. Chisenhall, Berlin L. Londono, Rebecca C. Christofferson, Christopher N. Mores

Louisiana State University, Baton Rouge, LA, United States

The principle arthropod vector of dengue virus is the *Aedes aegypti* mosquito, and in that vector the virus must disseminate to the salivary glands prior to being transmitted to the vertebrate host via salivation during probing and/or feeding. As has been shown previously, the saliva of mosquitoes contains a diverse cocktail of pharmacologically active compounds that are deposited simultaneously with the virus to the bite site of the vertebrate host. It is here that the mosquito's saliva modifies the local environment, perhaps in a way that facilitates the establishment of an infection. In order to determine whether dengue virus infection alters the protein composition of the saliva in the mosquito, we have analyzed the proteins expressed in *Aedes aegypti* salivary glands in infected mosquitoes and uninfected control mosquitoes via 2-D gel electrophoresis. Briefly, *Aedes aegypti* (Rockefeller) were orally exposed to bovine blood in Alsever's with and without dengue-2 (strain 1232). Mosquitoes were held for 9 days at 28° C before salivary glands were dissected; total proteins were extracted, and separated by 2-D electrophoresis. Mass spectroscopy analysis (LC-MS/MS) revealed that several proteins were differentially expressed between the two cohorts. In particular are several down-regulated proteins involved in ATP synthesis. We also have observed a decrease in a 30kD allergen protein and an increase in D7 in infected mosquito salivary glands, leading to an altered salivary composition that may create a more receptive environment for a successful viral infection. This research indicates the need to not only review the components of mosquito saliva that are being inoculated with the virus, but also highlights the potential direct effects the virus may have on the composition of the saliva due to salivary gland structural and functional changes in the infected invertebrate.

## VIRAL AND IMMUNOLOGICAL DETERMINANTS OF DENGUE VIRUS FITNESS AND VIRULENCE

**Molly OhAinle**<sup>1</sup>, Matthew Henn<sup>2</sup>, Yolanda Tellez<sup>3</sup>, Alexander Macalalad<sup>2</sup>, Aubree Gordon<sup>1</sup>, Andrea Nuñez<sup>3</sup>, Saira Saborío<sup>3</sup>, Niall Lennon<sup>2</sup>, Bruce Birren<sup>2</sup>, Angel Balmaseda<sup>3</sup>, Eva Harris<sup>1</sup>

<sup>1</sup>Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States, <sup>2</sup>Broad Institute, Cambridge, MA, United States, <sup>3</sup>Departamento de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua

Four serotypes of dengue virus (DENV1-4) circulate in humans, causing more illness than any other arthropod-borne virus. Despite decades of epidemiological research, we lack a sufficient understanding of the relative importance of host genetics, pre-existing immunity and viral evolution in dengue virus pathogenesis. We report here a significant increase in the incidence of severe dengue disease caused by DENV-2 in two independent studies of pediatric dengue in Managua, Nicaragua. Through full-length genome sequencing of viruses isolated from patients across several years (2005-2008), the increase in severity was found to be correlated with a clade replacement event occurring in DENV-2 circulating during the same time frame. Clade assignment by genotyping methods of additional viruses whose full-length sequence was not available increased the initial sample size substantially. Association analyses including clade and year suggests that a shift in viral genetics does not explain the increased severity observed in the later years of the studies. However, viral isolates derived from the replacing clade ("Clade 2") replicate more productively *in vitro* in human and mosquito cells, indicating that clade replacement involved the evolution of more fit DENV-2 viruses. Thus, our findings support a model in which increased viral fitness is not necessarily linked to increased pathogenesis. Consistent with this model, more in-depth analyses of clinical indicators of severity, such as low platelet count and hemoconcentration, suggest that less fit viruses ("Clade 1") are associated with more severe disease outcomes when stratified by year. Finally, we are exploring the alternative hypothesis that waning cross-reactive immunity in the population resulting from infection with a heterologous serotype (DENV-1, which circulated in Managua in 2003-5) is sufficient to explain the increased severity associated with DENV-2 infections in later years (2006-8) and are testing this by analyzing neutralization profiles of serum samples collected from our pediatric cohort study in 2004-2008. Our findings provide the first in-depth analysis of the contribution of relatively small genetic changes in viral sequence to viral fitness and pathogenicity and suggest that pre-existing immunity is the major determinant of dengue virus pathogenesis.

## 1310

### GENETIC AND PHENOTYPIC CHARACTERIZATION OF SYLVATIC DENGUE VIRUS TYPE 4 STRAINS

**Nikos Vasilakis**, Farooq Nasar, Shannan L. Rossi, Sandra V. Mayer, Robert B. Tesh, Scott C. Weaver, Mark D. Estes

University of Texas Medical Branch, Galveston, TX, United States

The four serotypes of endemic dengue viruses (DENV) circulate between humans and peridomestic *Aedes* mosquitoes. At present endemic DENV infect 100 million people per year, and a third of the global population is at risk. In contrast, sylvatic DENV strains are maintained in a transmission cycle between nonhuman primates and sylvatic *Aedes* species, and are evolutionarily and ecologically distinct from endemic DENV strains. Phylogenetic analyses place sylvatic strains basal to each of the endemic serotypes, supporting the hypothesis that each of the endemic DENV serotypes emerged independently from sylvatic ancestors. We utilized complete genome analyses of both sylvatic and endemic DENV serotype 4 (DENV-4) to expand our understanding of their genetic relationships. A high degree of conservation was observed in both the 5'- and 3'- untranslated genome regions, whereas considerable differences at the

nucleotide and amino acid levels were observed within the open reading frame. Additionally, replication of the two genotypes was compared in mammalian (Vero and Huh-7) and mosquito (C6/36) cultured cells. Understanding the genetic relationships and phenotypic differences between endemic and sylvatic DENV genotypes may provide valuable insight into DENV emergence and guide monitoring of future outbreaks.

## 1311

### FAST GROWTH DENGUE-LIKE CHIMERIC VIRUSES

Karen Boroughs, Betty Luy, Janae Stovall, **Claire Y. Huang**

Centers for Disease Control and Prevention, Fort Collins, CO, United States

Four chimeric West Nile/dengue viruses were engineered by expressing the pre-membrane-envelope (prM-E) gene region of dengue serotypes 1-4 (DEN 1-4) in the genetic backbone of West Nile virus. These viruses were stabilized by incorporating mutations which enhanced the fitness of the chimeras in Vero cells. They exhibited DEN serotype-specific antigenic properties and produced clear immune foci and plaques in Vero cell monolayers within 1 and 3 days, respectively. Compared to wild-type DEN viruses, these DEN-like chimeras replicated rapidly and reached peak titers at 3-5 days earlier in Vero cells and 2 days earlier in C6/36 cells. They achieved similar or higher titers than wild-type DEN viruses in the cell cultures. Despite their higher replication efficiency, these DEN-like chimeric viruses were attenuated in mice and had poor dissemination rates in mosquitoes. Due to their fast growth and attenuated properties, these viruses may be useful in various aspects of vaccine development, in diagnostic assays, and in DEN virus research.

## 1312

### ACCELERATED PLATELET APOPTOSIS IS ASSOCIATED WITH PLATELET PHAGOCYTOSIS AND THROMBOCYTOPENIA IN SECONDARY DENGUE VIRUS INFECTION

**Maria Terrese Alonzo**<sup>1</sup>, Talitha Lea Lacuesta<sup>2</sup>, Lady-anne Suarez<sup>2</sup>, Dan Takeuchi<sup>1</sup>, Cynthia Mapua<sup>3</sup>, Takeshi Kurosu<sup>4</sup>, Yukihiro Akeda<sup>1</sup>, Efren Dimaano<sup>2</sup>, Filipinas Natividad<sup>3</sup>, Kazunori Oishi<sup>1</sup>

<sup>1</sup>Laboratory for Clinical Research on Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan, <sup>2</sup>Department of Blood Borne Diseases, San Lazaro Hospital, Manila, Philippines, <sup>3</sup>Research and Biotechnology Division, St. Luke's Medical Center, Quezon City, Philippines, <sup>4</sup>Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

An increased platelet phagocytosis was demonstrated during the acute phase of patients with secondary dengue virus (DV) infection, as reported previously. To determine the role of apoptosis in the phagocytosis of platelets, the relationship between platelet phagocytosis by differentiated THP-1 macrophages and platelet apoptosis was examined by flowcytometry using freshly isolated platelets from 32 patients clinically diagnosed with DV infection at San Lazaro Hospital, Manila, Philippines in year 2009.

The levels of platelet apoptosis from patients were significantly increased during the acute and early convalescent phase of infection compared with those of the convalescent phase and healthy controls. In addition, a significant inverse correlation was found between the peripheral platelet counts, the levels of platelet apoptosis (by Annexin V binding:  $r = -0.491$ ,  $p = 0.001$ ; by caspase-3 activation:  $r = -0.507$ ,  $p = 0.001$ ) and the levels of platelet phagocytosis ( $r = -0.455$ ,  $p = 0.002$ ) among these patients. Furthermore, a significant direct correlation between the levels of platelet phagocytosis and platelet apoptosis (against Annexin V binding:  $r = 0.395$ ,  $p = 0.007$ ; against caspase-3 activation:  $r = 0.453$ ,  $p = 0.002$ ) was also found in these patients. Meanwhile, no effects were observed upon utilizing anti-Fc receptor IgG or anti-CR3 IgG as inhibitors in the phagocytosis of platelets by macrophages.

Collectively, our data suggest that accelerated phagocytosis of apoptotic platelets is involved in the mechanisms of thrombocytopenia in secondary DV infection. Further studies on the mechanisms of platelet apoptosis and platelet phagocytosis during the acute phase of secondary DV infection are warranted.

### 1313

#### PERMISSIVENESS OF BONE MARROW CELLS FOR DENGUE VIRUS INFECTION IS AGE-DEPENDENT

**Guey Chuen Perng**, Sansanee Noisakran, Hui-Mien Hsiao, Francois Villinger, Aftab Ansari

*Emory University School of Medicine, Atlanta, GA, United States*

Dengue is one of the most important mosquito-borne viral diseases affecting humans, with over half of the world's population living in areas at risk. Bone marrow suppression has been observed in dengue patients during the acute stage of infection associated with reduction of megakaryocytes. Studies of bone marrow biopsies from patients during acute infection indicate dengue virus infection induces bone marrow progenitor cells hypocellularity. Results from early attempts to investigate the possible underlying mechanisms leading to bone marrow suppression *in vitro* have been inconclusive. A systematic investigation on this subject was performed with bone marrow from 10 rhesus monkeys of various ages. Freshly collected bone marrow aspirates were infected with low dose of dengue virus, strain 16881 grown in Vero cells, at MOI=0.1. Cell smears were performed and supernatant fluids were collected daily for 10 consecutive days. Quantitative real-time RT-PCR was used to measure the viral titers in the supernatant fluids and immunohistochemistry staining with antibodies for cellular surface markers and dengue viral antigen was performed on smears. Results revealed that bone marrow from i) young monkeys (under 5 years old) were highly permissive to infection and able to support dengue virus replication with viral titers peaking at 2-3 days after infection; ii) older monkeys (over 5 years old) generated two patterns; viral titers declined from day 1 to day 10 and occasionally, viral titer peaked at 1 day after infection. Surface markers staining of sequential daily samples indicated that progenitor cells expressing CD235a and CD41 markers were positive for dengue viral antigen early (1-3 days) post infection, while cells with markers typical for dendritic cells or macrophages were positive for dengue viral antigen at later days (5-8) of infection. The significance of the findings will be discussed.

### 1314

#### COMMUNITY-BASED DELIVERY OF HEALTH CARE: WHAT IS THE CAPACITY FOR EXPANDING INTERVENTIONS?

**Joaniter I. Nankabirwa**<sup>1</sup>, Kristin Banek<sup>2</sup>, Deborah DiLiberto<sup>3</sup>, Lilian Taaka<sup>2</sup>, Clare Chandler<sup>3</sup>, Sarah Staedke<sup>3</sup>

<sup>1</sup>*Makerere University Kampala, Kampala, Uganda*, <sup>2</sup>*Uganda Malaria Surveillance Project, Infectious Disease Research Collaboration, Kampala, Uganda*, <sup>3</sup>*London School of Hygiene and Tropical Medicine, London, United Kingdom*

Prompt treatment with effective antimalarial drugs is one of the key strategies for reducing the burden of malaria, and community-based programs are advocated to improve access to treatment. In 2002, Uganda adopted a policy of home management of malaria (HMM), which is now scaling-up to integrated community case management (iCCM). Community health workers (CHWs) will provide presumptive treatment for malaria, pneumonia, and diarrhea to febrile children. To investigate challenges faced by CHWs in the existing HMM programme, we conducted a situation analysis in rural Eastern Uganda. We interviewed 100 CHWs selected using convenience sampling from five sub-counties in Tororo district. A structured questionnaire addressing training and supervision and a knowledge questionnaire were administered, and in-depth interviews were conducted. We identified major gaps in CHW training, knowledge, and supervision. Overall, CHWs scored poorly on the knowledge questionnaire (mean score 22%). Only 74% CHWs correctly

identified fever as the most common symptom of malaria in children, and recognition of danger signs of severe malaria was poor. Although 61% of CHWs had received training on management of malaria with artemether-lumefantrine (AL), few CHWs correctly described how AL should be administered. Only 23% said that they would refer a child who was not improving after two days. Recognition of non-malarial causes of fever in children was also poor. Only four CHWs reported receiving support supervision in the last six months. Interviews revealed that CMDs are involved in implementing multiple programmes led by different stakeholders, which are not integrated. Community-based programs provide opportunities to improve access to treatment, but their success depends on the capacity of CHWs to implement strategies. In Uganda, CHWs knowledge of appropriate management of malaria is limited, despite training, and they may be overstretched by stakeholders attempting to deliver community-based interventions. CHWs may lack capacity to deliver complex interventions successfully and sustainably. To ensure interventions are implemented appropriately, attention should be paid to training and support supervision of CHWs, and evaluation of the health impact of programmes.

### 1315

#### SUBOPTIMAL MANAGEMENT OF SEVERE MALARIA CASES IN UGANDAN HEALTH FACILITIES: A CROSS SECTIONAL SURVEY

**Jane Achan**<sup>1</sup>, James Tibenderana<sup>2</sup>, Daniel Kyabayinze<sup>2</sup>, Henry Maweje<sup>2</sup>, Rukaaka Mujizi<sup>2</sup>, Betty Mpeka<sup>2</sup>, Ambrose Talisuna<sup>3</sup>, Umberto D'Alessandro<sup>4</sup>

<sup>1</sup>*Makerere University, School of Medicine, Kampala, Uganda*, <sup>2</sup>*Malaria Consortium, Kampala, Uganda*, <sup>3</sup>*Medicines for Malaria Venture, Makerere University, School of Public Health, Kampala, Uganda*, <sup>4</sup>*Institute of Tropical Medicine, Antwerp, Belgium*

Malaria morbidity and mortality in Africa remains unacceptably high, partly due to sub-optimal case management. We evaluated the management practices of severe malaria in Ugandan health facilities by conducting a cross sectional survey using multi-stage sampling methods. Health facilities were selected in 11 districts in the eastern and mid-western parts of the country. The study instruments were adapted from the WHO hospital care assessment tools. Between June and August 2009, 105 health facilities were surveyed and 181 health workers and 868 patient/caregivers were interviewed. None of the inpatient facilities had all seven components of the basic care package for the management of severe malaria consistently available during the 3 months prior to the survey. Referral practices were appropriate in less than 10% (18/196) of the patients, while prompt care was reported by 29% (247/868) of the patients. Severe malaria was correctly diagnosed in 27% (233/868) of the patients. Though the quinine dose and regimen was correct in the majority of patients (611/868, 70%), it was administered in the correct volumes of 5% dextrose in only 18% (147/815) of the cases. Most patients (80%) had several doses of quinine administered in one single 500ml bottle of 5% dextrose. Medications were purchased by 385 (44%) patients and medical supplies by 478 patients (71%). These results highlight the challenges of correctly managing severe malaria in Uganda and other resource limited settings. Several priority areas need improvement, including triage and emergency care, referral practices, quality of diagnosis and treatment, health worker training, zero tolerance for stock outs for recommended medicines and ancillary treatments, functional referral systems, adequate infrastructure, better organization of hospital services, and regular supervision and clinical audits.



## 1316

### AN ASSESSMENT OF ADHERENCE TO ARTEMETHER-LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED MALARIA IN PHALOMBE, MALAWI, 2009

Kimberly E. Mace<sup>1</sup>, Dyson Mwandama<sup>2</sup>, James Jafari<sup>2</sup>, Madalitso Luka<sup>2</sup>, S. Patrick Kachur<sup>1</sup>, Scott J. Filler<sup>1</sup>, Don Mathanga<sup>2</sup>, Jacek Skarbinski<sup>1</sup>

<sup>1</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States,

<sup>2</sup>Malaria Alert Center, Malawi College of Medicine, Blantyre, Malawi

Malaria causes substantial morbidity and mortality in Malawi. Prompt and effective treatment is a cornerstone of malaria control. In 2007, due to increasing parasite resistance to the first-line treatment for uncomplicated malaria, Malawi replaced single-dose sulphadoxine-pyrimethamine treatment with a six-dose, three-day treatment regimen of artemether-lumefantrine (AL). Given concerns about the complex AL regimen, we assessed patient adherence to AL for the treatment of uncomplicated malaria in Phalombe District, Malawi. Adults and children with uncomplicated malaria were recruited at three health centers. To assess adherence, we conducted pill counts and in-home interviews on medication consumption 72-hours after patients received AL. Complete adherence was defined as correctly taking all six doses of AL as assessed by pill count and patient recall of number of doses, number of pills per dose, and timing for each dose. We recruited 427 patients, completed in-home interviews on 414 (97%), and analyzed 368 (86%) patients with complete data. Among 368 patients, 238 (65%) were completely adherent. Classifications of non-adherence included skipping doses, taking incorrect number of pills per dose, or taking doses at incorrect times. Factors significantly associated with adherence were a preference for AL over other medications (odds ratio (OR) 2.7,  $p < 0.001$ ), use of AL package for instructions, (OR 2.5,  $p = 0.02$ ), and direct observation of the first dose of AL (OR 2.4,  $p < 0.01$ ). In contrast, being  $< 5$  years old was associated with non-adherence (OR 0.5,  $p = 0.05$ ). In conclusion, two-thirds of patients assessed were completely adherent to a six-dose AL regimen for the treatment of uncomplicated malaria. Efforts to improve adherence should focus on children  $< 5$  years old, the age-group most vulnerable to malaria. Interventions including direct observation of the first dose, utilization of the AL package for instructions, and enhancing patient preference for AL have the potential to increase adherence and therefore improve cure rates, and possibly mitigate antimalarial drug resistance.

## 1317

### MAPPING THE PRIVATE SECTOR SUPPLY CHAIN TO UNDERSTAND THE RETAIL PRICES AND AVAILABILITY OF ANTIMALARIALS IN SIX LOW-INCOME COUNTRIES IN AFRICA AND SOUTH EAST ASIA

Catherine Goodman<sup>1</sup>, Edith Patouillard<sup>2</sup>, Sarah Tougher<sup>2</sup>, Benjamin Palafox<sup>2</sup>, Immo Kleinschmidt<sup>2</sup>, Martine-Esther Tassiba<sup>3</sup>, Louis-Daniel A. Tshisungu<sup>4</sup>, Sochea Phok<sup>5</sup>, Arogundade D. Ekundayo<sup>6</sup>, Peter Buyungo<sup>7</sup>, Felton Mpasela<sup>8</sup>, Desmond Chavasse<sup>9</sup>, Kate O'Connell<sup>9</sup>, Kara Hanson<sup>2</sup>

<sup>1</sup>London School of Hygiene & Tropical Medicine/KEMRI-Wellcome Trust, Nairobi, Kenya,

<sup>2</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom,

<sup>3</sup>PSI, Cotonou, Benin,

<sup>4</sup>Association de Santé Familiale, Kinshasa, The Democratic Republic of the Congo,

<sup>5</sup>PSI, Phnom Penh, Cambodia,

<sup>6</sup>Society for Family Health, Abuja, Nigeria,

<sup>7</sup>PACE, Kampala, Uganda,

<sup>8</sup>Society for Family Health, Lusaka, Zambia,

<sup>9</sup>PSI, Nairobi, Kenya

In many low-income settings the private sector plays a crucial role in the delivery of antimalarials, often complementing the formal public health system. In the context of the introduction of a global subsidy to improve access to artemisinin-based combination therapies (ACTs) it is important to understand private sector supply chains and how they vary across countries, as these have an important impact on price and availability, and

therefore equitable access. As part of the ACTwatch study, we undertook surveys of nationally representative samples of private sector antimalarial wholesalers and retailers, collecting volume, mark-up and provider characteristic data in 6 countries (Benin, Cambodia, DR Congo, Nigeria, Uganda, and Zambia). In total, structured interviews were completed with 688 wholesalers and 7048 retailers across the 6 countries between February 2009 and April 2010. We will present maps of the private sector antimalarial supply chains in each country, descriptions of their composition and characteristics, and estimates of availability and price mark-ups for antimalarials. For example, 81.8% of Zambian wholesalers had antimalarials available, while only 64.7% had an ACT in stock, 40.0% had an artemisinin monotherapy (AMT) and 60.0% had a non-artemisinin therapy (e.g. chloroquine) in stock at the time of interview. In terms of percentage price mark-up on ACTs, median wholesaler mark-ups (26.7%) were observed to be generally lower than median retail level mark-ups, which ranged from 42.9% in private pharmacies to 150% in grocery stores. Median percentage price mark-ups in Zambia for AMTs were similar to those for ACTs, 26.1% among wholesalers, and a range of 42.9% to 168% among private sector retailers. Results across countries will be contrasted and implications for interventions to improve ACT access through the private sector, such as the Affordable Medicines Facility for Malaria, will be explored.

## 1318

### CHANGES IN MALARIA IN SOUTHERN SENEGAL WITH THE INTRODUCTION OF ARTESUNATE PLUS AMODIAQUINE AND PARASITOLOGICAL DIAGNOSIS

Philippe Brasseur<sup>1</sup>, Oumar Gaye<sup>2</sup>, Malick Badiane<sup>3</sup>, Moustafa Cisse<sup>4</sup>, Patrice Agnamey<sup>5</sup>, Michel Vaillant<sup>6</sup>, Piero L. Olliaro<sup>7</sup>

<sup>1</sup>IRD, Dakar, Senegal,

<sup>2</sup>Faculté de Médecine, Université Cheikh Anta Diop, Dakar, Senegal,

<sup>3</sup>District Medical D'Oussouye, Oussouye, Senegal,

<sup>4</sup>PNLT Ministère de la Santé et de la Prévention, Dakar, Senegal,

<sup>5</sup>Laboratoire de parasitologie - mycologie CHU, Amiens, France,

<sup>6</sup>Unité d'Epidémiologie Clinique et de Santé Publique, CRP-Santé, Luxembourg, Luxembourg,

<sup>7</sup>World Health Organization, Geneva, Switzerland

In Senegal, antimalarial treatment policy changed from chloroquine or quinine on clinical grounds to artesunate/amodiaquine (ASAQ) on parasitological confirmation in 2006. RDTs are provided from 2007. In the District of Oussouye, the new policy was staggered in since 2000 in Mlomp and later elsewhere. Malaria is meso-endemic with transmission peaking July-December (EIR 25 in 2000). Data for 1996-2008 were extracted from the clinic registries of the referral health centre and the four peripheral dispensaries of the District of Oussouye. Data over time were analysed by logistic regression. Pluviometry and bednet distribution were also accounted. Over the entire 13-year period a total of 363,966 consultations occurred (mean 1.2 person/year) with 139,144 antimalarial treatments (on either clinical or parasitological grounds; 38% of all attendances) and a projected 32,384 true cases of malaria (~77% of antimalarial treatments were redundant.) In Mlomp (early implementation) compared to 1996, the number of consultations, antimalarial treatments and estimated malaria incidence increased initially until 1998/2000 and then decreased steadily to reach in 2008 OR (95%CI) of 0.39 (0.38-0.41), 0.18 (0.17-0.20) and 0.09 (0.08-0.11) respectively vs. 1996. The age of malaria patients changed over time; while the proportion of patients 0-5 and 6-10 years old decreased steadily and 11-15 remained overall constant, all categories  $> 15$  increased. In 2008, all categories  $> 10$  were all at higher risk than the 0-5 years (in particular, the RR(95%CI) for  $> 30$  years was 14 (1.5-131.7) Details on the comparative data from the other sites will be presented. In conclusion, there is a temporal correlation between the implementation of ASAQ and parasitological confirmation and decreasing consultations to the health facilities, fevers diagnosed and treated as malaria and estimated malaria incidence in this meso-endemic area. The age profile changes are compatible with decreased transmission intensity.

## 1319

### AN EVALUATION OF THE EFFECT OF TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS ON GAMETOCYTEMIA AND ASYMPTOMATIC PARASITEMIA IN HIV-EXPOSED CHILDREN IN RURAL UGANDA

Abel Kakuru<sup>1</sup>, Humphrey Wanzira<sup>1</sup>, Emmanuel Arinaitwe<sup>1</sup>, Victor Bigira<sup>1</sup>, Jaco Homby<sup>2</sup>, Moses Kamywa<sup>3</sup>, Jordan W. Tappero<sup>4</sup>, Grant Dorsey<sup>5</sup>, Taylor Sandison<sup>6</sup>

<sup>1</sup>Infectious Diseases Research Collaboration, Kampala, Uganda, <sup>2</sup>Institute for Global Health, University of California, San Francisco, San Francisco, CA, United States, <sup>3</sup>Department of Medicine, Makerere University, Kampala, Uganda, <sup>4</sup>GAP, Centers for Disease Control and Prevention, Atlanta, GA, United States, <sup>5</sup>Department of Medicine, University of California, San Francisco, San Francisco, CA, United States, <sup>6</sup>Department of Medicine, University of Washington, Seattle, WA, United States

Treatment with sulfadoxine-pyrimethamine (SP), an antifolate antimalarial, has been associated with increased gametocytemia, especially in the presence of antifolate resistance. However, data are limited regarding the effect of trimethoprim-sulfamethoxazole (TS) prophylaxis on gametocytemia. We previously reported that TS prophylaxis has a 40% protective efficacy against malaria among HIV-exposed (HIV-uninfected infants born to HIV-infected mothers) children, but data are lacking concerning the effect of TS on asymptomatic parasitemia (AP). Here, we examine the effects of TS prophylaxis on gametocytemia and AP. In an area of high malaria endemicity and antifolate resistance in rural Uganda, we randomized 185 HIV-exposed infants (median age= 9.6 months), following breastfeeding and a negative HIV PCR test, to discontinue or continue TS prophylaxis through age 2 years. Routine smears were obtained every 30 days, and time-at-risk was divided into calendar months. Gametocytemia and AP were diagnosed by microscopy (and absence of fever for AP). All smears performed within 7 days of a malaria episode and during malaria follow-up were censored in assessing for prevalence of AP. Among 98 infants randomized to continue TS, there were 28 episodes of gametocytemia over 1,068 months (2.6%), and among 87 infants randomized to stop TS, there were 8 episodes of gametocytemia over 845 months (1.0%) (RR=2.83, p=0.07). Among children taking TS, there were 77 AP episodes over 812 months (9.5%), and among children who discontinued TS, there were 78 AP episodes over 606 months (12.9%) (RR=0.74, p=0.18). Compared to AP in participants not taking TS, AP in children taking TS prophylaxis was less likely to progress to malaria within 7 days (RR=0.41, p=0.001). Though the overall prevalence of gametocytes was low, TS prophylaxis was associated with a trend toward increasing gametocytemia. Compared to children not taking TS, AP episodes among children taking TS prophylaxis were less likely to progress to clinical malaria, indicating that TS may prevent malaria at the erythrocytic stage.

## 1320

### INTERMITTENT PREVENTIVE THERAPY IN PREGNANCY WITH SULPHADOXINE-PYRIMETHAMINE (SP); 42 DAY *IN-VIVO* FOLLOW-UP STUDY AMONG ASYMPTOMATIC PARASITEMIC PREGNANT WOMEN IN AN AREA WITH HIGH SP RESISTANCE IN SOUTHERN MALAWI

Linda Kalilani<sup>1</sup>, Ebbie Chaluluka<sup>1</sup>, Gertrude Kalanda<sup>1</sup>, Kassoum Kayentao<sup>2</sup>, Steve Taylor<sup>3</sup>, Steve Meshnick<sup>3</sup>, Feiko ter Kuile<sup>4</sup>

<sup>1</sup>College of Medicine, University of Malawi, Blantyre, Malawi, <sup>2</sup>Malaria Research and Training Centre, Department of Epidemiology of Parasitological Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, Bamako, Mali, <sup>3</sup>University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, United States, <sup>4</sup>Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; Liverpool School of Tropical Medicine, Liverpool, Liverpool, United Kingdom

Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the control of malaria during pregnancy in sub-Saharan Africa. Malawi was the first country to introduce IPTp with SP in 1993. Parasite resistance has compromised the efficacy of SP in the case-management of symptomatic children, but SP has remained effective for IPTp in many areas of Africa. We conducted a 42-day in-vivo assessment of the parasitological response to IPTp-SP in women scheduled to receive their first dose of IPTp, to study the effect of SP resistance on the efficacy of IPTp-SP in clearing parasites and preventing new infections. HIV-negative asymptomatic parasitemic women of all gravidity were eligible if they provided written informed consent. Recruitment is ongoing in two antenatal clinics within one hour drive south-west of Blantyre. Between December 2009 and April 2010, 79 women were successfully followed weekly until day 42, or until the day of re-occurrence of parasitemia: 46 primi- and secundi-gravidae (G1+2) and 33 multigravidae (G3+). By day 42, 34 (43.0%) experienced a re-appearance of parasitemia; This was 3, 9, and 29 by day 7 (3.3%), day 14 (11.4%), and day 28 (36.7%), respectively. Primi-, and secundi-gravidae (29/46: 63.0%) were more likely to be parasitaemic by day 42 than multigravidae (5/33: 15.2%); RR 4.16, 95% CI 1.80-9.61. Molecular analyses for SP resistance-associated mutations in dhps 436, 437, 540 and 581, dhfr 51, 59 and 164 and pfprp1 1466, and genotyping to differentiate between recrudescence and new infections is ongoing. A study of the impact of IPTp-SP on placental malaria and birth outcome is also ongoing.

These preliminary results of the in-vivo follow-up suggest high rates of recrudescence and reinfection in primi-, and secundi-gravidae receiving IPTp with SP. This raises concern about the longevity of IPTp-SP in southern Malawi and stresses the need to explore alternative drugs to replace SP or alternative strategies to replace IPTp.

## 1321

### ALANYL-GLUTAMINE PREVENTS SMALL INTESTINAL EPITHELIAL APOPTOSIS *IN VITRO* AND IN A MURINE MODEL OF WEANLING MALNUTRITION

Priscilla M. Ueno<sup>1</sup>, Tara Willson<sup>1</sup>, David Wu<sup>1</sup>, Simon Hogan<sup>1</sup>, Orleancio G. de Azevedo<sup>2</sup>, Marjorie M. Guedes<sup>2</sup>, Aldo A. Lima<sup>2</sup>, Reinaldo B. Oriá<sup>2</sup>, Richard L. Guerrant<sup>3</sup>, D. Brent Polk<sup>4</sup>, Lee A. Denson<sup>1</sup>, Sean R. Moore<sup>1</sup>

<sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, <sup>2</sup>Federal University of Ceará, Fortaleza, Brazil, <sup>3</sup>University of Virginia, Charlottesville, VA, United States, <sup>4</sup>University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA, United States

Malnutrition contributes to over half of all child deaths in developing countries and is associated with an enteropathy characterized by villous atrophy and increased gut permeability. Ala-Gln, a stable glutamine

dipeptide, has recently been shown to enhance catch-up growth and gut integrity in underweight children from Northeast Brazil. We sought to test the hypothesis that Ala-Gln mediates these effects via anti-apoptotic mechanisms *in vitro* and *in vivo*. Colorimetric viability assays were performed in mouse small intestine epithelial (MSIE) cells in the presence of varying concentrations of Ala-Gln. Apoptosis was assessed by annexin and 7-AAD staining and flow cytometry. To determine Ala-Gln's *in vivo* effects, we randomized dams of 10-day old C57/B6 mice to standard chow or an isocaloric, Northeast Brazil "regional" diet (low protein, low fat). On day of life 21, pups were weaned to their dam's diet and randomized to Ala-Gln solution or plain drinking water. At 6 weeks of age, mice were sacrificed to obtain jejunal specimens for morphological, immunohistochemical, and Ussing chamber analyses. Ala-Gln promoted MSIE viability in a dose-response manner and reduced early apoptosis. Pups of dams that received the regional diet exhibited failure to thrive and villous blunting, as well as decreased epithelial proliferation and increased epithelial apoptosis (as measured by BrdU and caspase-3 staining, respectively). Despite no differences in catch-up growth, undernourished pups randomized to Ala-Gln showed significant improvements in villous height and epithelial proliferation/apoptosis. In conclusion, the regional diet induces failure to thrive and environmental enteropathy-like changes in weanling mice. Ala-Gln promotes enterocyte survival and normal villous architecture in the setting of malnutrition, independent of changes in weight. Further studies are needed to define the signaling pathways by which Ala-Gln mediates these cellular responses, which are critical to recovery from the reciprocal cycle of diarrhea and malnutrition.

### 1322

#### POLYMORPHISMS IN INFLAMMATORY MEDIATOR GENES CONFER PROTECTION FROM SYSTEMIC BACTERIAL INFECTIONS IN *PLASMODIUM FALCIPARUM*-INFECTED CHILDREN

Gregory C. Davenport<sup>1</sup>, Tom Were<sup>2</sup>, Collins O. Ouma<sup>2</sup>, Prakasha Kempaiah<sup>1</sup>, Samuel B. Anyona<sup>2</sup>, Evans Raballah<sup>2</sup>, John M. Ong'echa<sup>2</sup>, Jeremy Martinson<sup>3</sup>, Douglas Perkins<sup>1</sup>

<sup>1</sup>University of New Mexico, Albuquerque, NM, United States, <sup>2</sup>University of New Mexico/KEMRI, Kisumu, Kenya, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, United States

Malaria and bacteremia both cause significant morbidity and mortality in Kenyan children living in holoendemic *P. falciparum* regions. We have recently reported decreased parasitemia levels in these co-infected children without exacerbation of anemia, despite elevated levels in a number of pro- and anti-inflammatory mediators in co-infected children. To further explore these findings from a genetic perspective, we examined the following single nucleotide polymorphisms (SNPs) in IL-12 (T-1188C), TNF-alpha (G-238A, C-308T, A-376T, T-1031C), IFN-gamma (receptor G-56A, G+2200A), IL-4 (C-589T, C-1335T), and IL-10 (C-592A, C-819T, T-1082C) in relation to infection status (malaria mono-infected, Pf+, n=294; Gram[-] bacteremia and malaria co-infected, G[-]/Pf+, n=17; and Gram[+] bacteremia and malaria co-infected, G[+]/Pf+, n=9). Pearson's chi-square analysis identified associations between infection status and IFN-gammaR G-56A (P=0.071), IFN-gamma G+2200A (P=0.033), TNF-alpha C-308T (P=0.009), and IL-4 C-589T (P=0.024). Multinomial logistic regression analyses of these four SNPs, with infection status as the dependent variable (0, Pf+; 1, Bacteremia/Pf+ co-infected), and sickle cell status, HIV status, G6PD status, gender, and age as covariates, revealed significant protection from bacteremia in malaria parasitemic children for IFN-gammaR G-56A [AA, odds ratio (OR)=0.394, P=0.029], TNF-alpha C-308T [TT, OR=0.422, P=0.037], and IL-4 C-589T [CT, OR=0.455, P=0.034]. Another set of regression analyses using high-density parasitemia (HDP, >10,000 parasites/μL) as the dependent outcome variable, demonstrated that heterozygosity at the IFN-gammaR G-56A locus was associated with increased susceptibility to HDP (GA, OR=1.607, P=0.050). Thus, homozygous A alleles at IFN-gammaR -56 are associated with protection from bacteremia in children with malaria, while heterozygosity at the same locus predisposes children to HDP. Taken together, these findings suggest

that many of the SNPs important in malaria disease severity also play a significant role in acquisition of systemic bacterial infections in Kenyan children.

### 1323

#### RISK FACTORS OF *STREPTOCOCCUS SUIIS* INFECTION IN VIETNAM: A CASE-CONTROL STUDY

Nghia Ho Dang Trung<sup>1</sup>, Tu Le Thi Phuong<sup>2</sup>, Thai Cao Quang<sup>2</sup>, Hoang Nguyen Van Minh<sup>2</sup>, James Campbell<sup>2</sup>, Hien Tran Tinh<sup>3</sup>, Jeremy Farrar<sup>2</sup>, Constance Schultz<sup>2</sup>

<sup>1</sup>Hospital for Tropical Diseases, Ho Chi Minh, Vietnam, <sup>2</sup>Oxford University Clinical Research Unit, Ho Chi Minh, Vietnam, <sup>3</sup>Hospital for Tropical Diseases, Ho Chi Minh, Vietnam

*Streptococcus suis*, an emerging zoonotic infection, is the most common bacterial cause of adult bacterial meningitis in Vietnam. The explosive outbreak of *S. suis* infection in China in 2005 with hundreds of human cases and 39 deaths and emergence across South East Asia makes this an increasingly public health problem. We conducted a case-control study to identify the risk factors of *S. suis* infection in Vietnam. A standard case-control study with appropriate hospital and matched community controls for each patient. The study was conducted between May 2006 and June 2009 at Hospital for Tropical diseases in Ho Chi Minh City, Vietnam. Patients were confirmed by blood culture or cerebrospinal fluid (CSF) culture or real-time PCR. Risk factors were assessed by a standard questionnaire, including socio-demographic and cultural characteristics, medical history, and assessment of potential risk factors. We investigated whether the bacterial is carried by patients and healthy individuals using real-time PCR and culture of throat and rectal swab samples. We recruited 101 cases *S. suis* meningitis, 303 hospital controls and 300 community controls. By multivariate analysis, we found that the risk factors of *S. suis* infection included occupations related to pigs (OR1=3.83; 95%CI=[1.33-11.04] and OR2=5.56; 95%CI=[1.51-20.57]), exposures to pigs or pork in the previous 2 weeks with skin injuries (OR1=7.29; 95%CI=[1.92-27.64] and OR2=15.76; 95%CI=[2.94-84.45]) and eating "high risk" dishes in the last 2 weeks (OR1=2.32; 95%CI=[1.21-4.46] and OR2=4.67; 95%CI=[2.26-9.62]). *S. suis* DNA was detected in rectal and throat swabs of 7 patients and was cultured from 2 of these samples, but was not detected in such samples of 1522 healthy individuals or patients without *S. suis* infection. *S. suis* is an important and emerging public health issue in Asia and one with the potential for both endemic transmission and for explosive epidemics. This case control study, the largest prospective epidemiological assessment of this disease, has identified the most important risk factors associated with *S. suis* bacterial meningitis to be occupational exposure to pigs and pig products, preparation of pork and eating 'high risk' dishes popular in parts of Asia.

### 1324

#### HANSEN'S DISEASE (LEPROSY) AMONG UNITED STATES-RESIDING MICRONESIANS AND MARSHALLESE

Patricia A. Woodall

Tulane University, New Orleans, LA, United States

From 2004-2008, 13% of Hansen's Disease cases reported in the United States occurred among migrants from the Federated States of Micronesia and the Republic of the Marshall Islands, countries with high HD prevalence of 10-20/10,000. Citizens of these countries (former U.S. Trust Territory of the Pacific Islands) may freely enter and work in the US, not subject to immigration restrictions. Due to economic and climatologic factors, migration is increasing; ~2400 Marshallese/Micronesians move to the U.S. annually. This study included consolidation of data from various published reports of HD indicators in the countries of origin, analysis of 1990-2009 National Hansen's Disease Program surveillance and clinical data, and collection/analysis of qualitative data relevant to disease control issues among US-resident clusters. HD prevalence and case detection rates in the two source countries remain the highest in the world, with



fluctuations due to program activity, but with little progress toward the WHO leprosy elimination target of <1/10,000. Local community rates as high as 5% have been reported. 55% of US-resident Micronesian/Marshallese cases occurred in Hawaii. Among 74 US mainland cases in 26 states, 50% were diagnosed within 3 years of US entry, 63% did not complete treatment, and 80% had at least 1 complication, including advanced neuropathic disease. Since 1996, 17 cases have been reported in a single community in Arkansas, primarily young adult males with lepromatous disease. Comparison with rates in the Marshall Islands and in Hawaii suggests that fewer than half of cases in this community have been identified, with women, children, and tuberculoid disease under-represented. Cultural, socio-economic, and health-system barriers to HD care in this community are identified. With the goal of decreasing health disparity and preventing disability, case-finding and case-management interventions are needed in US-resident Marshallese/Micronesian communities as well as in the countries of origin.

## 1325

### POLYMORPHISMS ILE655VAL IN ERBB2/HER-2/NEU RECEPTOR IS ASSOCIATED WITH HANSEN'S DISEASE (LEPROSY) IN A BRAZILIAN POPULATION

Sérgio R. Araujo<sup>1</sup>, Kate Dupnik<sup>2</sup>, Maurício L. Nobre<sup>3</sup>, Adriana F. Barbosa<sup>1</sup>, Glória M. Monteiro<sup>1</sup>, Márcia S. Dias<sup>1</sup>, Pedro B. Trindade<sup>1</sup>, Carlos M. Gomes<sup>1</sup>, Sarra Jamieson<sup>4</sup>, Jenefer Blackwell<sup>4</sup>, Selma M. Jerônimo<sup>5</sup>

<sup>1</sup>Universidade Federal do Rio Grande do Norte, Natal, Brazil, <sup>2</sup>Weill Cornell Medical College, New York, NY, United States, <sup>3</sup>Secretaria de Saude, Governo do Rio Grande do Norte, Natal, Brazil, <sup>4</sup>University of Western Australia, Perth, Australia, <sup>5</sup>Universidade Federal do Rio Grande do Norte and INCT Doenças Tropicais, Natal, Brazil

Leprosy is an infectious disease caused by *Mycobacterium leprae* which can lead to severe permanent disability. *M. leprae* induces nervous degeneration by linkage to Schwann cell in periphery nervous system in part resulting from the interaction of the ErbB2 receptor and *M. leprae*. The objective of this study was to evaluate whether the polymorphisms in *ERBB2* gene is associated with leprosy. A total of 216 leprosy patients and 226 controls were genotyped for six markers located in *ERBB2* gene. The markers were rs2517955 and rs2517956 in the promoter region; rs1810132 and rs2952156 in intron regions, and rs1801200 and rs1058808 in exons of the *ERBB2* gene. Statistical analysis was performed by using Web-based tool Snpstats (<http://bioinfo.iconcologia.net/index.php?module=Snpstats>). Two SNPs were associated with Hansen's disease, respectively, SNP rs1801200 ( $p = 0.036$ , OR = 1.61, CI = 0.90 - 2.88) and the SNP rs2517956 ( $p = 0.047$ , OR = 1.53, CI = 0.84 - 2.76). The base change from A to G in the allele marker rs1801200 results in amino acid change in position 655 from isoleucine to valine. This amino acid is located in the transmembrane domain of the ErbB2 receptor, which is involved in the dimerization of ErbB2 monomers and its activation. The presence of valine induces a tighter linkage of ErbB2 monomers than isoleucine does, and results in greater stability and increased catalytic activity of ErbB2. In conclusion, presence of the polymorphic alleles in the markers rs1801200 and rs2517956 in *ERBB2* gene was found to be associated with Hansen's disease. Presence of Val in position 655 (rs1801200) results in greater stability of the two ErbB2 monomers and might increase its catalytic activity.

## 1326

### A QUICK AND COST-EFFECTIVE METHOD FOR THE DIAGNOSIS OF MYCOBACTERIUM ULCERANS DISEASE

Dziedzom K. de Souza, Charles Quay, Lydia Mosi, Daniel A. Boakye

Noguchi Memorial Institute for Medical Research, Legon, Accra, Ghana

*Mycobacterium ulcerans* causes the painless necrotizing skin disease Buruli ulcer, highly endemic in rural West and Central Africa. The mode

of transmission remains unknown largely due to the lack of early case diagnosis and late treatment seeking behavior of infected individuals. Diagnosis is based on clinical presentation and microscopy followed by PCR confirmation in reference laboratories. Complete diagnosis is therefore usually late, inefficient, time consuming and very expensive. Early diagnosis is important for effective treatment to prevent the morbid effects of the disease on affected individuals. We report the development of a simple and inexpensive test that could be used in poorly to medium resourced settings at point of care facilities based on the loop mediated isothermal amplification (LAMP) method. Four sets of primers, targeting various sections of the *M. ulcerans* genome, were designed for the reaction and the assay was developed and tested on five *M. ulcerans* strains from patients in Ghana and two American Type Culture Control (ATCC) reference isolates; Ghana #970321 (D19F9) and Benin #990826 (D27D14). To determine specificity, the assay was tested on the closely related *M. marinum* 1218 and other mycolactone producing mycobacteria; *M. marinum* DL240490, *M. liflandii* and *M. pseudoshotsii*. The assay was finally tested on DNA obtained from biopsy samples from infected laboratory animals, prepared using either boil preparation or Qiagen kit extraction methods. The test was successful for DNA obtained by both methods although the latter provided the best results. Our results revealed a high specificity of the LAMP assay for selectively detecting *M. ulcerans*. Compared to the conventional PCR, the new assay is cheaper and simpler and does not require the use of a thermal cycler or electrophoresis. Results are obtained within one and a half hours and visually observed under UV light. These observations indicate that the BU-LAMP assay is suitable for early disease diagnosis and application in low resource health facilities.

## 1327

### LANDSCAPE AND ENVIRONMENTAL INFLUENCES ON PRESENCE/ABSENCE OF MYCOBACTERIUM ULCERANS IN GHANA

Shannon McClintock<sup>1</sup>, Julie Clennon<sup>1</sup>, Ellen Whitney<sup>1</sup>, Edwin Ampadu<sup>2</sup>, William Opare<sup>2</sup>, Eric Benbow<sup>3</sup>, Richard Merritt<sup>4</sup>, Pamela Small<sup>5</sup>, Heather Williamson<sup>5</sup>, Daniel Boakye<sup>6</sup>, Jianguo Qi<sup>4</sup>, Lindsay Campbell<sup>4</sup>, Jenni van Ravensway<sup>4</sup>, Lance Waller<sup>1</sup>

<sup>1</sup>Emory University, Atlanta, GA, United States, <sup>2</sup>National Buruli Ulcer Control Program, Accra, Ghana, <sup>3</sup>University of Dayton, Dayton, OH, United States, <sup>4</sup>Michigan State University, East Lansing, MI, United States, <sup>5</sup>University of Tennessee, Knoxville, TN, United States, <sup>6</sup>Noguchi Memorial Institute for Medical Research, Accra, Ghana

Buruli ulcer is a neglected tropical skin disease caused by *Mycobacterium ulcerans* (MU) that is highly endemic in West Africa. While the mode of transmission is unknown, many epidemiological studies have found Buruli ulcer to be associated with different types of exposure to water sources. Sixty-eight aquatic sites used for daily domestic purposes by communities in the greater Accra and Ashanti regions of Ghana were sampled in 2005-2007 to test for the presence of *M. ulcerans*. We explored the spatial distribution of the MU positive and negative water bodies as well as identified site, water, land cover, and landscape characteristics associated with MU presence using logistic regression with model selection by AIC. Kullback's Bernoulli spatial scan statistic using circular windows found no significant local clusters of MU positive sites, and Ripley's K function showed no significant global clustering of MU positive sites compared to negative sites. The best fitting logistic regression model identified region, elevation, region by elevation interaction, presence of urban land cover within 100m, presence of forest land cover within 1km, water hardness, and region by water hardness interaction to be associated with the presence of MU. An empirical semivariogram of the residuals from the final model revealed no significant residual spatial autocorrelation. These results support the notion that MU is an environmental organism that exists in specific niches, but whose distribution in nature may not necessarily reflect the distribution of the disease. Understanding the spatial distribution of MU as well as factors associated with its presence can further research on modes of transmission as well as identify areas in need of surveillance for Buruli ulcer.

### THE SENSITIVITY OF STANDARD CIRCULATING FILARIAL ANTIGEN TESTS AND ULTRASONOGRAPHY FOR INDIVIDUAL DIAGNOSTICS AND EPIDEMIOLOGICAL SURVEILLANCE OF BANCROFTIAN FILARIASIS

Achim Hoerauf<sup>1</sup>, Ute Klarmann<sup>1</sup>, Alexander Y. Debrah<sup>2</sup>, Linda Batsa<sup>3</sup>, Ohene Adjei<sup>4</sup>, Sabine Mand<sup>1</sup>

<sup>1</sup>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany, <sup>2</sup>Faculty of Allied Health Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana, <sup>3</sup>Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana, <sup>4</sup>Komfo Anokye Teaching Hospital (KATH), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana

Significant advances were made in the diagnosis of lymphatic filariasis (LF) in the past years using two tests for the detection of circulating filarial antigen (CFA) in individuals with LF: the Og4C3-ELISA (TropBio®) and the immunochromatographic test (ICT; NOW® Filariasis). These tests have been mainly used in microfilariae (Mf) carriers and both resulted in high sensitivity. To verify parasitic infection also in amicrofilaremic individuals, ultrasonography (USG) of the scrotal area is frequently used. In this study Mf-load and CFA-status (Og4C3) were assessed in healthy adult volunteers (n=1976), 535 samples were additionally analysed with ICT. All men (n=1132) underwent ultrasound examination of the scrotum. Altogether 324 were Mf+ and 1652 were Mf-. Both tests, Og4C3 and ICT, showed a high sensitivity for detection of CFA in the Mf+ samples (99% and 100% respectively) but there was a significant difference between both tests regarding the Mf- samples (consistency only in 410/483 (85%) cases). USG revealed that 201 men were FDS+/Mf+, 151 FDS+/Mf-, 74 FDS-/Mf+ and 706 FDS-/Mf-. The sensitivity of Og4C3 and ICT was high in microfilaremic patients (99% or 100%). The sensitivity of the Og4C3 for FDS+/Mf- men was 91%, that of the ICT 82%. There was a significant difference between both tests in the assessment of the FDS-/Mf- patients (consistency in 113/140 (81%)). In 74/275 (27%) Mf+ men, life adult worms could not be detected by USG. In conclusion, confirmative to a former trial, in 73% of the Mf+ individuals life adult worms were detected by USG. The lower detection of the USG is presumably caused by adult worms located in sites of the body other than the scrotum. Og4C3 and ICT both show a high and comparable sensitivity in the detection of Mf+ individuals while in FDS+/Mf- cases the sensitivity of antigen detection is lower. Particularly in absence of Mf and FDS, Og4C3 and ICT show a lack of consistency. Therefore antigen results from Mf- individuals should be interpreted taking this caveat into account.

### IDENTIFICATION OF A WUCHERERIA BANCROFTI LARVAL STAGE SPECIFIC PROTEIN THAT IS BOTH SENSITIVE AND SPECIFIC IN DETECTING ANTIBODIES IN W. BANCROFTI INFECTED PATIENTS

Joseph Kubofcik, Doran L. Fink, Thomas B. Nutman  
National Institutes of Health, Bethesda, MD, United States

The current antibody tests used for mapping the distribution of lymphatic filariasis (LF) and for monitoring progress in elimination programs suffer from poor specificity because of considerable cross-reactivity with antibodies induced by other filarial infections such as *Loa loa*, *Onchocerca volvulus*, and *Mansonella* spp. Using the dCAS bioinformatics package, we assembled 2048 expressed sequence tags (EST) from the L3 infective larvae of *W. bancrofti* into non-redundant contigs which were then assessed for homology to protein and nucleotide databases as well as head-to-head against contig sets assembled from L3 larval ESTs of *B. malayi* (Bm - 5068 ESTs), *O. volvulus* (Ov - 4166 ESTs), and *Loa loa* (Ll- 3315 ESTs). Nineteen potential L3- and Wb-specific antigens were identified and expressed as fusion proteins with Renilla luciferase in mammalian cells. Screening of cell

lysates by a Luciferase Immunoprecipitation System (LIPS) assay revealed that only 1 of the 19 antigens (Wb-123) was both highly immunogenic and Wb-specific. Using a broad panel of well-defined sera from normal North Americans (n=53) and patients infected exclusively with Wb (n=43), Ll (n= 70), Ov (n=43), or intestinal helminths (n= 21), the Wb-123 based LIPS assay could identify sera from all of the Wb-infected individuals (MF+ or CAg+ from diverse geographic regions) with 100% sensitivity and 100% specificity compared to sera from uninfected controls and those with intestinal helminths. When specificities and sensitivities were assessed using sera from Ll-infected or Ov-infected individuals as the comparator, the sensitivities ranged between 98-100% and the specificities between 97-98%. Thus, we have identified an L3- and Wb-specific antigen that can be used not only as a rapid and specific tool to diagnose individual Wb infections but also as a sensitive, high-throughput, and potentially point-of care method for early detection of recrudescence infections in areas of control and for mapping new areas of Wb transmission.

### CARDIAC LESIONS IN AN AREA HYPERENDEMIC FOR LOIASIS IN CAMEROON

Jean Tenaguem<sup>1</sup>, Edwine Wawo-Yonta<sup>2</sup>, Raceline Ngounou Fotsing<sup>3</sup>, Joseph Kamtchum Tatuene<sup>2</sup>, Hugues Nana Djeunga<sup>4</sup>, Jean Bopda<sup>5</sup>, Adrian Hopkins<sup>6</sup>, Thomas B. Nutman<sup>7</sup>, Christopher Kuaban<sup>2</sup>, Michel Boussinesq<sup>8</sup>, Amy Klion<sup>9</sup>, Joseph Kamgno<sup>1</sup>

<sup>1</sup>Filariasis Research Center and Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon, <sup>2</sup>Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon, <sup>3</sup>Faculty of Sciences University of Yaounde I, Yaounde, Cameroon, <sup>4</sup>Filariasis Research Center and Faculty of Sciences, University of Yaounde I, Yaounde, Cameroon, <sup>5</sup>Filariasis Research Center, Yaounde, Cameroon, <sup>6</sup>Mectizan Donation Program, Decatur, GA, United States, <sup>7</sup>Helminth Immunology Section, National Institutes of Health, Bethesda, MD, United States, <sup>8</sup>Unité Mixte de Recherche 145, Institut de Recherche pour le Développement and Université Montpellier 1, Montpellier, France, <sup>9</sup>Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

Although the majority of patients with loiasis are asymptomatic despite high levels of blood microfilariae, characteristic symptoms include migratory angioedema and subconjunctival migration of the adult worm. Serious complications, including endomyocardial fibrosis (EMF), have been described; however, the prevalence of such complications in endemic areas is unknown and likely underestimated. To assess the cardiac complications related to loiasis, we performed a cross-sectional, study of 297 adult (>15 years of age) residents of a hyperendemic focus of loiasis in Cameroon. Subjects with evidence of onchocerciasis or lymphatic filariasis, a history of cardiovascular disease prior to their settlement in the study area or any antifilarial treatment taken during the last two years were excluded from the study. All subjects underwent a detailed clinical examination, assessment of microfilaremia by calibrated thick smear of daytime blood, *Loa loa* serology (SXP LIPS), and echocardiography performed by an experienced cardiologist. Of the 297 subjects, 180 had detectable *Loa* microfilaremia, 39 had both *Loa* and *Mansonella perstans* microfilaremia and 63 had no serologic or parasitologic evidence of *Loa* infection. Echocardiography was abnormal in a high percentage (84.5%) of patients and included valvular or endocardial calcifications (70%), diastolic dysfunction (35.7%), cavity dilatation (34.3%), valvular insufficiency (18.5%), left ventricular hypertrophy (9.8%), pericardial lesions (2.4%) and EMF (1.01%). Although the frequency and distribution of these abnormalities was not statistically different between subjects with and without loiasis, the number of uninfected subjects was small. Of note, all 3 subjects with EMF had detectable *Loa* infection, negative stool examination for intestinal helminths and marked eosinophilia. Although these data are consistent with an increased prevalence of cardiac

abnormalities, including EMF, in an area hyperendemic for loiasis, the role of loiasis in the pathogenesis of these abnormalities remains to be elucidated.

### 1331

#### TARGETING *WOLBACHIA* ENDOSYMBIONTS IN *ONCHOCERCA VOLVULUS* EFFECTIVELY CLEARS PERSISTENT MICROFILARIAE IN THE SKIN OF ONCHOCERCIASIS PATIENTS IN WHOM REPEATED IVERMECTIN TREATMENT HAD FAILED TO CLEAR

**Alexander Y. Debrah**<sup>1</sup>, Sabine Specht<sup>2</sup>, Sabine Mand<sup>2</sup>, Linda Batsa<sup>3</sup>, Ute Klarmann<sup>2</sup>, Yeboah Marfo-Debrekyei<sup>3</sup>, Alexander Kwarteng<sup>3</sup>, Mike Osei-Atweneboana<sup>4</sup>, Daniel Boakye<sup>4</sup>, Ohene Adjei<sup>5</sup>, Achim Hoerauf<sup>2</sup>

<sup>1</sup>Faculty of Allied Health Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana, <sup>2</sup>Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany, <sup>3</sup>Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana, <sup>4</sup>Noguchi Memorial Institute, Accra, Ghana, <sup>5</sup>School of Medical Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana

Ivermectin (IVM) has been the drug of choice for the treatment of onchocerciasis since 1987. However, there have been reports of persistent microfilariae (Mf) in the skin of some people after many rounds of IVM treatment in some districts in Ghana. These indications are consistent with the emergence of drug resistance or sub-optimal response to IVM. To assess the effect of targeting *Wolbachia* endosymbionts in *O. volvulus* on onchocerciasis patients in whom repeated IVM treatment had failed to mediate Mf clearance, 149 patients were recruited in 2 districts in Ghana where IVM resistance has been reported. They were treated with either 100mg/d doxycycline (Doxy) or matching placebo for 6 weeks. Three and 12 months after Doxy treatment, all patients took part in ongoing IVM mass treatment. Patients were snipped before, 12 and 20 months after treatment to assess the levels of Mf that IVM could not clear. Entomological work was also carried out in all the studied villages before and after Doxy treatment.

Before treatment, of the 73 patients allocated for doxycycline, 66% had persistent Mf in the skin and 34% had only nodules but no skin Mf, and of the 76 patients allocated for placebo, 63% had persistent Mf in the skin and 37% had only nodules (P=0.74). However, at 12 months after Doxy treatment, of the 72 Doxy-treated patients snipped, 10% still had low numbers of Mf in the skin and 90% had no Mf at all. Of the 71 placebo patients snipped, 58% still had Mf in the skin while 42% had no Mf (P<0.001). At 20 months post therapy, only 3% of the 69 Doxy patients had low Mf and 97% were Mf negative. In contrast, of the 71 placebo patients, 69% still had Mf while only 31% had no Mf. This difference between the Doxy and placebo groups was significant (P<0.001). Doxy cleared *Wolbachia* significantly compared to placebo group and shows embryostatic effect in the adult worms compared to placebo patients. A comparison between pre-treatment and post treatment transmission parameters indicated a significant reduction after intervention in most areas. Doxycycline clears *Wolbachia* from *O. volvulus* worms, and resulted in embryogenesis blockade. Therefore, targeting *Wolbachia* in *O. volvulus* is effective in clearing Mf in the skin of onchocerciasis patients in whom repeated standard treatment has failed to clear; thus strategies may be developed including anti-*Wolbachia* I treatment to control the re-emergence of onchocerciasis in areas where infections persist despite the use of IVM.

### 1332

#### HIGH DOSE BIENNIAL ALBENDAZOLE AND IVERMECTIN SUPPRESS *WUCHERERIA BANCROFTI* MICROFILARIAL LEVELS MORE EFFECTIVELY THAN STANDARD DOSE ANNUAL TREATMENT

**Benoit Dembele**<sup>1</sup>, Yaya I. Coulibaly<sup>1</sup>, Siaka Konate<sup>1</sup>, Housseini Dolo<sup>1</sup>, Siaka Y. Coulibaly<sup>1</sup>, Dramane Sanogo<sup>1</sup>, Lamine Soumaro<sup>1</sup>, Michel E. Coulibaly<sup>1</sup>, Salif S. Doumbia<sup>1</sup>, Abdallah A. Diallo<sup>1</sup>, Sekou F. Traore<sup>1</sup>, Adama D. Keita<sup>2</sup>, Thomas B. Nutman<sup>3</sup>, Amy D. Klion<sup>3</sup>

<sup>1</sup>University of Bamako, Bamako, Mali, <sup>2</sup>Hospital of Point G, Bamako, Mali, <sup>3</sup>Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD, United States

Annual mass treatment with albendazole and ivermectin is the mainstay of current strategies to interrupt transmission of *Wuchereria bancrofti* (Wb) in Africa. More effective microfilarial suppression could reduce the time necessary to interrupt transmission and ease the economic burden of such programs in countries with limited resources. To determine the effect of increased dose and frequency of albendazole/ivermectin (AI) treatment on microfilarial (mf) clearance, 40 Wb microfilaremic residents of an endemic area in Mali were randomized to receive three doses of standard annual AI therapy (400 mg/150 mcg/kg; n=21) or six doses of twice-yearly increased dose AI therapy (800 mg/400 mcg/kg; n=19). Mf levels were assessed by Nuclepore filtration of 1 ml of blood and circulating antigen (CAG) levels by TropBio™ ELISA. We have previously reported increased efficacy of twice-yearly high dose treatment in reducing mf counts at 12, 18 and 24 months as compared to standard dose annual therapy with no mf detected in subjects in the twice-yearly group at any time point after 6 months. At 30 months, only 1/17 subjects in the annual group and 0/17 subjects in the twice-yearly group had detectable mf (p=NS). As at prior time points, a significant and comparable decrease in CAG levels was seen in the annual and twice-yearly treatment groups at 30 months with geometric mean (GM) % pre-treatment levels of 74% and 54%, respectively. Thirty-six month followup is planned for July 2010. These findings suggest that increasing the dose and frequency of AI treatment leads to more rapid suppression of microfilaremia than standard annual therapy and that this effect is not due to an enhanced adulticidal effect. Consequently, twice-yearly high dose treatment is likely to have the greatest benefit in accelerating transmission interruption in regions where mass treatment has been non-existent or suboptimal. Additional studies examining the independent effects of dose and frequency are clearly needed.

### 1333

#### A HYDROCELECTOMY PROGRAM FOR LYMPHATIC FILARIASIS IN LÉOGANE, HAITI: CLINICAL INFORMATION AND SURGICAL OUTCOMES

**Nicole Kosacz**<sup>1</sup>, Melanie Strahm<sup>1</sup>, Yves Laurissaint<sup>2</sup>, Luccene Desir<sup>2</sup>, Jacquelin Roberts<sup>3</sup>, David Addiss<sup>4</sup>, Thomas Streit<sup>5</sup>, LeAnne Fox<sup>3</sup>

<sup>1</sup>Emory Rollins School of Public Health, Atlanta, GA, United States, <sup>2</sup>Lymphatic Filariasis Program, Hospital Sainte Croix, Léogane, Haiti, <sup>3</sup>Centers for Disease Control and Prevention, Atlanta, GA, United States, <sup>4</sup>The Fetzter Institute, Kalamazoo, MI, United States, <sup>5</sup>The University of Notre Dame, Notre Dame, IN, United States

Lymphatic filariasis (LF) has been endemic in Haiti for over 250 years with a current estimate of 8 million people at risk of infection. In Léogane Commune, up to 30% of adult males suffer from hydrocele, the most common manifestation of chronic LF. Since 2001, a surgical program providing hydrocelectomy has been in operation at Hôpital Sainte Croix and Hôpital Cardinal Légère in Léogane. We assessed clinical data and surgical outcomes for 491 men who underwent hydrocelectomy between 2001 and 2008. Patients ranged in age from 14-85 years (mean, 42 years) and reported an average of 5.6 years with the hydrocele (range, 3 days



- 26 years). Over this eight year period, a total of 792 hydrocelectomies were performed (bilateral hydrocelectomies were counted as two procedures) with the majority (98%) of these procedures utilizing the 'excision technique' where complete excision of the tunica vaginalis is performed. The average hydrocele volume was 510 cc (range 3-2,100 cc) and 116/390 (30%) men were positive for filarial antigen by ICT card test prior to surgery. Variability of hydrocele fluid types were noted intraoperatively including pure hydrocele (n=478) (60.4%), lymphocele (n=269) (34.0%), chylocele (n=23) (2.9%), hematochylocele (n=17) (2.1%), and hemocele (n=5) (0.6%). Only 32/491 (6.5%) men had a negative outcome following surgery, defined as hydrocele recurrence, development of a new hydrocele, post-operative infection, or hematoma formation. Potential predictors of negative clinical outcome will be highlighted and discussed. These results illustrate the clinical variability of filarial hydrocele and the success of the Léogane hydrocelectomy program.

### 1334

#### ECONOMIC AND PSYCHOSOCIAL IMPACT OF HYDROCELE AND THE BENEFITS OF HYDROCELECTOMY

**Nathaniel Yellu<sup>1</sup>**, John O. Gyapong<sup>1</sup>, Dominique Kyelem<sup>2</sup>, Molly Brady<sup>2</sup>, Mark Bradley<sup>3</sup>, Eric Ottesen<sup>2</sup>

<sup>1</sup>Research and Development Division, Ghana Health Service, Accra, Ghana, <sup>2</sup>Lymphatic Filariasis Support Centre, Task Force for Global Health, Atlanta, GA, United States, <sup>3</sup>GlaxoSmithKline, Brentford, United Kingdom

Hydrocele is a major public health problem in Lymphatic Filariasis (LF) endemic countries. It causes disability and negatively impacts on productivity, quality of life and sexuality. Global estimates suggest 80 countries are endemic for LF, affecting over 120 million people. In highly endemic countries, hydrocele can affect up to 20% of adult males. Globally, little quantitative data exist on the economic and psychosocial effects of hydrocele and the benefits surgery can provide. This study was undertaken in Ghana to provide greater understanding of the psychosocial and economic burden of hydrocele and to facilitate policy formulation. This was a longitudinal study, comprising of pre-surgical, surgical and a series of post surgical evaluation over a two year period. The pre-surgical phase involved identification and recruitment of respondents and confirmation of the presence of hydrocele and the surgical phase involved the provision of surgery. The post surgical phase involved evaluating the clinical outcome of surgery and assessing the economic and psychosocial effects of surgery at predetermined timelines. A modified time series evaluation scheme, where patients are assessed at six points: before surgery, and 3, 6, 12, 18 and 24 months after surgery was adopted. Data collection was done with semi-structured questionnaires and Focus Group Discussions. Of 1,201 men reporting scrotal swellings, 392 were confirmed to have hydrocele. Of these, 323 gave informed consent and were recruited into the study. Post-surgical evaluation identified significant improvement in economic situation (66.8%), performance of daily activities (95.0%), ability to work/engage in income generating activities (88.2%), family life (67.9%), sexual performance (35.2%), quality of life and self reliance among the respondents. The findings also showed significant reduction in personal health related costs as very few respondents sought medical treatment after surgery.

Filariasis predominantly affects rural communities that depend almost entirely on subsistence agriculture. Household economies are extremely fragile and unable to extend to surgery for hydrocele repair. Results of our study clearly show the economic and social benefits of hydrocelectomy and argue strongly for providing access to surgical repair in all programs targeting LF and the Neglected Tropical Diseases.

### 1336

#### PLASMODIUM RHOMBOID PROTEASE, ROM3, IS NECESSARY FOR DEVELOPMENT WITHIN THE MOSQUITO VECTOR

**Iset Medina Vera<sup>1</sup>**, Wandy Beatty<sup>2</sup>, Photini Sinnis<sup>3</sup>, Kami Kim<sup>1</sup>

<sup>1</sup>Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States, <sup>2</sup>Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, United States, <sup>3</sup>Department of Medical Parasitology, New York University School of Medicine, New York, NY, USA

Transmission of the malaria parasite into the mosquito vector occurs when the mosquito ingests gametocytes during a blood meal from an infected host. Within the midgut, ingested gametocytes transform into motile ookinetes that traverse the midgut epithelia and settle within the basal lamina. Nestled in this safe and nutrient-rich environment, the ookinete becomes sessile, rounds up and transforms into the oocyst. The oocyst becomes a spherical syncytium and enlarges to accommodate the thousands of nuclei which will be repartitioned to daughter sporozoites. The process of sporozoite budding within the oocyst is called sporogony. We characterized a rhomboid protease, ROM3 that is specifically expressed in the sexual stages of the malaria parasite. Using the rodent malaria model, *Plasmodium yoelii*, deletion mutants of pyROM3 were generated. We find that *pyrom3*<sup>-/-</sup> parasites progress normally through gametocytogenesis and gametogenesis leading to oocyst development, but are unable to undergo sporulation. ROM3 is necessary for the production of infectious sporozoites since *pyrom3*<sup>-/-</sup> parasites are unable to transmit disease to mice. Ultrastructural analysis of *pyrom3*<sup>-/-</sup> mutant oocysts reveals a defect in the early stages of sporulation prior to sporoblast formation and membrane retraction. The defect is characterized by accumulation of membranous whorls, unusually enlarged nuclei, and an inability to initiate membrane retraction for the onset of sporulation. This study provides novel insights into the function of a rhomboid protease in *Plasmodium* parasites during intracellular development. Further studies into how ROM3 exerts its function for the proper maturation and onset of sporulation should be helpful in the identification of potential substrates whose processing is required for transmission of malaria parasites.

### 1337

#### 3D ANALYSIS REVEALS COUPLED DYNAMICS OF CHROMATIN AND NUCLEAR PORES IN THE HUMAN MALARIA PARASITE *PLASMODIUM FALCIPARUM*

**Noa Dahan-Pasternak<sup>1</sup>**, Allon Weiner<sup>2</sup>, Eyal Shimoni<sup>3</sup>, Vera Shinder<sup>3</sup>, Michael Elbaum<sup>2</sup>, Ron Dzikowski<sup>1</sup>

<sup>1</sup>Department of Microbiology and Molecular Genetics, Hebrew University, Jerusalem, Israel, <sup>2</sup>Department of Materials and Interfaces, Weizmann Institute of Science, Rehovot, Israel, <sup>3</sup>Electron Microscopy Unit, Weizmann Institute of Science, Rehovot, Israel

The deadliest form of human malaria is caused by the protozoan parasite *Plasmodium falciparum*, which is believed to be responsible for millions of death cases each year. The parasite virulence is attributed to its ability to modify the infected erythrocyte by means of antigenic variation, in order to evade immune attack and maintain long-term chronic infections. The complex life cycle of malaria parasites is associated with tight transcriptional regulation of gene expression. Nuclear positioning may play an important role in the regulation of *P. falciparum* virulence genes. In order to investigate the nuclear dynamics in *P. falciparum* we have applied an emerging technique of electron microscopy that provides automated acquisition of serial section images as thin as 10 nm. Thus a single nucleus is spanned typically by 150 sections, allowing direct generation of a 3D model without requiring tomographic reconstruction. We generated 3D models of the parasite nucleus at distinct stages of development within the infected red blood cell. We found dramatic changes in chromatin organization coinciding to a previously-described pattern of gene expression during the mid- to late schizont phase. We also found a clear correlation between euchromatin positioning at the nuclear

envelope and the local distribution of nuclear pores, as well as a dynamic nuclear polarity during schizogony. Our results suggest that dynamics in nuclear architecture during parasite development are correlated with gene expression.

### 1338

#### 4D-LIFE CELL MICROSCOPY OF ASEQUAL PLASMODIUM FALCIPARUM DEVELOPMENT AND HOST CELL MODIFICATIONS

**Christof Gruring**, Arlett Heiber, Tim-Wolf Gilberger, Tobias Spielmann

*Molecular Parasitology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany*

The visualization of growing *Plasmodium falciparum* blood stage parasites is crucial for the understanding of dynamic cellular processes such as protein transport. However, this has not been achieved so far. We established 4D-imaging (time lapse of 3D reconstructions) of individual *P. falciparum* parasites across the entire asexual blood cycle. Our time lapse movies show an unexpectedly dynamic parasite. It provides a reference for the asexual development cycle that includes indicators for the build up and completion of host cell modifications, onset of feeding and active preparation for egress. Using 4D-imaging we analysed parasite-induced host cell modifications termed Maurer's clefts, structures important for the export of parasite proteins. Our data show that the Maurer's clefts pass through three distinct phases during parasite maturation. Further we show that Maurer's clefts are present much earlier in the cycle than generally thought and that no clefts are generated thereafter. This contradicts the widespread view that there is continued formation of clefts from the parasitophorous vacuole membrane surrounding the parasite. Consequently we find no indication for the proposed protein export via nascent clefts but show that different membrane associated proteins reach already formed clefts located in the host cell cytoplasm. Thus, in addition to providing a new view of the asexual blood development, our work challenges generally held views regarding the formation of Maurer's clefts and protein export in malaria parasites.

### 1339

#### SYSTEMIC AND LOCAL CONTROL OF DENDRITIC CELL (DC) POPULATIONS DURING GUT-DWELLING HELMINTH INFECTION: INSIGHTS INTO LOCAL VERSUS BYSTANDER EFFECTS OF CHRONIC INFECTIONS

**John Grainger**, Jason Hall, Elizabeth Wohlfert, Shruti Naik, Yamine Belkaid

*National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States*

Parasitic worms (helminths) have co-evolved alongside their host's immune system to establish long-term infections. Understanding the immunological basis of these interactions is important given the strong correlations between presence of infection and diminished local (e.g. Crohn's disease), and systemic, allergic or autoimmune conditions; known as the "hygiene hypothesis". Regulatory T-cells (Treg) play a key role in mediating protection, however, the contribution of other immune cell types, particularly antigen presenting cells (APC), remains unresolved. Using a murine model of chronic gut helminth infection, *Heligmosomoides polygyrus*, we characterize changes to local and systemic APC. We found that the most dramatically increased population in the gut are serosal macrophages. Despite this change, CD103+ lamina propria DC are maintained and the CD103+ DC to CD103--macrophage ratio is unaltered. This correlates with maintenance of Foxp3+ Treg conversion to food antigens even in the presence of Th2-cells, which are considered to be counter-regulatory to this process. Moreover, the CD103+ DC retain their ability to metabolize vitamin A to retinoic acid in the altered environment providing one explanation for the maintenance of Treg

conversion. Systemic changes to CD103 expression are also evident; in the spleen CD103 is upregulated on the CD8 $\alpha$ + DC. These data add to our understanding of how APC are altered during establishment of a chronic infection, and suggest that changes in DC populations and function can extend beyond the primary site of parasitism. This provides a previously unrecognized mechanism by which APC-mediated bystander suppression may contribute to inhibition of allergic and autoimmune reactivity.

### 1340

#### LARVAL EXCRETORY / SECRETORY PRODUCTS OF THE HELMINTH TRICHURIS SUIS MODULATE THE ONSET OF INFLAMMATORY DISEASES

**Matthew Hepworth**<sup>1</sup>, Ping Shen<sup>2</sup>, Eckard Hamelmann<sup>3</sup>, Simon Fillatreau<sup>2</sup>, Richard Lucius<sup>1</sup>, Susanne Hartmann<sup>1</sup>

<sup>1</sup>Humboldt University, Berlin, Germany, <sup>2</sup>German Arthritis Center (DRFZ), Berlin, Germany, <sup>3</sup>Charite Hospital, Berlin, Germany

Infections with parasitic helminths are highly prevalent in the developing world and are of particular importance as they have the ability to complicate vaccination and drug efficacy in endemic areas due to their potent immunomodulatory capacity. In recent years epidemiological studies have identified a strong correlation between loss of helminth infections in the western world and the development of autoimmune and inflammatory diseases - leading to a revision of the hygiene hypothesis to include helminths as a critical regulator of immune homeostasis. The ability of helminth-derived molecules to manipulate the immune system and interfere with the development of unrelated diseases thus provides the potential for development of new treatment strategies.

Utilising first stage larvae of the porcine helminth *Trichuris suis* we isolated potent parasite derived products, which demonstrated an immunomodulatory capacity *in vitro*. Furthermore, treatment with the *T. suis* products in a mouse model of airway hyperreactivity led to a significant reduction of disease parameters including reduced airway eosinophilia and lymphocyte infiltration, suppressed antigen specific cytokine responses and reduced antigen specific IgE. Similarly *T. suis* products were effective in the suppression of the development of Experimental Autoimmune Encephalomyelitis (EAE). Thus, products of *Trichuris suis* represent promising candidates for the development of drugs based on helminthic therapy.

### 1341

#### GUT MICROFLORA REGULATES GUT MACROFAUNA: EXPLOITATION OF THE INTESTINAL ECOSYSTEM BY A PARASITIC NEMATODE

K.S. Hayes, **Allison Bancroft**, M. Goldrick, C. Portsmouth, I.S. Roberts, R.k. Grencis

*University of Manchester, Manchester, United Kingdom*

*Trichuris muris* lives in close association with the host, embedding into the caecal epithelium, burrowing through cells and forming syncytial tunnels. We demonstrate for the first time that the *T. muris* life cycle is also intricately linked to the host gut microflora. *T. muris* eggs can be induced to hatch naturally *in vitro* by culturing with bacteria. We have identified the surface protein on gram negative bacteria that can facilitate this hatching. Using genetically modified *E. coli*, Fim H, an adhesin present on type I fimbriae was shown to be of major importance. In order to ascertain whether these types of interactions are required *in vivo*, broad spectrum antibiotic treated mice were infected with *T. muris*. We found that antibiotic treatment substantially reduced the number of bacteria in the gut and significantly reduced the establishment of these worms, indicating an effect on hatching. Furthermore, treatment also influenced the normal infection induced immune response mounted by the host, skewing towards a Th2 phenotype. Increased levels of IL-4 and IL-13 and reduced levels of pro inflammatory cytokines and IL-17 were observed. Critical interactions between bacteria (microflora), parasite (macrofauna) and

the host introduce a new and important dynamic to the intestinal niche which has fundamental implications for our current concepts of intestinal homeostasis and regulation of immunity.

### 1342

#### HOST IMMUNE RESPONSES TO INFECTION WITH LEISHMANIA GUYANENSIS

Annette Ives, G. Ruzzante, F. Prével, P. Launois, M. Breton, N. Fasel, S. Masina

University of Lausanne, Epalinges, Switzerland

Infections with *L.guyanensis* are distinguished by their ability to disseminate from the initial site of infection to the nasopharyngeal tissues forming destructive secondary lesions. Mucocutaneous Leishmaniasis (MCL) patients have hyper-inflammatory responses with a high degree macrophage and T cell infiltration into the lesion. We show that hamster derived metastatic (M+) or patient derived MCL *L.guyanensis* parasites induce elevated levels of chemokines and cytokines in infected BMMf, namely CXCL10, CCL5, TNF- $\alpha$ , IL-6, and IFN- $\beta$  as compared to BMMf infected with M-, or (Cutaneous Leishmaniasis) CL or *L. major* LV39 parasites. The induction of these cytokines and chemokines by M+ parasites was completely abrogated in infected TLR3-/- BMMf. *L. guyanensis* parasites can be infected with *Leishmaniavirus* (LRV1) and we detected the 5.3Kb dsRNA genome of LRV1 by gel electrophoresis in M+ or MCL promastigotes and showed by PCR with that M+ and MCL promastigotes have a higher viral load (LRVhigh) than M- or CL (LRVlow). Purified LRV1 dsRNA stimulated increased cytokine and chemokine transcripts in C57BL/6 BMMf, which was significantly diminished in TLR3-/- BMMf. Finally, we show by *in vivo* infection experiments that TLR3-/- mice were more resistant to infection with LRV1high M+ parasites than C57BL/6 mice as shown by a decreased footpad swelling peak associated with a lower parasitemia, whilst there were no observable difference in disease evolution in LRV1low M- parasites. This study shows that there is a correlation between the disseminating capability of parasites, presence of high LRV1 burden, and the induction of inflammation in the mammalian host. Could the presence of high LRV1 viral burden be involved in MCL development in humans?

### 1343

#### MULTIPLE ARGININE METHYLTRANSFERASES AND METHYLPROTEINS IN THE PARASITIC PROTOZOAN TRYPANOSOMA BRUCEI

John C. Fisk<sup>1</sup>, Jun Li<sup>2</sup>, Danielle L. Tomasello<sup>1</sup>, Jun Qu<sup>2</sup>, Laurie K. Read<sup>1</sup>

<sup>1</sup>Microbiology and Immunology, University at Buffalo, Buffalo, NY, United States, <sup>2</sup>Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, United States

Arginine methylation is a common posttranslational modification catalyzed by a family of enzymes termed protein arginine methyltransferases (PRMTs). In kinetoplastid parasites, gene expression is modulated post-transcriptionally by RNA stabilization, translation, and mitochondrial RNA editing. These processes rely on a large number of RNA binding proteins (RBPs), a class of proteins that are commonly methylated on arginine (arg) residues in yeast and mammals, suggesting a prominent role for PRMTs in kinetoplastids. Kinetoplastids stand out among single celled eukaryotes in that their genomes encode five putative PRMTs, a relatively large number. *In vitro* studies reveal both homologues of yeast and mammalian PRMTs, as well a novel, extraordinarily active Type III PRMT. *In vivo* RNAi studies in *T. brucei* highlight the Type I TbPRMT6 as an essential PRMT with a role in cytokinesis. Other PRMT knockdowns fail to exhibit a growth phenotype in PF, and studies are ongoing in BF. Lack of a growth phenotype may reflect redundancy between PRMTs, as observed in other organisms. We are currently investigating redundancy and cooperation between PRMTs by simultaneous RNAi studies. Regarding PRMT substrates, immunoblotting with anti-methylarg antibodies reveals arg methylproteins enriched in

the cytosol, nucleus, and mitochondrion of *T. brucei*. Currently, we are employing combined ETD/CID mass spectrometry to define the *T. brucei* arg methylproteome, and we have already identified methylproteins from many functional classes of proteins. *In vivo* studies are also underway involving the essential RNA editing factor TbRGG2, which is extensively methylated *in vitro* and *in vivo* to determine the role of methylation in its function. Together, these studies will provide insight into the role of arg methylation in kinetoplastid gene regulation.

### 1344

#### CELLULAR LOCALIZATION AND FUNCTIONAL CHARACTERIZATION OF A VOLTAGE-DEPENDENT POTASSIUM CHANNEL IN TRYPANOSOMA CRUZI

Veronica Jimenez<sup>1</sup>, John Wagner<sup>2</sup>, Roberto Docampo<sup>1</sup>

<sup>1</sup>Cellular Biology, University of Georgia, Athens, GA, United States,

<sup>2</sup>Physiology and Pharmacology, University of Georgia, Athens, GA, United States

Ion homeostasis is a dynamic mechanism that mediates adaptation to environmental and intracellular variations. In *Trypanosoma cruzi*, changes in potassium equilibrium seem to be involved in plasma membrane potential regulation, pH homeostasis, and osmotic balance. We identified, cloned and expressed a *T. cruzi* gene (Tc00.1047053511301.140) encoding a voltage-dependent potassium channel (TcKv). The predicted structure possesses a tetramerization domain and two transmembrane domains, characteristic of inwardrectifier potassium channels. TcKv is expressed in the three life cycle stages of the parasite, with a slightly different subcellular localization, being flagellum-related in trypomastigotes. When expressed in mutant yeast, TcKv restored the normal phenotype, suggesting its function as a K+ permeability pathway. To further characterize this channel the His-tagged protein was expressed in *E. coli*, purified and fused with liposomes in a reconstituted system. Using patchclamp technique we established that TcKv behaves as an inwardrectifier channel, with conductances of 54pS and 112pS at +80 and -80 mV, respectively. The selectivity sequence for monovalent cations is K>Cs>NH4>Rb>Na>Li. The relative permeability ratio K+/Na+ is about 3 and K+/Cl- is close to five, indicating a weak selectivity filter. Permeability for divalent cations was low, showing strong blockage by Ba2+ and Ca2+. Interestingly, when parasites are exposed to hyperosmotic conditions, TcKv localization changes. In epimastigotes it translocates to the plasma membrane, whereas in trypomastigotes is released to the medium, suggesting a differential role of TcKv in *T.cruzi* osmotic response of different stages. In conclusion, we have developed a reliable strategy to characterize ion channels in trypanosomatids, which could contribute to elucidate their physiological roles. [This work was funded in part by the American Heart Association and the NIH]

### 1345

#### THE SECRETED PSEUDOKINASE, ROP5, IS CRITICAL TO TOXOPLASMA PATHOGENESIS

Michael L. Reese<sup>1</sup>, Jon P. Boyle<sup>2</sup>, John C. Boothroyd<sup>1</sup>

<sup>1</sup>Microbiology and Immunology, Stanford University, Stanford, CA, United States, <sup>2</sup>Biological Science, University of Pittsburgh, Pittsburgh, PA, United States

*Toxoplasma gondii* secretes a variety of effector proteins into its host cell cytoplasm during invasion. We have identified one of these factors, the pseudokinase ROP5, as absolutely critical to pathogenesis in mice; while ablation of the ROP5 locus ( $\Delta$ ROP5) causes no phenotype to *Toxoplasma* growth *in vitro*,  $\Delta$ ROP5 parasites are completely unable to cause pathology in a mouse. Furthermore, allelic variation of ROP5 is responsible for a >104 difference in virulence (LD50) in a mouse model of disease. ROP5 appears to exert its profound effect on disease outcome through subversion of the innate immune system;  $\Delta$ ROP5 parasites elicit a significantly stronger pro-inflammatory response during early infection than do wild-type parasites, and appear to be cleared within 10 days post-infection. We



have solved the crystal structure of the pseudokinase domain of ROP5 and have found that polymorphisms in ROP5 between the avirulent and virulent alleles cluster almost exclusively in the substrate binding regions and former active site of the kinase domain, which we have verified as catalytically inactive, though it still maintains its ability to bind ATP. This strongly suggests that differences in virulence are mediated by differences in interaction of binding partners with ROP5's pseudokinase domain. We hypothesize that ROP5 is acting to dysregulate one or more host signaling networks, thereby influencing the outcome of disease. To address this question, we are using phospho-flow cytometry to compare the cellular activation states of the immune systems of mice infected with either wild-type or  $\Delta$ ROP5 parasites. In addition, we are interrogating ROP5's binding partners by co-immunoprecipitation and mass spectrometry.



The number(s) following author name refers to the abstract number.

## A

- Akanbi, Olusegun M. **243**  
 Aaskov, John **93**  
 Abaga, Simon 776  
 Abate, Teresa 1074  
 Abbot, Steve 987  
 Abdalla M, Wijdan 216  
 Abdallah, Mwanajaa S. 979  
 Abdel, Moustapha 1025  
 Abderrahim, Sadak 205  
 Abdoul Habib, Beavogui 1268  
 Abdoulaye, Adamou **182**  
 Abdoulaye, Djimde 1268  
 Abdulkhalilova, Gulnara 506  
 Abdul Kadir, Mohammad 347  
 Abdul-Rahman, Bassem 1025  
 Abdulla, Salim 1251, 979  
 Abebe, Lydia **443**  
 Abebe, Yonas 988  
 Abedin, Jaynal 348, 350  
 Abel, Jason 1168  
 Abel, Kristina 514  
 Abeyasinghe, Rabintra R. 737  
 Abeyasinghe, Nihal 520  
 Abildtrup, Ulla 1279  
 Abiou, Grace 83  
 Abolwafa, Reham M. 626  
 Abot, Esteban 806, 985  
 Abou El Naga, Iman **1150**  
 Above, Elisabetta 1042  
 Abraham, David 1189  
 Abraham, Ooriapadikal 675  
 Abraham, Susanne 675  
 Abubucker, Sahar 827, 1187  
 Abudho, Bernard 885  
 Acevedo, Veronica 594, 595  
 Achan, Jane 374, 1315  
 Acharya, Jyoti 430  
 Acharya, Pragyan 430  
 Achee, Nicole 176, 460, 463, 606, 607, 621, 623, 624, 996  
 Achidi, Eric A. 282  
 Acholonu, Alex D. W. **447**  
 Acosta, Héctor 466  
 Adam, Ishag 6  
 Adama, Gansane 158, 720  
 Adamani, William 797  
 Adams, A. P. 335  
 Adams, David P. **108**  
 Adams, John H. 370, 39, 478, 731, 732, 944  
 Adai, Vanessa K. **703**  
 Addiss, David 1333  
 Addo-Yobo, Frederick 883  
 Adedeji, Olumuyiwa N. 247  
 Adejumo, Adetunji **507**  
 Adekunle, Osuolale 752  
 Adelamo, SE 798  
 Adelli, Vijendar R. 713  
 Adelman, Zach N. 1120, 1121, 768  
 Adema, CM 1153, 1154, 454, **455**  
 Adema, Coen M. 453, 787  
 Ademowo, George O. 1233, **247**  
 Ademowo, Olusegun G. 1229, 1254  
 Adesina, Olubukola A. 1229, 1233  
 Adewole, Isaac F. 1229, 1233  
 Adeyinka, Adenike 507  
 Adjabeng, Michael 883  
 Adjei, Ohene 1328, 1331  
 Adroher, F.J. **657**  
 Aebi, Thomas 979  
 Aebig, Joan 164, 584, 805  
 Afebe, Godwin 1095  
 Afram, Yvonne **666**  
 Afrah, Nana A. 568  
 Afrane, Yaw 169, 178, 179, 271, 1210  
 Afroz, Aasma **349**  
 Ag Aboubacrine, Souleymane 672  
 Agaba, Steven 116, 1241  
 Agbenohevi, Prince 1025  
 Agbowai, Carine 276  
 Agnamey, Patrice 1318, 440  
 Aguayo, Nicolas 340  
 Agudelo, Piedad 900  
 Agudo, Roberto 340  
 Aguiar, Joao 740  
 Aguilar, Lyla 620  
 Aguilar, Pablo F. **1103**  
 Aguilar, Patricia V. 341, 344, 92  
 Aguirre, Sarah E. **189, 863**  
 Agunyo, Stella 68  
 Agwanda, Bernard 818  
 Ahadzie, Lawson 883  
 Ahlum, Jessica 1269  
 Ahmar, Beatriz 321  
 Ahmed, El-Hadi M. **718**  
 Ahmed, Jamal 639  
 Ahmed, Kazi I. 345  
 Ahmed, Md. Farid 71  
 Ahmed, Shadab 680  
 Ahmed, Tanvir 638  
 Ahmed, Zara 1200  
 Ahouangninou, Claude 278  
 Ahounou, Daniel 495  
 Ahumada, Adriana 807, 987, 988  
 Aikimbayev, Alim 193  
 Ajayi, IkeOluwapo O. 1229, **1243**  
 Ajeegah Uforka, Hilda 976  
 Ajjampur, Sitara S. R. 448  
 Akanbi, Olusegun M. 261, 262  
 Akao, Nobuaki 109  
 Akedo, Yukihiro 1312  
 Akhtar, Nayeema 638  
 Akhvlediani, Tamar 504  
 Akida, Juma 5  
 Akilah, J. D. 922  
 Akinboye, Emmanuel S. 237  
 Akinyi, Sheila **1110**  
 Akogbeto, Martin 495  
 Akpogheneta, Onome 1291  
 Aksoy, Serap 1219, 423, 56, 57, 633  
 Akstein, Ricardo B. 324  
 Al-Harbi, Naif O. 1144  
 Al-Mekhlafi, Hesham M. **318**  
 Alaba, Olufunke A. **751**  
 Alaii, Jane 1068  
 Alale, Michael **667**  
 Alam, Mohammad Murshid **638**  
 Alam, Md T. 400  
 Alam, Nur Haq 484  
 Alam, S 235  
 Alam, Uzma 633  
 Alarcon, Maritza E. 692, **693**, 1079  
 Alaro, James R. **983**  
 Albert, Jeff 348  
 Albert, Kamanyi 78  
 Albrecht, Svenja J. **1132**  
 Alefantis, Tim 586  
 Alegana, Victor A. 579, 749  
 Aleman, Ruben 819  
 Alemayehu, Sisay 24  
 Alexander, Mathew M. 748  
 Alexander, Neal **1139**, 461  
 Alexander, Marcia A. A. 141  
 Alford, Robert **769**, 773  
 Alfred, Tiono B. 158, 720, **838**  
 Ali, Doreen **753**  
 Ali, Hanan 216  
 Ali, Husham Y. M. **334**  
 Ali, Mohamed A. R. 1144  
 Alifrangis, Michael 1279, 5, 737, 950  
 Alioti, Matthew T. **386**  
 Allabi, Aurel 366  
 Allam, Sonia 1150  
 Allan, Sandra A. 617, **1013**  
 Allanson, Michael 663  
 Allebeck, Peter 357  
 Allen, Denise R. **1251**  
 Allen, Lee-Ann H. 1285  
 Almeida, Giulliana T. **1224**  
 Alonzo, Maria Terrese **1312**  
 Alphey, Luke **1020**, 180  
 Alphey, Nina **180**  
 Alphonse, Ouedraogo **158**, 720  
 Altamiranda, Mariano 1005  
 Altantuul, Damdin 489  
 Altayli, Ertan **315**  
 Althouse, Benjamin **394**  
 Aluvihare, Channa 769, 773  
 Alvarado-Domenech, Luisa 496  
 Alvarenga, Patricia H. 629  
 Alvarez, Celeste 763  
 Alvarez, Danielle 311  
 Alvarez, Dayra 319  
 Alvarez, Emilio 1246  
 Alves da Nobrega, Aglaer 442  
 Amador, Manuel A. 594, 595  
 Amadou, Konate T. 158, 720, 838  
 Amankwa, Joseph 883  
 Amarasinghe, Ananda 520  
 Amaratunga, Chanaki 434  
 Amathe, Ouedraogo 158  
 Amati, Mary I. 945  
 Ameh, David 46  
 Amemiya, Isabel 1305  
 Amerasinghe, Priyane H. 737  
 Ametepi, Paul 45  
 Amidou, Diarra 158, **720**  
 Amoako-Sakyi, Daniel **733**  
 Amore, Giusi 1058  
 Amos, Emily 40  
 Ampadu, Edwin 1026, 1327  
 Ampofo, William K. 666, 667, **883**, **1164**  
 Amri, Manel **1038**  
 Amsalu, Ribka 783, 1135  
 Amza, Abdou 1071  
 Anandaraja, Natasha 35  
 Ancca-Juarez, Jenny 1091, 1216  
 Anchang-Kimbi, Judith K. **282**  
 Andama, Alfred 676  
 Andereck, Jonathan W. 58  
 Anderegg, Claudia **1017**  
 Anders, Katherine **468**  
 Anders, Robin F. 164, 727, 980  
 Andersen, John F. 629  
 Anderson, Charles 807, 985, 986  
 Anderson, Jennifer M. 121, 845, 1178  
 Anderson, Kathryn B. **837**  
 Anderson, Larissa 363  
 Anderson, Michelle 1121  
 Anderson, Sheri L. 1123, **1185**, 195  
 Anderson, Timothy J. C. 551, 1228  
 Anderson, Tavis K. 1055, 1058, **1205**, 187  
 Andersson, Sarah 101, **102**  
 Andrade, Jorge Clarenco S. 1031  
 Andrade-Narvaez, Fernando J. **1218**  
 Andre, Richard 607  
 André Lin, Ouedraogo 720  
 Andreadis, Theodore G. 192, **197**, 877  
 Andrew, Erin V. W. 568  
 Andrew, Obasi 754  
 Andrews, Manya 579  
 Andrews, Phyllis 331, 795  
 Andrews, Wayne 192  
 Andriessen, Rob 1007  
 Andze, Gervais Ondobo 214  
 Añez, German **512**  
 Angelino, Elaine 401  
 Anges, Yadouleton 591  
 Anglero, Yesseinia 514  
 Angov, Evelina 1173, 1288, 585, 586, 978, 984  
 Angulo, Carlos 816  
 Angulo-Barturen, Iñigo 267, 714  
 Anibueze, Michael 797, 798  
 Aning, K.g. 1130  
 Anné, Jozef 784  
 Annoura, Takeshi 37  
 Anova, Lalaine 426  
 Ansa, Evelyn 840  
 Ansari, Aftab 1313  
 Anstey, Nicholas M. 258, 55, 850  
 Antara, Simon 1200  
 Antas, Paulo R. Z. 283  
 Anthony, Akpenyo 1071  
 Anthony, David R. **115**  
 Antia, Richard E. 230  
 Antoine, Dara 1268  
 Antonio, Christophe N. 1293  
 Antonio, Eloiza G. 1078  
 Antonio-Nkondjio, Christophe 865  
 Antonjaya, Ungke 14  
 Anyamba, Assaf 607  
 Anyirekun Fabrice, Some **474**  
 Anyona, Evans O. 546  
 Anyona, Samuel B. 1292, 1322, **545**, 546, 721, 723, 848  
 Anyorigiya, Thomas 945  
 Apiwathnasorn, Chamnarn 203, 461  
 Aponte, John 4



The number(s) following author name refers to the abstract number.

- Appawu, Maxwell 1009, 1010, 1014  
 Apperson, Charles S. **1002**  
 Appleby, Laura J. **1149**  
 Applegate, Roger D. 817  
 Appleyard, Bridget **569**  
 Aprahamian, Tamar 217  
 Aquise, Anamelva 789  
 Aragon, Anthony D. 1226  
 Aragon, Cindy 297  
 Arama, Charles 1288  
 Arana, Teresa 514  
 Arana, Yanina 789  
 Arango, Ana E. 1133, 340  
 Araujo, Sonia 692, 693  
 Araujo, Sérgio R. F. **1325**  
 Aravind, L. 425  
 Aravindhana, V 213  
 Araz, Remzi Engin 208, 314  
 Arbe-Barnes, Sarah 1244  
 Arce, Luana 621, 623  
 Arenas, Fanny 1132  
 Arévalo, Jorge 698, 703, 1087, 1087, 1093  
 Argüello, D. Fermin 395, 906  
 Arguello, John J. 832  
 Arguin, Paul 556  
 Arias, Patricia 794  
 Arie, Frederic 1266, 155  
 Arifeen, Shams E. 1198  
 Arifuzzaman, Mohammad 483  
 Arik, Anam J. **1122**  
 Arinaitwe, Emmanuel 1238, 1319  
 Ariza, Liana **650**  
 Arlian, Larry G. 631  
 Arman, Shaila 1197, **347**, 349  
 Armel, Djenontin **171**  
 Armoo, Samuel **273**  
 Armstrong, Philip M. 192, 197, **877**  
 Arnaud-Barbe, Nadege 835  
 Arnold, Benjamin F. **22**  
 Arora, R 235  
 Arrospide, Nancy 400  
 Arroyo, Rossana 449  
 Arruda, Paulo 925  
 Artemisinin-Based Combinations Study Group 1, 538  
 Arthur, Jen 396  
 Artsob, Harvey 880  
 Arumugam, Sridhar **223**  
 Arumugam, Thangavelu 581  
 Arvelo, Wences **1163**  
 Aryan, Azadeh **1121**  
 Aryjal, Amit 854  
 Asaah Gah, Humphrey 976  
 Asante, Ivy A. 883  
 Asante-poku, Adwoa **1130**  
 Asher, Constance 255  
 Ashley, Elizabeth 905  
 Ashley, Elizabeth A. 1101, 1248  
 Ashton, Ruth **1063**  
 Asiimwe, Doreen 1081  
 Asmah, Richard H. 1095  
 Asnis, Deborah 562, 80  
 Asoala, Victor 945  
 Assadou, Mahamadoun H. 805  
 Assumpção, Teresa C. F. **629**  
 Astete, Helvio 1001, 391, 625  
 Ataíde, Marco Antônio 280  
 Ataíde, Ricardo 1177  
 Athanazio, Daniel A. **1033**  
 Athrey, Giridhar 777  
 Atibu, Jef 7  
 Atieli, Harrysone E. **179**  
 Atkins, John F. 8  
 Ato, Manabu 699  
 Attardo, Geoffrey 863  
 Attardo, Geoffrey M. 56, **57**  
 Attia, Hanène 701  
 Atuguba, Frank 945  
 Aubouy, Agnes 83  
 Auko, Erick 639  
 Auliff, Alyson M. **478**  
 Avši-Županc, Tatjana 1167  
 Avci, Ismail Y. 1039  
 Avendaño, Adrián 821  
 Avery, Vicky M. 1257  
 Aviles, William 469  
 Avril, Marion 437, 726, 727  
 Awandare, Gordon A. **128**, **428**, **431**  
 Awasthi, Shally 30, 526  
 Awine, Timothy 945  
 Awono-Ambene, Parfait 865  
 Ayanful, Ruth **735**  
 Ayeh-Kumi, Patrick F. 1095, 1143, 1264  
 Ayena, Didier 1071  
 Ayers, Tracy 852  
 Ayi, Irene 1143  
 Ayi, Kodjo **118**  
 Ayieko, Cyrus **1289**  
 Ayisi, John M. 722, 1068  
 Ayodo, George 1211  
 Ayuk, Mary A. **1225**  
 Azad, Shamim 343  
 Aziz, Nabil 216  
 Azizz-Baumgartner, Eduardo 28  
 Aznar, Christine 1074, 240
- ## B
- Ba, Oumar 921  
 Ba, Yamar 921  
 Baber, Ibrahim 599  
 Babu, P 1044  
 Babu, Seshu 155  
 Babu, Subash **213**  
 Babuadze, George **199**  
 Bacchi, Cyrus J. 234, 683, 685, 1089  
 Bacellar, Maria Olívia A. R. **1090**  
 Bacon, David J. 400, 689  
 Badamchi-Zadeh, Alexander 777  
 Badgandi, Hemant B. **1125**  
 Badiane, Aida S. **277**  
 Badiane, Malick 1318  
 Badsha, Luna 1035  
 Badshah, Cyrus 507  
 Badu, Kingsley **271**  
 Badu Ofori, Samson 667  
 Baea, Manasseh 1067, 64  
 Baer, Alan 379  
 Bagayoko, Brehima 672  
 Bagenda, Danstan 490  
 Bah, Issa B. 131  
 Bahashwan, Saleh A. M. **1144**  
 Bai, Ying 818  
 Baiden, Rita **565**  
 Bailey, Dana 1094  
 Bailey, Jason 405, 896  
 Bailey, Michelle 826  
 Bailey, Robin 533  
 Bailey, Thomas C. 406  
 Bailleux, Fabrice 1050  
 Bain, Lisa 841  
 Baird, Kevin 105, 146  
 Bakare, Oladapo 237  
 Baker, Margaret 800, 801  
 Baker, Stephen 853, **854**  
 Balakrishnan, Kalpana 22  
 Balas, Claire 835  
 Balasegaram, M 235  
 Baldauf, Monica 763  
 Baldé, Cellou M. 902  
 Baldez, Arlete 283  
 Baldi, Mario **1077**  
 Baldiagai, Jean 214  
 Baldini, Francesco 1182  
 Bali, Aymen 701  
 Balilo, Marcel P. 408  
 Balinandi, Stephen 339  
 Baliraine, Frederick N. **374**  
 Balle II, Larry 777  
 Ballou, Ripley 161, 590  
 Ballut, Priscila C. 141  
 Balmaseda, Angel 100, 1309, 467, 469, 509, 516  
 Balsari, Satchit 115  
 Balsley, Nathaniel G. 165  
 Balthazard-Accou, Ketty 440  
 Balu, Bharath **370**, **39**  
 Bamadio, Amadou 1100  
 Bamani, Sanoussi 1069, 801  
 Bamba, Sory I. 1069  
 Bambra, Gurpreet 680  
 Banania, Glenna 806, 985  
 Bancroft, Allison 1341  
 Bandea, Rebecca **1190**, 445  
 Bandeira, Mauricio S. 1033  
 Bandyopadhyay, Kakali 445  
 Banek, Kristin **1303**, 1314  
 Banerjee, Moloy 238  
 Bangirana, Paul **404**  
 Banic, Dalma M. 283  
 Bantuchai, Sirasate **135**  
 Baptiste-Brown, Sharon 711  
 Baraka, Vito 5  
 Barban, Véronique 12, 510  
 Barbosa, Adriana F. 1325  
 Barbosa, Danielle R. Lima. **558**, 560  
 Barfod, Lea 436  
 Baric, Ralph S. 471  
 Barillas-Mury, Carolina 1015, 861  
 Barker, Christopher M. 19  
 Barker Jr, Robert H. 267, 714, 1083  
 Barletta, Francesca **485**  
 Barnadas, Céline 1260  
 Barnard, Bonnie 1011  
 Barnes, K.B. 960  
 Barnes, Kayla G. 401, 402, 1261  
 Barnett, Brian S. **84**  
 Barnett, Elizabeth D. 498  
 Barnhart, Rebecca 1252, 1253  
 Barnor, Jacob 667  
 Barnwell, John W. 365, 1110, 1111, 1112, 1287, 400, 954, 955  
 Barranco, Juan 780  
 Barrantes, Melvin 340  
 Barrera, Roberto 594, **595**  
 Barrett, Leah J. 641  
 Barron, Eduardo A. 816  
 Barros, Monica B. L. 502  
 Barrós, Nicolás 660  
 Barry, Aminata 31  
 Barry, Amadou 967  
 Barry, Vaughn 355  
 Barthel, Robert V. 883  
 Bartholomay, Lyric C. **828**, **862**  
 Bartlett, Jeanine 1168  
 Bartlett, John A. 1036, 856, 858  
 Baryahirwa, Stephen 45  
 Basáñez, Maria-Gloria 215, 564, 876  
 Basile, Alison J. **1056**  
 Basílico, Nicoletta 719  
 Basnyat, Buddha 854  
 Bassani, Diego G. 30, 526  
 Bassat, Quique 141, **264**, 294, **366**  
 Basta, Nicole E. **1023**  
 Bastidas, Javier 1008  
 Bastos, Cecilia M. 267  
 Basustaoglu, Ahmet Celal 208, 314  
 Batchelder, Jayda **932**  
 Batchelor, Adrian 980  
 Bates, Michael N. 457  
 Bates, Paul A. 1095  
 Bathurst, Ian C. 267, 269, 714, 1257  
 Batsa, Linda 1328, 1331  
 Battistuzzi, Fabia U. 1113  
 Baudin, Elisabeth 1101, 1248  
 Bauer, Valerie 446  
 Baum, Jake 427  
 Baumgartner, Eduardo A. 1197, 349  
 Bausch, Daniel G. 1053, 901  
 Baxter, Michael C. 712  
 Bayer, Angela M. 316, 317, 32  
 Beadell, Jon S. 423  
 Beasley, David W. 51  
 Beatty, Mark E. **913**, **915**, **916**, **917**  
 Beatty, P. Robert 99  
 Beatty, Wendy L. 824  
 Beaty, Barry J. **620**  
 Beaudet, Beth 234, 683  
 Beaulieu, Christian 688  
 Beavogui, Abdoul H 1263  
 Beck, Hans-Peter 1109  
 Becker, Justin S. 401  
 Becker, Melissa 108  
 Becker, Sara 1034  
 Becker-Dreps, Sylvia I. **357**  
 Beckius, Miraim L. 1034, 1037  
 Bedir, Orhan **208**  
 Beelen, Andrew 711  
 Beerntsen, Brenda 741, 742  
 Beeson, James G. , 427, 581, 727, 1176, **1177**  
 Begum, Yasmin 896

The number(s) following author name refers to the abstract number.

- Béhéton, Todoégnon 83, 501  
 Behura, Susanta K. **308**  
 Bei, Amy 277  
 Beijnen, Jos H. 233  
 Bel-Haj-Hamida, Nabil 701  
 Belay, Kassahun 553  
 Belayneh, Yordanos 24  
 Beldjebel, Irad 669  
 Belén Jiménez-Díaz, María 267  
 Bell, Andrew 1012  
 Bell, David 136  
 Belmonte, Maria 806, 985, 988  
 Beltramello, Martina 99  
 Ben-Aïssa, Khadija 702  
 Ben-Salah, Afif 49, 701  
 Benavente, Luis **553**  
 Benbow, Eric 1327  
 Benca, Juraj 669  
 Bendezu, Jorge 136  
 Benedict, Mark Quentin 184  
 Beneli, Cristina T. 658  
 Benhnini, Fouad 701  
 Benítez, Rocío 657  
 Bennett, Jason 807, 808, 984, 161, 590  
 Bennett, Julia 1023  
 Bennett, Shannon N. 881  
 Bennis, Sarah 582  
 Bennuru, Sasisekhar **829, 867**  
 Benoît, Joshua B. **56, 57**  
 Benoît, Nguuelefack T. 78  
 Bergmann-Leitner, Elke S. **585**, 586, 984  
 Berhe, Solomon 237  
 Berkard, Hilaria 1009, 1014  
 Berkeley, Lynette 852  
 Berkelman, Ruth L. 837  
 Bern, Caryn 1216  
 Bernard, Kristen A. **1206**, 1207  
 Bernhardt, Scott A. **774**  
 Bernier, Ulrich 1013  
 Berns, Abby 791  
 Berriman, Matthew 1228  
 Berthe, Abdoulaye 1030  
 Bertholet, Sylvie 1174  
 Bertolotti, Luigi 1058  
 Bertrand, Dongmo A. 78  
 Besansky, Nora J. 1181, 1293  
 Beshir, Khalid B. **477**  
 Besnard, Patrick 872  
 Bessong, Pascal 933  
 Best, Curtis 192  
 Bestman, Hannan K. 553  
 Bethel, Delia 808  
 Bethell, Delia B. 550, 1247, 1273,  
 Betramello, Martina 471  
 Bhardwaj, Rita **410**  
 Bhat, Najma 328  
 Bhatt, R.m. 603  
 Bhattacharya, Dipankar 515  
 Bhattacharya, Deepak X. X. **709**  
 Bhattarai, Achuyt 24  
 Bhavnani, Darlene **354**  
 Bhuiyan, Md. Saruar 855  
 Bhuiyan, Taufiqur R. 483, 484  
 Bickle, Quentin 529  
 Biden, Rita 953  
 Bidhidatta, Ladaporn 506  
 Bidlack, Ellen 192  
 Biedron, Caitlin 1200  
 Biggerstaff, Brad 389  
 Biggs, Holly M. **856**  
 Bigira, Victor 1238, 1319  
 Bigoga, Jude D. 1105  
 Biholong, Benjamin Didier 214  
 Billingsley, Peter F. 769, 773, 807  
 Biney, Ellen J. **1014**  
 Bingham, Glenda M. **813**  
 Bingham, Georgina V. 992  
 Binka, Fred N. 565, 953  
 Biron, David G. 181  
 Birren, Bruce W. 401, 402, 524, 1309  
 Bischoff, Emmanuel 864  
 Bishop, Henry 1043  
 Bissagnene, Emmanuel 1232  
 Björquist, Petter 12  
 Black, Cameron 688  
 Black 4th, William C. 774  
 Blackmore, Carina 389  
 Blackstock, Anna J. 152, 722  
 Blackwelder, William C. 161, 590, 803  
 Blackwell, Jenefer 1325  
 Blagborough, Andrew 160  
 Blair, Carol D. 774  
 Blair, Patrick J. 14  
 Blanas, Demetri **1239**  
 Blanchet, Denis 1074  
 Blanco, Natalia V. 912  
 Blaney, Joseph **380**  
 Blanford, Simon 1012  
 Blank, Walter A. **1223**  
 Blanton, Christopher 561  
 Blanton, Lucas S. 651  
 Blanton, Ronald E. 1223  
 Blasczyk, Rainer 1217  
 Blefari, Valdecir 706  
 Blitvich, Bradley J. **8**  
 Blood Zikursh, Melinda J. 226  
 Blum, Nancy L. **1236**  
 Boakye, Daniel A. 273, 632, 1009, 1010, 1014, 1143, 1326, 1327, 1331  
 Boatin, Boakye 215  
 Bobanga, Thierry L. 665  
 Bobogare, Albino 250, 569, 841  
 Bocangel Jr, Cesar 1216  
 Bocangel Sr, Cesar 1216  
 Bockarie, Moses 63  
 Bodhidatta, Ladaporn 481, **482**  
 Bodmer, T. 1130  
 Boehm, Alexandria B. 27  
 Boele van Hensbroek, Michael 1212, 1231  
 Boer, Melanie 1064  
 Boggild, Andrea K. 1087  
 Boiro, Mamadou Y. 902  
 Boissevain, Jane R. 933  
 Boivin, Michael J. 404  
 Bojang, Kalifa 782, 934  
 Bolaji, Oluseye O. 247  
 Boldenow, Peter J. **1001**  
 Bonhoeffer, Jan 492  
 Boni, Doris 1195  
 Bonizzoni, Mariangela **770**  
 Bonner, Kimberly **288**  
 Bonney, Evelyn 667  
 Bonney, Kofi 667, 883  
 Bonou, Désiré 278  
 Bonsall, Michael B. 180  
 Boobo, Alex 1081, 1081, 229  
 Booker, Michael L. **267, 1083**  
 Boopathi, P.A. 430  
 Booth, Garrett 53  
 Bopda, Jean 1330  
 Bopp, Cheryl 852  
 Borgdorff, Martiens 1128  
 Borges Costa, Lourrany **327, 329**  
 Borghini-Fuhrer, Isabelle 708  
 Borini, Katty 1216  
 Böröczky, Katalin 1002  
 Boroughs, Karen 1311  
 Borse, Rebekah 913  
 Bose, Carl 7  
 Bosisio, Enrica 719  
 Bossin, Hervé C. **21**, 59, 225, 597, 995, 999  
 Boström, Stéphanie 285, 436, 576, 937  
 Bouckenoghe, Alain 13, 836  
 Boudebouh, Najma 649  
 Boudko, Dmitri Y. **863, 1119**  
 Bougma, Roland 801  
 Bougouma, Edith C. 147, **571**, 728, 1105,  
 Boulay, Marc 296  
 Boulware, David 338  
 Bouraïma, Aziz 278  
 Bourke, Claire **416**  
 Bourpoern, Janpen 1131  
 Bousema, Teun 477, 564, 779, 876, 1272  
 Boussets, Philippe 1293  
 Boussinesq, Michel 1330  
 Boutin, Jean-Paul 891  
 Bouyer, Donald H. 651  
 Bouyer, Jeremy 420  
 Bowling, Tana **1089**, 234, 683  
 Boyer, Sebastien **615**  
 Boykin, David 238, 450  
 Boyle, Michelle J. **427**  
 Bozick, Brooke A. 978  
 Brackery, Aprielle 601, 989  
 Brackney, Doug E. **1203**  
 Bradfield, Jason 892  
 Bradley, Mark 1334  
 Brady, Molly 1334  
 Braga-Neto, Manuel B. **1235**  
 Branch, OraLee H. 946, 964, 973, 975, 977, 1291  
 Brandful, Jim 667  
 Brando, Clara **1175**  
 Brandt, Walter 807  
 Brandy, Yakini 237  
 Brant, Julia 443  
 Brant, Jonas 857  
 Bras Boqueras, Clara 573  
 Brasil, Patricia **970**  
 Brasov, Ioana E. 694  
 Brasseur, Philippe M. G. **440, 1318**  
 Brault, Aaron C. 8  
 Bravo, Doris 1195  
 Bravo, Elisa 562  
 Brawn, Jeffrey 1006, 1055, 1058  
 Brawn, Jeffrey D. 1205, 187  
 Bree, Mark 714  
 Breiman, Robert F. 487, 639, 818, 852, 1198  
 Brelsfoard, Corey **633**  
 Brena, Patricia 1136  
 Bressan, Clarisse d. 970  
 Bretscher, Michael T. **577**  
 Brewoo, Joe 375, 832  
 Briceno, Ireneo 624  
 Brindley, Paul J. 1225, 866  
 Brizard, Jean-Paul 181  
 Brobbel, Mirjam 634  
 Brogdon, William G. 170  
 Bronzan, Rachel N. 1071  
 Brooker, Simon 1063, 144, 533, 579, 781  
 Brooks, W. Abdullah 28  
 Brown, Alicja 51  
 Brown, Charles A. 1264  
 Brown, Claire E. **397**  
 Brown, Ivy K. 1203  
 Brown, Jeffrey 9  
 Brown, Julia E. **15**  
 Brown, Mark R. 760, 761, 762  
 Brown, Nick 288  
 Brown, William M. 1006  
 Bruce, Jane 155  
 Bruder, Joseph T. 165, 583, 740, 806, 984, 988, 1173  
 Brun, Reto 682  
 Brunell, Marla 981  
 Brunette, Gary 498  
 Brunetti, Enrico **1042**, 1161  
 Bryant, Nelva 1168  
 Bu, Lingyi 548  
 Bu, Wei 249  
 Bua, John 537  
 Buates, Sureemas **134**, 398  
 Buathong, Nillawan 1273  
 Buchholz, Arlene 1190  
 Buck, Gregory A. 329  
 Buckner, Frederick S. **1283**  
 Budd, Aidan 1186  
 Buddenborg, SK **1153**, 1154, 454, 455  
 Budge, Philip J. **67**  
 Budke, Christine M. 813  
 Buekens, Pierre 1080  
 Bugora, Hugo 250  
 Buhari, Oyofe 1164  
 Bui, Duy M. 466, 856  
 Bukirwa, Hasifa 1208, **1240**, 142  
 Bukrinsky, Michael I. 866  
 Bull, Peter C. 1177  
 Bullians, Mark 778  
 Bunn, Janice Y. 508  
 Bunyi, Mbogo 579  
 Burgos, Juan M. 1074  
 Burke, Melissa L. **413**  
 Burkhalter, Kristen 9  
 Burkhard, Peter 1175  
 Burkot, Thomas R. 194  
 Burns, Jr, James M. 940, 983  
 Bustamante, Carolina 1270  
 Bustamante, Victor H. 645  
 Bustinduy, Amaya L. **1066**, 1142

The number(s) following author name refers to the abstract number.

Butail, Sachit 1299  
 Butler, Brian P. 119  
 Buttenschoen, Klaus 1040  
 Butterworth, Alice S. 962  
 Butts, Jessica **969**  
 Buwembo, William **1022**  
 Buyungo, Peter 1317  
 Byamugisha, Edson 68, 68  
 Byarugaba, Justus 404  
 Byaruhanga, J 664  
 Bygbjerg, Ib 5, 312, 950  
 Byrum, Russ 380

## C

- Cabada, Miguel 446  
 Caban, Belkis Z. 594, 595  
 Cabezas, César 400, 943  
 Cabezas-Sanchez, Cesar 345A  
 Cabrera, Claudia 174  
 Caccone, Adalgisa 610, 776  
 Caccone, Gisella 423  
 Caci, Jennifer B. **90**  
 Cairo, Hedley **968**  
 Calavia Garsaball, Olga 573  
 Calcagno, Juan I. **894**  
 Calderon, Maritza M. 1091  
 Calderón-Arguedas, Ólger 821  
 Calderwood, Stephen B. 483, 484, 638, 855, 896  
 Caljon, Guy 1082  
 Calvo, Katya **677**  
 Calzada, Jose E. **319**  
 Cama, Vitaliano A. **1091, 316, 317**  
 Camara, Lansana 31  
 Camara, Mamadou 420  
 Cameron, Emilie 778  
 Cameron, James A. S. **295**  
 Camp, Patrick 1195  
 Campbell, Carl H. 756  
 Campbell, Corey L. 770, 860  
 Campbell, Christopher O. 370  
 Campbell, James I. 853, 1323  
 Campbell, Karen M. **393**  
 Campbell, Lindsay 1327  
 Campos, Erica C. 1085, 706, 707  
 Canales, Marco 1072, 1073  
 Canestrelli, Daniele 307  
 Canfield, Elizabeth 664  
 Cannella, Anthony P. **50**  
 Cannon, Ping 581  
 Canon, Ping 1107  
 Cao, Thuy T. 853  
 Cao Quang, Thai 1323  
 Capewell, Linda 637  
 Capparelli, Edmund 7  
 Cappellini, Maria Domenica 254  
 Cappello, Michael 1282  
 Caputo, Beniamino 1117, 307, 618  
 Carapau, Daniel 589  
 Cardinal, Marta V. 1074  
 Cardosa, Jane M. 89  
 Caridha, Diana 252, 715  
 Carlton, Elizabeth J. **457**  
 Carlton, Jane M. 449  
 Carmo, Theomira M. A. 1051, 1052  
 Carn, Gwenaelle 1101, 1248  
 Carnevale, Pierre 872  
 Carpenter, L. R. 817  
 Carpenter, Victoria 186  
 Carrasco, Paola **959**  
 Carrasco, Wilder 391  
 Carret, Celine 38  
 Carroll, Dustin 1252, 1253, 251, 252, 253, 255  
 Carroll, Darin S. 1168, 1170  
 Carter, E. Jane 1194  
 Carter, Jennifer **978**  
 Cartwright, Megan 437  
 Carvalho, Eunice B. 646  
 Carvalho, Edgar M. **679, 1090**  
 Carvalho, Lucas 1090  
 Carvalho, Marília S. 409  
 Carvalho, Raquel 1078  
 Carvalho, Renata R. 1078  
 Carvalho, Valéria L. 1159  
 Carvalho de Alvarenga, Inacio 442  
 Casanova, Lisa M. **444**  
 Casapia, Martin 1193  
 Casey, Joanne L. 732  
 Cash, Ayla A. 1047  
 Casimiro, Prisca N. 1105  
 Caskey, Marina 679  
 Caspi, Anat 372  
 Casseb, Lívia M. N. 1159  
 Casseb, Samir M. M. 1048, 1159  
 Castellanos, Maria E. 1102, **1280**  
 Castellanos-Gonzalez, Alejandro **446**  
 Castillo, Carmen Elena 461  
 Castillo, Rafael 236  
 Castillo, Roger 341, **342**  
 Castillo, Yesenia 794  
 Castrillon, Carlos **1093**  
 Castro, Jose 1077  
 Castro, Jonathan 777  
 Castro, Neviton 679  
 Castro-Llanos, Fanny **996**  
 Castro-Pinto, Denise B. 239  
 Cator, Lauren **605**  
 Cattamanchi, Adithya 676  
 Catteruccia, Flaminia 1182  
 Cavallaro, Elizabeth **442**  
 Caviedes, Luz 1132  
 Cazelles, Bernard 98  
 Cech, Patrick 979  
 Cedrone, Edward 326  
 Ceesay, Fatou 1255  
 Celatka, Cassandra 267, 714  
 Celes, Mara R. Nunes. 706, 707, 1085  
 Cepeda, David 486  
 Cercone, Emily 28  
 Cerna, Jean M. 816  
 Cernetich Ott, Amy 940  
 Cerón, Viviana 153  
 Cerqueira, Gustavo C. 1219  
 Cerroni, Matheus P. 1166  
 Cerutti, Francesco 1055, 1058  
 César Díaz, Sergi 573  
 Cespedes, Manuel 341, 92  
 Cevallos, Ana 486  
 Cevallos, William 354  
 Cha, Sung-Jae **373, 766**  
 Chacky, Franky 1017  
 Chadee, Dave D. 17, 170, 190  
 Chadwick, Chrystal M. 1206, 1207  
 Chae, Joon-Seok 820  
 Chaffee, Paul 580  
 Chafika, Faraj 205  
 Chagas Jr, Adenizar D. 1033  
 Chagas Jr., Adenizar 899  
 Chai, JY **162**  
 Chaichana, Panjaporn 1273  
 Chaiear, Naesinee 1131  
 Chaisson, Christine E. 498  
 Chakiath, Chinnamma 365  
 Chakib, Abdelfettah 649, 649  
 Chakravarty, J 235  
 Chakravarty, Sumana 769, 773, 807, 985, 986  
 Chaluluka, Ebbie 1320  
 Chamberlin, Judith 607  
 Chambers, Eric W. 21, **59**, 597, 999  
 Chamma, Nathália N. 558, 560  
 Chams, Linda M. **636**  
 Chan, Amanda S. 1157  
 Chan, Brian 1277  
 Chan, Jo-Anne 1177  
 Chan, King 829  
 Chan, Leslie 55  
 Chan, Teik-Chye 1027  
 Chanaimongkol, Somporn 191  
 Chancey, Caren J. 512, 1060  
 Chanchu, Chajya 574, 627  
 Chand, S. K. 196  
 Chanda, Javan 614  
 Chandani, Yasmin 101, 102  
 Chandler, Clare I. R. 532, **539**, **840**, 1302, 1303, 1304, 1314,  
 Chandra, Vemika 1127  
 Chandra Biswas, Subas 347  
 Chandrasekar, Pranatharthi 313  
 Chandre, Fabrice 465, 598, 875  
 Chang, Jaime 1103  
 Chang, Jung-San 505  
 Chang, Michelle 783  
 Changalucha, John M. 884  
 Chansamut, Nakit **398**  
 Chantha, Ngan 592  
 Chanturia, Gvantsa 199  
 Chao, Chien-Chung 1027, **654**  
 Chao, Day-Yu 919, 920  
 Chapagain, Moti L. **1059**  
 Chappuis, François 703  
 Chareonviriyaphap, Theeraphap 176, 463, 612  
 Charles, Brown 735  
 Charles, Richelle C. **855**  
 Charman, Susan A. 248, 715, 1244  
 Charron, Brigitte 403  
 Charunwatthana, Prakaykaew 851  
 Chattopadhyay, Rana 365, 987  
 Chaturvedi, Richa 587  
 Chau, Jennifer Y. **119**  
 Chaudhary, Ateefa 1292  
 Chauhan, Chitra 826  
 Chaurasiya, Narayan D. 713  
 Chavasse, Desmond 1317  
 Chaves, Luis F. 42, 187, 200, 619, 1058, 1077, 1205  
 Cheah, Phaikyeong 1250  
 Cheik Oumar Papa, Sangare 1268  
 Chelimo, Kiprotich **275**, 725  
 Chen, Cheng-Chen 227  
 Chen, Chaoqun **528**  
 Chen, Dar-Yeong 380  
 Chen, Daitao 683  
 Chen, Emily 987, 988  
 Chen, Hua-Wei 1024, 1027, 654  
 Chen, Jean 1162, 49  
 Chen, Jun-Hu 547  
 Chen, Lin H. 498, 51  
 Chen, Ping 583, **740**  
 Chen, Tien-Huang 1307  
 Chen, Wei-June **1307**  
 Chen, Yao-Shen 499  
 Chenet, Stella 1116  
 Chenet, Stella M. **936**  
 Cheng, Qin 478, **841**  
 Cheongsang, Michel Ayo 225  
 Cherrif, Mariama 728  
 Chesson, Joanne 1177  
 Chichester, Jessica A. 691, 982  
 Chico, Martha 529  
 Chidi, Njoku 754  
 Chikviladze, Tamar 504  
 Chikvi, Nancy 789  
 Chimma, Pattamawan 540  
 Ching, Wei-Mei 1024, **1027**, 654  
 Chinula, Dingani 614  
 Chiosis, Gabriella 260  
 Chipato, Tsungai 962  
 Chipeta, Paul 780  
 Chippaux, Jean-Philippe **902**  
 Chirenje, Mike Z. 1230  
 Chisenhall, Daniel M. 18, **1308**  
 Chishimba, Sandra 1097, **1213**, 130  
 Chitjamnongchai, Supapart 540  
 Chitnis, Nakul 577  
 Chodhuary, Shuburna 350  
 Choe, Se Eun **681**  
 Choi, BI 162  
 Choi, Bo 952  
 Choi, Young-Jun **771**  
 Choi, Young Ho 559, 952  
 Choisy, Marc 1000  
 Chokephaibulkit, Kulkanya 511  
 Chokheli, Maiko 504  
 Chondoka, Jodi 734  
 Chotivanich, Kesinee 540  
 Chotsiri, Palang 6  
 Choudhury, Nahid 93  
 Chowdhury, Fahima 483, 484, 638, 896  
 Chowdhury, Mohiul Islam 638  
 Chowdhury, Majeedul H. 71  
 Christelle, N'Dong 1268  
 Christensen, Bruce M. **227**, 386, 771  
 Christian, Elizabeth 523  
 Christofferson, Rebecca C. **1172**, 1308, 18, **909**  
 Chu, Brian 799, 801  
 Chu, Yui Yin 625  
 Chuang, Ching-Kai 1307  
 Chuang, Ilin 806, **808**, 981, **984**  
 Chuang, Shu-Fang 918, 919, 920



The number(s) following author name refers to the abstract number.

- Chuang, Ting-Wu 1104, **609**  
 Chubiniidze, Marine 504  
 Chueng, Kong 758  
 Chukwuocha, Uchechukwu M. C. **290**, 575  
 Chunju, An 1186  
 Chuo, Ching-Yi **914**  
 Chuo, James C. 920  
 Churcher, Thomas S. 1297, **564**, 876  
 Ciatelli, Susan 984  
 Cienfuegos, Astrid V. 1005, 310  
 Cindy, Korir 1112  
 Cintrón, Luis M. 466  
 Ciota, Alexander T. **1204**  
 Cirimotich, Chris 757, 765, 870  
 Cisse, B. 1214  
 Cisse, Moustafa 1318  
 Claborn, David M. 607  
 Clare, Strode 602  
 Clark, Daniel 337, 660  
 Clark, Danielle V. 504  
 Clark, Eva H. **1291**  
 Clark, Gary G. 600  
 Clark, Kristina B. **86**  
 Clarke, Oliver 1107  
 Clayton, April M. **757**, 870  
 Cleary, Thomas G. 1305, 485, 645  
 Clements, Archie 854  
 Clements, David 833  
 Clemons, Anthony 309  
 Clennon, Julie A. **1026**, 1192, 1327  
 Clowes, Petra 1169  
 Coffeng, Luc 215  
 Coghi, Paolo 719  
 Cohen, Adam 1196  
 Cohen, Joe 161, 590, 803  
 Cohen, Justin M. **785**  
 Cohen, Ted 1194  
 Cohnstaedt, Lee **617**  
 Cohuet, Anna 1297, 564  
 Coimbra, Terezinha Lisieux M. 1166  
 Colancecco, Alessandra 254  
 Colebunders, Robert 1234  
 Coleman, Bradley 714  
 Coleman, Judy 1124  
 Colford, John M. 22  
 Collaborators, for the MDS 30, 526  
 Collazo, Vanessa 1252, 1253, **255**  
 Coller, Beth-Ann **833**  
 Colley, Daniel G. 1148  
 Collie, Iain 1083  
 Collier, Martha 831  
 Collins, Frank 614  
 Collins, Jeffrey M. **725**  
 Collins, Katharine 160, 804  
 Collins, William E. 365  
 Colloca, Stefano 160  
 Coloma, Josefina 469  
 Colon, Lissy 496  
 Comach, Guillermo 340  
 Compaore, Salifou 31  
 Compean, J. Guillermo B. 16  
 Comte, Eric 1101, 1248  
 Comunale, Mary A. 940  
 Conceição-Silva, Fatima **502**  
 Condori, Rene E. **345A**  
 Conesa-Botella, Anali 1234  
 Conn, Jan E. 1004, 1005, 310  
 Connell, Jane 1064  
 Connor, Stephen 153  
 Conrad, Melissa D. **449**  
 Conrad, Patricia A. **926**  
 Conroy, Andrea L. **541**, **542**  
 Consentino, Massimo 81  
 Conteh, Solomon 986, 988  
 Contigiani, Marta S. 10  
 Contreras, Carmen 644, 645  
 Contreras, Juan Jose 974, **1115**  
 Conway, David J. 307, 427, 782, 934  
 Cook, Joseph A. 881  
 Cookson, Brad T. 844  
 Cooper, Philip **529**  
 Cooper, Philip J. 1191  
 Cooper, Roland 716  
 Coosemans, Marc 1082, 495  
 Coppel, Ross 164  
 Coppens, Isabelle 435  
 Corbel, Vincent 598, 875  
 Corbett, Yolanda 254  
 Cordon-Rosales, Celia 1003  
 Cordray, Michael S. 557  
 Cornejo del Carpio, Juan G. 1216  
 Cornel, Anthony J. 859  
 Cornelle, Sylvie 168, 616, 872, **875**  
 Cornelius, Claire 1164  
 Cornelius, Denise C. **330**  
 Cornine III, Frank 192  
 Coronel, Carolina 900  
 Corradin, Giampietro 728  
 Correa, Margarita M. **1004**, **1005**, **310**  
 Correa, Simon 160  
 Cortese, Joseph F. 267, 401, 714  
 Cortese, Riccardo 160  
 Cortez, Ricardo 183  
 Coscaron-Arias, Cecilia L. **624**  
 Coskun, Omer 315  
 Cosmas, Leonard O. 487  
 Costa, Anielle d. 970  
 Costa, Emiliana P. 518  
 Costa, Federico 409, **857**, 894  
 Costa-Santos, Marcela 502  
 Costantini, Carlo 1000, 1181, 1293  
 Cot, Michel 154, 501, 83  
 Coudeville, Laurent 1050  
 Coulibaly, Cheick A. 859  
 Coulibaly, Drissa 161, 572, 590, 803, 847  
 Coulibaly, Michel E. 1332, 432  
 Coulibaly, Sitanfoune Veronique 672  
 Coulibaly, Siaka Y. 1065, 1332, 432  
 Coulibaly, Yaya I. **1065**, 1332, 432, 672  
 Courtin, David 278  
 Cousin, Marc 292, 293, 294, 366, **367**, 873  
 Cousin, Remi 153  
 Coutinho-Abreu, Iliano V. 62  
 Cowden, Carter L. **33**  
 Cowman, Alan F. 581, 1107, 1176, 1177  
 Cox, Jonathan 781  
 Coyle, Christina M. 331, 795  
 Crabb, Brendan 581  
 Craft, Carl 265  
 Craft, J. C. 269, 1244  
 Cranfield, Mike 1113  
 Craver, Vinka 443  
 Crespo Llado, Keila N. 267  
 Crisanti, Andrea 978  
 Cromwell, Elizabeth A. 528  
 Cross, Nadia J. 1176, 727  
 Crowell, Joseph 51  
 Crump, John A. 1036, 856, 858  
 Cruz, Ana C. R. 1048  
 Cruz, Christopher D. **92**  
 Cruz, Julio V. **241**  
 Cruz, Ligia M. **663**  
 Cruz, R. Rhode 906  
 Cruz, Rochelle E. **1265**  
 Cruz-Licea, Veronica 1199  
 Cruz-Rivera, Ramon 496  
 Cserti-Gazdewich, Christine 117, 123, 849  
 Cualing, Hernani D. **210**  
 Cuba Cuba, Cesar A. 1074  
 Cucher, Marcela 814  
 Cuevas-Incle, Esteban 192  
 Cuervo, Patricia 1086  
 Cui, Liwang 744, 1276, 1269  
 Cui, Long 1269  
 Cui, Long **1276**  
 Culpepper, Janice 982  
 Cummings, Derek A. T. 394, 470  
 Cummings, James 808, 984  
 Cummins, Breschine **183**  
 Cunningham, Charles 1226, 411  
 Cuny, Gérard 420  
 Cupit, Pauline M. 1226, **411**  
 Cura, Carolina I. **1074**  
 Currier, Judith 962  
 Curti, Elena 740  
 Curtiss III, Roy 790  
 Cuyar-Bermudez, Liv 496  
 Cyr, Danielle L. **104**  
 Cyril-Olutayo, Mojisola 243, 261  
 Cysticercosis Working Group in Peru 1046  
 Czabotar, Peter 1107  
 Czege, Jozsef 431
- ## D
- D'Acremont, Valerie **52**  
 D'Alessandro, Sarah 254  
 D'Alessandro, Umberto **1**, 495, 974, 538, 784, 1315  
 D'Ippolito, João A. Costa. 1045  
 da Silva, Alexandre J. 240, 445, 556, 659, 1074, 1043, 1188, 1190,  
 da Silva, Eliana V. P. 1159  
 da Silva, João S. 706  
 da Silva, Sidnei 970  
 Dabire, Roch D. 1000, 1297  
 Dabo, Abdoulaye 1288  
 Dackouo, Blaise 1263  
 Dacuma, Mary Grace B. **567**  
 Dada-Adegbola, Hannah O. 1229, 1254  
 Dadzie, Samuel 1010  
 Dagoro, Henry 1067, 611  
 Dahan-Pasternak, Noa 1337  
 Dahlback, Madeleine 436  
 Daily, Johanna P. 397, 1261  
 Dake, Clarissa 586  
 Dalton, John P. 413  
 Dama, Emilie T. H. **696**  
 Damião, Alcinea O. 1031  
 Damintoti, Karou 719  
 Damon, Inger K. 1168, 1170, 408  
 Danboyi, J 798  
 Dani, Francesca Romana 1117  
 Daniel, Dodo 720  
 Daniel-Ribeiro, Cláudio T. 970  
 Daniels, Rachel F. 401, 402  
 Danso-Appiah, Anthony 890  
 Dao, Adama 1299, 182  
 Dao, Le D. 1271  
 Dao, Soukalo 672  
 Daou, Adama 1065  
 Daou, Modibo 1288, 161, 590  
 Daoudou, Messanh 278  
 Daraja, Ally 1298  
 Darapiseth, Sea 1247, 1273  
 Das, Ashis 1262, **430**, 739  
 Das, P 235  
 Das, Suchismita 757, **765**  
 Dasgupta, Debleena 1175  
 Dash, A. P. 196  
 Date, Kashmira A. **353**, **637**  
 Dauenberger, Claudia 979  
 Dauner, Allison **94**  
 Davaadorj, Rendoo 489  
 Dave, Sandeep 1127  
 Davenport, Gregory C. 1292, **1322**, 545, 546, 721, 723, 848  
 David, Kangoye T. 158  
 Davidson, Mario 84  
 Davies, April 441  
 Davies, Richard 883  
 Davies, Stephen J. 1158, 412, 788  
 Davila, Samuel Z. 406  
 Davis, Heather 164  
 Davis, Jennifer 27  
 Davis, J. Lucian 676  
 Davis, Richard 1164  
 Davis, Timothy M. E. 132  
 Dawes, Emma J. 564  
 Dawood, Ghaffar 1129  
 Day, Nicholas P. J. 851  
 Day, Timothy A. 828  
 Dayan, Gustavo **836**, 906  
 de Almeida, Marcos **1043**  
 de Alwis, Ruklanthi 471  
 de Araujo Lobo, Jaime M. **1053**  
 de Azevedo, Orleancio G. R. 1321  
 De Baetselier, Patrick 1082  
 de Cózar, Cristina 1246, **246**  
 De Donato, Marcos 321, **904**  
 De Doncker, Simonne 703  
 de Farias, Helena M. 857  
 de Jong, Menno D. 97  
 de Leon, Oscar F. 1003  
 De los Santos, Maxy 689  
 de Meeûs, Thierry 420

The number(s) following author name refers to the abstract number.

- De Pablos, Luis M. 1074  
 de Paula Eduardo, Maria Bernadete 1043  
 De Ridder, Karin 1082  
 de Rijk, Marjolein 1007  
 De Sanctis, Sabatino 81  
 De Silva, A Dharshan 520  
 de Silva, Aravinda M. 99, 471, 520, 831  
 De Sousa, Alexandra 1237, 1256  
 de Souza, Dzedzom K. **1326**  
 De Vlas, Sake J 215, 779  
 de Vries, Peter J. 97, 98, 116, 233, 1241  
 Deal, Jeffery L. 356  
 Dean, Lee 379  
 Deardorff, Eleanor R. **1061**  
 Deauvieu, Florence 835  
 Debache, Karim 450, 451  
 DeBarry, Jeremy 954  
 Debes, Jose **338**  
 Debrah, Alexander Y. 1328, **1331**  
 Debretson, Fitsum G. D. **103**  
 deBruyn, Becky 304  
 Dechavanne, Célia 278  
 Decker, Gregory M. 194  
 Decuyper, Saskia 703  
 Deepak, P 430  
 Deewathanawong, Prasit 613, 759  
 DeHecq, Jean S. 168  
 Deitz, Kevin C. **776**  
 del Cuadro Hidalgo, Daniel L. 460, 874  
 Del Valle, Luis J. 929  
 Delavechia, Thais 1090  
 Delgado, Christopher 784  
 Dell'Agli, Mario 719  
 della Torre, Alessandra **1117**, 1182, **307**, 618, 776  
 Dellagi, Koussay 701, 702  
 Deloron, Philippe 83, 154, 157, 274, 276, 436, 501  
 DelVecchio, Vito G. 586  
 Demas, Allison **954**, 955  
 Demba, Dembele 1268  
 Dembélé, Ahmadou 847, 1100  
 Dembélé, Benoit 432, 563, 1332  
 Dembele, Massitan 801  
 Dembele, Moussa B. 893  
 Dembele, Ousmane 1065  
 Dembélé, Robert 801, 886, 1069  
 Demby, Austin 637  
 Demeke, Leykun 1259  
 Demertzis, Lee Z. 406  
 Demetree, Edith 181, 875  
 Deming, Michael 1164  
 den Arend, Johan 755  
 den Boon, Saskia 676  
 Deneoud, Lise 274  
 Deng, Yan 548  
 Denoed, Lise 1232  
 Denson, Lee A. 1321  
 Dery, Dominic B. **172**  
 Desai, Kamal **1050**  
 Deschamps, Timothy 192  
 Desewu, Kwame 632  
 Desir, Luccene 1333  
 Desire, Kargougou W. 158  
 Devine, Gregor J. **460**, **874**  
 Dewasurendra, Rajika L. 284, 738  
 Deye, Gregory 426  
 Dhabangi, Aggrey 117, 123, 849  
 Dhara, Animesh **761**  
 Dhiman, Monisha **1281**  
 Dia, I 272  
 Dia, Ibrahima 307, 616  
 Diaby, Bani 111  
 Diakite, Mahamadou 1178, **1209**, 121, **563**, 845  
 Diakitè, Rokia 107  
 Diakitè, Seidina A. S. 121, 563, 845, 1209  
 Diallo, Amadou 934  
 Diallo, Abdallah A. 1332, 432  
 Diallo, Abdoulbaki I. 750  
 Diallo, Dapa A. 161, 590, 805, 893  
 Diallo, Fatoumata **107**  
 Diallo, Moussa 1299, 182  
 Diallo, Mawlouth 394, 921  
 Diallo, M'Bouye 599  
 Diallo, Mamadou C. 902  
 Diamond, Michael S. 99  
 Diao, Li Y. 694  
 Diarra, Amidou 147, 571, 728  
 Diarra, Ayouba 935  
 Diarra, Issa 1288, 847, 161, 590  
 Diarra, Souleymane 750  
 Dias, Márcia S. 1325  
 Diawara, Sory I. 1209, 563  
 Diaz, Diego 816  
 Díaz, Fredi 900  
 Diaz, Francisco 908  
 Diaz, James H. **822**  
 Diaz, Luis A. **10**  
 Diaz-López, Manuel 657  
 Dicko, Alassane **750**, 805, **967**  
 Dicko, Brehima 672  
 Dicko, Mohamed 967  
 Dieng, Thérèse 131  
 Dieng, Yémou 131  
 Diggs, Carter L. 161, 590, 803, 806, 984  
 DiLiberto, Deborah 1302, 1303, **1304**, 1314, 539  
 Dillingham, Rebecca A. 443, **933**  
 Dimaano, Efren 1312  
 Dimalibot, Judeline 567  
 DiMenna, Mark 1018  
 Dimitrova, Kristina 880  
 Dimopoulos, George 757, 765, 767, 870  
 Ding, Charles 249, 685  
 Diop, Abdou 1256  
 Diop, Ousmane M. 1164  
 Diop, Samba 563  
 Diosque, Patricio 1074  
 Diouf, Ababacar 1178  
 Diouf, Ibrahima 279  
 Diouf, Mame Birame 291, **44**  
 Dioum Ahouidi, Ambroise 277  
 Diriye, Abdi 38  
 DiTusa, Charles A. **270**  
 Diuk-Wasser, Maria **1008**  
 DiViata, Margaret A. 28  
 Djimde, Abdoulaye 294, 1100, 1263  
 Djogbénou, Luc S. **465**  
 Djouaka, Rousseau 602  
 Djuardi, Yenny **384**  
 Dkhar, H K. 1127  
 Dlugosz, Lisa 980  
 do Carmo, Ediclei L. 560  
 Dobler, Gerhard **11**, **1169**  
 Dobrilovic, Tina 436  
 Dobson, Stephen L. 21, 225, 59, 597, 999  
 Dodoli, Wilfred 753  
 Doodoo, Daniel 728, 733  
 Dodson, Brittany L. 1202  
 Doerig, Christian 372  
 Dogandemir, Gokhan 208  
 Dokomajilar, Christian 129  
 Dolo, Amagana 161, 590, 805  
 Dolo, Housseini 1332, 432  
 Don, Robert 1089, 234, 683, 685  
 Donaldson, Samantha 55  
 Dondorp, Arjen M. 1267, 54, 851  
 Dong, Tao 1139  
 Dong, Yuemei 765, 870  
 Donnelly, Martin J. 462  
 Donnelly, Sheila 413  
 Donnelly-Doman, Marilyn 766  
 Donovan, Danielle J. 187  
 Doolan, Denise L. 414, 806  
 Doranz, Benjamin J. 513, 523  
 Doritchamou, Justin **274**, 83  
 Dorkenoo, Ameyo 67  
 Dorkenoo, Meyo **1071**  
 Dorlo, Thomas P. C. **233**  
 Dorny, P 1044  
 Dorny, Pierre 1046, 792  
 Dorsey, Grant 1208, 1238, 129, 1290, 1319, 142, 962  
 dos Santos Barrado, Jean Carlos 442  
 Dosanjh, Nuvjeevan S. **988**  
 Dotson, Ellen 599  
 Doucoure, Souleymane **168**, **181**  
 Douglas, Alexander D. 804  
 Douglas, Douglas T. 280  
 Doumbia, Drissa 1065  
 Doumbia, Moussa 1065, 107  
 Doumbia, Mory 1209, 121, 563, 845  
 Doumbia, Mama N. 333  
 Doumbia, Saibou 121, 563, 845, 1209  
 Doumbia, Seydou 563, **566**, 599, 934, 935, 1209  
 Doumbia, Salif S. 1332, 432  
 Doumbo, Ogobara K. 161, 572, 590, 750, 803, 805, 847, 967, 893, 1100, 1263, 1288  
 Douguilh, Macaya 7  
 Dow, Geoffrey S. 252, 266, 268, **715**  
 Dow, Steven W. 878  
 Dowell, Floyd E. 177  
 Dowell, Kayla M. 177  
 Downs, Jennifer A. **884**  
 Doyle, Patricia S. **232**  
 Dozie, Ijeoma J. 575  
 Dozie, Ikechukwu N. S. 290, **575**  
 Drago, Andrea 618  
 Dragoo, JW 1153, 1154, **454**, 455  
 Drake, Lisa L. **186**, **863**  
 Drakeley, Chris J. 42, 564, 781, 876  
 Drame, Papa-Makhtar 616, 872  
 Draper, Simon J. 160, 804  
 Drebot, Michael A. 880, 1011  
 Dreibelbis, Robert S. **441**  
 Drew, Damien R. **1176**  
 Driguez, Patrick **414**  
 Dua, V. K. 196  
 Duarte, César A. B. 1052  
 Dube, Tina 161, 590  
 Dubois, Marie-Claude 161, 590  
 Duffull, Stephen B. 258  
 Duffy, Patrick E. 40, 126, 127, 163, 437, 587, 809, 844, 846, 871, 982  
 Duffy, Sandra **1257**  
 Duffy, Tomás 1074  
 Duggar, Chris 1164  
 Dujardin, Jean Claude 703, 1087  
 Duman-Scheel, Molly 309  
 Dumonteil, Eric O. 24, 1080  
 Duncan, Christopher J. A. 160, **804**  
 Dunlap, Brett 655  
 Dunn, John 655, 817  
 Dunn, William A. 770  
 Duong, Socheat 1266, 155  
 Duparc, Stephan 1244, 708, 711  
 Dupnik, Kate 1325  
 Durairaj, Natesan 22  
 Duraisingh, Manoj 277, 429, 714  
 Duran-Bedolla, Josefina 89  
 Durand, David 644  
 Durand, Salomon **943**  
 Durbin, Anna P. 89, 470, 584, **834**  
 Duri, Kerina. **1230**  
 Durvasula, Ravi 677  
 Dutil, Timothy S. 164  
 Dutta, Sheetij 1288, 161, 428, 590, 803, 978, **980**  
 Duvall, Adam S. 1070  
 Dwyer, Dennis M. 1084  
 Dyall, Julie 380  
 Dzik, Walter 117  
 Dzinjalama, Fraction K. 3, **960**
- 
- E**
- E Soto-Calle, Veronica 784  
 Eappen, Abraham 769, 773, 988  
 Earon, Allison 819  
 Easley, Rebecca 379  
 Easom, Eric 228, 249  
 Eastwood, Gillian **1054**  
 Ebel, Gregory D. 860, 1061, 1201, 1203  
 Echevarria, Aurea 239  
 Echodu, Richard **423**  
 Ecker, Lucie **1305**, 485, **929**  
 Eckhoff, Phillip **493**  
 Edelman, Robert 807  
 Edith, Bougouma C. 158, 720  
 Edmond, Convelbo 838  
 Edsbagge, Josefina 12  
 Edwards, Nick 160, 804

The number(s) following author name refers to the abstract number.

- Eggelte, Teunis A. 289  
 Egizi, Andrea **775**  
 Eguagie, John 887  
 Eholié, Serge P. 1232  
 Ehrbar, Dylan J. 1204  
 Eidex, Rachel 639  
 Eigege, Abel 1156, 797,798  
 Eiglmeier, Karin 864  
 Eisen, Lars 463, 620  
 Eisenberg, Joseph N. S. 354, 363  
 Eisenstein, Jana 855  
 Ekanayake, Sajeewane 94  
 Ekirapa, Elizabeth K. 537  
 Ekundayo, Arogundade D. 1317  
 El Mohammady, Hanan 895  
 El Nasery, Suzan 1150  
 El Sayed, Najib 1219  
 El Sayed, Nasr 895  
 El- Hassan, Ahmed M. 418, 1217  
 El-Baz, Hatim A. A. **76**  
 El-Gasim, Mahmood 1242  
 El-Hossary, Shabaan S. 207  
 Elango, Alamelu D. 552  
 Elder, B. Laurel **631**  
 Elder, John 391, 910  
 Elemile P., S 139  
 Elfaki, Mona E. E. **1217**  
 Elhadji, BA K. **1214**  
 Elias, Nyanda 1169  
 Elias, Sean 160  
 Elizondo, Douglas 100, 509, 516  
 Elliot, Salenna R. 1176  
 Ellis, Magda 414  
 Ellis, Ruth D. 164, **584**, 804, 805, 893  
 Ellis, S 235  
 Ellis, William 710  
 Ello, Frédéric N. A. **1232**  
 Elnaiem, Dia-Eldin 697  
 Elvine, Nguuelefack-Mbuyo P. **78**  
 Elwood, Daniel 834  
 Elyazar, Iqbal **146**  
 Emch, Michael 578, 963  
 Emerson, Paul M. 528, 601, 989  
 Emmanuel, Evens 440  
 Emrich, Scott J. 941  
 Emukah, Emmanuel 69, 754, 887, 1156  
 Endeladze, Marina 504  
 Endeshaw, Tekola 601, 989  
 Endo, Yaeta 942  
 Endy, Timothy P. 837  
 Engel, Juan C. 232, **422**  
 Enger, Kyle S. **439**  
 Enkhtuvshin, Biraasuren 489  
 Enriquez, Andrea 819  
 Enyaru, John C. K. 423  
 Enyong, Peter 214  
 Epstein, Judith E. 492, **807**, 931, 971,972, 985  
 Erazo, Silvia 529  
 Erdman, Laura **123**, 849  
 Erhart, Annette 495, 784, 974  
 Erickson, Sara M. 227  
 Ermler, Megan **336**  
 Ermont, Caroline 157  
 Eron, Joe 962  
 Esan, Michael 1212  
 Escalante, Ananias A. **1113**, 400, 552, 744, 936, 954  
 Escalante-Mejia, Patricia 1216  
 Esch, Kevin J. **925**  
 Esin, Suzan 314  
 Eskin, Eleazar 401  
 Espejo, Victoria 340  
 Esperance, Ouedraogo 158, 720  
 Espinel, Mauricio 1279  
 Espinosa, Manuel 185  
 Espinoza, Nereyda 486  
 Essbauer, Sandra 11  
 Esselstyn, Jake 881  
 Estela, Abel 1136  
 Estes, Mark D. 1310, 89  
 Esteves, Gabriela S. 899  
 Estevez, Alejandra 1163  
 Eugène, Kiti 591  
 Evans, Brian P. 191, 202, 656  
 Evans, Chris 868  
 Evans, Carlton A. 1132  
 Evans, Darin **797**  
 Eversole, Rob 382  
 Ewer, Katie 160, 804  
 Eyamba, Albert 214  
 Eyanu, Sam 1220, 684  
 Eyigun, Can Polat 315  
 Eyigun, Can P. 1039  
 Ezeabikwa, M 69  
 Ezinmegnon, Sem 276
- F**
- Faaruaia, Marc 21, 995, 999  
 Fabrice, Chandre 171  
 Fabris, Paolo 1161  
 Facchinelli, Luca 16  
 Faccioli, Lúcia H. 658  
 Fairhurst, Rick M. 121, 434, 845, 1178  
 Fairlamb, Alan 1083  
 Fairley, Jessica K. **1070**, **491**  
 Faiz, Md. A. 54  
 Falade, Catherine O. **1229**, **1233**, 1243, **1254**, 247, 294  
 Faldetta, Kimberly F. **973**  
 Fally, Markus 473  
 Famanta, Aminata 1209  
 Fan, Erkang 1283  
 Fang, Chi-Tai 392  
 Fantu, Ribka 24  
 Farag, Tamer H. 852  
 Faragher, Brian 1212  
 Farajollahi, Ary 192  
 Farfán-Ale, José Arturo 620  
 Farhat, Abdelbasset A. 238  
 Faria, Adriana R. 1028  
 Farooq, Fouzia 583, 806  
 Farrance, Christine E. 982  
 Farrar, Jeremy 1323, 468, 853, 854, 98  
 Farrell, David 1195  
 Farrell, Margaret 504  
 Faruque, Md. Omar 70  
 Fasimoye, Rotimi 243  
 Fasina, Abiola A. **525**  
 Fataki, O 665  
 Fatema, Kaniz 638  
 Fatih, Touria 649  
 Faucher, Jean-François 501, **83**  
 Favier, François 168  
 Fay, Michael P. 121, 164, 584, 804, 805, 845  
 Faye, Babacar 1237, 131, 279, 312, 403, 1214  
 Faye, E. 1214  
 Faye, O. 1214  
 Faye, Oumar 131  
 Faye, Ousmane **921**  
 Faye, Sylvain 1237  
 Fayed, Ahmad A. 1144  
 Fedders, Charlotte 492  
 Fegan, Greg 579  
 Feikin, Daniel 353  
 Feikin, Daniel R. 487  
 Felger, Ingrid 1109  
 Felgner, Philip L. 414  
 Felices, Vidal 92  
 Felicioli, Antonio 1117  
 Felix, Gilberto 594, 595  
 Feller, Avi 38  
 Felling, Barbara 101, 102  
 Feltwell, Theresa 38  
 Felzemburgh, Ridalva D. M. 409  
 Fennell, Clare 372  
 Fennell, Sean 553  
 Ferdausi, Dilara 70  
 Ferdig, Michael T. 941  
 Ferguson, Heather 1298  
 Ferguson, Neil M. 876  
 Fernandes, Prabhavathi 265, 269, 1137  
 Fernandez, Marina 363  
 Fernando, Anu 1221  
 Fernando, Deepika 284, 738  
 Feroldi, Emmanuel **13**  
 Ferragine, Christine E. **412**  
 Ferreira, Ivani B. 1166  
 Ferreira, Marcelo U. 737  
 Fidock, David A. 371, 48  
 Fievet, Nadine 154, 276, 285  
 Figueira, Claudio P. 899  
 Filice, Carlo 1042  
 Filler, Scott 45, 1208, 1259, 1316  
 Fimlaid, Kelly A. 508  
 Finaurini, Sara 254  
 Finberg, Robert W. 431  
 Fink, Doran L. 1329  
 Finney, Constance A. M. **117**  
 Finney, Olivia C. 809  
 Firth, Andrew E. 8  
 Fischer, Kerstin **824**, 827  
 Fischer, Peter U. 824, 827  
 Fisk, John C. 1343  
 Fitzgerald, Daniel F. 884  
 Fitzgerald, Katherine 336  
 Fitzgerald, Margaret 1231  
 Fitzpatrick, Kelly A. 1036, 1061, 1203, 858  
 Fitzpatrick, Meagan 1008  
 Flak, Audrey 211  
 Flannery, Ellen **309**  
 Flaspohler, John A. 1215  
 Fleckenstein, Lawrence 7, 708  
 Flegel, Willy A. 53  
 Fleming, Fiona 801  
 Fletcher, Joseph 542  
 Flibotte, Stephane 1096  
 Fligner, Corinne L. 126  
 Flisser, Ana **1199**  
 Florence, Salvatory 850  
 Flores, Rosemary 1220, 684, 691  
 Florez, Zulibeth 174  
 Floriano, Elaine M. 658  
 Floyd, David 267  
 Flynn, Barbara 1173  
 Foggie, Tarra 621, 623  
 Folarin, Onikepe A. 1245, **1270**, 2, 746  
 Foley, Michael 732  
 Foley, Mick 980  
 Fongoro, Sahare 672  
 Fonseca, Bruna 283  
 Fonseca, Benedito A. L. **1166**, **518**, **519**  
 Fonseca, Dina M. **1016**, 1201, 775, **778**  
 Fonseca, Elivelton S. 1155  
 Fontenille, Didier 1293, 1297  
 Fontoura, Beatriz M. A. 372  
 Foo, Karen 360, 885  
 Foppa, Ivo M. 183, **1062**, **912**  
 Forney, Kristen 33  
 Forquer, Isaac 716  
 Forrat, Remi 836  
 Forshaw, Adam **705**  
 Forshey, Brett M. 342, 391, 622, 910  
 Fortes, Filomeno 872  
 Forys, Michelle A. **453**, 787  
 Fotie, Jean 682  
 Fouda, Manal I. 76  
 Fouet, Caroline **1181**  
 Fowkes, Freya J. I. **727**  
 Fowler, Elizabeth 51  
 Fox, Annette 1139  
 Fox, Christopher B. 1174, 164  
 Fox, Jeffrey 1119  
 Fox, LeAnne 1333, 211  
 Fox, Lindsay L. 843  
 Fracisco, Susan D. 265, 266, 270  
 Fraga, Debora B. M. 409  
 Francis, Filbert 5  
 Francischetti, Ivo M. B. 629  
 Franco, Pagnoni 838  
 Franco, Roberto A. S.. 558  
 Franklin, Bernardo S. **280**  
 Franz, Alexander W. E. 198, **305**  
 Frearson, Julie 1083  
 Fredrick, Charlie 55  
 Freeman, Daniel L. **1275**, 476  
 Freeman, Jennifer C. **234**, **1089**  
 Freiberg, Alexander N. 378  
 Freire, Janaina 1078  
 Freitas, Debora B. 1103  
 Freitas, Luiz A. R. 1051  
 Freitas, Patrícia P. S. 1166  
 Freund, Yvonne 228, 249, 683, 685  
 Freye, James D. 655  
 Fried, Michal 127, 437, 587, 844, 846  
 Friis, Henrik 407



The number(s) following author name refers to the abstract number.

Frimpong, Samuel **671**  
 Fritzen, Charissa **655, 817**  
 Frogier, Henri 999  
 Frolov, Ilya 375  
 Frosch, Anne E. P. 1274  
 Fruth, A 634  
 Fry, Alicia 28  
 Fry, Scott 91  
 Fryauff, David J. 808, **945**  
 Fuchs, Jeremy F. 386, 771  
 Fuehrer, Hans-Peter 473  
 Fuentes, Patricia 1132  
 Fujiwara, Ricardo T. 1152  
 Fukuda, Mark 550, 808, 1247, 1273  
 Fukumoto, Megumi 166  
 Fuller, Lauren 831  
 Furlotte, Nicholas A. 401  
 Furman, Barry D. 207, 626  
 Furst, Jessica 795  
 Furuya, Tetsuya **1106**

## G

Gaayeb Juliàn, Lobna **494**  
 Gadea, Nilda 903  
 Gadgil, Meghana A. **351**  
 Galan, Francisco 836  
 Galappaththy, Gawrie N. L. 737  
 Galarza, Ivonne 466, 496  
 Galdos-Cardenas, Gerson 1216  
 Galen, James 329  
 Galinski, Mary R. 1110, 1111, 1112  
 Galinsky, Kevin 402  
 Gallagher, Glen 389  
 Gallardo-Romero, Nadia 1168  
 Galler, Ricardo 899  
 Galloway, Renee L. 1034, 856  
 Galvin, William 194  
 Gambhir, Manoj **63**  
 Gamboa, Dionicia 1115, 136, 784, 974  
 Gamboa, Ricardo 794  
 Gamboa-León, Rubi **1080**  
 Gamero, Maria E. 1133  
 Gamo, Francisco-Javier 1246, 246  
 Gandhi, Kavita **572**  
 Ganesan, Karthikeyan 1275  
 Ganeshan, Harini 806, 985, 987  
 Gangnard, Stéphane 157  
 Ganley-Leal, Lisa M. 786, 1148  
 Gansane, Adama **147, 728**  
 Gao, Lixin 988  
 Garba, Amadou 888  
 Garcia, André 278, 501  
 Garcia, Hugo 1046  
 Garcia, Hector H. 789, 790, 794, 812, 814, 816, 1043  
 Garcia, Josefina 1133, 340  
 Garcia, Josselyn 819  
 Garcia, Stephen 1292  
 Garcia-Bustos, Jose F. 1246  
 Garcia-Gubern, Carlos 466, 496  
 García-Rejón, Julián 620  
 Garcia-Rubio, Luis H. 1099  
 Gardner, Allison 1006

Gardner, Adrian **1194**  
 Gardner, Malcolm J. 396  
 Gardner, Sean 252, 715  
 Garelli, Fernando **185**  
 Garg, Navneet 924  
 Garg, Nisha J. 1281, 700  
 Garg, Shilpi **1262**, 430, 739  
 Garms, Rolf 68  
 Garner, Paul 890  
 Garnier, Thierry 864  
 Garry, Robert F. 901  
 Garuti, Helen 267  
 Gasasira, Anne 142, 1208  
 Gasque, Phillippe 168  
 Gass, Katherine **65**, 799  
 Gatton, Michelle 841  
 Gaukel, Eric 234, 683, 685  
 Gaur, Upasna 1285, 898  
 Gavidia, Cesar M. 789, 812, 814, **816**  
 Gaye, Oumar 1237, 1256, 131, 312, 403, 1318, 279, 1214  
 Gaywee, Jariyanart **574, 627**  
 Gaze, Soraya 414  
 Gazzinelli, Andrea 1152, 1155  
 Gazzinelli, Ricardo T. 280  
 Gbadero, Daniel 84  
 Gbadoe, Adama Dodji 292, 293, 873  
 Gbotosho, Grace O. 1245, 2, 746  
 Gbotosho, Olusola G. 1270  
 Geary, Timothy G. 830  
 Gebre, Teshome 601, 989  
 Gebre, Wondwoosen 680  
 Gebresellasia, Sintayehu 1259  
 Geiss, Brian J. 774  
 Gellida Royo, Meritxell 573  
 Genton, Blaise 52, 748, 839, **979**  
 Gentsch, Jon 1163  
 George, Michael D. 119  
 George, Phillip 1182  
 George, Sarah 907  
 Gerard, Craig 849  
 Gerena, Lucia 268, 712  
 Gerlovina, Inna 580  
 German, Michel 21  
 Gething, Peter W. 105, 145, 146, 749  
 Getis, Arthur 1001  
 Gettayacamin, Montip 248, 265, **266**, 270  
 Getz, Tony 40  
 Ghani, Azra C. 150, 745, 876  
 Ghansah, Anita 632  
 Gharbi, Adel 49  
 Ghedin, Elodie 1284, 825, 829  
 Gialdi, Cesare 81  
 Giampietro, Corradin 720  
 Giavedoni, Luis 514  
 Gibbons, Robert V. **1049**, 837, 95  
 Gichuki, Charity W. 545  
 Gil, Ana I. 1305, 485  
 Gil, Padonou 591  
 Gilbert, Nicolas L. 1193  
 Gilbert, Sarah C. 160, 804  
 Gilbreath III, Thomas M. **1295**, 1296  
 Gilles, Jeremie 184

Gillespie, John R. 1283  
 Gillespie, Thomas R. 1170, **320**, 664  
 Gillis, Tom 1137  
 Gilman, Robert H. 789, 790, 794, 816, 1091, 1132, 1216  
 Gimonneau, Geoffrey **1000**  
 Giordani, Maria T. **1161**  
 Giorgobiani, Ekaterine 199  
 Girerd-Chambaz, Yves 510  
 Girma, Samuel 1259  
 Githeko, Andrew K. 169, 178, 179, 75, 271  
 Githinji, Sophie 145  
 Gitonga, Caroline W. **144, 781**  
 Gittelman, David M. 965  
 Gittens, Genelle 237  
 Giudice, Angela 1090  
 Glaser, Kathleen 326  
 Glennon, Erin **1024**  
 Glesby, Marshall 679  
 Gleva, Erika 498  
 Glover, Simon J. 541, 843  
 Glunt, Katey **991**  
 Gneme, Awa 864  
 Gnidehou, Sédami **157**, 274  
 Gnirke, Andreas 402  
 Gobena, Kedir 1259  
 Gobert, Geoffrey N. 413, 414, 1222  
 Goblirsch, Sam 1042  
 Godeaux, Olivier 161, 590  
 Goenaga, Sergio 174  
 Goethert, Heidi **823**  
 Goia, Mauricio 442  
 Goldberg, Tony L. 1187, 664, 055, **1058**, 1205,  
 Golden, Frances 600  
 Golden, Hannah 1175  
 Goldman, Ann 800  
 Goldschmidt, Lauren 691  
 Golovina, Tatiana 691  
 Gomes, Carlos M. 1325  
 Gómez, Claudio 174  
 Gomez, Delphina 632, 1009  
 Gómez, Doris 174, 1032  
 Gomez, Guillermo 446  
 Gómez, Giovan F. 1004, 310  
 Gomez, Jorge 1133, 340  
 Gomez, Melba 1267, 905  
 Gomez, Miguel G. 241  
 Gómez Alegria, Claudio J. 998  
 Gómez Bertomeu, Frederic 573  
 Gómez Camargo, Doris E. **998**  
 Gomez-Puerta, Luis 1091  
 Gomis, J.f. 1214  
 Gomo, Exnevia 407  
 Gonahasa, Samuel 244  
 Goncalves, André H. O. 894  
 Goncalves, Loredana 693  
 Gong, Lauren S. **148, 1179**  
 Goñi, Sandra 10  
 Gontijo, Célia M. F. 1078  
 Gonzaga, Victor E. 32, **1136**, 316, 317  
 Gonzales, Elsa 337  
 Gonzales-Peralta, C. 798

Gonzalez, Armando E. 789, 790, 794, 812, 816  
 Gonzalez, Ana S. 1003  
 Gonzalez, Brunnell 904  
 Gonzalez, Emico 1046  
 González, Elsa 660  
 Gonzalez, Jose Carlos 1008  
 Gonzalez, Jorge 449  
 González, Martha 900  
 González, Raquel 294  
 Gonzalez, Sachy-Orr 164  
 Gonzalez-Dominguez, Fernando 1199  
 González-Ramírez, Claudia 1080  
 González-Zeno, Gladys 395  
 Goodhew, Brook 1216  
 Goodman, Catherine 534, 579, 1251, 1317  
 Gorchakov, Rodion 335, 375  
 Gordon, Aubree 1309, **467, 469**, **516**  
 Goshit, D 798  
 Gosi, Panita 1273  
 Gotuzzo, Eduardo 1072, 1073, 337, 61, 660  
 Gouagna, Louis C. 1297  
 Gould, Fred 16  
 Gowda, Kalpana 583  
 Gozalvez, Guillermo 794  
 Graeff-Teixeira, Carlos 659  
 Graf, Paul C. F. 32, 316, 317, 689, 903, 943, 1116  
 Grainger, John 867, 1339  
 Granger, Donald L. 850  
 Gratz, Jean 480  
 Graves, Patricia M. 601, **754**, 989  
 Gray, Emilie 1181  
 Gray, Karen-ann 841  
 Gray, Kimberly K. **378**  
 Gray, Laurie R. 226, 66  
 Green, Esther 1017  
 Green, Sharone 1206  
 Greenberg, Jacob A. **1018**  
 Greenberg, Lior J. **944**  
 Greenberg, Robert M. 1227  
 Greene, George C. 356  
 Greenhouse, Bryan **1179**, 129, 1290, 148, 374, 580  
 Greenwood, Brian 1023  
 Greenwood, B.m. 1214  
 Gregoricus, Nicole 1163  
 Gregory, Christopher **389**, 466, **496**  
 Gregory, Michael J. **486**  
 Greisman, Laura R. 795  
 Grewal, Paul 586  
 Grieco, John 176, 463, 606, 607, 621, 623, 624, 996  
 Grier, Richard L. 165, 583  
 Griffin, Jamie T. 745, **876**  
 Griffing, Sean M. **400**  
 Griffith, Qyana K. **786**  
 Griffith, Sandy 711  
 Grijalva, Mario J. 819  
 Grimaldos, Carlos 891  
 Grimberg, Brian T. 944  
 Grindel, Dana 379  
 Grinev, Andriyan 512

The number(s) following author name refers to the abstract number.

Grivoyannis, Anastasia **1100, 670**  
 Grobusch, Martin P. 811  
 Grogl, Max 1092, 49, 694  
 Gross, Tiffany 768, 1121  
 Grossman, Sharon R. 401  
 Gruener, Beate 1040  
 Gruner, Anne Charlotte 1113  
 Grurary, Alexandra **472**  
 Gruring, Christof 1338  
 Gu, Lin-Lin 1171  
 Guagliardo, Sarah 1008  
 Gubler, Duane J. 20  
 Guedes, Marjorie M. 1321  
 Guedez, Shirley M. 391  
 Gueirard, Pascale 372  
 Guelbeogo, Moussa 864  
 Guerfali, Fatma Z. 701, **702**  
 Guerin, Philippe J. 1101, 1248  
 Guerra, Cristina 1046  
 Guerra, Carlos A. 146  
 Guerra, Yolanda 582  
 Guerrant, Richard L. 327, 329, 641, 642, 643, 646, 647, 648, 933, 1235, 1321,  
 Guerrero, Melanie 808, 984  
 Guerrero Bravo, Jose E. 267, 714  
 Guevara, Carolina 341, 342, 92  
 Gueye, Ali 403  
 Guezala, Claudia 1136  
 Guilarte, Del Valle 904  
 Guillen, Catherine 794  
 Guimarães, Isabel 857  
 Guindo, Aldiouma 1263  
 Guindo, Ando B. 161, 590  
 Guindo, Merepen A. 805, **893**  
 Guindo, Oumar 672  
 Guindo, Ousmane 805  
 Guindo, S 272  
 Guitard, Juliette 157  
 Guizani-Tabbane, Lamia 702  
 Gujjar, Ramesh 1275, 476  
 Gül, Hanefi C. 1039  
 Guler, Jennifer L. **476**  
 Gulia, Monika **762**  
 Gulia, Sandrine 12  
 Gumbo, Felicity Z. 1230  
 Gunasekera, Anusha 807  
 Gunasena, Sunethra 520  
 Gunawardena, Geethika Sharmini A. **737**  
 Gundersen, Svein Gunnar 407  
 Gunn, Bonnie 790  
 Guo, Qin 1175  
 Gupta, Lalita 861  
 Gupta, Pawan **1127**  
 Gupta, Shivali **700**  
 Gurarie, David 1142  
 Gurgel-Gonçalves, Rodrigo 1074  
 Gurjav, Ulzijiargal **964**  
 Gurley, Emily S. 1197, 345, 349  
 Gürtler, Ricardo E. 185, 1074  
 Gusovsky, Fabian 280  
 Gut, Jiri 249  
 Gutiérrez, Andrés 703  
 Gutierrez, Gamaliel 100, 467, 509  
 Gutiérrez, Lina A. 1004, 310  
 Gutierrez, Maria 1244  
 Gutiérrez, Maria Elena 153

Gutiérrez, Patricia 153  
 Gutman, Julie R. **887**  
 Gutteridge, Clare E. **712**  
 Guwatudde, David 640  
 Guy, Bruno **835, 96**  
 Guzman, Hilda 377  
 Guzman, Javier 535  
 Gwamaka, Moses M. **846**  
 Gyan, Ben 733  
 Gyapong, John O. 1334  
 Gyorkos, Theresa W. **1193**

## H

Ha, Kwon-Soo 547  
 Ha, Tuan M. 853  
 Ha, Vinh 853  
 Haas, Helmut 786  
 Habashy, Engy Emil 1025  
 Habomugisha, Peace 68  
 Haddad, Danny 533  
 Haddad, João Paulo A. 1155  
 Hagos, Biniam 326  
 Hahn, Sigrid **35**  
 Haidara, Fadima Cheick 107, 1065  
 Hailegiorgis, Bereket **1259**  
 Hailemariam, Tiruneh 1284  
 Haj Hamida Nabil, Bel 49  
 Halage, Ali **640**  
 Halder, Amal K. 23, 26  
 Hall, Chris A. **421**  
 Hall, Millicent C. **1010**  
 Hall, Rebecca L. **323**  
 Haller, Aurelia 907  
 Hallett, Rachel L. 477, 567, **1272**  
 Halliday, Jo 818  
 Halloran, M. Elizabeth 1023  
 Halsey, Eric S. 32, 92, 340, 341, 342, 344, 391, 903, 1133  
 Halstead, Fenella 804  
 Hamapumbu, Harry 47  
 Hamar, Alassane 1232  
 Hamel, Mary 353, 781  
 Hamer, Davidson H. 498  
 Hamer, Gabriel L. 187, 1006, 1055, 1058, 1205  
 Hamidou, Niangaly 1268  
 Hamma, Maiga **1268**  
 Han, Cong 548  
 Han, Eun-Taek **547**  
 Han, Seung Hee 559, 952  
 Hanafi, Hanafi A. **207, 626**  
 Hancock, Kathy 790  
 Hand, Carla C. **570, 578**  
 Hanington, Patrick C. 453, 455, **787**  
 Hanley, Kathy 394  
 Hanon, Jean-Baptiste 494  
 Hanpithakpong, Warunee 6  
 Hansen, Curt 580  
 Hansen, Hans 280  
 Hansen, Immo A. 186, 189, 772, 863  
 Hanson, Christy 800  
 Hanson, Kara 1317, 534  
 Hansson, Stefan R. 937  
 Hansukjariya, Pranee 266

Hapairai, Limb K. M. 21, **597**  
 Happi, Anise N. **230**  
 Happi, Christian 401  
 Happi, Christian T. 1245, 1270, 2, 746  
 Haque, Md. Ziaul 70  
 Haque, Rashidul 480  
 Harding-Esch, Emma 533  
 Hardjopawiro, Loretta 968  
 Hardstone, Melissa C. 759  
 Harmen, Sonia 1064  
 Harnett, Margaret M. 217  
 Harnett, William **217**  
 Harrell, Emma 711  
 Harrell II, Robert A. 769, 773  
 Harrington, Laura C. 200, 605, 613, **759**  
 Harrington, Whitney E. 127  
 Harris, Beth 1195  
 Harris, Caroline **1297, 564**  
 Harris, Eva 99, **100, 467, 469, 509, 516, 1309**  
 Harris, Erin 245, 364, 716  
 Harris, Ivor 841  
 Harris, Jamal 1208  
 Harris, Julie 442  
 Harris, Jason B. 483, **484, 638, 855, 896**  
 Harris, Juliana V. **122**  
 Harris, Meghan 1083  
 Harrison, Lisa M. 1282  
 Hartl, Daniel L. 401, 737  
 Harutyunyan, Vachagan **951**  
 Hasan, Md. Mahamudul 70  
 Hasan, Mahtab U. 54  
 Hasin, Marufa 345  
 Haskew, Christopher 561  
 Hassan, Hamisu **922**  
 Hassan, Hassan K. 216, 879  
 Hassan-King, Musa 1023  
 Hassar, Mohammed 649  
 Haugen, Morgan 309  
 Hauser, Naomi **664**  
 Hausser, Nicole 1019  
 Havt, Alexandre 646, 647  
 Hawkes, Michael 541, 72  
 Hawkridge, Anthony 1128  
 Hay, Bruce A. 764  
 Hay, John G. 544  
 Hay, Simon I. 105, 146, 785  
 Haydon, Daniel 1298  
 Hayes, Ericka V. 406  
 Hayman, Edward 51  
 Haynes, J. David 128, 428, 980  
 He, Shanshan 682  
 Healer, Julie 1107, 1176, **581**  
 Healy, Sara A. 809  
 Heaton, Alexis 101, 102  
 Heining, Uli 492  
 Heinrich, Norbert 1169  
 Helbig, Sina **331**  
 Helegbe, Gideon K. **724**  
 Helinski, Michelle E. 759  
 Hemingway-Foday, Jennifer 7  
 Hemphill, Andrew **1041, 450, 451, 815**  
 Henderson, Klara 535  
 Hendrix, Craig W. 1242

Henebry, Geoffrey M. 1104  
 Henkle, Emily 1198  
 Henn, Matthew R. 524, 1309  
 Hennig, Nils 35  
 Henry-Halldin, Cara N. 173, **188, 464**  
 Hensley, Lisa E. 381  
 Hepburn, Matthew J. 381, 504  
 Hepler, Robert 589  
 Heppner, D. G. 161, 590, 803, 809  
 Hepworth, Matthew 1340  
 Herath, H M. Bandara. 257  
 Hermann, Emmanuel 494  
 Hermann, Jonathan 402  
 Hermsen, Cornelus C. 37  
 Hernandez, Eddy 812  
 Hernandez, Jean 1291, 946, **975**  
 Hernandez, Jean N. 973, 977, 964  
 Hernandez, Salvador 497, 892  
 Hernandez, Yunuen **1084**  
 Hernández-Campos, Alicia 236  
 Hernández-Luis, Francisco 236  
 Herrera, Raul 41, **871**  
 Herrera, Socrates 987  
 Herrmann, Corina 815  
 Hervé, Jean P. 168  
 Herwaldt, Barbara L. 323  
 Hess, Ann 860  
 Hetzel, Manuel 611  
 Hickman, Mark R. 364, 716, 1092  
 Hickner, Paul V. **304**  
 Hidalgo, Marilyn 900  
 Higazi, Tarig 216  
 Higgins, Denise 1011  
 Higgins, James **1195**  
 Higgins, Sarah 424, 544  
 Higgs, Stephen 1019  
 Hightower, Allen W. 885  
 Higueta, Erika C. 1004  
 Hii, Jeffrey 569  
 Hildreth, Michael B. 609  
 Hill, Adrian V. S. 160, 804  
 Hill, Jenny 503, 749  
 Hill, Kevin J. 879  
 Hill, Vincent 360  
 Hill, Zelee 77  
 Hillyer, Julián F. 58, 1184  
 Himeno, K 162  
 Hinds, Sarah B. 266  
 Hines, Jarrett **1226**  
 Hinrichs, Dave 716  
 Hinsley, Wes 876  
 Hirayama, Kenji 724  
 Hisaeda, H 162  
 Hise, Amy G. 336  
 Hittner, James B. 1292, 545, 546, 848  
 Hiwat, Helene **1007**  
 Hlavsa, Michele C. 323, 324  
 Ho, Keith 939  
 Ho, Mei-Fong 250  
 Ho Dang Trung, Nghia **1323**  
 Hoan, Thi Bach Duong 527  
 Hoang, Phuc L. 853  
 Hodara, Vida 514  
 Hodder, Anthony 581, **1107, 1176**  
 Hodges, James S. 1211  
 Hodgkins, Susan R. 862

The number(s) following author name refers to the abstract number.

Hodgson, Abraham 945  
 Hoel, David F. 626  
 Hoerauf, Achim 1328, 1331, 223  
 Hofecker, Verena 473  
 Hoffman, Stephen L. 365, 769, 773, 807, 931, 985, 986, 987, 988  
 Hofkin, Bruce 1018  
 Hogan, Simon 1321  
 Hoglund, Richard 6  
 Hol, Wim G. J. 1283  
 Holbrook, Michael R. 378  
 Holland, Gary N. 324  
 Hollingsworth, Deirdre **150**, 876  
 Holm, Inge 864  
 Holmes, Bryan 137, 957, 958  
 Hölscher, Michael 1169  
 Holt, Kathryn **362**, 854  
 Holtzman, Douglas 691  
 Holzman, Samuel 35  
 Homma, Akira 899  
 Hommel, Mirja 727  
 Homsy, Jaco 1238, 1319  
 Hongjun, Li 1147  
 Honko, Anna 381  
 Hood-Nowotny, Rebecca 187  
 Hoon Eum, Jai 761  
 Hooper, Pamela 533  
 Hooper, PJ **801**, 802  
 Hoos, David 1259  
 Hopkins, Adrian 1330  
 Hopkins, Donald 69, 887  
 Hoppé, Mark A. **593**  
 Hoque, Md. G. 54  
 Hora, Ricardo A. 1138  
 Horby, Peter 1139  
 Horne, Peter 390  
 Horton, Ashley A. **859**  
 Hosie, Heather **586**  
 Hospenthal, Duane R. 1034, 1037  
 Hossain, M. J. 343, **882**  
 Hossain, Shah M. 473  
 Hosseini-pour, Mina 962  
 Hou, Levi 569  
 Houghton, Raymond **1162**, **49**  
 Houghton, Eric R. **480**  
 House, Brent 161, 504, 588, 806, 590  
 Houzé, Pascal 83  
 Howard, John J. 192, 197  
 Howard, Randall F. 1174, 164  
 Howell, Katherine 1177  
 Howes, Rosalind E. 105  
 Hoy, Ron R. 605  
 Hsiang, Michelle S. **129**  
 Hsiao, Hui-Mien 1313, 505, 511, 86  
 Hsieh, Matthew M. 53  
 Hu, Susan C. 914  
 Hua-ying, Zhou 668  
 Huaman, Alfredo **341**, 342  
 Huamani, Nelly 814  
 Huang, Chang-Yi (Charlie) **91**  
 Huang, Claire Y. **1311**, 832, 907  
 Huang, Fusheng 286  
 Huang, Junjun 655, 817  
 Huang, JH 918  
 Huang, Laurence 676

Huang, Scott YJ 918  
 Huang, Yaming 744, 1269  
 Huang, Yuefang 221  
 Hubbard, Alan 22  
 Huber, Erin 1027  
 Hübner, Marc P. 1191, 383, **388**  
 Huda, Tarique M. N. **23**, 26  
 Hudson, Thomas H. 364  
 Huebner, Marc 529  
 Huestis, Diana L. 182  
 Hufert, Frank 11  
 Hughes, Christine 1168  
 Hughes, D. 960  
 Hughes, Grant L. **628**  
 Hughes, Stephen M. 712  
 Hugo, Leon E. R. 177  
 Huijben, Silvie **1277**  
 Huis in 't Veld, Diana 1234  
 Huitema, Alwin D. R. 233  
 Humphrys, Michael 637  
 Hun-Opfer, Laya 821  
 Hunsawong, Taweewun 95  
 Hunsperger, Elizabeth 389, 466, 88  
 Hunt, Adam 137, 957, 958  
 Hunt, Philip 294  
 Hunt-Cooke, Angela 160, 804  
 Hunter, Kari 981  
 Hürlimann, Eveline 889  
 Hurt, Darrell E. 41  
 Husain, Tupur 1173  
 Hussain, Rabia 1129  
 Hutson, Christina L. **1168**  
 Huttenhower, Curtis 947  
 Huttering, Alexandra D. 1192, **438**  
 Huy, Nguyen T. 724  
 Huyghe, Jeroen R. 337  
 Huynh, Bich-Tram **154**  
 Huynh, Jeremy 471  
 Huzzella, Louis 380  
 Hviid, Lars 436  
 Hwang, Jimée 1259

**I**  
 Ibadova, Gulnara **506**  
 Ibitokou, Samad **276**  
 Ibrahim, B 798, 1156  
 Ibrahim, Muntasser E. 418  
 Idro, Richard 404  
 Iga, Jonah 1260  
 Ikwang, Anne 752, 922  
 Ilboudo, Denise P. 719  
 Im-erbsin, Rawiwan 266  
 Imnadze, Paata 199  
 Imrie, Allison 472  
 Inamnuay, Laksanee 266  
 Incardona, Sandra 136  
 Indontri, Bungauang 574  
 Iñiguez, Volga 33, 113  
 Iordanskiy, Sergey 866  
 Iosava, Merab 199  
 Irakoze, Ange 1200  
 Iriemenam, Nnaemeka C. **722**  
 Irwin, Patrick 1057  
 Isaacs, Alison T. **301**  
 Isabel, Elise 688  
 Iserte, Javier 10

Ishengoma, Deus **5**, **950**  
 Ishida, Hiroshi 426  
 Ishikawa, Koichi 667  
 Ishizaka, Sally T. 280  
 Islam, Manoshi 28  
 Islam, M. S. 345  
 Issa, Nebie 158  
 Issiaka, Soulama 158, 720, 1105  
 Itveerakul, Mali 1247  
 Iverson, Jennifer 818  
 Ives, Annette 1342  
 Iwabuchi, Kazuya 699  
 Iwagami, Moritoshi **1271**  
 Izurieta, Ricardo 663

**J**  
 Jaba, Hugo 996  
 Jabbarzadeh, Shirin 194  
 Jacob, Barnor 666  
 Jacobs, Robert 234, 683, 685, 1089  
 Jacobs-Lorena, Marcelo 373, 766  
 Jadhav, Ajit 1282  
 Jafali, James 1316  
 Jahan, Rowan 70, 71  
 Jahrling, Peter 380  
 James, Anthony A. 1124, 301, 305, 311, 770  
 James, Eric 807  
 Jamieson, Sarra 1325  
 Jamjoom, Manal 1095  
 Janes, Joel 948  
 Jang, Won-Jong 820  
 Jannat, Kaniz K. 28  
 Janse, Chris J. 37, 714  
 Jaralla, Ibtehal 80  
 Jaramillo, Luz M. 310  
 Jarman, Richard G. 95  
 Jarnagin, Kurt **228**  
 Jasinskiene, Nijole 301, 305  
 Jasper, Louis 49  
 Jawara, Mussa 307, 776  
 Jayaraman, T **1044**  
 Jean Baptiste, Yaro 720  
 Jeannin, Charles **999**  
 Jeffries, David 46  
 Jegede, Samuel A. 1243  
 Jelicks, Linda A. 1085, 707  
 Jen, Yen-Hua 505  
 Jenkins, Dlorah **359**  
 Jenks, Matthew 683, 685  
 Jensen, Anja T. R. 549  
 Jensen, Bryan C. 1215  
 Jerônimo, Selma M. B. 898, 925, 1325  
 Jerzak, Greta V. S. 1204  
 Jessen, Leon 157  
 Jett, Catherine 380  
 Jha, Aashish 1290  
 Jha, Prabhat 30, 526  
 Jia, Xianli 944  
 Jiang, Bing 987  
 Jiang, Dao-Jun 222  
 Jiang, Jianlin **1112**  
 Jiang, Lubin 128  
 Jiang, Rays H. Y. **429**

Jianrong, Dai 1147  
 Jibunor, Victoria 887  
 Jilani, Md. Abu 70  
 Jilip, Jenarun 55  
 Jima, Daddi 1259  
 Jimba, Masamine 1271  
 Jimenez, Juan 1043  
 Jimenez, Veronica 1344  
 Jiménez, Mónica Marcela 153  
 Jimenez-Diaz, Maria B. 714  
 Jimenez-Diaz, Belen 249  
 Jin, Albert J. 41  
 Jin, Xiannu 1252, **1253**, 255  
 Jirage, Dayadevi 1092  
 Jiya, J 798  
 Joergensen, Louise 549  
 John, Chandy C. 281, 404, 1211, 1289  
 John, Davis 436, 549  
 John, Manohar 855  
 Johnson, Ann-Marie F 18  
 Johnson, Barbara W. 1003  
 Johnson, Casey 51  
 Johnson, Charles A. 401  
 Johnson, Jacob 426, 710  
 Johnson, Joshua C. 381  
 Johnson, Jacob D. 1092, **364**  
 Johnson, Reed 380  
 Johnson, Jr., Warren D. 884  
 Johnston, Geoffrey L. **48**  
 Johnston, Richard B. 23, 26  
 Johnston, Stephanie 556  
 Joice, Regina **947**  
 Jones, David 164  
 Jones, Joel J. 553, 1101, 1248  
 Jones, Jeffrey L. 323, **324**  
 Jones, Malcolm K. 414  
 Jones, R. M. 982  
 Jones, Samantha N. 731, 732, 1098  
 Jones-Engel, Lisa 1113  
 Joseph, Chabi 171  
 Joseph, Hayley **212**  
 Josephine, Obiezu 754  
 Joshi, Manju B. 1084  
 Jou, Shin- Yi 521  
 Jouin, Patrick 181  
 Joyce, Kevin 637  
 Juarez, Diana **344**  
 Jubithana, Marjolein 968  
 Juhn, Jennifer **1124**  
 Julander, Justin G. 51  
 Julian, Timothy R. 27  
 Juliano, Jonathan J. 1108, 842  
 Jullien, Vincent 1101, 1248, 6  
 Juma, Elizabeth 144, 145  
 Jun, Gyo 138  
 Jung, BK 162  
 Jung, Jae-Wan 547  
 Jung, Jaean 559  
 Jung, Suk Chan 681  
 Jung, Yun-Jae 138  
 Jura, Walter G. Z. O. 1289

## K

Kaatano, Godfrey M. 884



The number(s) following author name refers to the abstract number.

- Kaba, Dramane 420  
 Kaba, Stephen A. 1175  
 Kabanda, Alice 1200  
 Kabanywanyi, Abdunoor M. **748**, 954, 955  
 Kabatereine, Narcis 1063  
 Kabeja, Adeline 1200  
 Kabore, Achille 800  
 Kachur, S. Patrick 561, 783, 954, 955, 1251, 1259, 1316  
 Kader Chowdhury, Fazlul 347  
 Kadir, Mohammad A. 1197, 349  
 Kadjo-Adje, H. 1164  
 Kaewsatien, Pradith 574, 627  
 Kagaha, Alexander 29  
 Kaguthi, Grace K. **1128**  
 Kahama-Marro, Judith 52  
 Kahi, Vincet 639  
 Kahle, Kristen M. **513**  
 Kahn, Ashraful I. 484, 896  
 Kahn, Geoffrey D. 316, 317  
 Kahn, Laura H. 530  
 Kain, Kevin C. 117, 118, 123, 424, 541, 542, 544, 849, 939  
 Kakani, Sravan 1165  
 Kakeeto, Stella 1208, 142  
 Kaku, Koki 109  
 Kakuru, Abel 1238, **1319**  
 Kal, A 798  
 Kalanda, Gertrude 1320  
 Kalandadze, Irine 199  
 Kalangayire, Placide 116  
 Kaldas, Rania M. 207  
 Kaligirwa, Nadine 116, 1241  
 Kalilani, Linda **1320**  
 Kalilani-Phiri, Linda 961  
 Källander, Karin **77**  
 Kallestal, Carina 357  
 Kalluvya, Samuel E. 884  
 Kalsy, Anuj 855  
 Kalu, A 1076  
 Kalu, Akpaka 144  
 Kamali, Maryam **302**  
 Kamanga, Aniset 47, 734  
 Kamate, Beh 805  
 Kamau, Edwin **1098, 555**  
 Kamdem, Colince 1293  
 Kamgno, Joseph **1330**  
 Kamtchum Tatuene, Joseph 1330  
 Kanya, Moses 142, 1208, 1238, 1302, 1319  
 Kanashvili, Marine 504  
 Kanayama, Atsuhiko 109, 159  
 Kaneko, Akira **42**  
 Kang, Gagandeep 448  
 Kang, Hyun Min 401  
 Kang, Hae Ji **881**  
 Kang, Seung Won 681  
 Kangwana, Beth B. P. **579**  
 Kankaew, Prasan **191, 203**  
 Kanki, Phylis 1229, 1233  
 Kannan, Arun 448  
 Kano, Shigeyuki 1271, 166  
 Kanost, Michael R. 1186  
 Kanyangalika, Joseph 3  
 Kao, Chuan-Liang 918, 919, 920  
 Kapa, August 1067, 611  
 Kaphiyo, James 637  
 Kapilananda, G M. G. 737  
 Kapito-Tembo, Atupele **1231**  
 Kaplan, Bruce 530  
 Kaplan, Laran 1016  
 Kaplan, Ray 868  
 Kaplinski, Michelle 1216  
 Kappe, Stefan H. 809  
 Karakaya, Fatma 314  
 Karaman, Bulent 1039  
 Karanja, Diana M. S. 885, 1068, 1148, 1234  
 Karanja, Peris 144  
 Karchmer, Adolf W. 498  
 Kareem, Kevin 1168, 1170  
 Karema, Corine 1200  
 Kariuki, Michael 741, 742  
 Kariuki, Simon 781  
 Karkey, Abhilasha 854  
 Karl, Stephan **132**  
 Karlsson, Elinor K. 401  
 Karumuna, Charles 1240  
 Karunaweera, Nadira D. **284, 737, 738**  
 Kasereka, Masumbuko C. **72**  
 Kasinathan, Ravi S. **1227**  
 Kaslow, David 589  
 Kaspar, Naomi 288  
 Kassa, Moges 1259  
 Kassegne, Sethson **31**  
 Kassogué, Yaya 182  
 Kast, Kristopher 309  
 Katarbarwa, Moses 68, 69, 214, 216, 887  
 Katakura, Ken 699  
 Kataraihya, Johannes 5  
 Katebe, Cecilia N. 747  
 Katiti, Dianah **229**  
 Katureebe, Charles 45  
 Kaufman, Michael G. 187  
 Kaufusi, Pakieli 85  
 Kaur, Harparkash **289**  
 Kawai, Vivian 1132  
 Kawathekar, P. W. 196  
 Kayatani, Alexander 1291  
 Kayendeke, Miriam 1302, 1304  
 Kayentao, Kassoum 1320  
 Kayirangwa, Eugenie 1200  
 Kaza, Lakshmi S. 956  
 Kazibwe, Anne J. 1081, 229  
 Kazura, James W. 63, **64**, 66, 226, 611, 1067  
 Keating, Joseph 934  
 Keating, Julie A. **515**  
 Keckler, Mary S. 1168  
 Keh, Chris **1290**  
 Kehn-Hall, Kylene **379**  
 Keita, Adama D. 1332  
 Keita, Adama M. 333  
 Keita, Abdoul S. 1209  
 Keita, Modibo 672, 1065  
 Keita, Moussa 599  
 Keita, Mahamadou M. 1023, **1030**, 1065, 333, 672  
 Keita, Soumaila 672  
 Keitany, Gladys 587  
 Keka Chi, Frederick 976  
 Kelada, Andrew Y. 1084  
 Kelley, James F. **85**  
 Kelly, Jane X. **716**  
 Kelly, Rosmarie 194, 9  
 Kemere, Jordan 129, **580**  
 Kempaiah, Prakasha 1292, 1322, 545, 546, 721, **723**  
 Kendall, Emily A. 896  
 Kengluetcha, Ampornpan - 656  
 Kennedy, Erin D. 211, 885  
 Kennel, Audrey 835  
 Kenney, Joan L. **335**  
 Kenrick, Nwordu 754  
 Kent, Rebekah J. **9**  
 Keogh, Carolyn 200  
 Kern, Peter **1040**, 811  
 Kern, Steven E. **292**, 873  
 Kersh, Gilbert J. 1036, 858  
 Kersten, Marie José 97  
 Kestens, Luc 1234  
 Keven, John Bosco 188, 464  
 Keven, John 611  
 Keven, John K. 173  
 Khaila, Tadala 637  
 Khalid, Hassan S. 718  
 Khalil, Eltahir A. G. 1217, 418  
 Khamag, Haneen 497  
 Khan, Ashraful I. 483  
 Khan, Dawlat 343  
 Khan, Ikhlas 710  
 Khan, Shujaat A. **562**  
 Khan, Shahid M. 37  
 Khan, Shaheed M. 714  
 Khan, Salah U. 345  
 Khan, Wasif A. 473  
 Khatun, Mst. Afsana 71  
 Khemawoot, Phisit 1273, 550  
 Khlainanee, Nittaya 202  
 Khodiev, Aybek 506  
 Khoo, Cynthia C. H. **198**, 305  
 Khoo, Serena 55  
 Khraiwesh, Mozna H. **237**  
 Khush, Ranjiv S. 22  
 Kiang, Richard K. 1134  
 Kibiki, Gibson 480  
 Kiboi, Daniel M. **1258**  
 Kiechel, Jean-Rene 1101, 1248  
 Kightlinger, Lon 609  
 Kigozi, Ruth 1208  
 Kihara, Jimmy 144  
 Kikuchi, Mihoko 724  
 Kilic, Abdullah 208  
 Killeen, Gerry F. 177, 614  
 Kilowoko, Mary 52  
 Kilpatrick, A. Marm **1201**  
 Kim, Dong-Min 635, **1021**  
 Kim, Dal Young 375  
 Kim, HJ 162  
 Kim, Hyeonsuk **559, 952**  
 Kim, Heung-Chul 607, 820  
 Kim, Hani **849**  
 Kim, TY 162  
 Kimani, Maureen 802  
 Kimber, Michael J. 828  
 Kimbi Kuokuo, Helen 976  
 Kimmel, Rhonda 1070  
 Kimura, Mari 759  
 Kinabo, Grace D. 1036, 856, 858  
 King, Chwan-Chuen 392, 914, 918, 919, **920**  
 King, Charles H. 1047, 1066, 1070, 1142, **1165**, 1294, 336, 491  
 King, Christopher L. 1070, 1286, 491, 64, 731, 732, 944  
 King, Jonathan D. 528  
 King, Jonas G. **1184**, 58  
 King, Jennifer P. 113  
 King, Russell 624  
 Kinney, Richard M. 832  
 Kinung'hi, Safari 884  
 Kipar, Anja 1049  
 Kipkeu, Chemtai 264  
 Kiplagat, Samuel 1292  
 Kiplagat, Sammy K. **848**  
 Kirabira, Peter **488**  
 Kirchoff, Louis V. 497  
 Kirk, Kiaran 371  
 Kirkpatrick, Beth D. 508, 834  
 Kirkwood, Betty 77  
 Kironde, Fred 1022, 730  
 Kironui, Viola 749  
 Kisac, Peter 151, 669  
 Kissinger, Jessica C. 954  
 Kitron, Uriel 1055, 1058, 1066, 1070, 1077, 1205, 1294, 187, 194, 200, 390, 391, 619, 910  
 Kiwanuka, Suzanne 490  
 Kiwuwa, Steven 730  
 Kizito, Fred 142  
 Kizito, James 532, 539  
 Kjetland, Eyrun F. **407**  
 Kjos, Sonia 1074  
 Klarmann, Ute **1328**, 1331  
 Kleim, Jörg-Peter 711  
 Klein, Harvey G. 53  
 Klein, Jennifer H. 1174  
 Klein, Terry A. 607, **820**  
 Kleinschmidt, Immo 1317, **297**, 534, 745  
 Kline, Daniel **600**  
 Klinger, Jeffrey D. 267, 714  
 Klion, Amy 1330, 1332, 432, 53  
 Kloos, Helmut 1152, 1155  
 Kloos, Zachary A. 66, **226**  
 Klungthong, Chonticha **95**  
 Knap, Nataša 1167  
 Knapp, Elisabeth 1220, 684, **691**  
 Knobel, Darryn 818  
 Knox, Tessa B. 600, 924, 992  
 Ko, Albert I. 1031, 409, 857, 894, 899  
 Koama, Jean B. 1200  
 Kobayashi, Tamaki 1213, 130, 47  
 Kobylinski, Kevin C. **459**  
 Koch, Matthew A. 7  
 Kochar, Dhanpat K. 1262, 430, 739  
 Kochar, Sanjay K. 430, 1262  
 Kochel, Tadeusz J. 92, 94, 340, 341, 342, 344, 391, 622, 910, 1133  
 Kodio, Aly 1100  
 Koenker, Hannah **296**  
 Koewsathit, Jittasak 627  
 Kogelman, Laura **498**  
 Kohar, Henry 553  
 Koimbu, Gussy 611

The number(s) following author name refers to the abstract number.

- Koita, Ousmane A. **934**, 935  
 Kokku, Premalatha 682  
 Kolaczinski, Jan 1063  
 Kolling, Glynis 643  
 Komar, Nicholas 1003  
 Komcharoen, Srawuth 266  
 Komisar, Jack 1173, 807, 808  
 Konare, Moussa 750  
 Konaté, Amadou T. 147, 571, 728  
 Konaté, Drissa 121, 563, **845**,  
**1209**  
 Konaté, L 272  
 Konate, Lassana 307, 616  
 Konate, Siaka 1332, **209**, 432  
 Konde-Lule, Joseph 417  
 Kone, Abdoulaye K. 161, 590, 847  
 Kone, Massiriba 599  
 Kone, Mamady 805  
 Koné, Nouhoum 111  
 Konovalova, Svetlana V. 165, 583  
 Konradsen, Flemming 737  
 Koo, Tae-Hee 559  
 Kopydlowski, Karen M. 364, 431  
 Koram, Kwadwo A. 1264, 735,  
 945, 1025  
 Korir, Cindy C. 1110, 1111  
 Korkusol, Achareeya **202**  
 Kortepeter, Mark G. **381**  
 Koru, Ozgur 1039, 208, **314**, 315  
 Korva, Misa **1167**  
 Kosacz, Nicole **1333**  
 Kosasih, Herman 14  
 Kosoy, Michael **818**  
 Kotloff, Karen 107, 111, 333, 852  
 Kotova, Svetlana 41  
 Koukounari, Artemis 886  
 koura, Ghislain K. **501**  
 Kouriba, Bouréma 161, 590, 847  
 Kourouma, Nana 333  
 Kovacs, Michael 432  
 Kovzun, Kuzma V. 1283  
 Kozar, Michael P. 1252, 1253, 245,  
 251, 252, 253, 255, 256, 265,  
 266, 270, 364, 715  
 Kraemer, Thomas 691  
 Kraft, Shannon M. **358**  
 Kraiselburd, Edmundo N. 514  
 Kramer, Laura D. 778, 1201, 1202,  
 1204  
 Kramer, Martin **1083**, 267  
 Krasaesub, Somporn 398  
 Krastins, Bryan 855  
 Kratzer, Wolfgang 1040  
 Krause, Darren 841  
 Krause, Michael A. 121, 845  
 Krcmery, Vladimir **151**, **669**  
 Krebs, Bethany 1006, 1058, 187  
 Kreishman-Deitrick, Mara 49  
 Kremer, Michael 361  
 Krespo-Llado, Keila N. 714  
 Krezanoski, Paul J. **299**  
 Krief, Sabrina 1113  
 Krieger, Marco A. 1052  
 Kristensen, Thomas K. 888, 889  
 Krochmann, Niels P. 1040  
 Kroenraad, Constantianus J. M.  
 1007  
 Krogstad, Donald J. 934, **935**  
 Kronmann, Karl 1025, 1164, 632,  
 883, 971  
 Kropf, Christian 450  
 Krudsood, Srivicha 1271, 366  
 Kruglov, Oleg 633  
 Kuaban, Christopher 1330  
 Kuan, Guillermina 100, 469  
 Kubofcik, Joseph **1329**  
 Kuchta, Alison L. **483**  
 Kuchuloria, Tinatin **504**  
 Kudva, Indira T. 855  
 Kudzala, Amose 25  
 Kuhn, Walter (Ted) **1306**  
 Kukutla, Phanidhar 1296, **763**  
 Kumar, Mukesh 1059  
 Kumar, N P. 213  
 Kumar, Rajesh 30, 526  
 Kumar, Sanjai 425  
 Kumar, Sanjeev 861  
 Kumaraswami, V 213  
 Kumari, P 235  
 Kumwenda, Taida 1097  
 Kuntawunginn, Worachet 1273  
 Kuras, Annerose H. 21  
 Kurewa, Edith Nyaradzai 407  
 Kurosu, Takeshi 1312  
 Kurtis, Jonathan D. 846  
 Kusriastuti, Rita 146  
 Küster, Tatiana 1041, 815  
 Kuttasingkee, Narupon 574, 627  
 Kuwahata, Melissa 250  
 Kuyenda, Redson 961  
 Kwakye-Nuako, Godwin **1095**  
 Kwara, Awewura 674  
 Kwarteng, Alexander 1331  
 Kweka, Eliningaya J. **178**, **1295**  
 Kweon, Chang Hee 681  
 Kyabayinza, Daniel 244, 1315  
 Kydyrbayev, Zhailaubay **1160**  
 Kyebambe, Peterson S. **1029**  
 Kyelem, Dominique 1334, 65, 799,  
 801, **802**  
 Kyle, Dennis E. 238, 1099  
 Kyorku, Charles A. 1010  
 Kyungu, Ester 52  
 Lambrechts, Louis **20**  
 Lameyre, Valerie 403  
 Lamine, Diakite M. 893  
 Lammie, Patrick 212, 382, 65, 799  
 Lamphier, Marc 280  
 Lanar, David E. 1175, 1288, 161,  
 590  
 Lanata, Claudio F. 1305, 485, 645  
 Lanciotti, Robert S. 1011  
 Landela, Ange L. 665  
 Lander, Eric 401  
 Landry, Losi 250  
 Lane, Michael A. 406  
 Lang, Jean 470, 510, 835, 836, **96**  
 Lang, Stefanie 320  
 Lang, Song 456  
 Langbong, Bimi 735  
 Langsley, Gordon 434  
 Lankowski, Alexander **695**  
 Lanteri, Charlotte 1252, 248, 266,  
 252, 715  
 Lantoss, George 795  
 Lantova, Lucie 60  
 Lanzaro, Gregory C. 697, 859  
 Lanzavecchia, Antonio 471, 99  
 Laouini, Dhafer **701**, 702  
 Lapiere, Bruno 598  
 Lapierre, Didier 582  
 Lapp, Stacey **1111**  
 Larbi, John 271  
 Largier, John 926  
 Larocque, Renee 1193  
 LaRocque, Regina C. 855, 896  
 Larrieu, Edmundo 813  
 Larson, David **1191**, 383, 388  
 Larson, Peter S. **756**  
 Lartey, Margaret 674  
 Laserson, Kayla 1128, 353, 781,  
 852  
 Latthiwongsakorn, Napaporn 95  
 Laufer, Miriam K. 3, 960, 961,  
 1274  
 Laurens, Matthew B. 161, **590**,  
 803, 807, 847  
 Laurissaint, Yves 1333  
 Lavsten, Thomas 436  
 Lavtsen, Thomas 549  
 Lawler, James V. 381  
 Lawrie, Alison M. 160, 804  
 Lazaga, Nelson I. B. 1059  
 Le, Bich Lien 468  
 Le Mire, Jacques 872  
 Le Port, Agnès 278  
 Le Thi Phuong, Tu 1323  
 Leach, Amanda 582, 803  
 Lebowitz, Jacob 41  
 Lee, Cynthia K. 51  
 Lee, Clarence M. 1225, 237  
 Lee, Dong-Kyu 607  
 Lee, Doris 688  
 Lee, JJ 162  
 Lee, Seung-Hyun 1021  
 Lee, Stephanie 1069  
 Lee, Susan Shin-Jung 499  
 Lee, Serej D. 1260  
 Lee, Yoosook 859  
 Lee-Stroka, Agnes 1060  
 Leed, Susan E. **1092**  
 Leemingsawat, Somjai 203  
 Leenders, Anne 1115  
 Legrand, Anne-Marie 21  
 Lehane, Adele M. **371**  
 Lehman, Leopold Gustave **976**  
 Lehmann, Tovi 1299, 182  
 Leimanis, Mara 1250  
 Leitner, Elke 1173  
 Leitner, Wolfgang W. 585  
 Lejano, Jennlynn 806, 985  
 Lek, Dysoley 1266, 155  
 Leke, Rose F. 726  
 Lemieux, George 228  
 Lemieux, Jacob 38  
 Lemnge, Martha 5, 436, 549, 576,  
 937, 950  
 Lengeler, Christian 52, 748  
 Lenhart, Audrey **461**  
 Lennon, Niall 524, 1309  
 Leon, Juan S. 33, 113  
 Leon, Leonor Laura P. **239**  
 Leon, Renato 1279  
 LeRoux, Michelle 1261  
 Lescano, Andres G. 316, 317, 32,  
 903, 943  
 Letson, G. William 520  
 Letson, William G. 915  
 Levin, Michael 819  
 Levin, Mariano J. 1074  
 Levine, David 348  
 Levine, Gail 972  
 Levine, Mikaela 714  
 Levine, Myron M. 107, 333  
 Levine, Mike M. 852  
 Levy, Karen **363**  
 Levy, Michael Z. 1091, 1216  
 Lewis, Fred A. 1223  
 Lewis, Robbyn 834  
 Ley, Bettina 979  
 Li, Ben-Wen **222**  
 Li, Fengwu 301  
 Li, Hongwei 1126  
 Li, Jun **303**  
 Li, Lin 825  
 Li, Ming 807  
 Li, Minglin 987, 988  
 Li, Qianjun **1171**  
 Li, Quiqui 252, 253  
 Li, Qiqui 245, 256, 716  
 Li, Shan 896  
 Li, Tao 769, 773, 988  
 Li, Tiger ZR **918**  
 Li, Ting 990  
 Li, Yuexin 716  
 Li, ZY Tiger 920  
 Li, Zheng-Rong T. 919  
 Liang, YanMei 1148, 786  
 Libaud, Anaëlle 905  
 Libraty, Daniel H. 837  
 Liebman, Kelly A. **622**  
 Lien, Vu T. K. 1139  
 Lievens, Marc 582  
 Ligaajju, Allan 730  
 Ligon, Grant 444  
 Likaka, Andrew 637  
 Liles, Conrad 117, 118, 544  
 Liley, Ken 841  
 Lillie, Patrick J. 160, 804

The number(s) following author name refers to the abstract number.

- Lim, Pei-Yin **1207**  
 Lima, Aldo A. M. 1321, **641**, 642, 643, 646, **647**, 648, 1235  
 Lima, Helena C. A. V. 894  
 Lima, Ila F. N. **646**, 647  
 Lima, Noélia L. 641, 646  
 Lima, Patrícia M. 1045  
 Lima Junior, Josué C. 283  
 Lima Neto, Jones B. **648**  
 Limbach, Keith 583, 740, 806, 984  
 Limkittikul, Kriengsak 470  
 Limpawattana, Panita 1131  
 Lin, Ai J. 253, 256, 266, 270  
 Lin, Clara 1107  
 Lin, C.D. 393  
 Lin, Hung-Mo 152  
 Lin, Hsiu-Pin 918, 920  
 Lin, Jessica 550, 1108, 1247  
 Lin, Jin-wen 714  
 Lin, Michael 129  
 Lin, Ta-Chun 521  
 Lin, Yahui 548  
 Linares, Olinto 292  
 Lindblade, Kim 1163  
 Lindegardh, Niklas 1250, 6  
 Lindergard, Gabriella 743  
 Lindow, Janet C. **508**  
 Lindsay, Steve 46  
 Lindsey, Michael 777  
 Linehan, Mary 800, 801  
 Lisboa, Luciana 1152  
 Liu, Chung-Ming 392  
 Liu, Canhui 826, 868  
 Liu, Hanlan 714  
 Liu, Jie 480  
 Liu, Jing 825  
 Liu, Liang 249  
 Liu, Nannan **990**  
 Liu, Shi Fan 1223  
 Liu, Xianjun 256  
 Livengood, Jill 907  
 Lizak, Martin 791  
 Llanos-Cuentas, Alejandro 231, 689, 690, 703, 974  
 Lluque, Angela M. **644**  
 Lo, Yeung Y. **726**  
 Lobo, Neil 614  
 Lobo, Rômulo R. 519  
 Lockman, Shahin 962  
 Lograsso, Joe 587  
 Logue, Christopher 10  
 Logue, Christopher H. 878  
 Logvinenko, Tanya 855  
 Loharikar, Anagha **25**  
 Loiseau, Claire 1114  
 Lok, James B. 1189  
 Loker, Eric S. 453, 455, 787  
 Lokomba, Vicky 7  
 Lokossou, Adjimon Gatiem **278**  
 Lon, Chanthap 1247, 1273, 550  
 London, Alicia 22  
 Londono, Berlin L. 1308, **18**  
 Long, Carol A. 121, 160, 584, 804, 805, 806, 845, 1178,  
 Long, Kacey 344  
 Long, Kanya C. **1019**  
 Long, Yong 156  
 Loo, Jennifer 1196  
 Lopansri, Bert K. 850  
 Lopera-Mesa, Tatiana M. 121, 543, 845, 1178  
 Lopez, Adriana S. 323, 324  
 Lopez, Beatriz 1163  
 López, Catalina 153  
 Lopez, Giovanni 337, **660**  
 Lopez, Victor 996  
 Lord, Cynthia C. 195  
 Lorenzi, Olga D. 466, 496  
 Loria-Cervera, Ely N. 1218  
 Loroño-Pino, María Alba 620  
 Losoya, Arturo 620  
 Lotharius, Julie 269  
 Louis, David 763  
 Loukas, Alex 414  
 Loumedjinon, Franck 278  
 LoVerde, Philip T. 1228  
 Lovin, Diane D. 304  
 Lovings, Kenyetta 536  
 Lowell, Jennifer L. **1011**  
 Lowrance, David 1200  
 Lowther, Sara A. 637  
 Lozano-Fuentes, Saul 620  
 Lu, Yanhui 1242  
 Lu, Ziyue 424  
 lube-Becker, Antina 634  
 Lubega, George W. 1220, 220, 684, 691  
 Luby, Stephen P. 23, 26, 28, 34, 343, 345, 347, 348, 349, 350, 351, 1197  
 Lucas, Bob 589  
 Lucas, Carmen 1116, 400  
 Lucas, David 829  
 Lucchi, Naomi 1255  
 Lucchi, Naomi W. 954, **955**  
 Luckey, Marla 363  
 Luckhart, Shirley 1004, 1005, 1183, 119, 310, 758, 859  
 Ludwig, Albrecht 855  
 Lugo de Yarbuh, Ana 692, 1079  
 Luka, Madalitso 1316  
 Luke, Catherine 834  
 Lukens, Amanda K. 401, 1261  
 Lukhnova, Larissa **193**  
 Lumsden, Joanne M. **1174**  
 Lund, Ole 157  
 Lungu, Rudia 637  
 Lunjwire, Kwibuka J. 72  
 Luo, Y-h 810  
 Luong, ThuLan 1252, 1253, 255, **256**  
 Luoto, Jill 348  
 Luplertlop, Natthanej 181  
 Lushbaugh, William B. 330  
 Lusingu, John 285, 436, 549, 576, 937  
 Lustigman, Sara 1284, **825**  
 Lutterloh, Emily C. **637**  
 Luty, Adrian J.F. 276, 285, 436, 779  
 Luxemburger, Christine 470  
 Luy, Betty 1311  
 Lwamafa, D K W 68  
 Lwanira, Catherine **730**  
 Lwin, Khin Maung 1250  
 Lwitiho, Sudi 950  
 Lydy, Shari **819**  
 Lyimo, Issa **1298**  
 Lyke, Kirsten E. **1288**, 161, 590, 807, 985  
 Lynch, Matthew 296  
 Lynch, Michele M. 983  
 Lyon, Matthew 1306  
 Lyons, Arthur 90
- ## M
- Ma, Gordon 55  
 Mabey, David 533  
 Macalalad, Alexander 1309  
 MacDonald, Nicholas 163, 437, 871  
 Mace, Kimberly E. **1316**  
 Macedo, Julio O. 1033  
 Macedo De Oliveira, Alexandre 400  
 Machado, Eleuza R. 658  
 Machevo, Sonia 264  
 Machicado, Jorge 1072, **1073**  
 Machunda, Ester B. 979  
 Maciel, Jamilly G. 1235  
 Mackay, Andrew J. **594**, 595  
 Mackenzie, Charles 216, 382, 830  
 Mackinnon, Margaret 145  
 MacNeil, Adam 339  
 Maco, Vicente **61**  
 Madanitsa, Mwayi 961  
 Madden, Gregory 327  
 Madebe, Rashid 5, 950  
 Madhubala, Rentala 1088  
 Madi, Kambaba 214  
 Madrid, Elise 791, **792**  
 Mady, Rasha 1150  
 Madyarov, Ruslan 506  
 Maes, Ilse 703  
 Maeser, Pascal 686  
 Maestre, Ronald Y. **174**, 998, 1032  
 Mafuyai, H 798  
 Magak, Gideon N. 281, 1289  
 Magalhaes, Belisa L. 141  
 Magambo, Japheth K. 224  
 Magill, Alan 49, 266, 270, 365, 368, 426, 710, 1249  
 Magistrado, Pamela 436, 549, 576, 937  
 Magloire, Roc 783  
 Magnussen, P 312  
 Magtanong, Ruth **930**  
 Mahabir, Ron S. **17**, 190  
 Mahajan, Sahil 1127  
 Mahamud, Abdirahman **639**  
 Mahanty, Siddhartha **1046**, 432, **791**, 792  
 Mahapatra, Lily 387  
 Maher, Steven P. 370, 39  
 Maheswaram, Pavan 956  
 Mahmoud, Eiman 1157  
 Mahmoud, Hanaa M. 626  
 Mahmud, Minhaj 348  
 Mai, Absalom 611  
 Mai, Le Q. 1139  
 Maiava, Fuatai 212  
 Maiden, Martin 1023  
 Maier, Alex 581  
 Maier, Alexander G. 1177  
 Maiga, Amadou 672  
 Maiga, Hamma 1100  
 Mailu, Boniface M. **396**  
 Maiotelesi, Santina 492  
 Maire, Nicolas 577  
 Maiteki-Sebuguzi, Catherine 1302, 148  
 Maizels, Rick M. 415  
 Majajan, Babita 425  
 Majam, Victoria 425  
 Majda, Laboudi **205**  
 Makanani, Bonus 961  
 Makanga, Michael 292, 293, 873  
 Makhviladze, Manana 504  
 Makkiya, Adil **1035**  
 Makoutode, Patrick 83  
 Makowski, Kai 880  
 Maksoud, Mohamed Abdel 504  
 Malagón, David 657  
 Malambo, Dacia I. 998, 1032  
 Malecela, Ezekiel 5  
 Malenga, Albert 961  
 Maleo, Josephine 670  
 Malhotra, Indu 1070, **1286**, 491  
 Malila, Aggrey 748  
 Malone, Joseph 1259  
 Malone, Patrick 972  
 Maloney, David J. 1282  
 Maloney, James 212  
 Malvestio, Lygia M. M. 1085, **706**, **707**  
 Mamadou, Diallo **668**  
 Mamadou, Tekete 1268  
 Mamatkulov, Adkham 506  
 Mamun, Md. Al 347  
 Mamuya, Simon 27  
 Man, Wing Y. N. 886  
 Manage, Dammika 1265  
 Mancini, Emiliano **1182**  
 Mand, Sabine 1328, 1331  
 Manda, Hortance **623**, 996  
 Manda, Robert 637  
 Mandal, Swati **1088**  
 Mandike, Renata 1017, 5  
 Mandoko, Alain N. 665  
 Mann, Victoria H. 1225, 866  
 Mannila, Ann 715  
 Manoncourt, Serge 1164  
 Manong, Doris 4  
 Manoukis, Nicholas C. **1299**, 599  
 Manque, Patricio 329  
 Mansour, Adel 895  
 Mantel, Nathalie **12**, 510  
 Mantilla, Gilma 153  
 Mappingure, Munyaradzi P. 1230  
 Mapua, Cynthia 1312  
 Maranich, Ashley M. **1037**  
 Marcos, Luis A. **1072**, 1073  
 Marfo-Debrekyei, Yeboah 1331  
 Margolis, Harold 520  
 Margolis, Harold S. 915  
 Mariama, Charrif 720  
 Marie, Jérôme 21, **995**, 999  
 Marimoutou, Catherine **376**, **891**  
 Marin, Juan C. 1005  
 Marini, Francesca **618**  
 Marinotti, Osvaldo 1124, 311, 770  
 Markianos, Kyriacos 864



The number(s) following author name refers to the abstract number.

- Markus, Miles B. **125**  
 Maro, Athanasia 480  
 Maro, Venance P. 1036, 856, 858  
 Márquez-Navarro, Adrián 236  
 Marquino, Wilmer 400  
 Marra, A. 1214  
 Marrast, Anne Claire 292, 293, 367  
 Marsh, Kevin 1177, 38  
 Marshall, John M. **596, 764**  
 Marshall, Laura N. **1157**  
 Marston, Barbara 24  
 Marti, Jacques 702  
 Marti, Matthias 429, 947  
 Martijn, Martijn 666  
 Martin, Akogbeto 171  
 Martin, Akogbeto C. **591**  
 Martin, Diana **1216**  
 Martin, John 1187  
 Martin, Laura 1132, 164, 584  
 Martin, Nicholas 623  
 Martinez, Criseyda **1114**  
 Martinez, Melween 514  
 Martínez, Mara 814  
 Martínez, Ruth 900  
 Martínez-Gutierrez, Marlen 908  
 Martinson, Jeremy 1322  
 Martyak, Timothy 833  
 Marwaha, Alka 476  
 Marzal, Miguel 1046  
 Mashao, Mmbangiseni 443  
 Mason, Carl J. **481, 482, 506**  
 Masonga, Rhoda 3  
 Massawe, Lydia 576  
 Massé, Frédéric 688  
 Masseno, Victor 38  
 Masserigne, Soumaré 1232  
 Massougbodji, Achille 154, 274, 276, 285, 495, 902  
 Massung, Robert F. 1036, 858  
 Mastrobuoni, Guido 1117  
 Masuku, Humphreys 25  
 Masuoka, Penny M. **607**  
 Mata, Carlos 821  
 Mathanga, Don P. 3, 753, 756, 1316  
 Mather, Frances J. 1080  
 Mathias, Abraham 297  
 Mathieu, Els 1069, 1071, 67  
 Mathisen, Glenn E. **897**  
 Mathison, Blaine A. **556, 1043**  
 Mathur, Geetika **311**  
 Matias, Abraham 776  
 Matindii, Atua 570, 578, 963  
 Matoso, Leonardo F. **1152, 1155**  
 Matovu, Enock **1081, 229**  
 Matrevi, Sena A. **1264**  
 Matthews, Jacqueline 1221  
 Matthews, Keith 1221  
 Mattia, Kimberly-Anne 513, **523**  
 Matton, Priscilla 192  
 Matute, Juan Carlos 469  
 Maude, Richard J. **1267, 54, 851**  
 Maue, Alexander 729, 1289  
 Mauro, Marino 717  
 Maves, Ryan C. 486, **903**  
 Mawejje, Henry 1315  
 Mawindo, Patricia 961  
 Maximillan, Mpina 979  
 Mayé, Ambroisine 495  
 Mayer, Sandra V. 1310, 89  
 Maynard, Sean K. 788  
 Mays, Gary 893  
 Mazonett, Enrique 1032  
 Mazet, Jonna A. K. 926  
 Mazinda, Charles S. 1101, 1248  
 Mbagala, Thabiti A. 979  
 Mbehela, Edgar 1298  
 Mbina, Kasian 1298  
 Mbonye, Martin **928**  
 Mboup, Souleymane 1261, 277, 401, 402  
 Mbwau, Moses 151  
 McAlister, David 1200  
 McBride, Alan J. 899, 1033  
 McBride, Flávia 899, 1033  
 McCall, Philip 461  
 McCallum, Fiona 1177  
 McCalmont, William 245, 252, 712, 715  
 McCarthy, James 569  
 McCarthy, James S. **250, 962**  
 McCartney-Melstad, Anna 296  
 McCauley, John 883  
 McClellan, Holly 163  
 McClintock, Shannon **1327, 212**  
 McCollum, Andrea M. 400, **408**  
 McCoy, Andrea 945, **1173**  
 McCoy, Margaret E. 1175  
 McCutchan, Thomas 425  
 McDonald, Alina 535  
 McDonald, Chloe E. R. **939**  
 McDowell, Erin 1168  
 McElligott, James T. **356**  
 McElnea, Catriona 91  
 McElroy, Kate L. 524  
 McElroy, Peter 1017, 288  
 McFarland, Deborah 797  
 McGrath, Shannon 583, 806  
 McGready, Rose 727  
 McHenry, Amy 731  
 Mchomvu, Frances 850  
 McKerrow, James H. 228, 232  
 McLaws, Mary-Louise 886  
 McLennan, John D. 104, 114, **352, 531**  
 McMahan, Ku L. **346**  
 McManus, Donald P. 413, 414  
 McMorrow, Meredith 783  
 McNair, Nina 332  
 McNeal, Monica 1198  
 McNulty, Samantha N. **827**  
 McWilliam, Hamish 414  
 Mduluza, Takafira 407, 415  
 Mead, Daniel G. 9, 1091, 194  
 Mead, Jan R. **332**  
 Meade, John C. 330  
 Medeiros, Marco A. 899  
 Medina Blasini, Yiraima E. 466  
 Meek, Sylvia 155, 77  
 Meeks, Janet 472  
 Mehlotra, Rajeev K. 66, 226  
 Mehta, Anand 940  
 Mehta, Sanjay 50  
 Meibalan, Elamaran **940**  
 Meister, Stephan 372  
 Mejia, Guy **1032**  
 Mejia, Rojelio **53**  
 Mejía-Jaramillo, Ana M. 1074  
 Melaku, Zenebe 1259  
 Melby, Peter C. 687  
 Melendez, Victor 1252, 1253, 248, 251, 253, 255, 256, 715, 716  
 Meleshkevitch, Ella **1119, 863**  
 Melim, Dayana 904  
 Mellon, Christophe 688  
 Melnikov, Alex 402  
 Melnikow, Elena **1284, 825**  
 Melo, Maria N. 1078  
 Melrose, Wayne **1064, 212**  
 Meltzer, Martin I. 913  
 Membe, Gladys 961  
 Mena, Leandro 330  
 Meñaça, Arantza **568**  
 Ménard, Robert 372  
 Mende, Katrin **1034, 1037**  
 Mendez, Juan **694**  
 Mendonça, Patrícia R. 519  
 Menéndez, Clara 264  
 Meneses, Claudio 697  
 Menezes, Colin N. 811  
 Menezes, Gisele B. L. 1052  
 Meng, Liu 668  
 Meng, Zhaojing 829  
 Menon, Jayaram 55  
 Menon, Manoj 1208, 25, 45, 965, 969  
 Mens, Petra F. 116, 1241  
 Mensah-Attipoe, Israel 1095  
 Menten, Joris 495  
 Menzies, Holly 1064  
 Mercado, Erik 485, 644  
 Mercado, Juan Carlos 469  
 Mercer, David R. 21, 995  
 Mercer, Luke T. 234, 683, 1089  
 Merquior, Vânia L. C. 1028  
 Merritt, Ethan A. 1283  
 Merritt, Richard 1327  
 Mert, Gurkan **1039**  
 Meshnick, Steven R. 550, 570, 578, 676, 7, 842, 962, 963, 1108, 1231, 1320,  
 Messer, William **471**  
 Messina, Jane 578, **963**  
 Mestra, Alberto 636  
 Metelo, E 665  
 Metenou, Simon **432**  
 Méthot, Nathalie 688  
 Mett, Vadim 982  
 Metta, Emmy 1251  
 Metzler, Ryan 1119  
 Meyer, Derek 664  
 Meyer, Esmeralda V. 1110, 1112  
 Meyer, Joel 160  
 Meyer, Michelle 91  
 Meymandi, Sheba K. 497, 892  
 Mguta, Charles 884  
 Mharakurwa, Sungano **1097, 1213, 130, 300, 47, 475, 734**  
 Miao, Miao **1269, 744**  
 Miao, Qianqian (Doreen) **1094**  
 Michael, Edwin 63, 796  
 Michael, Obaro S. 1245, **2, 746**  
 Michel, Kristin **1186, 773**  
 Michelli, Elvia 904  
 Michelucci, Elena 1117  
 Middha, Sheetal 430  
 Midega, Ernest **662**  
 Midekisa, Alemayehu 1104  
 Midzi, Nicholas 407, 415  
 Migot-Nabias, Florence 278  
 Miguel, Edward 361  
 Mihaylova, Borislava 1267  
 Mikolon, Andrea B. 345  
 Milbrath, Meghan **87**  
 Millhous, Wilbur K. 365, 1099  
 Miller, Ann K. **711**  
 Miller, Barry 9  
 Miller, Cathy L. 8  
 Miller, David A. 690  
 Miller, Louis H. 41, 128, 164, 437, 584, 805, 871, 893  
 Miller, Woutrina A. 926  
 Millet, Pascal **905**  
 Milligan, P.J.M. 1214  
 Millimono, Edouard 902  
 Mills, Jaquie 367  
 Milner, Danny A. 230, 401, 402, 934, 947  
 Milner, Erin 252, 715  
 Miltien, Julie 111  
 Mingle, Julius A. A. 666  
 Minja, Daniel 285, 436, 576, 937  
 Minning, Todd A. **1096**  
 Mintz, Eric 442, 637, 852  
 Miri, Emmanuel 69, 1156, 754, 797, 798, 887  
 Misse, Dorothé 168, 181  
 Mita-Mendoza, Neida K. 434  
 Mitchel, Ellen 1128  
 Mitchell, Katrina B. 884  
 Mitchell, Robert 589  
 Mitchell, Sara N. **462**  
 Mitre, Edward 1191, 383, 388, 529  
 Mitreva, Makedonka **1187, 222, 827**  
 Mittelholzer, Christian 1175  
 Miura, Kazutoyo **1178, 164, 584, 804, 805, 845**  
 Miura, Toyokazu 942  
 Mixson-Hayden, Tonya 400  
 Miyahira, Yasushi **109, 159**  
 Mizuno, Yasutaka **527**  
 Mkannez, Ghada 701  
 Mkoji, Gerald M. 411  
 Mkulama, Mtawa 1097  
 Mnzava, Ally 288  
 Moch, J. Kathleen 128, 428, 431  
 Modabber, Farrokh 235  
 Moe, Christine L. 1192, 355, 438  
 Moehrl, Joerg J. **1244**  
 Mogi, Motoyoshi 778  
 Mohamed, Khadeeja 711  
 Mohamed, Rhajaoui 205  
 Mohammed, Yousif G. 718  
 Mohan, Manisha 228  
 Mohan, V 213  
 Moktar, Norhayati 318  
 Molaei, Goudarz **192, 197**  
 Molestina, Robert E. **326**  
 Molina, Adriana María 153  
 Molina-Cruz, Alvaro **861**  
 Mollik, Md. Ariful Haque **70, 71**

The number(s) following author name refers to the abstract number.

- Mollura, Daniel 380  
 Molteni, Fabrizio 1017  
 Molyneux, David 1065  
 Molyneux, Malcolm E. 541, 842  
 Monath, Thomas P. **51**, 530  
 Moncayo, Abelardo 655, 817  
 Mondal, Utpal K. 343  
 Moneti, Gloriano 1117  
 Mongkolsirichaikul, Duangrat 1049  
 Monkanna, Taweesak 202, 656  
 Monney, Thierry 451  
 Monroe, Steve 637  
 Montarsi, Fabrizio 618  
 Monteiro, Glória M. G. 1325  
 Monteiro, Gloria R. Monteiro R. G. **898**  
 Monteiro, Manuel C. S. A. 647  
 Monteiro da Silva, Beatriz N. 1028  
 Montes, Martín 660  
 Montgomery, Brian 390  
 Montgomery, Jacqui 947  
 Montgomery, Joel M. 1136, 1138, 316, 317, 32  
 Montgomery, Susan P. 1068, 885  
 Montgomery, Walter 192  
 Monti, Diego 719  
 Montip, Gettayacamin 712  
 Moon, Jennifer 49, 1162  
 Moon, Jay 252, 715  
 Moonen, Bruno 785  
 Moono, Petros 47  
 Moore, Joseph 234  
 Moore, Julia L. **458**  
 Moore, Sarah J. 177  
 Moore, Sean R. **1321**, 647  
 Moormann, Ann M. 725  
 Moorthy, Vasee 492  
 Mora, Gustavo 1032  
 Mora, Leonor 321  
 Morahan, Belinda 947  
 Moraes, Jaqueline M. 1028  
 Morales, Francisco J. **1279**  
 Morales, Maria Luisa 1136  
 Morales-Betoulle, Maria E. 512, 1003  
 Moran, Mary **535**  
 Morand, Serge 1000  
 Morassutti, Alessandra L. **659**  
 Morelos, Jorge 1032  
 Moreno, Elio A. 692, 693, 1079  
 Moreno, Elizabeth C. **1078**  
 Moreno, Yovany **830**  
 Moreno-Molek, Susan 956  
 Mores, Christopher N. 18, 1053, 1172, 1308, 909  
 Moretz, Samuel E. 1178  
 Morgado, Fernanda N. 502  
 Morgan, Douglas R. 357  
 Morgan, Marjorie S. 631  
 Morgan, William M. 1227  
 Mori, Akio 304  
 Morin, Merribeth 51  
 Morkowski, Stan 1162, 49  
 Morlais, Isabelle 1297, 564, 875  
 Morris, Carrie **7**  
 Morris, Joel A. **608**  
 Morris, Shaun K. **30**, **526**  
 Morrison, Amy C. 1001, 391, 622, 625, 910, 996  
 Morrissey, Anne B. 856, 858, 1036  
 Mosher, Aryc W. 601, 754  
 Mosi, Lydia 1326  
 Mosites, Emily 817  
 Mosquito, Susan G. 644  
 Moss, William J. 1198, 1213, 130, 47  
 Mossbrugger, Ilona 489  
 Mossel, Eric C. **878**  
 Mostafa, Manal **895**  
 Mota, Rosa R. M. S. 646  
 Mott, Glenn A. **1221**  
 Mouchet, François 168, 181  
 Moudy, Robin M. **1202**  
 Mount, Howard T. 939  
 Moura, Hercules 1045  
 Moussiliou, Azizath 274  
 Mpakiza, Ashley C. 843  
 Mpasela, Felton 1317  
 Mpeka, Betty 1315  
 Mpuruti, Juma 979  
 Muchiri, Eric M. 491, 1066, 1286, 1294  
 Mudeppa, Devaraja 396  
 Mudhune, Sandra A. **145**  
 Muehlenbachs, Atis **126**, **127**  
 Mueller, Ellen 383, 388  
 Mueller, Ivo 1260, 4, 464, 611, 839  
 Mues, Katherine **211**  
 Mugasa, Joseph **554**  
 Mugisha, Rwenyonyi 1022  
 Mugittu, Kefas 1109  
 Muhimpundu, Marie Aimée 1200  
 Muhindo, Bosco 639  
 Muiruri, Alice 843  
 Mujica, G 813  
 Mujizi, Rukaaka 1315  
 Mukabayire, Odette 1200  
 Mukanga, David 488  
 Mukasa, Mark K. 730  
 Mukemba, Jackson P. **850**  
 Mukherjee, Bhramar 354  
 Mukhtar, Moawia M. 418  
 Mulamba, Seraphin M. **287**  
 Mulenga, Musapa 1213, 757, 870  
 Muli, John M. 151  
 Muliylil, J 1044  
 Mull, Bonnie **360**  
 Müller, Fredrik 1230  
 Muller, Ivo 1176  
 Müller, Joachim 1041, 815  
 Muller, Kerstin 1217  
 Müller, Maria L. 1003  
 Muller, Pie 462  
 Mundal, Kirk D. **994**, **996**  
 Mungai, Peter 1066, 1286, 1294, 491  
 Muniz, Andre 679  
 Munoz, Benito 267  
 Munoz, Beatriz 296  
 Munoz, Jorge 389  
 Muñoz-Jordán, Jorge L. 89, 466, 514, 524  
 Muok, Erick M. O. 1068, **1234**  
 Muratova, Olga 982  
 Muriithi, Steven 38  
 Muringo, Linda 555  
 Murphy, Brian 834  
 Murphy, Jitta 160  
 Murphy, Jittawadee 807, 808, 809, 978, 984  
 Murphy, Sean C. 809, **844**  
 Murray, Clinton K. 1034, 1037  
 Musa, Ahmed M. 1217, 418  
 Musapa, Mulenga 1097, **300**, 475  
 Musie, Edgar 933  
 Musiychuk, Konstantin 982  
 Muskavitch, Mard A. 934  
 Musoke, Charles 117, 123, 849  
 Mustapha, Azelmat 205  
 Musyoki, Jennifer 38  
 Mutabingwa, Theonest K. 846  
 Mutapi, Francisca **1145**, 1149, 415  
 Mutebi, Aloysius 537  
 Muth, Sinuon 1266  
 Mutombo, Ngoy P. **886**  
 Mutuku, Francis 1066  
 Mutuku, Francis M. **1294**  
 Mutumanje, Elissa 654  
 Muwonga, Jeremie 570, 578, 963  
 Muwonge, James 45  
 Muyembe, Jean J. 408  
 Muzaffar, Sindhu 1129  
 Muzny, Christine 330  
 Muzzafer, Riffat 897  
 Mwai, Leah **38**  
 Mwaikambo, Esther D. 850  
 Mwandagaliirwa, Kashamuka 570, 578, 963  
 Mwandama, Dyson 1316  
 Mwangi, Jonathan M. 36, **399**  
 Mwanje, Mariam 144  
 Mwapasa, Victor 1231  
 Mwenesi, Halima 536  
 Mwingira, Felista **1109**  
 Mwinzi, Pauline 786, 885, 1068, 1148, 1234  
 Mwisongo, Aziza J. S. **369**  
 Mwitwa, Alex 288, 5  
 Mworozzi, Edson A. 73  
 Myers, Bennett 165, 740  
 Myint, Hla Y. 416, **1249**  
 Myint, Khin S. A.. 1049  
 Myles, Kevin M. 1120, 1121, 768
- ## N
- Nabhan, Joseph F. 830  
 Nabirye, Christine 1304, 532  
 Nadesakumaran, Kogulan **173**, 188  
 Nadkarni, Abhijeet 507  
 Naeem-Ullah, Unsar 1124  
 Nagahawatte, Ajith 444  
 Nagel, Mary 893  
 Nagpal, B. N. **196**  
 Nagwekar, Rekha 680  
 Nahar, Nazmun 343, 345, 347  
 Nahas, Debbie 589  
 Nahlen, Bernard 722  
 Nahum, Alain 264, 495  
 Naiene, Jeremias 637  
 Nair, G. B. 405  
 Nair, Shalini 551  
 Najjemba, Robinah 949  
 Najnin, Nusrat **348**  
 Nakanwagi, Grace 244  
 Nakazawa, Shusuke 1271  
 Namaalwa, Milly **927**  
 Namayanja, Monica 322, **1220**, 684, 691  
 Namboodiri, Aryan M. 722  
 Nana Djeunga, Hugues 1330  
 Nanayakkara, Dhammika 710  
 Nanayakkara, N P. D. **257**, 368, 713  
 Nankabirwa, Joaniter I. N. 1303, **1314**, **244**, 532  
 Nankya, Florence R. K. 532, **1302**, 1304  
 Nanteza, Ann 1220, **684**, 691, 220  
 Nanuashvili, Alexander 504  
 Nanyonjo, Agnes 77  
 Naquira, Cesar 812, 1216  
 Naranjo, Nelson J. 1005  
 Narayan, Sunil K. 793  
 Narayanan, Aarthi 379  
 Narayanan, Jothikumar 955  
 Nardin, Elizabeth 589  
 Nare, Bakela 1089, 234, 683, 685  
 Narkiewicz, Sophia 443  
 Narum, David L. **41**, 164, 437, 727, 871, 1173  
 Narvaez, Carlos F. 517  
 Narvaez, Federico 100, 467, 509, 516  
 Nasar, Farooq 1310  
 Nasci, Roger 9  
 Nascimento, Eliana T. 898  
 Nascimento, José M. Sousa. 560  
 Nash, Oyekanmi 1254  
 Nash, Theodore E. 791, 792, 1046  
 Nasr, Sussann 1208, 45  
 Nasreen, Sharifa 1197, 349  
 Nasrin, Dilruba 852  
 Nassali, Ruth K. **142**  
 Nastasi, Bonnie 932  
 Nataraj, Loganayaki 82  
 Nataro, James P. 648, 852  
 Nath Chowdhury, Milli 688  
 Nathalie, Convelbo 838  
 Nathan, Michael B. 600  
 Nathan, Rose 288  
 Natividad, Filipinas 1312  
 Naumov, Anatolie 370  
 Naumova, Elena N. 448  
 Nausch, Norman **415**  
 Navarro, Juan Carlos 1008  
 Navia, Daniela **114**  
 Nawin, K 235  
 Nayiga, Susan 1240  
 Ndao, Momar 1094, **688**, 88  
 Ndhlovu, Patricia D. 407  
 Ndiath, Mahamadou M. **106**  
 Ndiath, Mamadou O. 494  
 Ndiaye, Daouda 1261, 131, 277, 40, 402, 934, 935  
 Ndiaye, Ibrahima 403  
 Ndiaye, Jean Louis 131, 312, 403, 1214, 1237, 1256, 279  
 Ndiaye, Magatte 279, 736, 1105, 1237

The number(s) following author name refers to the abstract number.

- Ndiaye, Mouhamed **1237, 1256**  
 Ndiaye, Salif 291, 44  
 Ndiaye, Youssoupha 1237, 1239, **259**  
 Ndir, Omar 1261, 277  
 Ndirangu, James 639  
 Ndjakani, Yassa 1255  
 Ndo, Cyrille 865  
 Ndour, C. T. 312  
 Nduba, Videlis N. 1128  
 Nduka, Florence **298**  
 Nduma, Happy 480  
 Ndyomugenyi, Richard 45, 68  
 Neafsey, Daniel E. 401, **402**, 429  
 Nebie, Issa 147, 728, 779  
 Nebie Issa, Ouedraogo 720  
 Neesanant, Pimnapar 482  
 Nerima, Barbara **686**  
 Nerurkar, Vivek R. 1059, 85  
 Neto, João Firmino Neto F. 898  
 Neto, Jones L. B.. 642, **643**  
 Netshandama, Vhonani 933  
 Neupane, Ganesh-Prasad **635**  
 Newbold, Chris 38  
 Newman, Christina **1055**, 1058  
 Newman, Robert D. 965  
 Neyra, Joan M. 1138  
 Ng'ang'a, Zipporah W. N. 1234  
 Ngondi, Jeremiah 754  
 Ngoudajio Nguetse, Christian 976  
 Ngounou Fotsing, Raceline 1330  
 Nguhi, Margaret 639  
 Nguyen, An T. **619**  
 Nguyen, Chinh T. 853  
 Nguyen, Hoang V. M. 853  
 Nguyen, Minh Nguyet 468  
 Nguyen, Nga T. T. 853  
 Nguyen, Nam V. 98  
 Nguyen, Tien 1089  
 Nguyen, Thanh Hung 468  
 Nguyen, Truc Vy 621, 623  
 Nguyen, Vu 871  
 Nguyen, Vinh T. 853  
 Nguyen, Vinh Chau V. 468  
 Nguyen Van Minh, Hoang 1323  
 Niambale, Mohamed B. 805  
 Niangaly, Amadou 590, 803, 847, 161  
 Niangaly, Hamidou 1100, 1263  
 Niare, Fanta **111**  
 Nicand, Elisabeth 891  
 Niccolini, Alberto 1117  
 Nichol, Stuart 339  
 Nichols, Joan 446  
 Nicholson, William L. 1036, 858  
 Nicodemus, Wendy 1300  
 Nicoll-Griffith, Deborah 688  
 Nicosia, Alfredo 160  
 Nicosia, Vincenzo **81**  
 Nielsen, Birgitte B. 576  
 Nielsen, Morten 436  
 Nielsen, Robin 981  
 Nikiema, Jean-Baptiste 719  
 Nimzing, J 69  
 Nisalak, Ananda 837, 95  
 Nixon, Douglas F. 1290  
 Nizame, Md. Fosiul A. **1197, 350**  
 Njenfa, Sammy M. 224  
 Njideka, Okpala T. 754  
 Njoku, A. J. 447  
 Njoku, Vitalis I. 447  
 Njomo, Doris W. **224**  
 Nkhoma, Standwell **551**  
 Nkrumah, Bernard **1141**  
 Nkrumah, Francis 945  
 Nkunda, Richard 1200  
 Nkwengulila, Gamba 1109  
 Nkya, Watoky 5  
 Noble, Agustina 124  
 Nobre, Maurício L. 1325  
 Noe, Andy 683  
 Noedl, Harald 473  
 Noel, Megan 101, 102  
 Nogueira-Torres, Benjamin 236  
 Noisakran, Sansanee 1313, **511, 86**  
 Nolan, Thomas J. 1189  
 Noland, Gregory **1211**, 1289, 281  
 Noor, Abdisalan M. 144, 145, 579  
 Norris, Douglas E. 167, 201, 300  
 Norris, Laura C. **167**  
 Norval, Suzanne 715  
 Nosten, Francois **1250**, 6, 727  
 Nouhoum, Diallo 1268  
 Noukpo, Julien 278  
 Nour, Bakri Y. M. 718  
 Nour El-Din, El-Shaimaa M. 207  
 Novak, Joseph J. 266  
 Novak, Robert J. 608  
 Nsadha, Zachariah 1220, 684  
 Nseng, Gloria 297  
 Nsibu, Celestin N. 665  
 Nsobya, Samuel L. 374  
 Ntumngia, Francis B. **731**, 732  
 Nuchprayoon, Surang **218**  
 Null, Clair **361**  
 Nunes, Márcio R. T. 1048, 1159  
 Nunes-Monteiro, Sandra S. M. 647  
 Nuñez, Andrea 100, 1309, 467, 509, 516  
 Nuñez, Gladys 486  
 Nunez, Jorge **689**  
 Nurhayati, N 14  
 Nurmukhambetova, Saule 1174  
 Nuruzzaman, Md. 350  
 Nuss, Andrew **760**  
 Nussenzweig, Ruth S. 372  
 Nussenzweig, Victor 372  
 Nutman, Thomas B. 1189, 1329, 1330, 1332, 213, 385, 387, 432, 53, 829, 867  
 Nwaiwu, Obiyo 264  
 Nwakanama, Davis 307, 934  
 Nwane, Philippe 214  
 Nwosu, Eugene 298  
 Nyabeyu Nyabeyu, Herve 976  
 Nyagonde, Nyagonde 950  
 Nyakoe, Nancy 555  
 Nyakundi, Ruth K. **120**  
 Nyamongo, Mary A. 224  
 Nyamwija, A 664  
 Nyandigisi, Andrew J. 579  
 Nyangahu, Bartholomew O. **281**  
 Nyangiri, Oscar A. 105  
 Nyarko, Alexander 667  
 Nyarko, Edward 1025  
 Nyatanyi, Thierry 1200  
 Nyirenda, Oswald 3, 960, 961  
 Nyoka, Raymond 639  
 Nyunt, Myaing M. **1242**  
 Nzarubara, Bridget 1179, 1290  
 Nzelu, Chukwunonso O. **632**  
 Nzila, Alexis 38  
 Nzussouo, N T. 883  
 Ohn, Mya 1250  
 Ohnishi, Kenji 109  
 Ohrt, Colin 1249, 248, 166, 270, 368, 426, 710, 711, 713, 717  
 Ohta, Nobuo 667  
 Oishi, Kazunori 1312  
 Ojorongbe O., O 139  
 Okedi, Loyce 423, 633  
 Okell, Lucy C. **745**, 876  
 Okello, Patrick 45  
 Okenge, Augustin 570  
 Okiro, Emelda A. 145  
 Okocha, Ndudi 1156, 887  
 Okoh, Chukwuyem **752**  
 Okoth, George O. 487  
 Okpala, NT 69  
 Oku, Hiroyuki **166**  
 Oku, Yuzaburo 699  
 Okuboyejo, Titilope M. 1245, 746, 2  
 Olabige, Olutayo 507  
 Olack, Beatrice **487**  
 Oladiran, Fiyinfolu 292, 293, 294, 873  
 Olarte, Liset 1305  
 Oleinikov, Andrew V. **40,587**  
 Olinger, Gene G. 381  
 Oliva, Clelia **184**  
 Oliveira, Bruna M. C. 1235  
 Oliveira, Giselle A. **1015**  
 Oliveira, Jefferson S. 642, 648  
 Oliveira, Paulo 679  
 Oliveira, Rodrigo C. 1152, 1155  
 Oliveira-Ferreira, Joseli 283  
 Oliver, Joanne 192, 197  
 Oliver, Lindsay D. 1036, 858  
 Oliver, Shannon 363  
 Olliaro, Piero L. 905, 1109, **1318, 890**  
 Olmeda, Raul 253, 255, 256  
 Olomi, Raimos 549  
 Olowe, Adekunle O. **139, 634**  
 Olson, Kenneth E. 198, 305, 311, 774, 860, 878  
 Olson, Victoria A. 1168  
 Olutayo, Mojisola C. 262  
 Omar, Sabah 1272  
 Omari, Susan 288  
 Omer, Saad B. 1198  
 Omonkhua, Akhere A. A. 243, 261, **262**  
 Omore, Richard 852  
 Onapa, Ambrose 801  
 Oneko, Olola 670  
 Onen, Nur F. 406  
 Ong'echa, John M. 1292, 1322, 545, 546, 721, 723, 848  
 Onguru, Daniel O. 786, **1148**  
 Onlamoon, Nattawat 511  
 Ono, Takeshi 109, 159  
 Onwuliri, Celestine O. E. 290  
 Onyamboko, Marie A. 7  
 Onyango, Jacinta J. 1036, 856, 858  
 Onyor, Pamela A. 953  
 Ooi, Eng E. 89  
 Ooi, Winnie W. 498  
 Oommen, A 1044  
 Opere, William 1026, 1327

## O

- O'Brochta, David A. 769, **773**  
 O'Connor, Annette 925  
 O'Connor, Linda-Lou **225**  
 O'Dowd, Aisling 486  
 O'Hanlon, Simon **215**  
 O'Neil, Michael T. 265, 266, 364, 365, 478, 712, 716, 1092  
 O'Neill, Matt 581  
 O'Reilly, Ciara E. 24, 852  
 O'Shea, Matthew 1080  
 O'Connell, Kate 1317  
 Oakley, Miranda S. M. **425**  
 Obaldi, Nicanor 252  
 Obaldia III, Nicanor 268  
 Obare, Peter B. 953  
 Obenauer, Peter J. 207, 626  
 Oberstaller, Jenna 954  
 Oberste, Steve 466  
 Obiakor, Harold T. **437**  
 Obiezu, J 69  
 Ochoa, Theresa J. 1305, 485, 644, 645, 929  
 Ochola, Elizabeth 885  
 Ochola, Sam A. 145  
 Ochong, Edwin O. **1278**  
 Ockenhouse, Christian F. 128, 555, 806, 807, 808, 809, 971, 978, 981, 984, 1098, 1173, 1174  
 Ockers, Sandra 320  
 OConnell, Kate 534  
 Odero, Kennedy O. 487  
 Odhiambo, Gladys 1068  
 Odoch, Walter D. **417**  
 Odofin, Lynda U. **1076**  
 Odoom, Shirley Cameron 632, 1025  
 Oduola, Ayoade M. J. 1270, 2  
 Oduor, Albert 781  
 Oduro, Abraham R. **782**, 945  
 Oesterholt, Mayke 276, **285**, 436, 937  
 Ofulla, Ayub V. 281, 1148, 1289  
 Ogah, G 1156  
 Ogah, G 798  
 Ogange, Lorraine 1068, 1196  
 Ogata, Steven 833  
 Ogobara, Doumbo 1268  
 Ogola, George O. Ogola O. 1234  
 Ogungbamigbe, T O. 139  
 Ogunkunle, Oluwatoyin O. 1254  
 Ogunro, S P. 139  
 Ogutu, Bernhards 264, 292, **293**, 294, 565, **873, 953**  
 Ogutu, David 68  
 Ogwal, Alex **678**  
 Ogwang, Sheila 353  
 OhAinle, Molly **1309**

The number(s) following author name refers to the abstract number.

Opata, Harry 883  
 Opiyo, Elizabeth 423  
 Opoka, Robert O. 404  
 Orach, Christopher G. 488  
 Oramasionwu, Gloria E. **557**  
 Oravec, Tamas 117  
 Ord, Rosalynn L. **946**  
 Orengo, Jamie 435  
 Orge, Glória 679  
 Oriá, Reinaldo B. 648, 1321  
 Oriango, Robin 781  
 Oriero, Eniyou C. 307  
 Orinda, G 721  
 Orogade, Adeola **1140**  
 Oronsaye, Praise I. O. **500**  
 Orozco, Maria 987  
 Orozco - Fernández, María del Carmen **698**  
 Orr, Matthew 683, **685**  
 Orshan, Laor 175, 206  
 Ortega, Oscar 100, 467, 469  
 Ortega, Ynes R. **325**  
 Ortiz, Ernesto 1136  
 Ortiz, Gloria 362  
 Ortiz, Gloria M. 358  
 Ortíz, Jusara 821  
 Ortiz, Lucía 1102, 1280  
 Ortiz, Marian 871  
 Ortiz-Baez, Fernando 496  
 Osano, Sarah V. 579  
 Osanya, Alex O. 862  
 Osborne, Matthew 192  
 Osei-Atweneboana, Mike 1331  
 Osier, Faith 145  
 Osorio, Elvia Y. 687  
 Osorio, Jorge E. 375, **832, 907, 908**  
 Osorio, Salua 153  
 Ospina, Marta 908  
 Osters, Graciela **938**  
 Österholt, Mayke 576  
 Osuna, Antonio 1074  
 Oswald, William E. 438  
 Oteino, Juliana 722  
 Othoro, Caroline 717, 722  
 Otieno, Michael F. 721  
 Otieno, Silas 1272  
 Otogbe, Felix K. J. 67  
 Otsuki, Hitoshi 942  
 Otten, Mac 965  
 Ottendorfer, Christy L. **879**  
 Ottesen, Eric 1334, 65, 799, 800, 801  
 Ottinger, Elizabeth 589  
 Ottones, Florence 702  
 Ou, Ruguang 741, 742  
 Ouattara, Amed **803**  
 Ouedraogo, Alphonse 147, 571, 728  
 Ouedraogo, Andre Lin 147, **728, 779**  
 Ouedraogo, Esperance 147, 728  
 Ouedraogo, Issa N. 571  
 Ouendo, Edgard 83  
 Ouiminga, Mariama 1232  
 Ouma, Collins 721, 848  
 Ouma, Collins O. **1292, 1322, 545, 546, 723**

Ouma Yamo, Emmanuel 553  
 Oumar Bila, Traore 1268  
 Oundo, Joseph 852  
 Ousmane, Toure 1268  
 Outbreak Investigation Team, Malawi-Mozambique 637  
 Overgaard, Hans 610  
 Overgaard, Hans J. 776  
 Oviedo, Gisela 529  
 Ovsyannikova, Inna G. 725  
 Owour, Mercy 1196  
 Owusu Frempong, Henry 1141  
 Owusu-Agyei, Seth 577  
 Oyoyo, Buhari A. 883  
 Oza, Sandra 1083

## P

Paaajmans, Krijn **1012**  
 Pacheco, M. Andreina 1113, **552, 936**  
 Pacheco-Tucuch, Freddy 1080  
 Paci, Gabrielle 674  
 Padilla, Norma R. 1102, 1280, **997**  
 Padilla Garcia, Eva 497  
 Pahl, Michelle 101, 102  
 Pakpour, Nazzy 758  
 Pal, Subhamoy 94  
 Palafox, Benjamin 1317, 534  
 Paley, Derek 1299  
 Paliwadana, Paba 520  
 Pallavi, Rani 430  
 Palma, Sandra 789  
 Pam, D 798  
 Pance, Alena 39  
 Panchalingam, Sandra 333, 852  
 Pancharoen, Chitsanu 13  
 Pandey, Janardan P. 722  
 Pandey, K 235  
 Pandharkar, Trupti 238  
 Pandit, Jayesh 579  
 Panella, Nicholas A. 1003  
 Pantoja, Petraleigh 514  
 Paoaafaite, Tuterarii 995, 999  
 Papastogiannidis, Petros 267, 714  
 Pappa, Vasiliki **610**  
 Paragas, Jason 380  
 Paraná, Raymundo 1051  
 Parapini, Silvia 719  
 Parashar, Umesh 1163  
 Parbie, Prince 883  
 Pare, Alain Brice 801  
 Paredes, Adriana 1046  
 Paredes, Jose L. 1079  
 Parham, Robin 683  
 Parija, Subhash C. 793  
 Pariyo, George W. 537, 73  
 Park, Christine 985  
 Park, Daniel J. **401**  
 Park, Gregory 281  
 Park, Hyeram 688  
 Park, Jae-Won **138**  
 Park, Kyung-Hee 820  
 Park, Sarah Y. 1190  
 Parks, Elliot 833  
 Parola, Philippe 649  
 Parraga, Isabel M. 1066

Parriott, Sandi K. 266  
 Parsons, Marilyn **1215**  
 Parsons, Melissa 831  
 Parsons, Michele B. 852  
 Parsons, Theresa 1242  
 Partidos, Charalambos **375, 832**  
 Paskewitz, Susan M. **1057**  
 Pasteur, Nicole 465  
 Patel, Janus 1099  
 Patel, Vishal 1261  
 Pates Jamet, Helen V. **924, 992**  
 Patil, Anand 105, 146  
 Patonay, Jennifer 421  
 Patouillard, Edith 1317, **534**  
 Patramool, Sirilaksana 168, 181  
 Patrick, Donald A. 238, 682  
 Pattanapanyasat, Kovit 511, **540**  
 Patterson, Noelle B. **583, 740, 806, 984**  
 Pava, Zuleima **133**  
 Pavluck, Alex L. **799**  
 Paxton, William A. 666  
 Payne, Anne F. 1202, 1204  
 Paz-Soldan, Valerie 391, 910  
 Pazylov, Yerlan 193  
 Pearson, Richard D. Pearson D. 898  
 Pedro, Renata S. 970  
 Peel, Bethany 597  
 Pefley, Ranae M. 1283  
 Pehrson, Caroline **937**  
 Pelecanos, Anita 250  
 Pell, Christopher 568  
 Pelletreau, Sonia **1069**  
 Pelosi, Paolo 1117  
 Pena, Rodolfo 357  
 Peña-Orellana, Marisol 906  
 Peñaranda, S. 466  
 Pengsaa, Krisana 470  
 Peniche, Alex G. **687**  
 Pennetier, Cédric **598**  
 Pennington, Pamela M. **1102, 997**  
 Pensulo, Paul 843  
 Perales, Joe 234, 1089  
 Perales, Renzo 698  
 Peralta, José Mauro 445, 1045  
 Peralta, Regina Helena H. S. **1045**  
 Pereira, Fernanda A. 1051, 1052  
 Pereira, Luciano A. O. S. 1051  
 Pereira, Luiz E. 1166  
 Perelygin, Andrey A. **1188**  
 Peres, José M. Veloso. 560  
 Pérez, Maria Angeles 100, 467, 509, 516  
 Perez, Wilton 357  
 Perez-Aguilar, Mary C. 693  
 Pérez-Guerra, Carmen L. **906**  
 Perkins, Douglas 1292, 1322, 545, 546, 721, 723, 848  
 Perlmann, Hedvig 42  
 Perng, Guey Chuen **1313, 86, 505, 511, 1049**  
 Perry, Robert 291, 44  
 Person, Bobbie **1196, 885**  
 Persson, Ola 950  
 Petersen, Christine A. 925  
 Peterson, David S. 954  
 Peterson, Megan 396  
 Peterson, Nathan A. **452**

Petrarca, Vincenzo 307  
 Petrella, Selma M. C. N. 1166  
 Petty, Brent G. 1242  
 Pfarr, Kenneth M 223  
 Pfeffer, Martin 11  
 Phae Pyo, Aung 6  
 Pham, Minh V. 853  
 Pham, Quang 471  
 Pham, Tuyet T. N. 853  
 Phan, My V. T. **853**  
 Phanouvong, Souly **1301**  
 Phillipina, Sister 52  
 Phillips, Aaron T. 878  
 Phillips, Margaret A. 476  
 Phiri, Abel 637  
 Phiri, Kamija **1212, 1231, 780**  
 Phiri, Masiliso 1213, **130**  
 Phok, Sochea 1317, 534  
 Phyo, Aung Phya 1250  
 Piccoli, Luca 1042  
 Pickering, Amy J. **27**  
 Picolo, Vanessa 239  
 Piel, Fred B. **105**  
 Pieniasek, Norman J. 1188  
 Pierce, Kristen 834  
 Pierre, Kamtchoung 78  
 Pikacha, Junilyn 569  
 Pilcher, Christopher D. 129  
 Pillai, Dylan R. 260  
 Pimentel, Billy 1025  
 Pimentel, Guillermo 504, 883  
 Pimentel, Tais A. P. F. 1175  
 Pinder, Margaret 46  
 Pindolia, Deepa **140**  
 Pineda, Vanessa 319  
 Pinger, Robert 304  
 Pinoges, Loretxu 1101, 1248  
 Pinto, Joao 776  
 Pinto, Paulo M. 659  
 Pinto, Vera 436  
 Pinto-Caballero, Jesus A. 1091  
 Piper, Joseph 198, 305  
 Pippitt, Julia 1080  
 Piriou, Erwan 725  
 Piscioti, Ibeth 998  
 Pitaluga, Andre N. **60**  
 Plante, Kenneth 375  
 Plassmeyer, Matthew L. 41  
 Plattner, Jacob 228, 249, 683, 685  
 Ploemen, Ivo H. J. **37**  
 Plowe, Christopher V. 1288, 161, 3, 572, 590, 803, 807, 847, 960  
 Pluschke, Gerd 979  
 Plushke, G. 1130  
 Podolsky, Michael 855  
 Podust, Larissa 232  
 Poinson, Anne 616, 872  
 Polack, Sarah 533  
 Poland, Gregory A. 725  
 Polhemus, Mark 808, 981, 984, 1174  
 Polk, D. B. 1321  
 Pollack, Yaakov 434  
 Pollakis, Georgios 666  
 Polley, Spencer 477  
 Polman, Katja 1234  
 Polsomboon, Suppaluck **176, 463**  
 Polson, Karen A. **170**



The number(s) following author name refers to the abstract number.

Polsrila, Korakot 540  
 Pombi, Marco 1000, 618  
 Pommier de Santi, Vincent 891  
 Pongtavornpinyo, Wirichada 1267  
 Ponlawat, Alongkot 191, 203  
 Ponmee, Napawan 476  
 Ponnusamy, Loganathan 1002  
 Pontes, Núbia N. 898  
 Pool, Christopher D. 1282, 978, 980  
 Pool, Robert 568  
 Poole-Smith, B. K. **88**  
 Poolpanichupatam, Yongyuth 95  
 Poore, Duke D. **251**  
 Popova, Lyudmila 1119  
 Porcella, Stephen F. 36  
 Porter, Kim A. 962  
 Poulton, Ian 160, 804  
 Povall, Sue 503  
 Póvoa, Marinete M. 558, 560, 604  
 Powell, Jeffrey R. 15, 610  
 Powell, Tim D. 832  
 Powers, Ann 10, 878, 1003  
 Powers, Ann C. 375  
 Prabhakaran, V 1044  
 Prabhu, Malavika **1036, 858**  
 Prada, Ana M. 644  
 Prado, Cibele M. 1085, 706, **707**  
 Prakash, Aishya 211  
 Prasad, Abhishek 860  
 Prats, Sara 1246  
 Prazeres, Assis S. C. 1048  
 Premji, Zulfiqarali 292, 293, **294, 479, 873**  
 Premoli, Gloria 1079  
 Prentice, Jennifer L. 844  
 Pribluda, Victor S. **923**  
 Price, David **772**  
 Prichard, Roger 1220, 684, 691  
 Pritt, Bobbi S. 630  
 Proper, Walter 1300  
 Proux, Stephane 1250  
 Provost-Javier, Katie N. **1118**  
 Pruszyński, Catherine A. **522**  
 Przysiecki, Craig **589**  
 Ptitsyn, Andre 860  
 Public Health Team, IRAC **993**  
 Puente, Jose Luis 645  
 Puffer, Bridget A. 523  
 Pukuta, Elizabeth 408  
 Puplampu, Naiki 1025, 632  
 Purcell, Bret K. 381  
 Puzey, Kenneth A. 137, 957, 958  
 Pybus, Brandon S. **1252, 1253, 248, 251, 253, 255, 716**  
 Pyo, KH 162

## Q

Quade, Charles 1326  
 Queiroz, Adriano 409  
 Queiroz, Claudia 1228  
 Quetz, Josiane S. 646  
 Quick, Robert 24, 25, 353  
 Quicke, Kendra M. 1122  
 Quigley, Robert L. **110**  
 Quijada, Isaurea 904  
 Quiñones, Martha Lucía 153  
 Quintero Gil, Carolina **908**  
 Quinto, Ebony 1208, 45  
 Quiroz, Wendy L. 391  
 Quispe, Elizabeth 789  
 Quispe, Jose A. 1138  
 Quispe-Machaca, Victor 1091  
 Quites, Humberto F. O. 1152, **1155**  
 Quiviger, Mickael 157  
 Qvarnstrom, Yvonne 1190, **240**

## R

Raballah, Evans 1292, 1322, 545, **721, 723, 848**  
 Raccurt, Christian 440  
 Rachaphaew, Nattawan 398  
 Radke, Elizabeth 389  
 Raghunathan, Pratima 1200  
 Ragland, Dan 380  
 Rahim, Sibtain 962  
 Rahman, Abir A. 552  
 Rahman, Mohammad Arif 638  
 Rahman, M. Taufiq-Ur 70, 71  
 Rahman, Md. Abdur 41  
 Rahman, Md. Z. 345  
 Rahman, Taibur 483  
 Rahmatullah, Mohammed 70, 71  
 Rai, Ganesh 1282  
 Rai, M 235  
 Raikhel, Alexander 863  
 Raimondo, Domenico 1182  
 Rajae, El Aouad 205  
 Rajahram, Giri S. 55  
 Rajakaruna, Rupika S. 737  
 Rajan, Latha 932  
 Rajapandi, Thavamani **328**  
 Rajkumar, Paramasivan 22  
 Rajshekhar, V 1044  
 Rakers, Lindsay 798, 1156  
 Ralph, Stuart A. 427  
 Ram, Pavani K. **28, 350, 351**  
 Ramalho-Ortigao, Marcelo **62**  
 Ramamurthy, T. 405  
 Ramanathan, Roshan **1189**  
 Ramaprabha, Prabhakar 22  
 Ramasamy, Gowthaman 396  
 Ramaswamy, Padmavathi 22  
 Ramirez, Ana L. 1003  
 Ramirez, Jose L. **767**  
 Ramirez, Maria J. 241  
 Ramírez, Viani 906  
 Ramos, Enrique 1032  
 Ramos, Simone G. 658  
 Ramos-Castaneda, Jose 89  
 Randolph, Ryan 234, 683  
 Ranford-Cartwright, Lisa **36, 372, 399, 554**  
 Ranson, Hilary 602  
 Rao, M M. 213  
 Rao, Ramakrishna U. **221**  
 Raoult, Didier 649  
 Raqib, Rubhana 1198  
 Rarau, Patricia 4, 839  
 Rasch, Vibeke 576  
 Rasgon, Jason L. 1118, 201, 628  
 Rashidnoor, RafaatSaba 1035  
 Rashu, Rasheduzzaman 483  
 Rathod, Pradipsinh K. 1275, 396, 476  
 Rausch, Kelly 164, 584, 805  
 Ravel, Sophie 420  
 Ravinetto, Raffaella M. **538**  
 Rawlins, Samuel C. 170  
 Raychaudhuri, Syamal 1162, 49  
 Rayner, Julian C. 370, 39  
 Razak, Abdul 74  
 Razaki, Osse 171  
 Razuri, Hugo 1136  
 Read, Andrew 991, 1012, 1277  
 Read, Kevin 715  
 Recuenco, Sergio 345A  
 Reddy, Michael 297, 610, 776  
 Reddy, Michael R. 1201  
 Reddy, Vamsi P. 777  
 Redwood, Yanique 637  
 Reechaipichitkul, Wipa 1131  
 Reed, Steven G. 164, 1174, 988  
 Reeder, John 4  
 Reese, Michael L. 1345  
 Reese, NeCole 1252, 1253, 255  
 Reeve, David 1064  
 Reeve, Richard 1298  
 Refos, Ferdinand 968  
 Regier, Allison 941  
 Regis, David 806  
 Regmi, Sandesh 1219  
 Regmi, Shanti 481  
 Rehman, Andrea 297  
 Reid, Carolyn 238, 682  
 Reid, J.S. 960  
 Reiling, Linda 1177  
 Reimer, Lisa 1067, 66, 173, 188, 464, **611**  
 Reis, Dener C. 1155  
 Reis, Eliana A. G. **1031, 1052**  
 Reis, Mitermayer G. 1031, 1033, **1051, 1052, 409, 857, 894, 899**  
 Reis, Renato B. 409, 857  
 Reisen, William K. 19  
 Reiter, Christopher D. **165**  
 Reiter, Karine 41, 437, 871  
 Reithinger, Richard 1259  
 Remais, Justin 458, 63  
 Remoue, F 272  
 Remoue, Franck 168, 181, 494, **616, 872, 875**  
 Requena, Edwin 996  
 Resende, Mafalda 436  
 Rewerts, Cindy 234, 683, 685  
 Rey, Gloria 900  
 Reyes, Sean **245**  
 Reyes, Sharina 807  
 Reyes-Urbe, Patricia I. 698, **1086**  
 Reynolds, Alison 503  
 Reynolds, Mary G. 408  
 Rhajaoui, Mohamed **1151**  
 Rheingans, Richard 441  
 Ribeiro, Guilherme S. 1031, **409, 857, 894**  
 Ribeiro, José M. C. 1299, 629, 829  
 Ribeiro-Gomes, Flavia 867  
 Richards, Allen L. 820  
 Richards, Frank O. 68, **69, 214, 216, 754, 797, 798, 887, 1156**  
 Richards, Jack S. 427, 581, 727  
 Richards, Samantha 945  
 Richards, Stephanie L. 1123, 1185, **195**  
 Richards-Kortum, Rebecca R. 557  
 Richardson, Jason 191, 202, 656, 808  
 Richie, Nancy O. 806  
 Richie, Thomas 1173, 492, 583, 588, 740, 806, 807, 808, 971, 972, 984, 985  
 Richman, Adam 769, 773, 807  
 Richter, Mary Etna **1120**  
 Ricklefs, Stacy M. 36  
 Riedel, Nadine **889**  
 Riehle, Michael A. 1122, 1125  
 Riehle, Michelle M. **864**  
 Riemann, Bryan 108  
 Rifkin, Ian R. 217  
 Riga, Alan 956  
 Riglar, David T. 427  
 Rijken, Marcus 6  
 Rimi, Nadia A. **345**  
 Rinaldi, Gabriel 1225, 866  
 Riner, Diana K. 606, **788**  
 Ringwald, Pascal 473  
 Rios, Esther J. 391  
 Rios, Maria 1060, 512  
 Riou, Patrice 510  
 Riscoe, Mike 716  
 Ristow, Paula **899**  
 Ritchie, Scott A. 390, 59, 999  
 Rivard, Robert 381  
 Riveau, G 272  
 Riveau, Gilles 494, 616  
 Rivera, Francheska 514  
 Riveros, Maribel 645  
 Riyadh, Md. Asrafuzzaman 638  
 Rizvon, Kaleem 680  
 Rizzo-Price, Patricia A. 893  
 Roarty, Joseph 108  
 Rob, Hoshne N. 350  
 Robb, Katharine 363  
 Roberts, Anne **972**  
 Roberts, Jacquelin 1333  
 Roberts, Renee N. **741, 742**  
 Robles-Murguía, Maricela 62  
 Roca, Yelin 168  
 Roca-Feltrr, Arantxa **780**  
 Rocca, Keith M. 722  
 Rocco, Iray M. 1166  
 Rocha, Crisanta 516  
 Rocha, Filomena S. P. 1028  
 Rocha, Gisele 899  
 Roche, Aubree J. 1036, 858  
 Roche, Gregory 101, 102  
 Roche, James K. 327, 329, 642, 648  
 Rochford, Rosemary 1289, **717, 725, 729**

The number(s) following author name refers to the abstract number.

Rock, Fernando 228  
 Rodrigo, Leighton G. 712  
 Rodriguero, Marcela 1074  
 Rodrigues, Amabelia 905  
 Rodrigues, Daniele S. G. 1048  
 Rodrigues, Janneth 861  
 Rodrigues, Laura C. 529  
 Rodrigues, Maria G. 857  
 Rodrigues, Raphael S. 643  
 Rodrigues, Sueli G. 1048  
 Rodrigues-Silva, Rodrigo N. **283**  
 Rodriguez, Ana 435  
 Rodriguez, Bernal 1077  
 Rodriguez, Carlos 660  
 Rodriguez, Idia V. 514  
 Rodriguez, Jairo A. 517  
 Rodriguez, Maria E. 321  
 Rodriguez, Mary L. 814  
 Rodriguez, Nilda E. **1285**  
 Rodriguez, Silvia 1046, **794**, 812  
 Rodríguez Ferrucci, Hugo 874  
 Rodriguez-Acosta, Rosa L. **395**, 906  
 Rodulfo, Hectorina **321**, 904  
 Roeffen, Will **779**, 982  
 Roellig, Dawn M. 1091  
 Rogayah, Hanifah 146  
 Rogers, David 1182  
 Rogers, William O. **1266**, **155**  
 Rogerson, Stephen 4, 542, 1177  
 Rogier, Christophe 750, 967  
 Rojas-Aguirre, Yareli **236**  
 Rollin, Pierre 339  
 Rollinson, David 888  
 Romanò, Luisa 1161  
 Romero, Ada 1133  
 Romero, Candice 1136  
 Rona, Luisa D. 60  
 Roncal, Norma 252, 715  
 Ronzoni, Luisa 254  
 Rook, Kimberly A. 28  
 Roos, David S. 372  
 Rosane B. Oliveira, Rosane B. 280  
 Rosas Aguirre, Angel 874  
 Rose, Jeffrey 280  
 Rose, Joan B. 439  
 Rosecrans, Kathryn 1080  
 Rosen, David M. 401  
 Rosenblatt, Jon E. 630  
 Rosenthal, Philip J. 1179, 1278, 1290, 148, 249, 374  
 Rosenzvit, Mara 814  
 Rosero, Doris A. 1004  
 Ross, Rachael 1069  
 Rossi, Marcos A. 1085, 706, 707  
 Rossi, Shannan L. 1310, 89  
 Rossignol, Marie 875  
 Rothman, Alan L. 837  
 Rothstein, Yarrow **710**  
 Rout, Jonathan 211  
 Rowe, Christopher 871  
 Roy, Alma 9  
 Roy, Smriti 347  
 Royals, Michael A. 832  
 Roza, Afroza K. 345  
 Ruang-areerate, Toon 574, 627  
 Rubaale, Tom 68  
 Rubach, Matthew P. 850

Rubahika, Denis **45**  
 Ruiz, Daniel **153**  
 Ruiz, Joaquim 644  
 Ruiz, Joaquin 929  
 Ruiz, Marilyn O. **1006**, 1055, 1058, 1205, 187  
 Ruiz-Agelvis, Claudia 692  
 Rukelibuga, Joseph **1200**  
 Rulisa, Stephen **116**, **1241**  
 Rupprecht, Charles 345A  
 Rush, Amy C. 222  
 Rusine, John 1200  
 Russ, Carsten 402  
 Russart, Nathan M. 652  
 Russell, Richard C. 995, 999  
 Russell, Tanya 1298  
 Russo, Elizabeth 25  
 Russomando, Graciela 1074  
 Rutebemberwa, Elizeus **73**  
 Ruyonga, John 1200  
 Rwego, Innocent 1170  
 Rwego, Innocent B. 320, 664  
 Ryan, Edward T. 483, 484, 638, 855, 896  
 Ryan, Peter A. 177  
 Ryder, Robert 7

## S

Saathoff, Elmar 1169  
 Sabchareon, Arunee 470  
 Sabeti, Pardis 401, 402  
 Saborio, Saira 1309  
 Sabot, Oliver J. 785  
 Sachs, Paige **606**  
 Sacko, Moussa 886  
 Sadou, Aboubacar 1263  
 Sadowski, Brett W. 712  
 Saganda, Wilbrod 1036, 856, 858  
 Sagara, Issaka 1100, 292, 293, **805**, 873, 893, 967  
 Sagiyev, Zaurbek 193  
 Sagnon, N'Fale 864  
 Sagoe, Kwamena W. C. 666  
 Saha, Amit 483  
 Sahu, Priyadarshi S. **793**  
 Sahu, Rajnish 713  
 Saiki, Flávia A. 518  
 Saito, Tais B. **651**  
 Sajid, Mohammed 37  
 Sakai, Richard 893  
 Sakanari, Judy 228  
 Sakpaisal, Pimmada 627  
 Sakthivel, Ramanavelan 372  
 Sakurai, Tatsuya 699  
 Sakyi, Kojo Y. 1014  
 Salanti, Ali 274, 285, 436  
 Salas, Carola 1116  
 Salata, Robert 962  
 Salazar, Ferdinand V. **463**  
 Saldaña, Azael 319  
 Salgado, Doris M. **517**  
 Salha, Daniella R. A. M. 898  
 Salib, Mary 4  
 Salinas, Nichole 277  
 Sall, Amadou Alpha 394, 921  
 Salleh, Fatmah M. 318

Sallustro, Federica 99, 471  
 Salzer, Johanna 320  
 Salzer, Johanna S. **1170**  
 Sam-Yellowe, Tobili Y. **956**  
 Sama, Wilson 577  
 Samake, Mariam 1030  
 Samarakoon, Upeka **941**  
 Samb, B 272  
 Samb, Badara 616  
 Sambo, Y 798  
 Sames, William J. 820  
 Samie, Amidou 443, 933  
 Sampath, Aruna 368, 426, 710, 713, 717  
 Sanabria, Arturo **1300**  
 Sánchez, César 660  
 Sanchez, Felix 1133, 340, 467  
 Sanchez, Juan F. **32**  
 Sanchez, Roxana 325  
 Sanchez-Chiroque, Juan Francisco 316, 317  
 Sanchez-Vargas, Irma 305, 311  
 Sande, James 953  
 Sander, Oliver 292, 873  
 Sanders, John W. 316, 317, 32  
 Sandin, Ramon L. 210  
 Sandison, Taylor 1238, 1319  
 Sang, Rosemary C. 1047  
 Sangare, Cheik Omar Papa 1263  
 Sangaré, Eve 563  
 Sangjun, Nopadol 627  
 Sangu, Willy 52, 850  
 Sankaré, Moussa H. 1065  
 Sanogo, Dramane 432, 1332  
 Sanogo, Doh 333  
 Sanogo, Kassim 1100  
 Sanogo, Sintry 893  
 Sanon, Souleymane 147, 728  
 Sanprasert, Vivornpun 218, 387  
 Sansores, Manuel A. 241  
 Santamaria, Cynthia 1094  
 Santana, Lhissa N. **80**  
 Santangelo, Joseph 907  
 Santiago, Gilberto A. **524**  
 Santiago, Helton C. **867**  
 Santiago, Luis M. 466, 796, 906  
 Santiago, Marta A. 502  
 Santin, McKale E. **137**, **957**, **958**  
 Santivanez, Saul J. **812**, **814**, 816  
 Santos, Andrea C. 409, 1031  
 Santos, Balbino L. 409  
 Santos, Cleiton S. 1033, 899  
 Santos, Fátima 283  
 Santos, Helena L. C. **445**  
 Santos, Maria 249  
 Santos, Matheus T. 679  
 Santos, Nilzelene 857  
 Santos, Norlan 857  
 Santos, Silvane 679  
 Sanz, Laura **1246**, 246  
 Sara, Dann 446  
 Saralamba, Sompob 1267  
 Sardelis, Michael 607  
 Sarih, M'hammed **649**  
 Sariol, Ses 1247  
 Sariol, Carlos A. **514**, 831  
 Sarkar, Rajiv **448**  
 Sarr, JB **272**

Sarr, Jean B. 494  
 Sarr, Ousmane 277, 401, 402  
 Sarracino, David A. 855  
 Sartono, Erliyani 384  
 Sathyanarayanan, Vishwanath **74**  
 Sattabongkot, Jetsumon 1108, 266, 398, 808  
 Satyanarayana, Neha 776  
 Sauber-Schatz, Erin 389  
 Sauerwein, Robert 37, 779, 982  
 Saunders, David L. 808, 1247, 1273, 550  
 Savage, Amy F. **1219**  
 Savarino, Stephen J. 486  
 Saveria, Tracy **587**  
 Saville, Melanie 96  
 Sawa, Patrick 1272  
 Sawadogo, Adrien 1232  
 Sawadogo, Richard 719  
 Sawanyawisuth, Kittisak **1131**  
 Sawanyawisuth, Kanlayanee 1131  
 Sawasaki, Tatsuya 942  
 Sawe, Fred 962  
 Saxena, Vishal 1262, 430, **739**  
 Saye, Renion 803, 805, 893  
 Sayeed, Abdullah A. **54**  
 Sayo, Renato 806, 985  
 Schaap, Dick 1221  
 Schacht, Anne-Marie 494  
 Schaecher, Kurt 550  
 Schaffner, Stephen F. 401  
 Schäl, Coby 1002  
 Schantz, Peter M. **810**  
 Schatch, AM 272  
 Scheike, Thomas 576  
 Schellenberg, David 782  
 Schetters, Theo 1221  
 Schewitaak, Tong 216  
 Schier, Joshua 637  
 Schijman, Alejandro 240  
 Schijman, Alejandro G. 1074  
 Schilling, Katharine A. **852**  
 Schillinger, Julia 449  
 Schlarman, Maggie 741, **742**  
 Schlienger, Raymond 367, 748  
 Schloegel, Jesse L. 731, **732**  
 Schmelz, Eric 1013  
 Schmid, Melody **697**  
 Schmiegelow, Christentze 285, 436, **576**, 937  
 Schnorbusch, Kathy 703  
 Schoepflin, Sonja 1109  
 Scholl, Sabrina 815  
 Schousboe, Mette L. 737, 1279  
 Schramm, Birgit **1101**, **1248**  
 Schroeder, Jay A. 652  
 Schubach, Armando O. 502  
 Schultsz, Constance 1323  
 Schwabe, Christopher 297  
 Schwendeman, Andrew 791  
 Scott, Erick 791  
 Scott, Thomas W. 1001, 20, 391, 393, 622, 625, 910  
 Se, Youry 1247, 1273, 550  
 Sebeny, Peter 895  
 Sebuguzi, Catherine M. **532**  
 Seckova, Silvia 669

The number(s) following author name refers to the abstract number.

- Secor, Evan 360, 449, 885, 1068, 1148, 1287  
 Sedegah, Martha 740, **806**, 807, 984, **985**, 987, 988  
 Sedegah, Mary Y. 434  
 Seder, Robert 1173  
 Sedillo, Jennifer 370  
 Sehgal, Ravinder N. M. 1114  
 Seidou, Mouhamadou C. **992**  
 Sejvar, James 637  
 Seke, Judith 569  
 Sekouba, Keita 893  
 Sellamuthu, Manian **82**  
 Sem, Rithy 1266  
 Sembene, Mbacke 872  
 Sembuche, Samuel 5  
 Semenova, Elena 583  
 Semenya, Amma A. **1287**  
 Semnani, Roshanak T. **387**, 829  
 Semple, Matthew 91  
 Semunigus, Paulos 1104  
 Senaratne, Tharanga Niroshini 402  
 Senay, Gabriel 1104  
 Sene, Papa Diogoye **1261**  
 Senghor, S 272  
 Senn, Nicolas 1176, **4**, **839**  
 Senthong, Vichai 1131  
 Serebrennikova, Yulia **1099**  
 Sereejaiatham, Patcharaporn 284, 738  
 Serghides, Lena **424**  
 Serrano, Adelfa E. 267, 714  
 Setha, To 592  
 Sethabutr, Orntipa 481, 482  
 Seto, Edmund 456, 457  
 Sévéno, Martial 181, 875  
 Severson, David W. 304, 308, 309  
 Sevilleja, Jesus E. 1235, 327, 329  
 Sewnet, Tegene 24  
 Seydel, Karl B. 541, **843**, 947  
 Seyoum, Akilu **614**  
 Sghaier, Rabiaa-Manel 701  
 Shackelford, David 715  
 Shadid, Khalid A. 1144  
 Shadomy, Sean V. 856  
 Shafer, Donna 584  
 Shaffer, Doug 962  
 Shaffer, Jeffrey 901, 1080  
 Shah, Pankhil 621, 623  
 Shah, Pratab 677  
 Shah, Taslima 786  
 Shahid, Firdaus 1129  
 Shahinas, Dea **260**  
 Shahum, Andrea 669  
 Shamloul, Moneim 982  
 Shan, Guangliang 548  
 Shandera, Wayne X. 959  
 Shang, Chuin-Shee **392**, 918  
 Shanks, G. Dennis **43**, 841  
 Shao, Dingding **548**  
 Shao, John F. 856  
 Shapiro, Karen 926  
 Sharakhov, Igor V. 302, 865, 1182  
 Sharakhova, Maria **865**  
 Shargie, Estifanos B. 601  
 Sharker, M. A. Yusuf. 343, 351  
 Sharma, B 235  
 Sharma, Karmesh L. **190**  
 Sharma, Satish 982  
 Sharrock, Wesley 841  
 Sheehy, Susanne H. **160**, 804  
 Sheen, Patricia 1132  
 Sheikh, Alaullah 855  
 Shekalaghe, Seif 1272  
 Sheth, Anandi 25  
 Shi, Pei-Yong 1061  
 Shi, Yinghui 388  
 Shi, Ya Ping 722  
 Shiao, Shin-Hong **306**, 863  
 Shibata, Sayaka 1283  
 Shiff, Clive J. 1097, 47, 475  
 Shih, Yu-Tzu 1307  
 Shimp, Jr., Richard L. 41, 437, 871  
 Shin, Chang-Sik 708  
 Shin, EH 162  
 Shirin, Tahmina 484  
 Shisler, Joanna L. 1170  
 Shittu, Shefiu 507  
 Shivairo, Robert S. 75  
 Shiver, John 589  
 Shlyakhter, Ilya 401  
 Shoemaker, Trevor **339**  
 Shokoples, Sandra 1265  
 Shott, Joseph P. 893  
 Shrestha, Bhola Ram 481  
 Shrestha, Sanjaya 481  
 Shuaibu, Mohammed N. 724  
 Shuck-Lee, Deidra 1164  
 Siame, Mwiche **734**  
 Siba, Peter 1067, 226, 4, 464, 611, 64, 66, 1176, 1260  
 Sidamonidze, Ketevan 199  
 Sidibé, Issa 420  
 Siedl, Anja 473  
 Siedl, Christoph 1244  
 Sifuna, Peter **149**  
 Sihuinchá, Moises 1001  
 Siika, Abraham 962  
 Sikaala, Chadwick 614  
 Sikulu, Maggy **177**  
 Silapong, Sasikorn 481  
 Silengo, Shawn J. 832  
 Silumbe, Kafula **747**  
 Silva, Eduardo E. T. 647  
 Silva, Jailton 894  
 Silva, Mayra 1048, 1159  
 Silva, Maria E. **790**  
 Silva, Nilzelene S. 1031  
 Silva, Sheyla 516  
 Silva Filho, Hermes P. 1052  
 Silver, Karlee L. 542, **544**, 939  
 Sim, B. Kim Lee 769, 773, 807, **987**, 988  
 Sim, Derek 1277  
 Simard, Frederic 1000, 865  
 Simeonov, Anton 1282  
 Simmons, Cameron 98, 468  
 Simmons, Mark P. 774  
 Simon, Fabrice 376  
 Simondon, F 272  
 Simondon, Francois 872  
 Simplicio, Harusha 884  
 Simpore, Jacques 719  
 Simpson, Julie A. 727  
 Sumpungwe, Gamariel 1300  
 Sinden, Robert 160  
 Singh, Amber 10  
 Singh, Anushrita 196  
 Singh, Neeru 196  
 Singh, Sompal 196  
 Singh, Sanjay 731, 732  
 Singh Thakur, Shraavan 956  
 Singhasivanon, Pratap 1250  
 Singlovic, Jan 1267  
 Singo, Alukheti 443  
 Sinha, P K. 235  
 Sinoon, Muth 1271  
 Siqueira, André M. **141**  
 Sirima, Sodiomon B. 147, 1105, 571, 728, 779  
 Sirot, Laura K. 759  
 Sissoko, Mady 161, 590  
 Sissoko, Mody 1100  
 Sissoko, Mahamadou S. 161, 590, 805  
 Sissoko, Seydou 333  
 Sisti, Maggie 51  
 Sjoblom, Jessica E. **531**  
 Sjorgren, Robert 169  
 Skarbinski, Jacek 1316  
 Skelly, Patrick J. 410  
 Skerlj, Renato 267, 714  
 Skinner-Adams, Tina S. 962  
 Sladeczkova, Veronika 669  
 Slater, Hannah 215, **796**  
 Sled, John G. 939  
 Sligar, Jessica 683  
 Slotman, Michel A. 297, 776, **777**  
 Slutsker, Laurence 722  
 Small, Christopher 1006  
 Small, Jennifer 607  
 Small, Pamela 1327  
 Smartt, Chelsea T. **1123**, 1185  
 Smer, Aiman M. 497, 892  
 Smilkstein, Martin 716  
 Smith, Bryan L. 252, **268**  
 Smith, Chris 1114  
 Smith, David L. 146, 48, 785  
 Smith, Emily R. **113**, **1192**, 33, **355**, 363  
 Smith, Helen J. **29**  
 Smith, Joseph 437  
 Smith, James 443  
 Smith, Jennifer **533**  
 Smith, Joseph D. 726, 727, 948  
 Smith, Matthew B. 712  
 Smith, Mark R. 305  
 Smith, Peter 565  
 Smith, Richard 1101, 1248  
 Smith, Scott 1168  
 Smith, Stephen C. **601**, 989  
 Smith, Tom 577  
 Smithers, Hannah M. **1183**  
 Smole, Sandra 192  
 Snounou, Georges 1109, 1113  
 Snow, Robert W. 144, 145, 579, 749  
 Snyder, Greg 864  
 Soares, Alberto M. 641, 646, 647  
 Soares, Renata O. A. 239  
 Sobel, Jeremy 442  
 Soberon, Valeria 689  
 Sobsey, Mark 346, 358, 362, 444  
 Socheat, Duong 1247, 1271, 1273, 534, 550, **592**  
 Sodahlon, Yao 1071, 67  
 Sodiomon Bienvenu, Sirima 158, 720, 838  
 Sodayer, Regis 835  
 Soebiyanto, Radina P. **1134**  
 Soerensen, Thomas D. 755  
 Sognikini, Edmond 1071  
 Sogoba, Dramane 672  
 Sogoba, Nafomon **599**  
 Sohler, Marzia P. 1045  
 Soisson, Lorraine 161, 590, 803, 806, 984  
 Sokhna, C. 1214  
 Sokhna, Cheikh 616  
 Sokolova, Jaroslava 669  
 Solano, Philippe **420**  
 Solari, Aldo 1074  
 Solomadin, Maksim 193  
 Solomon, Jonathan 830  
 Solomon, Tom 1049  
 Soloviova, Kateryna 388  
 Soma, Vijaya L. **948**  
 Somda, Martin B. **1075**  
 Sommerfelt, A. Elisabeth **536**  
 Somsri, Kiatisak 574, 627  
 Song, Chuanzhe 828  
 Song, Jin-Won 820  
 Sorensen, Bess E. 846  
 Sorgi, Carlos A. 658  
 Soriano Arandes, Antonio **573**  
 Sornsakrin, Siriporn 482  
 Sosa, Silvia M. 1003  
 Sosa-Bibiano, Erika I. 1218  
 Soto, Giselle 1132  
 Soto-Calle, Veronica E. **974**  
 Soto-Gómez, Eunice 906  
 Soulama, Issiaka 147, 571, 728  
 Souleymane, Dama 1268  
 Souleymane, Sanon 158, 720  
 Soumaoro, Lamine 1332, 432  
 Soumare, Massitan D. 1069  
 Sousa, Jason 1252, 1253, 245, 248, 251, **252**, 253, 255, 256, 715, 716  
 Southern, Dorothy 1197, 349  
 Souvannasang, Lattha 859  
 Souza, Lorena J. 1152  
 Souza, Renato P. 1166  
 Souza-Neto, Jayme 765, 767, 870  
 Sovero, Merly **1133**, **340**  
 Sow, Abdourahmane 131  
 Sow, Cheikh 616  
 Sow, Doudou 1237, 1256, **131**  
 Sow, Samba O. 1023, 1030, 1065, 107, 111, 333  
 Sowunmi, Akin 1270  
 Sowunmi, Akintunde 2, **746**, **1245**  
 Spaccapelo, Roberta 978  
 Spadafora, Carmenza 428, **431**  
 Speake, Cate 126  
 Spear, Robert C. 63, 456, 457  
 Specht, Sabine 1331  
 Spencer, Lynn 781  
 Speybroeck, Niko 974  
 Spinks, Daniel 1083  
 Spinola, Manuel 1077

The number(s) following author name refers to the abstract number.

- Spring, Michele 806, 808, **981**, 984  
 Sratongno, Panudda 540  
 Sridaran, Sankar 400  
 Srinivasamoorthy, Ganesh 954  
 Srinivasan, Prakash 437  
 Srivastava, Aruna 196  
 Srivastava, Harish C. **603**  
 Sriwichai, Sabaithip 1247, 550  
 Ssekabira, Umaru 1236  
 Ssempebwa, John 640  
 Ssemwanga, David K. 640  
 Sserwanga, Asadu **1208**, 142  
 St. Claire, Marisa 380  
 St.Pierre, Timothy G. 132  
 Stadelmann, Britta 1041, 815  
 Staedke, Sarah G. 1240, 1302, 1303, 1304, 1314, 532, 539  
 Stafford, Richard E. 987, 988  
 Stancil, Jeffrey D. 1001  
 Standish, Katherine 100, 509  
 Stanisic, Danielle I. 4, 1176  
 Stanley, William 881  
 Stansbury, SD 1153, **1154**, 454, 455  
 Staples, Erin 1011  
 Stark, Lillian M. 389, 879  
 Starzengruber, Peter **473**  
 Stauber, Christine 358, 359, 362  
 Stauffer, William 338  
 Stedman, Timothy 1105, 1106, 328  
 Steel, Cathy **385**  
 Stefaniak, Maureen E. 583  
 Stein, Mónica 997  
 Steinhoff, Mark C. **1198**  
 Steketee, Richard 722  
 Stephens, Chad E. 450  
 Stephens, Lindsey 35  
 Steritz, Matthew 763  
 Sterling, Charles R. 789  
 Stevens, Yvonne 1162, 49  
 Stevenson, Jennifer **781**  
 Stewart, Ann 271  
 Stewart, Barbara S. 1206  
 Stiles, Jonathan 1255  
 Stinchcomb, Dan T. 375, 832, 907  
 Stine, O. C. **405**, **896**  
 Stins, Monique 373, 948  
 Stock, Roberto P. 902  
 Stocker, J T. 388  
 Stoddard, Robyn A. 856  
 Stoddard, Steven T. **391**, 622, 625, 910  
 Stoffel, Sabine 979  
 Stolk, Wilma 215  
 Storer, Fabio 283  
 Storms, Aaron D. **795**  
 Stothard, Russell 888  
 Stoute, José A. 122, 128, 428, 431  
 Stouten, Jessica 715  
 Stovall, Janae 1311  
 Stoyanov, Cristina 1173  
 Strahm, Melanie 1333  
 Strand, Micheal R. 761, 762  
 Straus, Lianne 568  
 Stray-Pedersen, Babill 1230  
 Streatfield, Stephen 982  
 Streit, Thomas 1333  
 Stresman, Gillian H. **47**, 130  
 Striker, Robert 515  
 Stringer, Elizabeth 962  
 Strub-Wourgaft, N 235  
 Stuart, James 1023  
 Stuber, Tod 1195  
 Su, Xin-Zhuan 36  
 Suarez, Lady-anne 1312  
 Suarez, Luis 341, 92  
 Suarez, Victor 341, 92  
 Subbarao, Kanta 834  
 Subramaniam, Krishanthi **433**  
 Subudhi, Amit K. 430  
 Sucupira, Izis M. C. **604**  
 Suhara, Fumiko 109  
 Sukhbaatar, Munkhzul 472  
 Sukupolvi-Petty, Soila 99  
 Sullivan, David 1097, 948  
 Sullivan, JoAnn S. 1287  
 Sullivan, Steven 449  
 Sullivan, Jr., William J. 372  
 Sultana, Nadira K. **34**  
 Sultana, Rebeca **343**, 345  
 Sumari, Deborah 954, 955  
 Sumbele, Irene U. N. **143**  
 Summer, Andrea P. 356  
 Sun, Xiaodong 548  
 Sundar, Shyam **235**  
 Sundaygar, Timothy 1101, 1248  
 Sungvornyothin, Sungsit 176  
 Sunyakumthorn, Piyanate **653**  
 Supali, Taniawati 384  
 Supawat, Krongkaew 482  
 Supriadi, Indri R. **258**  
 Surachetpong, Win 1183, **758**  
 Surasombatpattana, Pornapat **181**  
 Surender, J 213  
 Suriyaphol, Prapat 284, 738  
 Susomboon, Pannapa 1271  
 Sutherland, Colin 1272, 477  
 Sutherland, Laura J. **1047**  
 Suttiaprapa, Sutas 1225, **866**  
 Sutton, Patrick L. 964, 977  
 Suwandono, Agus **14**  
 Suwannachote, Nantawan 612  
 Suwonkerd, Wannapa 176, **612**  
 Suzuki, Akemi 1166  
 Sverremark-Ekström, Eva 282  
 Swahn, Monica 359  
 Swalm, Christopher 1080  
 Swaminathan, Subramanian **313**, **675**  
 Swedberg, Gote 1022  
 Swoboda, Paul 473  
 Sy, Ousmane 1256  
 Sybertz, Edmund 267, 714  
 Sylla, Khadime **279**  
 Sylla, Mamadou B. **333**  
 Sztejn, Marcelo B. 1288  
 Szumlas, Daniel E. 626
- T**
- Taaka, Lilian 1303, 1314  
 Tabachnick, Walter J. 1185, 195  
 Tachibana, Shin-Ichiro 42  
 Tack, Danielle M. 90  
 Tackett, Carol O. 896  
 Taecharak, Vorachet 482  
 Tagbor, Harry 568  
 Tagoe, Janice A. **1025**  
 Taha, Hesham M. 680  
 Tainchum, Krajana 176  
 Tairaka, Jack 1176  
 Takahashi, Daniele 894  
 Takala-Harrison, Shannon 161, 572, 590, 803  
 Takamoto, Masaya 109  
 Takayama, Eiji 109  
 Takem, Ebako N. **46**  
 Takeo, Satoru 42, 581, **942**  
 Takeuchi, Dan 1312  
 Takeuchi, Tsutomu 109  
 Takhampunya, Ratee 202, 398, **656**  
 Takken, Willem 1007  
 Talat, Najeeha **1129**  
 Talbot, Jeffrey 799  
 Taldone, Tony 260  
 Taleo, George 42  
 Talisuna, Ambrose 374, 538, 1240, 1315  
 Talkington, Deborah 637  
 Talla Diaw, Oumar 888  
 Talla Nzussouo, Ndahwouh **1164**  
 Talledo, Michael J. **337**  
 Talley, Angela K. **809**, 844  
 Tally, John 694  
 Tam, Clarence 520  
 Tamarozzi, Francesca 1042  
 Tamboura, Boubou 1023, 1030, 333  
 Tami, Adriana 1241  
 Tammaro, Federica 1182  
 Tamminga, Cindy **492**, 806, 807, 808, **971**, 972, 984  
 Tan, Asako 941  
 Tanabe, Kazuyuki 42  
 Tanajura, Davi 679  
 Tang, Petrus 1307  
 Tang, Thuong C. 853  
 Tangpukdee, Noppadon 1271  
 Tangteung, Anchalee 252  
 Taniuchi, Mami 480  
 Tanner, Marcel 979  
 Tanowitz, Herbert B. 1085, 331  
 Tanowitz, Herbert T. 707  
 Tantalean, Manuel E. 61  
 Tanyuksel, Mehmet 208, 314, 315  
 Tapia, Lorena **1116**  
 Tapia, Milagritos 1030, 107, 333  
 Tappero, Jordan W. 1238, 1319  
 Taracena, Mabel 997  
 Taramelli, Donatella **254**, **719**  
 Tarbell, Kristin V. 388  
 Tarleton, Rick 1096  
 Tarning, Joel 1250, **6**  
 Tarpley, Margaret 84  
 Tarsitani, Gianfranco 618  
 Tarun, Jr., Salvador Z. **869**  
 Tassiba, Martine-Esther 1317  
 Tassinari, Wagner S. 409  
 Tatem, Andrew J. 785  
 Tatu, Utpal 430  
 Tauil, Pedro L. 970  
 Tausie, Blessius 25  
 Tavares-Neto, José 1048  
 Tavul, Livingstone 1176  
 Tawiah, Naa Adjleley **1143**  
 Taylor, Christina M. 1187  
 Taylor, Diane W. 1291, 726  
 Taylor, Ethel V. **24**  
 Taylor, Lizeth 821  
 Taylor, Myra **673**  
 Taylor, Steve M. 570, **578**, **676**, **842**, 963, 1320  
 Taylor, Terrie E. 3, 541, 843, 947, 960  
 Tchania, Corinne 403  
 Tchuem Tchuente, Louis-Albert **888**  
 Technical Working Group on Urban NTDs 802  
 Teelen, Karina Teelen 779  
 Tefe-Silva, Cristiane **658**  
 Teixeira, Ludmilla D. 1028  
 Teixeira, Lucia M. **1028**  
 Teja-isavadharm, Paktiya 1273  
 Teka, Hiwot 1104  
 Tekwani, Babu L. 257, 368, **713**, 717  
 Telford III, Sam R. 817, 823  
 Telleria, Erich 60  
 Tellez, Yolanda 1309  
 Tello, Luis 812  
 Tenaguem, Jean 1330  
 tenAsbroek, Guus 77  
 Tene, Billy F. **1293**  
 ter Kuile, Feiko O. 1212, 503, 722, 749, 1320  
 ter Meulen, Jan 589  
 Teran, Rommy 529  
 Terashima, Angelica 1072, 1073  
 Terlouw, Dianne J. 780  
 Tesh, Robert B. 1019, 1310, 377, 89  
 Teshi, Takele 1259  
 Test, Matthew R. 1223  
 Tetteh, Kevin K. A. 427  
 Tetuanui, Albert 21, 999  
 Tetui, Moses **490**, **537**  
 Tewari, Kavita 1173  
 Texeira, Tony 192  
 Thai, Khoa T. D. **97**, **98**  
 Thaisomboonsuk, Butsaya 95  
 Thangaraj, Bhuvaneshwari 448  
 Thavamani, Rajapandi 1105  
 Theander, Thor 276, 436, 549, 576, 937  
 Théophile, Dimo 78  
 Thera, Mahamadou A. **161**, 572, 590, 803, 847  
 Thesing, Philip 3, 960, 961  
 Thiam, C. 272  
 Thiemann, Tara C. **19**  
 Thierier, James H. 896  
 Thiéro, Daouda 1209  
 Thior, Pape Moussa 44  
 Thirumalapura, Nagaraja 651  
 Thomas, Charles 1066  
 Thomas, Craig J. 1282  
 Thomas, Frédéric 181  
 Thomas, John H. **755**



The number(s) following author name refers to the abstract number.

- Thomas, Matthew 991, 1012  
 Thomas, Nicole 807, **931**  
 Thomas, Stephen J. 837  
 Thomas, Wendy Marie **112**  
 Thompson, Joanne **743**  
 Thomsen, Edward **1067**, 173, 188, 464, 611, 64, 66  
 Thomson, Cindy 907  
 Thompson, Darby 161, 590  
 Thomson, Madeleine 153  
 Thongrungrat, Supatra 203  
 Thorne, Mike 833  
 Thuma, Philip 47, 130, 475, 734, 1097, 1213  
 Thumar, Bhavin 834  
 Thurmn, D.J. 810  
 Thwing, Julie I. **291**  
 Tibenderana, James 77, 244, 374, 1315  
 Tibery, Cecilia 834  
 Tidwell, Richard R. 238, 682  
 Tiga, Diana 900  
 Timinao, Lincoln **1260**  
 Timmermans, Ans 1247  
 Tine, Roger C. 131, 279, **312**, 1237  
 Ting, Chi-Yin 918  
 Tinoco, Yeny 1136  
 Tinto, Halidou 538  
 Tiono, Alfred B. 147, 292, 293, 571, 728, 873  
 Tippett Barr, Beth 637  
 Tisch, Daniel J. 1067, 226, 63, 64, **66**, 1286  
 Tissera, Hasitha A. **520**  
 Tiwananthagorn, Saruda **699**  
 Tokumasu, Fuyuki 938  
 Tolbert, LaDonna 1098  
 Tolia, Niraj 277  
 Tolo, Youssouf 1100, 161, 590, 847  
 Tomasello, Danielle 1277  
 Tomashek, Kay M. 389, 395, **466**, 496, 906  
 Tomasini, Nicolás 1074  
 Tonnessen, Bradley W. 411  
 Topurua, Ore 1260  
 Torii, Motomi 581, 942  
 Torrero, Marina N. **383**, 388  
 Torres, Katherine 136  
 Torres, Lindsay P. 977  
 Torres, Magdaly 357  
 Torres, Scott 800, 801  
 Torres-Velez, Fernando 791  
 Torrie, Leah 1083  
 Tosh, Donna 808  
 Toto, Jean-Claude 872  
 Tougher, Sarah 1317, 534  
 Touil-Boukoffa, Chafia 1038  
 Toure, Hamidou A. 672  
 Toure, Seydou 801  
 Townner, Jon 339  
 Townes, David 291, 637  
 Townes, David A. **561**, **783**  
 Trager, Lauren 1173  
 Traina, Mahmoud I. **497**, **892**  
 Tramontano, Anna 1182  
 Tran, Thi Thuy 468  
 Tran, Tinh Hien 468  
 Tran Tinh, Hien 1323  
 Traore, Aliou 1100  
 Traore, Abdel K. 672  
 Traore, Abdoulaye M. 672  
 Traore, Idrissa 161, 590  
 Traore, Djibril 750  
 Traore, Karim 121, 161, 563, 572, 590, 845, 847, 1100, 1209  
 Traore, Mamadou 801  
 Traore, Oumar Bila 1100  
 Traoré, Sékou F. 182, 432, 563, 599, 1209, 1299, 1332  
 Traore, Zoumana Isaac 1100  
 Trapaga-Barrientos, José 620  
 Trape, J.f. 1214  
 Traub-Cseko, Yara M. 60  
 Travaglio, Manuela 618  
 Travassos, Mark A. **847**  
 Travassos da Rosa, Amelia P. 377  
 Travi, Bruno L. 687  
 Trent, Dennis W. 51  
 Triana-Chávez, Omar 1074  
 Trichilo, Jessica 586  
 Trieu, Angela 414  
 Trilar, Tomi 1167  
 Trindade, Pedro B. 1325  
 Trinelli, Maria 185  
 Tripathi, Abhai 948  
 Triqui, Choukri 157  
 Trivedi, Arti 677  
 Tronchet, Carole 26  
 Trongtokit, Yuwadee 461  
 Trop, Stefanie 757  
 Troye-Blomberg, Marita 276, 282, 285, 42, 436, 733  
 Troyo, Adriana **821**  
 Trueba, Gabriel 354  
 Truel, Beatriz 816  
 Trybiec, Mariela 904  
 Tsai, Hung-Chin **499**  
 Tsai, Jih-Jin **505**  
 Tsai, Kun-Hsien 392, 914  
 Tsai, Wen-Yang 911  
 Tsang, Victor 794  
 Tsang, V.C.W. 810  
 Tsang, Victor C. W. 790  
 Tse, Jeanette G. 434  
 Tseng, Yu-Ting 499  
 Tsertsvadze, Nikoloz 199  
 Tsertsvadze, Tengiz 504  
 Tshetu, Antoinette K. 570, 578, 7, 963  
 Tshisungu, Louis-Daniel A. 1317  
 Tshiswaka-Kashalala, Gauthier 751  
 Tsokos, George C. 431  
 Tsolis, Renee M. 119  
 Tsuboi, Takafumi 42, 547, 581, 942  
 Tsui, Rachel E. **630**  
 Tsukayama, Pablo 689  
 Tu, Zhijian 302  
 Tuikue Ndam, Nicaise 157, 274, 436  
 Tullo, Greg 121, 845, 1178  
 Tumwesigye, Nazarius M. 417  
 Tungtaeng, Anchalee 248, 265, 266  
 Tungwony, Carol 149  
 Tuni, Makiva 569  
 Turner, Louise 549  
 Tusiime, Ronald N. **949**  
 Tuteja, Renu 372  
 Tweheyo, Raymond 537  
 Tyne, Daria V. 1261  
 Tyner, Stuart D. 1247, **1273**, 550  
 Tzertzinis, George 868
- ## U
- Ubben, David 264, 292, 293, 873  
 Uboldi, Alex 1107, 581  
 Uchime, Onyinyechukwu 41  
 Uddin, M. Ikhtear 484  
 Uddin, Taher 484  
 Udhyakumar, Venkatachalam 400, 954, 955  
 Udomsangpetch, Rachanee 398  
 Ueno, Priscilla M. 1321  
 Ueta, Marlene T. 658  
 Ugaddan, George 567  
 Ughasi, Josephine C. **1009**  
 Ukoha, Ndukwe 298  
 Ukoha, Ndukwe K. 752  
 Ukuga, C. N. 447  
 Umaru, J 798  
 Umemoto, Saori 109, 159  
 Umesumbu, Solange E. **665**  
 Umulisa, Noella 1200  
 Unicomb, Leanne 1197, 23, 26, 347, 348, 349, 350, 351  
 Unnasch, Thomas R. 1284, 216, 825, **826**, **868**, 879  
 Upcroft, Jacqueline 449  
 Urban, Joyce 600  
 Urban, Joe 867  
 Uргаonkar, Sameer 714  
 Utzinger, Jürg 889, 890
- ## V
- V'ant Hoog, Anja 1128  
 Vaca, Maritza 529  
 Vaillant, Michel 235, 440, 1318  
 Valbuena, Gustavo 900  
 Valeh, Parastou S. 1101, 1248  
 Valencia, Braulio M. **231**, 689, **690**  
 Valencia, Cristian 1087  
 Valencia, Teresa 1132  
 Valentim, Claudia **1228**  
 Valerio, Laura 16  
 Valim, Clarissa 935  
 Valks, Andrea 91  
 Valley, Andrew 250, 841  
 Van Camp, Guy 337  
 Van de Gegte-Bolmer, Marga 779  
 van de Hoef, Diana L. **435**  
 Van Den Abbeele, Jan **1082**  
 Van den Eede, Peter **784**  
 van der Auwera, Gert 1087  
 van Doorn, H R. 98  
 van Eijk, Anna Maria 503, 569, 722, 749  
 van Gemert, Geert-Jan 37  
 Van Gessel, Yvonne 1049  
 Van Laer, Lut 337  
 van Loen, Harry 495, 495  
 van Overmeir, Chantal 495  
 Van Panhuis, Willem G. **470**  
 van Ravensway, Jenni 1327  
 van Schaijk, Ben 37  
 Van Tyne, Daria 401  
 Van Voorhies, Wayne 772  
 Van Voorhis, Wesley C. 1283  
 Van Wynsberghe, Nicole R. 1218  
 Vanaerschot, Manu 703  
 Vanham, Guido 337  
 VanRoekel, Denise L. 609  
 Varani, Stefania 276  
 Vardo-Zalik, Anne M. 1210  
 Vargas, Martha 929  
 Varma, Sudhir 1189  
 Varnado, Wendy 9  
 Vasconcelos, Helena B. 1159  
 Vasconcelos, Pedro F. C. **1048**, **1159**  
 Vasilakis, Nikos **1310**, **89**  
 Vasquez Carmago, Fabio 688  
 Vaughan, Jefferson A. **652**  
 Vazquez-Prokopec, Gonzalo M. **194**, **390**, 391, **910**  
 Veenstra, Timothy D. 829  
 Vega, Martha Rocío 517  
 Vega, Particia D. 978  
 Vekemans, Johan 161, **582**, 590, 803  
 Veland, Nicolas **1087**  
 Velasco-Villa, Andres 345A  
 Velasquez, Daniel 316, 317  
 Velez, Ivan D. 907  
 Velmurugan, Soundarapandian **365**, 988  
 Vendrame, Celia 1090  
 Venkata, Raghava M. 1044  
 Venkatesan, Meera **1274**  
 Vennerstrom, Jonathan L. 1244  
 Vera, Delphis M. **1138**  
 Vera, Iset Medina 1336  
 Verastegui, Manuela R. **789**, 812, 816, 1216  
 Verdonck, Kristien 337, 660  
 Verhave, Jan Peter 779  
 Verjovski-Almeida, Sergio 1224  
 Verley, Janice 680  
 Verlinde, Christophe L. M. J. 1283  
 Verma, D K. 235  
 Verma, N 235  
 Verma, Saguna 1059  
 Vermeersch, Audrey 905  
 Vermeire, Jon J. **1282**  
 Vernick, Kenneth D. 864  
 Veron, Vincent 240  
 Verstraeten, Tom 582  
 Verver, Susan 1128  
 Verweij, Jaco 480  
 Vestergaard, Lasse 950  
 Via, Allegra 1182  
 Vial, Thomas 12  
 Viana, Giselle M. Rachid. 558, **560**  
 Vianou, Bertin 276  
 Vidal, Jaume 1246  
 Viera, Sara 267

The number(s) following author name refers to the abstract number.

Viladpai-nguen, Samuel J. 727  
 Vilcarronero, Stalin F. **79**  
 Vilchez, Gustavo 1305  
 Villanueva-Lizama, Liliana E. 1218  
 Villar, Luis A. **900**  
 Villarreal, Juana 1079  
 Villasis, Elizabeth **136**  
 Villegas, Elci 461  
 Villegas, Leopoldo 954, 968  
 Villegas, Rossana 124  
 Villinger, Francois 1313  
 Villinski, Jeffrey T. 207  
 Vincent, Corbel 171  
 Vinetz, Joseph M. 301  
 Vinje, Jan 1163  
 Vivier, Elodie 376  
 Viwami, Firmine 274  
 Vlachou, Dina 564  
 Vo, Long T. 98  
 Volf, Petr 60  
 Volkman, Sarah 1261, 401, 402, 934  
 Volper, Esther 1059, 85  
 Voronkova, Valentina 40  
 Voronov, Dmitry 1119, 863  
 Vounatsou, Penelope 889  
 Vrabec, Sara 1026  
 Vrzal, Erin 1013  
 Vujcikova, Julia 669  
 Vulule, John M. 1211, 1292, 545, 545, 546, 721, 725, 781, 848, 852  
 Vuolo, Elena **419**  
 Vyankandondera, Joseph 116

## W

W Jr, Elsio A. 1031  
 Wabwire-Mangen, Fred 949  
 Wagacha, John B. 639  
 Wagar, Erick J. 953  
 Wagman, Joseph **621**  
 Wagner, Danielle 33  
 Wahala, Wahala 831, 99  
 Wahlers, Kerstin **811**  
 Waitumbi, John 1098, 149, 271, 555, 75  
 Walbeck, Justin 183  
 Walker, David H. 651  
 Walker, Edward D. 1006, 1055, 1058, 1205, 1294, 187  
 Walker, Larry 1249, 248, 257, **368**, 426, 710, 713, 717  
 Wallander, Wes W. 926  
 Waller, Lance A. 1026, 1327  
 Walls, Colleen D. **1158**  
 Walsh, Douglas S. 1273, 953  
 Walsh, Rachael K. **16**  
 Walter, Annie 168  
 Walter, Verena 264, 293, 294, 367  
 Walters, Adam 444  
 Wamachi, Alex 1286  
 Wamani, Joseph 68  
 Wane, Justin 1200  
 Wang, Amy 1288  
 Wang, Eryu 375  
 Wang, Guangze 156

Wang, Heng 548  
 Wang, Mei-Hui **1180**  
 Wang, Michael 238  
 Wang, Ruobing 809, 844, 987  
 Wang, Shanqing 156  
 Wang, Tongmin 956  
 Wang, Wei-Kung **911**  
 Wang, Xiaoxia **1142**  
 Wang, Xin-Min 589  
 Wang, Ying **1296**  
 Wang, Yanyan **286**  
 Wang, Yue 547  
 Wang, Ying 763  
 Wang, Zhengyuan 1187  
 Wang, Zhensheng 548  
 Wani, Emanuel L. **901**  
 Wanionek, Kimberli 834  
 Wanjala, Christine L. **75**  
 Wanjala, Esther Atsabina 930  
 Wanzira, Humphrey **1238**, 1319  
 Warashina, Wesley 1190  
 Ward, Brian J. 88, 1094  
 Ward, Honorine 328, 448  
 Ward, S.A. 960  
 Ware, Lisa 808  
 Warimwe, George 1177  
 Warner, Jeffrey 1064  
 Warren, Cirle A. 327, 642, 643, 1235  
 Warsame, Marian 1267  
 Wasinpiyamongkol, Ladawan 181  
 Wasserberg, Gideon **204**  
 Wasunna, Beatice **242**  
 Watanaveeradej, Veerachai 13  
 Waterman, Paige 981  
 Wattanavijitkul, Thitima **708**  
 Watts, Douglas 394  
 Wawo-Yonta, Edwine 1330  
 Weatherall, David J. 105  
 Weatherly, D B. 1096  
 Weaver, Angela **800**  
 Weaver, Scott C. 1310, 335, 375, 394, 89  
 Webster, Alison 711  
 Webster, Bonnie 888  
 Webster, Joanne P. 886  
 Weger, James 375  
 Wei, Chunyan 548  
 Wei, Hans H. **426**, 1252  
 Wei, Wang **1147**  
 Weidmann, Manfred 11  
 Weil, Gary J. 221, 222, **406**, 824, 827  
 Weill, Mylène 465  
 Weina, Peter J. 694  
 Weinberg, Diego 185  
 Weinberg, J Brice 850  
 Weinkopff, Tiffany S. **382**  
 Weis, Kristina 389  
 Weiss, Sonja 1168  
 Weiss, Walter 1173  
 Wele, Mamadou **1263**  
 Weller, Nina 1169  
 Wells, Natalie 971  
 Wen, Tzai-Hung 392, 914, 918, 919, 920  
 Wen, Zhiyun 589  
 Weng, Shaojie 165

Wenzler, Tanja 682  
 Werbovetz, Karl 238, **682**  
 Were, Tom 1292, 1322, 545, **546**, 721, 723, 848  
 Wesche, David 7  
 Wesson, Dawn M. 1002  
 West, Sheila 296  
 Westby, Kathleen 655, 817  
 Westerfeld, Nicole 979  
 Whalen, Christopher 935  
 Wheeler, Sarah S. 19  
 White, Gregory S. 879  
 White, John 1275, 476  
 White, Karen 248, 715  
 White, Lisa J. 1267  
 White, Laura J. 514, **831**  
 White, Michael 876  
 White, Nicholas J. 1249, 1250, 1267, 851, 905  
 White, Sarah 1212  
 White Jr, Arthur Clinton 446  
 Whitehead, Stephen 834  
 Whitman, Timothy 972  
 Whitney, Ellen A. S. 1026, 1327  
 Whitty, Chris J. M. 840  
 Wibowo, Heri 384  
 Wickremasinghe, Renu 42  
 Widjaja, Susana 14  
 Wiegand, Roger 267, 401, 402, 714  
 Wieler, Lothar 634  
 Wiesner, J.L. 960  
 Wijesinghe, Rushika 250  
 Wilairatana, Polrat 1271  
 Wilhelm, April K. **674**  
 Wilkerson, Richard 778  
 Wilkins, Patricia 659  
 William, Jack 808  
 William, Maya 14  
 William, Timothy **55**  
 Williams, Amanda 320  
 Williams, Craig 778  
 Williams, Diana L. 1132  
 Williams, David L. 1282  
 Williams, Holly 561  
 Williams, Katherine L. **99**  
 Williams, Timothy **101**, 102  
 Williams, Thomas N. 105  
 Williamson, Heather 1327  
 Williamson, John M. **152**, 722  
 Williamson, Kim C. 947  
 Williamson, Kathryn S. 844  
 Willis, Kelly 1236  
 Willoquet, Janine R. 16  
 Wills, Bridget 468  
 Wills, Norma M. 8  
 Willsey, Graham G. 1204  
 Willson, Tara 1321  
 Wilmore, Joel **729**  
 Wilson, Danny W. 1176, 427  
 Wilson, Marianna 324  
 Wilson, M. Maximillion 671  
 Wilson, Mark 867  
 Wilson, Michael D. 1009, 1014, 1025, 273, 632, 735  
 Wilson, Mary E. 1285, 498  
 Wilson, Mary E. 898, 925  
 Wilson, Mark L. 1001, 756

Wilson, Nana O. **1255**  
 Wilson, Ray 1221  
 Wimberly, Michael C. **1104**, 609  
 Winch, Peter J. 1197, 349  
 Wini, Lyndes 569  
 Winter, Michael R. 498  
 Winter, Rolf 716  
 Winzeler, Elizabeth A. 372  
 Wirth, Dyann F. 267, 401, 402, 714, 737, 934, 1261  
 Wirtz, Robert A. 177  
 Wismarini, Desak M. 146  
 Wismeijer, Josta A. 97  
 Wittlin, Sergio 1244, 267, 269, 714  
 Witzig, Claudia **602**  
 Witzig, Richard 690  
 Wölfel, Roman **489**  
 Wolfner, Mariana F. 759  
 Won, Kimberly 65, 799, **885**  
 Wondji, Charles 602  
 Wong, Christina C. Y. B. 1282  
 Wong, Jacklyn **625**  
 Wong, Michelle 811  
 Wood, Chloe 806  
 Woodall, Jack **530**  
 Woodall, Patricia A. **1324**  
 Woods, Helen 503  
 Working Group in Peru, Cysticercosis 794  
 Worodria, William 676  
 Wright, Linda 7  
 Wring, Stephen 234, **683**, 685  
 Wu, Anne 249  
 Wu, David 1321  
 Wu, Feng-Chiang 521  
 Wu, Shuenn-Jue 94  
 Wu, Yineng 1219  
 Wu, Yimin 163, **164**, 584  
 Wu, Yukun 590, 161  
 Wu, Yineng 633  
 Wu, Yimin 804, 805, 871, 982  
 Wu-Hsieh, Betty **521**, 920  
 Wunder Jr., Elsio A. 409, 894, 899  
 Wurapa, Eyako 972  
 Wylie, Blair **961**  
 Wynn, Thomas 867

## X

Xayavong, Maniphet 556  
 Xia, Ai 302, 865  
 Xia, Chen 668  
 Xiao, Dan **156**  
 Xie, Lisa 245, 256  
 Xu, Hui 589  
 Xu, Jiannong 1296, 763  
 Xu, Qiang 990  
 Xu, Ray 987  
 Xu, Shulin 825, 868

## Y

Yabsley, Michael 817  
 Yadav, R.s. 603

The number(s) following author name refers to the abstract number.

Yadava, Anjali 1174, 808  
 Yadeta, Damtew 989  
 Yahya, Raida S. 76  
 Yamada, Jun 159  
 Yamaguchi, Yoko 109, 159  
 Yamaoka3, Shoji 667  
 Yamins, Daniel 401  
 Yan, Guiyun 1180, 1210, 1295,  
 1296, 169, 178, 179, 271  
 Yan, He 668  
 Yan, Yongping 156  
 Yanagi, Tetsuo 724  
 Yanagihara, Richard 881  
 Yang, Baojun **1126**  
 Yang, Chao-Fu 1307  
 Yang, Guangxiao 56  
 Yang, Kun **1146**  
 Yang, Yongkun 1175  
 Yang, Zhaoqing 1269, 744  
 Yanni, Emad 498  
 Yano, Kazuhiko 166  
 Yanow, Stephanie K. 1265  
 Yarlett, Nigel 1089, 234, 683, 685  
 Yaro, Alpha S. 1299, 182  
 Yaro, Jean-Baptiste 147, 728  
 Yasin, 'Azlin M. 318  
 Yasmin, Tabassum 680  
 Yasnot, Maria F. **124**, 636  
 Yasuoka, Junko 1271  
 Yaya, Souleymanou 214  
 Yazdanbakhsh, Maria 384  
 Ye, Li 711  
 Yeboah-Manu, D. 1130  
 Yellu, Nathaniel **1334**  
 Yelmene, Michele 833  
 Yen, Tsai-Ying **919**, 920  
 Yen, Yu-Ting 521  
 Yeo, Tsin Wen 258, 55, 850  
 Yerukhim, Ekaterina 336  
 Yesupriya, Ajay 722  
 Yi, Suk H. 607  
 Yingsiwaphat, Vorraphun 831  
 Yingyuen, Kritsanai 1273  
 Yinkore, Paul 887  
 Yoda, Bernadette 801  
 Yohannes, Gedeon 601  
 Yohannes Anshebo, Gedeon **989**  
 Yoo, Samuel 676  
 Yoon, Steven S. 965, 969  
 Yoshino, Timothy P. 452  
 Yost, Samantha A. 1123  
 Yougouda, Abdoulaye 214  
 Young, Paul 91  
 Young, Sylvia 895  
 Youngpakool, Khwananong 574,  
 627  
 Younis, Brima M. 1217  
 Yousheng, Liang 1147  
 Youssouf, Kabore 158  
 Yu, Xin 1037  
 Yu-huang, Zheng 668  
 Yunus, Emran B. 473  
 Yusibov, Vidadi 1220, 684, 691,  
**982**

## Z

Zaatour, Amor 49, 701  
 Zabaleta, Tatiana 517  
 Zahid, Sadia **680**  
 Zaki, Sherif 1168  
 Zaky, Weam I. Z. **219**  
 Zalis, Mariano G. 1270  
 Zaman, K 1198  
 Zambrano, Betzana 836  
 Zamora Perea, Elvira 460, 874  
 Zanga, Mimie M. 665  
 Zapata, Paula Andrea 153  
 Zarife, Maria A. 1051, 1052  
 Zarroug, Isam 216  
 Zayed, Abdelbaset B. M. **626**  
 Zeng, Qiang 245, 252, 715  
 Zervos, Thomas M. **977**  
 Zhang, Jing 245, 256  
 Zhang, Jian 286  
 Zhang, Lianhui 548  
 Zhang, Lee 990  
 Zhang, Lan 990  
 Zhang, Min **372**  
 Zhang, Ping 245  
 Zhang, Xing **201**  
 Zhang, Y. K. 249  
 Zhang, Yanling 437  
 Zhang, Zhiwen 654, 1024, 1027  
 Zhang, Zhongsheng 1283  
 Zhang, Zaixing 548  
 Zheng, Wanjun 280  
 Zhong, Bo **456**, 457  
 Zhong, Kathleen 542  
 Zhou, Goufa 178, 179, 271, **1210**  
 Zhou, Hong 1178  
 Zhou, Weidong 379  
 Zhu, Daming **163**, 584  
 Zhu, Xiaohua **238**  
 Zhumadilova, Zaure 193  
 Zi, Chen 668  
 Ziegler, Sarah A. 1019, **377**  
 Zijlstra, Ed E. **418**  
 Zimic, Mirko 703  
 Zimmerman, Allison 173, 188  
 Zimmerman, Peter A. 1067, 173,  
 188, 226, 64, 66, 464, 611,  
 944, 1260  
 Zoerhoff, Katie 800, 801  
 Zolia, Yah M. 1101, 1248  
 Zöllner, Gudrun 11  
 Zollner, Gabriela **175**, **206**  
 Zorig, Lhagvajav 489  
 Zou, Gang 1207  
 Zou, Xiaoyan 588  
 Zoumana Isaac, Traore 1268  
 Zubacova, Zuzana 449  
 Zumpolle, Catrien 97  
 Zurbriggen, Rinaldo 979  
 Zurovac, Dejan 145  
 Zuspahn, Jordan A. **434**  
 Zwane, Alix 361  
 Zwang, Julien 1250  
 Zyambo, Rabson 1300  
 Zyzak, Michael **588**





